[
    {
        "id": "TCGA-AX-A1CF-01Z-00-DX2.97DE8134-0D44-4FCE-BA8A-46AD7D215133-1",
        "image": "TCGA-UCEC/TCGA-AX-A1CF-01Z-00-DX2.97DE8134-0D44-4FCE-BA8A-46AD7D215133.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong Cytokeratin 7 reactivity, no expression of Cytokeratin 20 and Vimentin, and moderate expression of CEA, what is the molecular subtype in this cancer type? A) CN_HIGH B) Triple Negative C) Luminal A D) Basal-like"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AX-A1CF-01Z-00-DX1.4D594C9B-FA5E-49A4-9F68-3E18BF038FE2-1",
        "image": "TCGA-UCEC/TCGA-AX-A1CF-01Z-00-DX1.4D594C9B-FA5E-49A4-9F68-3E18BF038FE2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong Cytokeratin 7 reactivity, no expression of Cytokeratin 20 and Vimentin, and moderate expression of CEA, what is the molecular subtype in this cancer type? A) CN_HIGH B) Triple Negative C) Luminal A D) Basal-like"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AP-A1E0-01Z-00-DX1.9B50EE3B-6BEA-4A85-ACA5-5EEBF40635DD-1",
        "image": "TCGA-UCEC/TCGA-AP-A1E0-01Z-00-DX1.9B50EE3B-6BEA-4A85-ACA5-5EEBF40635DD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing no evidence of metastatic tumor with Cytokeratin (AE1/AE3) and the presence of staining for mismatch repair proteins, what is the molecular subtype in this colon cancer? A) POLE-mutant B) MSI-H C) MSI-L D) MSS"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-EO-A3AV-01Z-00-DX1.C49B393E-E190-4877-839C-CD63D141721A-1",
        "image": "TCGA-UCEC/TCGA-EO-A3AV-01Z-00-DX1.C49B393E-E190-4877-839C-CD63D141721A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing ER positivity, PR negativity, and p16 negativity, what is the molecular subtype in this cancer?  A) Luminal A B) HER2-enriched C) Luminal B D) Basal-like"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A5-A0R9-01Z-00-DX1.743A968C-231F-41E4-ADC8-E26FC228E437-1",
        "image": "TCGA-UCEC/TCGA-A5-A0R9-01Z-00-DX1.743A968C-231F-41E4-ADC8-E26FC228E437.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing no “occult” keratin-positive metastatic tumor cells in the pelvic lymph nodes, rare tubal epithelial cells with positive nuclear staining, and positive mesothelial cell staining in a uterine adenomatoid tumor, what is the molecular subtype in this uterine carcinoma?   A) CN_HIGH   B) CN_LOW   C) MSI-H   D) POLE-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-A5-A0RA-01Z-00-DX1.2F3D35B2-0602-47C5-9C8C-8C8A3CFF5E04-1",
        "image": "TCGA-UCEC/TCGA-A5-A0RA-01Z-00-DX1.2F3D35B2-0602-47C5-9C8C-8C8A3CFF5E04.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing no \"occult\" keratin-positive metastatic tumor cells identified in both right and left pelvic lymph nodes but dissection strays of tumor present adjacent to the nodes in this carcinoma, what is the molecular subtype? A) HER2-enriched B) CN_LOW C) BRCA-mutant D) EGFR-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-D1-A0ZU-01Z-00-DX1.7A7702BC-48F1-4EB1-9B9E-C270FF66B2DA-1",
        "image": "TCGA-UCEC/TCGA-D1-A0ZU-01Z-00-DX1.7A7702BC-48F1-4EB1-9B9E-C270FF66B2DA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong and diffuse reactivity of p53 and MIB-1 in the anterior uterine serosa, no reactivity of estrogen receptors in the same area, aberrant loss of MLH1 and PMS2 expression, and intact expression of MSH2 and MSH6 in endometrial cancer sections, what is the molecular subtype in this endometrial cancer? A) CN_LOW B) POLE-mutant C) MSI D) p53 wild-type"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AJ-A3BH-01Z-00-DX1.0331F525-1598-40D2-95C9-D480F7F57AE4-1",
        "image": "TCGA-UCEC/TCGA-AJ-A3BH-01Z-00-DX1.0331F525-1598-40D2-95C9-D480F7F57AE4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive expression for Estrogen receptor and Cytokeratin AE1/AE3, negative expression for Progesterone receptor, WT1, and p53, and patchy positivity for p16, what is the molecular subtype in this cancer? A) Luminal A B) Triple-negative C) Basal-like D) MSI"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BG-A0VW-01Z-00-DX1.35FBE3EF-4892-42BF-8524-3DBAC00493F9-1",
        "image": "TCGA-UCEC/TCGA-BG-A0VW-01Z-00-DX1.35FBE3EF-4892-42BF-8524-3DBAC00493F9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing patchy positive P16, negative P53 and 263, positive CEA, D2-40, and CD34 in endothelial, lymphatic, and vascular channels, which molecular subtype does this cancer belong to? A) MSS B) MSI C) HPV+ D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-AJ-A3BF-01Z-00-DX1.33BB61EB-231D-42B1-BB02-5A956DE6ED1E-1",
        "image": "TCGA-UCEC/TCGA-AJ-A3BF-01Z-00-DX1.33BB61EB-231D-42B1-BB02-5A956DE6ED1E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing PS3 strongly positive in tumor cells, consistent with serous carcinoma, what is the molecular subtype in this ovarian cancer? A) CN_LOW B) CN_HIGH C) MSI D) MMR-deficient"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-B5-A11V-01Z-00-DX1.A4D88075-88AA-45D2-B6BB-E214004D4EB8-1",
        "image": "TCGA-UCEC/TCGA-B5-A11V-01Z-00-DX1.A4D88075-88AA-45D2-B6BB-E214004D4EB8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results of the left ovarian nodule showing strong positivity for Inhibin and Calretinin, and the right ovarian nodule showing strong Inhibin staining and weak Actin staining, what is the molecular subtype in this ovarian tumor? A) CN_LOW B) HRD C) POLE-ultramutated D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AP-A059-01Z-00-DX1.903852FB-B865-429E-A9DF-D80A19BD1A8D-1",
        "image": "TCGA-UCEC/TCGA-AP-A059-01Z-00-DX1.903852FB-B865-429E-A9DF-D80A19BD1A8D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a loss of MSH6 protein and trace reactions of MLH1 and MSH2 proteins, which are not diagnostic, what is the molecular subtype in this endometrial carcinoma? A) MSI B) POLE C) MSS D) ER+"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EY-A72D-01Z-00-DX1.4303F43E-9702-4089-A854-4072C87A1FAC-1",
        "image": "TCGA-UCEC/TCGA-EY-A72D-01Z-00-DX1.4303F43E-9702-4089-A854-4072C87A1FAC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong positivity for P16, P63, and CAM 5.2, subset positivity for Vimentin, and negative results for S-100, CEA, CD56, ER, and PR in this cervical tumor, what is the molecular subtype of this tumor? A) CN_HIGH B) HPV+ C) MSI D) Her2+"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EY-A3QX-01Z-00-DX1.CA5162F1-A8A0-4FF3-A253-ADE265744B07-1",
        "image": "TCGA-UCEC/TCGA-EY-A3QX-01Z-00-DX1.CA5162F1-A8A0-4FF3-A253-ADE265744B07.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing WT1 with scant scattered weak positive staining, E-cadherin positive, Estrogen Receptor (ER) positive (2-3+, 75%), and Progesterone Receptor (PR) weakly positive (2+, 10%), what is the molecular subtype in this cancer case? A) Luminal A B) CN_HIGH C) Basal-like D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-FI-A2CY-01Z-00-DX1.A18FF3DB-C078-4E9C-8D74-948408C71D55-1",
        "image": "TCGA-UCEC/TCGA-FI-A2CY-01Z-00-DX1.A18FF3DB-C078-4E9C-8D74-948408C71D55.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p16 is focally positive, p53 is focally weak positive in some areas, ER is weakly and focally expressed in tumor cells, and PR is focally expressed in tumor cells, what is the molecular subtype in this uterine carcinoma? A) MSI-H B) POLE-ultramutated C) CN_HIGH D) MMR-deficient"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-PG-A916-01Z-00-DX2.E6AFA173-6E18-4194-BB65-9BD7F7652237-1",
        "image": "TCGA-UCEC/TCGA-PG-A916-01Z-00-DX2.E6AFA173-6E18-4194-BB65-9BD7F7652237.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing ER positivity at approximately 70%, PR positivity at approximately 50%, and negative p53 staining, what is the molecular subtype in this cancer? A) Basal-like B) HER2-enriched C) Luminal A D) Claudin-low"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-PG-A916-01Z-00-DX4.970A790E-649C-4D4D-98DB-7DF6A7045A14-1",
        "image": "TCGA-UCEC/TCGA-PG-A916-01Z-00-DX4.970A790E-649C-4D4D-98DB-7DF6A7045A14.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing ER positivity at approximately 70%, PR positivity at approximately 50%, and negative p53 staining, what is the molecular subtype in this cancer? A) Basal-like B) HER2-enriched C) Luminal A D) Claudin-low"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-PG-A916-01Z-00-DX5.C87132C9-F354-4EAD-A89C-DF85D3890338-1",
        "image": "TCGA-UCEC/TCGA-PG-A916-01Z-00-DX5.C87132C9-F354-4EAD-A89C-DF85D3890338.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing ER positivity at approximately 70%, PR positivity at approximately 50%, and negative p53 staining, what is the molecular subtype in this cancer? A) Basal-like B) HER2-enriched C) Luminal A D) Claudin-low"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-PG-A916-01Z-00-DX7.1F385796-7AEC-43CE-9F6A-564204BA9BE6-1",
        "image": "TCGA-UCEC/TCGA-PG-A916-01Z-00-DX7.1F385796-7AEC-43CE-9F6A-564204BA9BE6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing ER positivity at approximately 70%, PR positivity at approximately 50%, and negative p53 staining, what is the molecular subtype in this cancer? A) Basal-like B) HER2-enriched C) Luminal A D) Claudin-low"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-PG-A916-01Z-00-DX1.EE02736A-4198-4880-9791-8AA6899533D1-1",
        "image": "TCGA-UCEC/TCGA-PG-A916-01Z-00-DX1.EE02736A-4198-4880-9791-8AA6899533D1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing ER positivity at approximately 70%, PR positivity at approximately 50%, and negative p53 staining, what is the molecular subtype in this cancer? A) Basal-like B) HER2-enriched C) Luminal A D) Claudin-low"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-PG-A916-01Z-00-DX6.32D62843-11DB-4653-990E-80A3EEB59612-1",
        "image": "TCGA-UCEC/TCGA-PG-A916-01Z-00-DX6.32D62843-11DB-4653-990E-80A3EEB59612.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing ER positivity at approximately 70%, PR positivity at approximately 50%, and negative p53 staining, what is the molecular subtype in this cancer? A) Basal-like B) HER2-enriched C) Luminal A D) Claudin-low"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-PG-A916-01Z-00-DX3.9D178CFC-D024-4C63-8D5F-6884ED1D835B-1",
        "image": "TCGA-UCEC/TCGA-PG-A916-01Z-00-DX3.9D178CFC-D024-4C63-8D5F-6884ED1D835B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing ER positivity at approximately 70%, PR positivity at approximately 50%, and negative p53 staining, what is the molecular subtype in this cancer? A) Basal-like B) HER2-enriched C) Luminal A D) Claudin-low"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-PG-A917-01Z-00-DX2.DFE283A9-971C-4114-A06D-28FEB52AAA7A-1",
        "image": "TCGA-UCEC/TCGA-PG-A917-01Z-00-DX2.DFE283A9-971C-4114-A06D-28FEB52AAA7A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing ER positive with intermediate to strong intensity and PR positive with strong intensity, what is the molecular subtype in this cancer type? A) HER2-enriched B) Luminal A C) Basal-like D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-PG-A917-01Z-00-DX1.4DB12583-7DA3-4110-A3F9-F31B9ADA0A24-1",
        "image": "TCGA-UCEC/TCGA-PG-A917-01Z-00-DX1.4DB12583-7DA3-4110-A3F9-F31B9ADA0A24.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing ER positive with intermediate to strong intensity and PR positive with strong intensity, what is the molecular subtype in this cancer type? A) HER2-enriched B) Luminal A C) Basal-like D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-PG-A917-01Z-00-DX3.9F8BF767-4F44-4B89-B852-FB826C3E0BAE-1",
        "image": "TCGA-UCEC/TCGA-PG-A917-01Z-00-DX3.9F8BF767-4F44-4B89-B852-FB826C3E0BAE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing ER positive with intermediate to strong intensity and PR positive with strong intensity, what is the molecular subtype in this cancer type? A) HER2-enriched B) Luminal A C) Basal-like D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-D1-A2G6-01Z-00-DX1.A57A4F81-DE2D-434C-AF88-EAB77DD96FBB-1",
        "image": "TCGA-UCEC/TCGA-D1-A2G6-01Z-00-DX1.A57A4F81-DE2D-434C-AF88-EAB77DD96FBB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing focal positivity for estrogen receptor, negativity for progesterone receptor and pCEA, positivity for Vimentin, and negativity for HPV in situ hybridization, what is the molecular subtype in this endometrial carcinoma?   A) POLE-mutant   B) MSS   C) MSI   D) Serous-like   ═"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BG-A187-01Z-00-DX1.F2C20D22-4D9A-43B9-AF01-307031F9F842-1",
        "image": "TCGA-UCEC/TCGA-BG-A187-01Z-00-DX1.F2C20D22-4D9A-43B9-AF01-307031F9F842.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing D2-40 and CD31 supportive of diagnosis, what is the molecular subtype in this cancer? A) CN_LOW B) TP53-mutant C) EBV-associated D) HRD"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A5-A2K7-01Z-00-DX1.A19C8321-DB5A-4884-94B1-E7EAE990A4BC-1",
        "image": "TCGA-UCEC/TCGA-A5-A2K7-01Z-00-DX1.A19C8321-DB5A-4884-94B1-E7EAE990A4BC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing 80% positivity for Vimentin, 10% negative for CEA, 80% positivity for ER, and patchy (40%) positivity for p16, what is the molecular subtype in this cancer? A) Basal-like B) MSI C) Luminal A D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-PG-A6IB-01Z-00-DX3.82A8C097-478B-4B6E-BB16-7461529B524F-1",
        "image": "TCGA-UCEC/TCGA-PG-A6IB-01Z-00-DX3.82A8C097-478B-4B6E-BB16-7461529B524F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative expression for P53, ER, and PR, what is the molecular subtype in this cancer?   A) Basal-like   B) HER2-enriched   C) Luminal A   D) MSI"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-PG-A6IB-01Z-00-DX4.631A44B6-43E0-4481-AF1F-3EB484784672-1",
        "image": "TCGA-UCEC/TCGA-PG-A6IB-01Z-00-DX4.631A44B6-43E0-4481-AF1F-3EB484784672.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative expression for P53, ER, and PR, what is the molecular subtype in this cancer?   A) Basal-like   B) HER2-enriched   C) Luminal A   D) MSI"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-PG-A6IB-01Z-00-DX1.575AC6BD-6ABA-468D-9A46-DC61BD92269C-1",
        "image": "TCGA-UCEC/TCGA-PG-A6IB-01Z-00-DX1.575AC6BD-6ABA-468D-9A46-DC61BD92269C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative expression for P53, ER, and PR, what is the molecular subtype in this cancer?   A) Basal-like   B) HER2-enriched   C) Luminal A   D) MSI"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-PG-A6IB-01Z-00-DX2.C943409D-2569-4C84-874A-773AC7CEE834-1",
        "image": "TCGA-UCEC/TCGA-PG-A6IB-01Z-00-DX2.C943409D-2569-4C84-874A-773AC7CEE834.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative expression for P53, ER, and PR, what is the molecular subtype in this cancer?   A) Basal-like   B) HER2-enriched   C) Luminal A   D) MSI"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EY-A2OM-01Z-00-DX1.A704D5CF-011B-4A17-AA5D-1634556CC719-1",
        "image": "TCGA-UCEC/TCGA-EY-A2OM-01Z-00-DX1.A704D5CF-011B-4A17-AA5D-1634556CC719.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive estrogen receptor (ER) with 2+ intensity at 50%, negative progesterone receptor (PR), weak p53 staining, patchy p16 staining, and negative synaptophysin and chromogranin, what is the molecular subtype in this case of endometrial carcinoma?   A) MSS   B) MSI   C) p53-mutant   D) POLE-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-A5-A7WK-01Z-00-DX1.A3C77356-8EEE-4901-A4A0-72FD934947C0-1",
        "image": "TCGA-UCEC/TCGA-A5-A7WK-01Z-00-DX1.A3C77356-8EEE-4901-A4A0-72FD934947C0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive staining of calretinin in mesothelial cells, positive nuclear staining of WT1 in tumor cells, and negative p16 in tumor cells, what is the molecular subtype in this cancer? A) CN_HIGH B) BRCA-mutated C) EBV-associated D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EY-A2OP-01Z-00-DX1.8F54BEC3-5B57-47CB-95D0-BE55CC35048A-1",
        "image": "TCGA-UCEC/TCGA-EY-A2OP-01Z-00-DX1.8F54BEC3-5B57-47CB-95D0-BE55CC35048A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing 60-70% of tumor cells with moderate nuclear immunoreactivity for Estrogen Receptor, 5% for Progesterone Receptor, and negative for p63, what is the molecular subtype in this cancer?   A) Luminal A   B) Basal-like   C) Triple-negative   D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-B5-A1MX-01Z-00-DX1.FAC60C1A-5927-403E-BCC2-E92F2F08ADC4-1",
        "image": "TCGA-UCEC/TCGA-B5-A1MX-01Z-00-DX1.FAC60C1A-5927-403E-BCC2-E92F2F08ADC4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong/diffuse EMA positivity, focal CK7 and CD99 positivity, and negative Chromogranin and Synaptophysin, what is the molecular subtype in this cancer? A) Synovial Sarcoma B) MSI C) Neuroendocrine Tumor D) Adenocarcinoma"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-FI-A2D4-01Z-00-DX1.33A1223C-343A-458F-94B8-F5AF7B8ED8BF-1",
        "image": "TCGA-UCEC/TCGA-FI-A2D4-01Z-00-DX1.33A1223C-343A-458F-94B8-F5AF7B8ED8BF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing 5-10% strong positivity for estrogen receptor (ER) and progesterone receptor (PR), and retained expression of MLH1, PMS2, MSH2, and MSH6, what is the molecular subtype in this cancer? A) Luminal B B) MSI C) Triple-negative D) Basal-like"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AP-A0LM-01Z-00-DX1.E62A4E2F-FE13-47E4-B02C-E19E38737A37-1",
        "image": "TCGA-UCEC/TCGA-AP-A0LM-01Z-00-DX1.E62A4E2F-FE13-47E4-B02C-E19E38737A37.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive PR, no expression of ER and P53, membrane pattern of immunoreactivity for Beta-Catenin, and a moderate-high Ki-67 labeling index, what is the molecular subtype in this endometrial carcinoma? A) POLE B) MSI-H C) Serous-like D) CN-low"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1GI-01Z-00-DX1.52F00E05-DD77-4A1A-A4AC-2BACE1275DEF-1",
        "image": "TCGA-UCEC/TCGA-EY-A1GI-01Z-00-DX1.52F00E05-DD77-4A1A-A4AC-2BACE1275DEF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing ER and PR immunohistochemistry previously performed, what is the molecular subtype in this cancer type? A) Luminal A B) Basal-like C) HER2-enriched D) POLE"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1GR-01Z-00-DX1.D3F1F9ED-E35F-406B-91AA-CFEED868A028-1",
        "image": "TCGA-UCEC/TCGA-EY-A1GR-01Z-00-DX1.D3F1F9ED-E35F-406B-91AA-CFEED868A028.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results of ER positive (1-2+, 85%) and PR positive (2+, 65%) reactivity, what is the molecular subtype in this uterine carcinoma? A) CN_HIGH B) MSI-high C) POLE-mutant D) HPV-associated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EY-A210-01Z-00-DX1.4DA60F90-B0ED-4353-B274-4B9CF460D942-1",
        "image": "TCGA-UCEC/TCGA-EY-A210-01Z-00-DX1.4DA60F90-B0ED-4353-B274-4B9CF460D942.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an estrogen receptor positive status at 1+ and 40%, and a negative progesterone receptor, what is the molecular subtype in this breast cancer? A) Luminal A B) Luminal B C) HER2-enriched D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1GU-01Z-00-DX1.99FAECE9-9A7B-49D2-9AA8-9AC857B5203F-1",
        "image": "TCGA-UCEC/TCGA-EY-A1GU-01Z-00-DX1.99FAECE9-9A7B-49D2-9AA8-9AC857B5203F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing Estrogen Receptor (ER) positive (2+, 80%) and Progesterone Receptor (PR) positive (2-3+, 75%), what is the molecular subtype in this breast cancer? A) Triple-negative B) HER2-enriched C) Luminal A D) Basal-like"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1GF-01Z-00-DX1.985D1D48-4752-498B-934E-0C24BDEC6121-1",
        "image": "TCGA-UCEC/TCGA-EY-A1GF-01Z-00-DX1.985D1D48-4752-498B-934E-0C24BDEC6121.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing greater than 90% of tumor cells with strong nuclear staining for both estrogen and progesterone receptors, what is the molecular subtype in this breast cancer? A) HER2-enriched B) Triple-negative C) Luminal A D) Basal-like"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-SJ-A6ZI-01Z-00-DX1.87B9D431-5067-4E93-911C-5B1E58995DDB-1",
        "image": "TCGA-UCEC/TCGA-SJ-A6ZI-01Z-00-DX1.87B9D431-5067-4E93-911C-5B1E58995DDB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing that both p16 and p53 are not reactive, what is the molecular subtype in this cancer? A) HPV-related B) MSI C) EBV-associated D) MSS"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1GO-01Z-00-DX1.CE05FC2C-67CA-49CE-8586-AD7B4C00D7FD-1",
        "image": "TCGA-UCEC/TCGA-EY-A1GO-01Z-00-DX1.CE05FC2C-67CA-49CE-8586-AD7B4C00D7FD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative expression for both Estrogen Receptor (ER) and Progesterone Receptor (PR), what is the molecular subtype in this cancer type? A) Luminal A B) HER2-enriched C) Triple-negative D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-B5-A0JR-01Z-00-DX1.997DA62A-D4E3-46FD-8948-4DBE23C0E8E9-1",
        "image": "TCGA-UCEC/TCGA-B5-A0JR-01Z-00-DX1.997DA62A-D4E3-46FD-8948-4DBE23C0E8E9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative expression for both Chromogranin and Synaptophysin, what is the molecular subtype in this cancer? A) Neuroendocrine B) Adenocarcinoma C) Squamous cell carcinoma D) MSI"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1GH-01Z-00-DX1.D420D827-C543-4A42-8029-174A6B3E814D-1",
        "image": "TCGA-UCEC/TCGA-EY-A1GH-01Z-00-DX1.D420D827-C543-4A42-8029-174A6B3E814D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing Estrogen Receptor (ER) positive at 2+ and 80%, and Progesterone Receptor (PR) positive at 3+ and 95%, what is the molecular subtype in this cancer? A) HER2-positive B) Triple-negative C) Luminal A D) Basal-like"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AP-A1DV-01Z-00-DX1.87B3CD38-6F49-4E51-B6F0-7B270CAEBE83-1",
        "image": "TCGA-UCEC/TCGA-AP-A1DV-01Z-00-DX1.87B3CD38-6F49-4E51-B6F0-7B270CAEBE83.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive staining for HR and vimentin, with previous tests indicating negativity for p16 and limited CEA positivity, what is the molecular subtype in this endometrial cancer?  A) Copy number high   B) MSI   C) POLE   D) Copy number low"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1GT-01Z-00-DX1.670FBAA0-500C-403E-9F06-42DB61CB6EB1-1",
        "image": "TCGA-UCEC/TCGA-EY-A1GT-01Z-00-DX1.670FBAA0-500C-403E-9F06-42DB61CB6EB1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing ER positivity (1+, 20%) and weak PR positivity (1+, 2%) in the endometrium, and ER positivity (3+, 70%) and PR positivity (3+, 65%) in the right ovary, what is the molecular subtype in this ovarian cancer? A) CN_HIGH B) CN_LOW C) TP53_mutant D) BRCA_associated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1GS-01Z-00-DX1.48C094CA-DD66-4B76-9B1E-0E8C83BFB9D8-1",
        "image": "TCGA-UCEC/TCGA-EY-A1GS-01Z-00-DX1.48C094CA-DD66-4B76-9B1E-0E8C83BFB9D8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWhat is the molecular subtype in this endometrial carcinoma, given the IHC results showing negative estrogen and progesterone receptors, diffuse positivity for P53, and WT-1 negativity? A) CN_HIGH B) Microsatellite Instability (MSI) C) POLE-mutant D) Uterine Serous Carcinoma"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AJ-A3BD-01Z-00-DX1.C8E89499-C587-4B76-B6A7-FF7491F42591-1",
        "image": "TCGA-UCEC/TCGA-AJ-A3BD-01Z-00-DX1.C8E89499-C587-4B76-B6A7-FF7491F42591.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive p53 and negative WT1, what is the molecular subtype in this carcinoma? A) CN_HIGH B) CN_LOW C) MSI D) POLE-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EO-A22U-01Z-00-DX1.EA352123-3B7C-4FDB-97CD-44F8377B33A0-1",
        "image": "TCGA-UCEC/TCGA-EO-A22U-01Z-00-DX1.EA352123-3B7C-4FDB-97CD-44F8377B33A0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing ER positive in glandular areas but negative in solid areas, p53 with weak focal staining in glandular areas and patchy positive in solid areas, and p16 negative in glandular areas with patchy positive in solid areas, what is the molecular subtype in this endometrial carcinoma? A) POLE-ultramutated B) MSI-H C) TP53-mutant D) CN-high"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AP-A5FX-01Z-00-DX1.E10576DD-310B-46E3-91CB-0273C06DF53F-1",
        "image": "TCGA-UCEC/TCGA-AP-A5FX-01Z-00-DX1.E10576DD-310B-46E3-91CB-0273C06DF53F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong positivity for BR, positivity for PH, CK7, and P53, what is the molecular subtype in this serous carcinoma? A) CN_HIGH B) MSI C) HPV-associated D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DI-A1NN-01Z-00-DX1.D95D5127-9E1D-4B26-BE00-60F7C3B09B4F-1",
        "image": "TCGA-UCEC/TCGA-DI-A1NN-01Z-00-DX1.D95D5127-9E1D-4B26-BE00-60F7C3B09B4F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results with all markers (PMS-2, MLH1, MSH6, MSH2) showing positive expression, what is the molecular subtype in this carcinoma? A) MSI B) MSS C) POLE-mutant D) CN_HIGH"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-EO-A22T-01Z-00-DX1.9947473F-E77F-49FA-8428-73E6D35CE7E7-1",
        "image": "TCGA-UCEC/TCGA-EO-A22T-01Z-00-DX1.9947473F-E77F-49FA-8428-73E6D35CE7E7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing Estrogen Receptor positivity in glandular areas, focal positivity of Progesterone Receptor in glandular areas, but negativity for ER and PR in the solid component, and negative results for P53, Synaptophysin, and Chromogranin, what is the molecular subtype in this cancer? A) HR-positive/HER2-negative  B) MSI C) Triple-negative D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EY-A3L3-01Z-00-DX1.AACED5AD-50DE-4A90-8559-9D455081C54D-1",
        "image": "TCGA-UCEC/TCGA-EY-A3L3-01Z-00-DX1.AACED5AD-50DE-4A90-8559-9D455081C54D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffuse staining for both P53 and P16, what is the molecular subtype in this cancer type? A) CN_LOW   B) CN_HIGH   C) GS   D) MSI"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-AX-A06F-01Z-00-DX1.0DA1ED86-DF47-4357-B301-BFE32DB9E241-1",
        "image": "TCGA-UCEC/TCGA-AX-A06F-01Z-00-DX1.0DA1ED86-DF47-4357-B301-BFE32DB9E241.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong Cytokeratin 7 reactivity in all sites, focal strong dot cytoplasmic reactivity of Cytokeratin 20 in the ileum, focal reactivity of Chromogranin in the endometrium and ileum, no Synaptophysin reactivity, and weak CD56 reactivity in the ileum, what is the molecular subtype in this carcinoma? A) POLE B) Neuroendocrine C) Adenocarcinoma D) Basal-like"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AX-A06F-01Z-00-DX2.0046C5EE-7C44-4CE8-977A-A8BD3CC331B0-1",
        "image": "TCGA-UCEC/TCGA-AX-A06F-01Z-00-DX2.0046C5EE-7C44-4CE8-977A-A8BD3CC331B0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong Cytokeratin 7 reactivity in all sites, focal strong dot cytoplasmic reactivity of Cytokeratin 20 in the ileum, focal reactivity of Chromogranin in the endometrium and ileum, no Synaptophysin reactivity, and weak CD56 reactivity in the ileum, what is the molecular subtype in this carcinoma? A) POLE B) Neuroendocrine C) Adenocarcinoma D) Basal-like"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D1-A0ZQ-01Z-00-DX1.B2F36A73-674A-4083-997D-A667B42B8411-1",
        "image": "TCGA-UCEC/TCGA-D1-A0ZQ-01Z-00-DX1.B2F36A73-674A-4083-997D-A667B42B8411.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing weak and spotty immunoreactivity for p53, what is the molecular subtype in this cancer diagnosis? A) Luminal A B) HER2-enriched C) CN_LOW D) Basal-like"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AJ-A5DW-01Z-00-DX1.43384999-B08F-4D79-AD31-7194C28B04D5-1",
        "image": "TCGA-UCEC/TCGA-AJ-A5DW-01Z-00-DX1.43384999-B08F-4D79-AD31-7194C28B04D5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing intact expression of MLH1, PMS2, MSH2, and MSH6, what is the molecular subtype in this colorectal cancer?   A) MSS   B) MSI   C) POLE-mutant   D) HPV+"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EO-A3AZ-01Z-00-DX1.113D4EE1-7922-432D-B43B-947756060983-1",
        "image": "TCGA-UCEC/TCGA-EO-A3AZ-01Z-00-DX1.113D4EE1-7922-432D-B43B-947756060983.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p16 positivity, p53 positivity in serous carcinoma but negativity in endometrioid carcinoma, negative PR in serous carcinoma, and positive ER in endometrioid carcinoma, what is the molecular subtype in this endometrial carcinoma?   A) MSI   B) POLE-mutant   C) MMR-deficient   D) MSS"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BG-A0M7-01Z-00-DX1.2C9BFCAB-7696-4CCA-BA67-9C3CFC238A67-1",
        "image": "TCGA-UCEC/TCGA-BG-A0M7-01Z-00-DX1.2C9BFCAB-7696-4CCA-BA67-9C3CFC238A67.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing the tumor is positive for ER and PR, what is the molecular subtype in this breast carcinoma? A) HER2-enriched B) Luminal A C) Triple-negative D) Basal-like"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-EY-A548-01Z-00-DX1.63A132B8-29CF-4DDC-A39D-EC636A555D5D-1",
        "image": "TCGA-UCEC/TCGA-EY-A548-01Z-00-DX1.63A132B8-29CF-4DDC-A39D-EC636A555D5D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results where CD10 shows reactivity in the endometrial glands and stroma within adenomyosis involved by carcinoma, and no invasive carcinoma is identified, what is the molecular subtype in this endometrial carcinoma? A) MSS B) MSI C) POLE-mutant D) HPV+"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-EO-A1Y5-01Z-00-DX1.E32687DB-FBDD-40E3-BBD2-9BD3BE53C769-1",
        "image": "TCGA-UCEC/TCGA-EO-A1Y5-01Z-00-DX1.E32687DB-FBDD-40E3-BBD2-9BD3BE53C769.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffuse and strong positivity for P53 and p16, focal positivity for ER, negativity for WT-1 and PR, and intact MSH-6, PMS-2, MLH-1, and MLH-2, what is the molecular subtype in this uterine carcinoma?   A) CN_LOW   B) CN_HIGH   C) MSI-H   D) POLE-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-B5-A5OC-01Z-00-DX1.ACC32938-6C55-4A0C-AA70-FD947D31698D-1",
        "image": "TCGA-UCEC/TCGA-B5-A5OC-01Z-00-DX1.ACC32938-6C55-4A0C-AA70-FD947D31698D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive ER and PR, negative HER2/neu, negative HPV 16/18 DNA, and focally positive p16, what is the molecular subtype in this endometrial carcinoma? A) MSS B) POLE-mutant C) MSI D) p53-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-PG-A914-01Z-00-DX6.AF10CFC6-3016-4523-9A01-5EF8A06B3CDD-1",
        "image": "TCGA-UCEC/TCGA-PG-A914-01Z-00-DX6.AF10CFC6-3016-4523-9A01-5EF8A06B3CDD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing 50% weak to moderate nuclear staining for Estrogen Receptor, no nuclear staining for Progesterone Receptor, and negative HER2/neu expression, what is the molecular subtype in this case of uterine carcinoma? A) CN_HIGH B) MSI-H C) POLE-mutant D) HPV-positive"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-PG-A914-01Z-00-DX2.3E26BE80-C385-4DB2-AECC-B5E607BC1FEB-1",
        "image": "TCGA-UCEC/TCGA-PG-A914-01Z-00-DX2.3E26BE80-C385-4DB2-AECC-B5E607BC1FEB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing 50% weak to moderate nuclear staining for Estrogen Receptor, no nuclear staining for Progesterone Receptor, and negative HER2/neu expression, what is the molecular subtype in this case of uterine carcinoma? A) CN_HIGH B) MSI-H C) POLE-mutant D) HPV-positive"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-PG-A914-01Z-00-DX3.AB9CCE16-89DF-4C0F-AB07-E5CA4E168EC6-1",
        "image": "TCGA-UCEC/TCGA-PG-A914-01Z-00-DX3.AB9CCE16-89DF-4C0F-AB07-E5CA4E168EC6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing 50% weak to moderate nuclear staining for Estrogen Receptor, no nuclear staining for Progesterone Receptor, and negative HER2/neu expression, what is the molecular subtype in this case of uterine carcinoma? A) CN_HIGH B) MSI-H C) POLE-mutant D) HPV-positive"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-PG-A914-01Z-00-DX4.33C67F98-A8C3-4C3A-B630-D12014C645EC-1",
        "image": "TCGA-UCEC/TCGA-PG-A914-01Z-00-DX4.33C67F98-A8C3-4C3A-B630-D12014C645EC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing 50% weak to moderate nuclear staining for Estrogen Receptor, no nuclear staining for Progesterone Receptor, and negative HER2/neu expression, what is the molecular subtype in this case of uterine carcinoma? A) CN_HIGH B) MSI-H C) POLE-mutant D) HPV-positive"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-PG-A914-01Z-00-DX5.75C61081-9AB3-4237-B2CE-EFCBA1F22343-1",
        "image": "TCGA-UCEC/TCGA-PG-A914-01Z-00-DX5.75C61081-9AB3-4237-B2CE-EFCBA1F22343.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing 50% weak to moderate nuclear staining for Estrogen Receptor, no nuclear staining for Progesterone Receptor, and negative HER2/neu expression, what is the molecular subtype in this case of uterine carcinoma? A) CN_HIGH B) MSI-H C) POLE-mutant D) HPV-positive"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-PG-A914-01Z-00-DX1.84F19325-D7E3-4CB3-B887-05C7D7D7A9CF-1",
        "image": "TCGA-UCEC/TCGA-PG-A914-01Z-00-DX1.84F19325-D7E3-4CB3-B887-05C7D7D7A9CF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing 50% weak to moderate nuclear staining for Estrogen Receptor, no nuclear staining for Progesterone Receptor, and negative HER2/neu expression, what is the molecular subtype in this case of uterine carcinoma? A) CN_HIGH B) MSI-H C) POLE-mutant D) HPV-positive"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BG-A0MA-01Z-00-DX1.98944ce9-d364-4c77-8c2e-bfb47e4cc503-1",
        "image": "TCGA-UCEC/TCGA-BG-A0MA-01Z-00-DX1.98944ce9-d364-4c77-8c2e-bfb47e4cc503.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative expression of Estrogen and Progesterone receptors in endometrial adenocarcinoma, what is the molecular subtype? A) POLE-ultramutated B) CN_LOW C) MSI-H D) p53-abnormal"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-EY-A547-01Z-00-DX1.BBB65F45-F107-4DF1-939F-4E79ED3D982D-1",
        "image": "TCGA-UCEC/TCGA-EY-A547-01Z-00-DX1.BBB65F45-F107-4DF1-939F-4E79ED3D982D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing Estrogen receptor positive (2+, 70%) and Progesterone receptor positive (2-3+, 70%), what is the molecular subtype in this cancer? A) CN_HIGH B) HER2-enriched C) Basal-like D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-EY-A549-01Z-00-DX1.137D940A-210D-4DBA-B204-E9995D4F1FB7-1",
        "image": "TCGA-UCEC/TCGA-EY-A549-01Z-00-DX1.137D940A-210D-4DBA-B204-E9995D4F1FB7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing patchy weak positivity for P53, heterogeneous positivity for P16, and strong diffuse positivity (3+, 90%) for both estrogen receptor and progesterone receptor, what is the molecular subtype in this cancer type?   A) Basal-like   B) Luminal A   C) HER2-enriched   D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-D1-A177-01Z-00-DX1.C2BC53F3-F7D7-4ED0-93BB-303A4D8AE602-1",
        "image": "TCGA-UCEC/TCGA-D1-A177-01Z-00-DX1.C2BC53F3-F7D7-4ED0-93BB-303A4D8AE602.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing Estrogen Receptor (ER) positive with 51-75% tumor nuclei staining and Progesterone Receptor (PR) positive with 26-50% tumor nuclei staining, what is the molecular subtype in this endometrial carcinoma?   A) MSI   B) Serous-like   C) POLE-mutant   D) Copy-number low"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-EY-A2ON-01Z-00-DX1.F1B8DF0C-35F8-4FB7-A53C-1FCDDC5CFF4F-1",
        "image": "TCGA-UCEC/TCGA-EY-A2ON-01Z-00-DX1.F1B8DF0C-35F8-4FB7-A53C-1FCDDC5CFF4F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing weakly positive estrogen receptor (10% with very weak intensity), positive progesterone receptor (10% with 1 to 2+ intensity), and CD31 supporting both lymphovascular space invasion and myometrial tumor, what is the molecular subtype in this carcinoma? A) CN_HIGH B) HER2-enriched C) Basal-like D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A5-AB3J-01Z-00-DX1.87E7C55F-F850-47D0-B5E4-8545F2504C92-1",
        "image": "TCGA-UCEC/TCGA-A5-AB3J-01Z-00-DX1.87E7C55F-F850-47D0-B5E4-8545F2504C92.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing Cytokeratin 7 positivity, Cytokeratin 20 negativity, positive Estrogen Receptor, positive PAX8, positive (patchy 1+-2+) PAX2 (endometrial), and intact expression of DNA mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), what is the molecular subtype in this uterine carcinoma? A) CN_HIGH B) POLE-ultramutated C) CN_LOW D) MSI-H"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A5-A0G5-01Z-00-DX1.BF825B39-7B00-45DE-9517-BE596E4ED6E5-1",
        "image": "TCGA-UCEC/TCGA-A5-A0G5-01Z-00-DX1.BF825B39-7B00-45DE-9517-BE596E4ED6E5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive nuclear staining for p53 in tubal epithelial cells and most neoplastic cells, along with rare positive staining for WT1 in the uterine carcinoma cells, what is the molecular subtype in this uterine carcinoma? A) CN_HIGH B) POLE-ultramutated C) MSI-H (Microsatellite Instability-High) D) CN_LOW"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AP-A0L8-01Z-00-DX1.B318A012-89CC-4DBD-8225-1FD546814FC8-1",
        "image": "TCGA-UCEC/TCGA-AP-A0L8-01Z-00-DX1.B318A012-89CC-4DBD-8225-1FD546814FC8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive Keratin (CAM5.2) and negative LCA (CD45), what is the molecular subtype in this carcinoma? A) Basal-like B) Luminal A C) CN_HIGH D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-EY-A2OO-01Z-00-DX1.D0308E23-7B22-41BF-AFD0-B874D40A765B-1",
        "image": "TCGA-UCEC/TCGA-EY-A2OO-01Z-00-DX1.D0308E23-7B22-41BF-AFD0-B874D40A765B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing Estrogen Receptor (ER) negative with 1+, <1% expression, and Progesterone Receptor (PR) negative, what is the molecular subtype in this breast carcinoma? A) Luminal A B) Basal-like C) HER2-enriched D) CN_HIGH"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-AX-A0IU-01Z-00-DX1.5CF6D90F-F7E6-4169-9002-BCC727108630-1",
        "image": "TCGA-UCEC/TCGA-AX-A0IU-01Z-00-DX1.5CF6D90F-F7E6-4169-9002-BCC727108630.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p53 negativity, partially positive p16, partially weakly positive ER, partially positive PR, mostly negative CEA, negative Vimentin and Epi17, stromal CD10 positivity with tumor involvement, and negative Mucicarmine, what is the molecular subtype in this cancer type? A) CN_HIGH B) Luminal A C) Basal-like D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AX-A0IU-01Z-00-DX2.B8A89AB7-F119-49CB-BC05-F200F11DC5DE-1",
        "image": "TCGA-UCEC/TCGA-AX-A0IU-01Z-00-DX2.B8A89AB7-F119-49CB-BC05-F200F11DC5DE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p53 negativity, partially positive p16, partially weakly positive ER, partially positive PR, mostly negative CEA, negative Vimentin and Epi17, stromal CD10 positivity with tumor involvement, and negative Mucicarmine, what is the molecular subtype in this cancer type? A) CN_HIGH B) Luminal A C) Basal-like D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-JU-AAVI-01Z-00-DX2.ECF6F478-03AD-4876-81BD-6B2AF7639C50-1",
        "image": "TCGA-UCEC/TCGA-JU-AAVI-01Z-00-DX2.ECF6F478-03AD-4876-81BD-6B2AF7639C50.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffuse positivity for AE1/AE3, diffuse staining for p53 and p16, and no staining for ER, what is the molecular subtype in this carcinoma? A) Luminal A B) Basal-like C) CN_HIGH D) MMR-deficient"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-JU-AAVI-01Z-00-DX1.35992BA3-2E87-4584-B2A9-B1DE21C66E04-1",
        "image": "TCGA-UCEC/TCGA-JU-AAVI-01Z-00-DX1.35992BA3-2E87-4584-B2A9-B1DE21C66E04.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffuse positivity for AE1/AE3, diffuse staining for p53 and p16, and no staining for ER, what is the molecular subtype in this carcinoma? A) Luminal A B) Basal-like C) CN_HIGH D) MMR-deficient"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AJ-A3TW-01Z-00-DX1.09261278-DD37-474A-88A1-9AC20CDBCB7E-1",
        "image": "TCGA-UCEC/TCGA-AJ-A3TW-01Z-00-DX1.09261278-DD37-474A-88A1-9AC20CDBCB7E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffuse positivity for p53, which is consistent with serous carcinoma, what is the molecular subtype in this cancer type? A) CN_HIGH B) MSI C) POLE-mutant D) HRD"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D1-A15X-01Z-00-DX1.07030C76-038F-4671-AB04-809F2821889D-1",
        "image": "TCGA-UCEC/TCGA-D1-A15X-01Z-00-DX1.07030C76-038F-4671-AB04-809F2821889D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive p53 and negative WT-1, what is the molecular subtype in this ovarian carcinoma? A) CN_HIGH B) CN_LOW C) MSI-H D) POLE-ultramutated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BG-A2L7-01Z-00-DX1.A4C5AE92-F6A1-44F2-A7E1-3BE2903166AD-1",
        "image": "TCGA-UCEC/TCGA-BG-A2L7-01Z-00-DX1.A4C5AE92-F6A1-44F2-A7E1-3BE2903166AD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positivity for CAM 5.2, AE1/AE3, and Vimentin, and predominantly negative expression of CD10 and negative Desmin, what is the molecular subtype in this cancer? A) Mesenchymal B) Sarcomatoid C) MSI D) Hepatoid"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-A5-A0GV-01Z-00-DX1.7B0AFEBB-1CDE-4A01-8AE8-768D360C6ED2-1",
        "image": "TCGA-UCEC/TCGA-A5-A0GV-01Z-00-DX1.7B0AFEBB-1CDE-4A01-8AE8-768D360C6ED2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing no “occult” keratin-positive metastatic tumor cells identified with Keratin AE1/AE3 in BI, CI, C2, and C3 testings, what is the molecular subtype in this unspecified carcinoma? A) Basal-like B) Luminal A C) CN_LOW D) HER2-positive"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1GV-01Z-00-DX1.104EAF42-A771-4F1C-85B7-8D058FF24FD2-1",
        "image": "TCGA-UCEC/TCGA-EY-A1GV-01Z-00-DX1.104EAF42-A771-4F1C-85B7-8D058FF24FD2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing estrogen receptor negative (1+, <1%), progesterone receptor negative (0), and positive vascular endothelial marker indicating lymphovascular invasion, what is the molecular subtype in this cancer? A) TNBC B) HER2-enriched C) CN_LOW D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AJ-A23N-01Z-00-DX1.42F1DEED-AF28-4B78-B41C-F560F932F8F7-1",
        "image": "TCGA-UCEC/TCGA-AJ-A23N-01Z-00-DX1.42F1DEED-AF28-4B78-B41C-F560F932F8F7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive expression for WT-1 and p53, what is the molecular subtype in this carcinoma? A) CN_HIGH B) Basal-like C) HER2-enriched D) MSI"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AJ-A3EJ-01Z-00-DX1.02F60545-9B62-441D-A4C7-AE493BA6A43E-1",
        "image": "TCGA-UCEC/TCGA-AJ-A3EJ-01Z-00-DX1.02F60545-9B62-441D-A4C7-AE493BA6A43E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive p53 and Estrogen receptor in the majority of lesional cells, what is the molecular subtype in this serous carcinoma? A) CN_HIGH B) Endometrioid C) Mucinous D) Clear cell"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-PG-A7D5-01Z-00-DX1.3B12F210-014B-408D-83A9-9D23BD5E306A-1",
        "image": "TCGA-UCEC/TCGA-PG-A7D5-01Z-00-DX1.3B12F210-014B-408D-83A9-9D23BD5E306A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing 0% ER staining, less than 1% PR nuclear staining, and positive P53 in neoplastic cells, what is the molecular subtype in this cancer? A) Luminal A B) Basal-like C) CN_HIGH D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1GQ-01Z-00-DX1.03D52C6F-515E-4A4F-A08E-31D773BCC67F-1",
        "image": "TCGA-UCEC/TCGA-EY-A1GQ-01Z-00-DX1.03D52C6F-515E-4A4F-A08E-31D773BCC67F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing Estrogen receptor (ER) positive (2+, 90%) and Progesterone receptor (PR) positive (2+, 90%), what is the molecular subtype in this cancer case? A) Luminal A B) Triple-negative C) HER2-enriched D) Basal-like"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1H0-01Z-00-DX1.997119C8-F3D8-468A-8F39-673FE1D5D678-1",
        "image": "TCGA-UCEC/TCGA-EY-A1H0-01Z-00-DX1.997119C8-F3D8-468A-8F39-673FE1D5D678.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing estrogen receptor (2+, 80%) positivity and progesterone receptor (3+, 90%) positivity, what is the molecular subtype in this cancer? A) Luminal A B) HER2-enriched C) Basal-like D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1GX-01Z-00-DX1.3A4A5506-8F32-4238-B404-439CC153D106-1",
        "image": "TCGA-UCEC/TCGA-EY-A1GX-01Z-00-DX1.3A4A5506-8F32-4238-B404-439CC153D106.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing estrogen receptor positivity in 30% of tumor cells, progesterone receptor positivity in 70% of tumor cells, and strong Cytokeratin AE1/AE3 positivity, what is the molecular subtype in this endometrioid adenocarcinoma?  A) CN_HIGH B) POLE-mutant C) MSI D) Serous-like"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-PG-A5BC-01Z-00-DX7.267346BC-B6C5-4613-9B19-460672319141-1",
        "image": "TCGA-UCEC/TCGA-PG-A5BC-01Z-00-DX7.267346BC-B6C5-4613-9B19-460672319141.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative ER, positive PR, and positive p53, what is the molecular subtype in this cancer? A) Luminal A B) Basal-like C) CN_HIGH D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-PG-A5BC-01Z-00-DX6.D526A895-B369-47B9-8903-8731BCD0A1BB-1",
        "image": "TCGA-UCEC/TCGA-PG-A5BC-01Z-00-DX6.D526A895-B369-47B9-8903-8731BCD0A1BB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative ER, positive PR, and positive p53, what is the molecular subtype in this cancer? A) Luminal A B) Basal-like C) CN_HIGH D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-PG-A5BC-01Z-00-DX1.B19A6D20-0D68-4C34-8FE2-EB8B42B98100-1",
        "image": "TCGA-UCEC/TCGA-PG-A5BC-01Z-00-DX1.B19A6D20-0D68-4C34-8FE2-EB8B42B98100.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative ER, positive PR, and positive p53, what is the molecular subtype in this cancer? A) Luminal A B) Basal-like C) CN_HIGH D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-PG-A5BC-01Z-00-DX2.0681A7E4-EB48-49F2-8CE9-5BE2154FC05D-1",
        "image": "TCGA-UCEC/TCGA-PG-A5BC-01Z-00-DX2.0681A7E4-EB48-49F2-8CE9-5BE2154FC05D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative ER, positive PR, and positive p53, what is the molecular subtype in this cancer? A) Luminal A B) Basal-like C) CN_HIGH D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-PG-A5BC-01Z-00-DX5.5D10994A-40E6-4327-A9C0-6FEA2AC6B771-1",
        "image": "TCGA-UCEC/TCGA-PG-A5BC-01Z-00-DX5.5D10994A-40E6-4327-A9C0-6FEA2AC6B771.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative ER, positive PR, and positive p53, what is the molecular subtype in this cancer? A) Luminal A B) Basal-like C) CN_HIGH D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-PG-A5BC-01Z-00-DX3.001CCA67-1A3A-45FB-AA92-36011BDF9D02-1",
        "image": "TCGA-UCEC/TCGA-PG-A5BC-01Z-00-DX3.001CCA67-1A3A-45FB-AA92-36011BDF9D02.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative ER, positive PR, and positive p53, what is the molecular subtype in this cancer? A) Luminal A B) Basal-like C) CN_HIGH D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-SL-A6JA-01Z-00-DX1.5D844B94-AD82-4285-88A4-9EAB046DDCC2-1",
        "image": "TCGA-UCEC/TCGA-SL-A6JA-01Z-00-DX1.5D844B94-AD82-4285-88A4-9EAB046DDCC2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing D240 immunostain positive for lymphatic invasion and CD31 immunostain negative for vascular invasion, what is the molecular subtype in this cancer?    A) MSI   B) Her2-enriched   C) Luminal A   D) Basal-like"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1GD-01Z-00-DX1.21309AC8-599D-42A2-B855-ECB858E87E36-1",
        "image": "TCGA-UCEC/TCGA-EY-A1GD-01Z-00-DX1.21309AC8-599D-42A2-B855-ECB858E87E36.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive estrogen receptor (2-3+, 90%), positive progesterone receptor (3+, 90%), and HMB45 positive in leiomyomatosis, what is the molecular subtype in this endometrial carcinoma?   A) POLE   B) MSI   C) p53-mutant   D) Hormone receptor-positive"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-SL-A6J9-01Z-00-DX1.EB90A566-4AD9-4C33-91D6-C29C3914DEC7-1",
        "image": "TCGA-UCEC/TCGA-SL-A6J9-01Z-00-DX1.EB90A566-4AD9-4C33-91D6-C29C3914DEC7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive expression for MLH-1, MSH-2, MSH-6, and PMS-2, what is the molecular subtype in this cancer? A) MSI-H B) MSS C) POLE-Mutant D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-EY-A215-01Z-00-DX1.E64C6134-1E9B-4777-A42E-75C3518CF358-1",
        "image": "TCGA-UCEC/TCGA-EY-A215-01Z-00-DX1.E64C6134-1E9B-4777-A42E-75C3518CF358.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing that the tumor estrogen receptor is positive (2-3+, 90%) and progesterone receptor is positive (2-3+, 75%), what is the molecular subtype in this breast cancer? A) Triple-negative B) HER2-enriched C) Luminal A D) Basal-like"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AJ-A3EK-01Z-00-DX1.DD530B21-F6F5-4DE0-B5FE-8417587796EA-1",
        "image": "TCGA-UCEC/TCGA-AJ-A3EK-01Z-00-DX1.DD530B21-F6F5-4DE0-B5FE-8417587796EA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing extensive positive expression of P53, positive expression of ER, and negative expression of WT1, what is the molecular subtype in this endometrial carcinoma? A) POLE B) MMR-deficient C) p53 abnormal D) Endometrioid"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AJ-A3OK-01Z-00-DX1.F8611C3B-1FED-4F44-B614-9CE3AB57BE37-1",
        "image": "TCGA-UCEC/TCGA-AJ-A3OK-01Z-00-DX1.F8611C3B-1FED-4F44-B614-9CE3AB57BE37.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing P53 diffuse strong nuclear staining, what is the molecular subtype in this cancer type? A) CN_HIGH B) MSI-H C) CN_LOW D) ERBB2-enriched"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1GE-01Z-00-DX1.69411DF4-DEC6-499F-AC43-6126AB1BEE12-1",
        "image": "TCGA-UCEC/TCGA-EY-A1GE-01Z-00-DX1.69411DF4-DEC6-499F-AC43-6126AB1BEE12.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing estrogen receptor positivity in approximately 80% of tumor cells with moderate nuclear staining and progesterone receptor positivity in 10-20% of cells with weak or moderate nuclear staining, what is the molecular subtype in this carcinoma? A) HER2-enriched B) Basal-like C) Triple-negative D) CN_LOW"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AJ-A3I9-01Z-00-DX1.95C61689-4147-49EC-A6DE-F97FE4E1050B-1",
        "image": "TCGA-UCEC/TCGA-AJ-A3I9-01Z-00-DX1.95C61689-4147-49EC-A6DE-F97FE4E1050B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing normal expression of MLH1, MSH2, MSH6, and PMS2, indicating no evidence of MSI, what is the molecular subtype in this cancer? A) MSI B) CN_LOW C) POLE-mutant D) EMAST+"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-A5-A3LO-01Z-00-DX1.FACB4663-13FE-4E37-88F8-BA6BD3815F7A-1",
        "image": "TCGA-UCEC/TCGA-A5-A3LO-01Z-00-DX1.FACB4663-13FE-4E37-88F8-BA6BD3815F7A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing patchy positive staining for Cytokeratin 6 and Cytokeratin 8, what is the molecular subtype in this cancer? A) Luminal A B) CN_HIGH C) Basal-like D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1GK-01Z-00-DX1.855EEBFB-BA55-4109-A417-F6A64E6E7A80-1",
        "image": "TCGA-UCEC/TCGA-EY-A1GK-01Z-00-DX1.855EEBFB-BA55-4109-A417-F6A64E6E7A80.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing Estrogen Receptor (ER) positive at 2+ with 80% expression and Progesterone Receptor (PR) positive at 3+ with 85% expression, what is the molecular subtype in this endometrial carcinoma? A) Serous-like B) MSI C) Hormonal receptor-positive D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-EY-A1GL-01Z-00-DX1.26A5893F-D736-42EE-8463-F58307766D46-1",
        "image": "TCGA-UCEC/TCGA-EY-A1GL-01Z-00-DX1.26A5893F-D736-42EE-8463-F58307766D46.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing ER positive (2+, 15) and PR weakly positive (1+, <5%), what is the molecular subtype in this breast carcinoma? A) Luminal A B) Luminal B C) HER2-Enriched D) Triple-Negative"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-GM-A2DO-01Z-00-DX1.60817A51-93B7-483D-ABC9-8ED6341C6660-1",
        "image": "TCGA-BRCA/TCGA-GM-A2DO-01Z-00-DX1.60817A51-93B7-483D-ABC9-8ED6341C6660.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing a high positive rate for estrogen receptor (90%), positive progesterone receptor (80%), negative HER-2/neu overexpression, and high Ki-67 index (35% to 65%), what is the molecular subtype of this breast cancer? A) HER2-enriched   B) Luminal A   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XJ-01Z-00-DX1.660DDF8D-6816-4EBE-AF37-6F7A374F4E9E-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XJ-01Z-00-DX1.660DDF8D-6816-4EBE-AF37-6F7A374F4E9E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results with estrogen receptors present in over 75% of neoplastic cell nuclei, progesterone receptors in 10-75%, and a positive HER2 status (Score  3+), what is the molecular subtype of this breast cancer?   A) HER2-enriched   B) Luminal A   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-GM-A2DH-01Z-00-DX1.5790F15F-2A0F-4929-8FE4-18A557007989-1",
        "image": "TCGA-BRCA/TCGA-GM-A2DH-01Z-00-DX1.5790F15F-2A0F-4929-8FE4-18A557007989.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results of low positive estrogen receptor (5%), negative progesterone receptor, and a high Ki-67 index (approximately 50%), what is the molecular subtype of this tumor? A) Luminal B B) HER2-enriched C) Basal D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XM-01Z-00-DX1.5F6A140E-5D20-45F6-B76F-0F98AB27AD08-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XM-01Z-00-DX1.5F6A140E-5D20-45F6-B76F-0F98AB27AD08.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing over 75% positivity for both estrogen and progesterone receptors, along with negative HER2 protein expression (Score  1+), what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AO-A0J7-01Z-00-DX1.DBA7BA24-CEEF-4636-87BB-D12D8DF016A3-1",
        "image": "TCGA-BRCA/TCGA-AO-A0J7-01Z-00-DX1.DBA7BA24-CEEF-4636-87BB-D12D8DF016A3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (90% strong nuclear staining), negative progesterone receptor, negative HER2, and positive E-cadherin, what is the molecular subtype of this case? A) HER2-enriched   B) Luminal A   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XC-01Z-00-DX1.E7494388-838B-4D35-9CA1-77017CBE77F2-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XC-01Z-00-DX1.E7494388-838B-4D35-9CA1-77017CBE77F2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical findings of estrogen receptors and progesterone receptors both present in over 75% of neoplastic cell nuclei, a HER2 negative reaction with a score of 1+, and other marker results, what is the molecular subtype of this breast cancer?  A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XC-01Z-00-DX2.10BA8536-D6AF-460E-9796-EB77FFE3EF5B-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XC-01Z-00-DX2.10BA8536-D6AF-460E-9796-EB77FFE3EF5B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical findings of estrogen receptors and progesterone receptors both present in over 75% of neoplastic cell nuclei, a HER2 negative reaction with a score of 1+, and other marker results, what is the molecular subtype of this breast cancer?  A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A570-01Z-00-DX1.64E5F2CA-9396-40DC-A300-04A54657BDE6-1",
        "image": "TCGA-BRCA/TCGA-E2-A570-01Z-00-DX1.64E5F2CA-9396-40DC-A300-04A54657BDE6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the IHC results with both ER and PR positive and HER2 negative by FISH, what is the molecular subtype identified in this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-GM-A2DF-01Z-00-DX1.CD0BE6D7-2DB3-4193-84CC-F9BE7BF18CC2-1",
        "image": "TCGA-BRCA/TCGA-GM-A2DF-01Z-00-DX1.CD0BE6D7-2DB3-4193-84CC-F9BE7BF18CC2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results showing negative expressions for estrogen receptor, progesterone receptor, and HER-2/neu overexpression, what is the molecular subtype of this tumor?   A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-E2-A14N-01Z-00-DX1.15F5644F-CA9F-4688-B56E-BCC00CA4769B-1",
        "image": "TCGA-BRCA/TCGA-E2-A14N-01Z-00-DX1.15F5644F-CA9F-4688-B56E-BCC00CA4769B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results with negative estrogen receptor (Allred Score 0), negative progesterone receptor (Allred Score 0), and negative HER2 status (0% tumor staining), what is the molecular subtype of the breast cancer? A) Luminal A   B) Luminal B   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-LD-A66U-01Z-00-DX1.AEC25C62-0519-47ED-A85B-2A964BA2BA87-1",
        "image": "TCGA-BRCA/TCGA-LD-A66U-01Z-00-DX1.AEC25C62-0519-47ED-A85B-2A964BA2BA87.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith immunohistochemical results showing positive cytokeratin stain for micrometastasis in the axillary sentinel lymph node, and negative for calponin and p63 in a small focus of invasive carcinoma, what is the molecular subtype of this tumor? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XQ-01Z-00-DX1.1A17A5C7-F14B-4AD2-AD5F-D3400D86A366-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XQ-01Z-00-DX1.1A17A5C7-F14B-4AD2-AD5F-D3400D86A366.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negative estrogen receptors, progesterone receptors present in less than 10% of cells, and a HER2 score of 1+, what is the molecular subtype of this cancer?   A) HER2-enriched   B) Luminal A   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-B6-A0IP-01Z-00-DX1.3723A250-AA4B-4AFE-A692-C1311E9BA268-1",
        "image": "TCGA-BRCA/TCGA-B6-A0IP-01Z-00-DX1.3723A250-AA4B-4AFE-A692-C1311E9BA268.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith immunohistochemical results indicating positive estrogen receptor (ER) and progesterone receptor (PR) statuses, both with significant FMOL values, what is the molecular subtype of this breast cancer?  A) HER2-enriched   B) Luminal B   C) Basal   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A141-01Z-00-DX1.10F6EEB2-C920-43FF-B5A7-B5A651CBDBE3-1",
        "image": "TCGA-BRCA/TCGA-D8-A141-01Z-00-DX1.10F6EEB2-C920-43FF-B5A7-B5A651CBDBE3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating absence of estrogen receptor expression, a 75% positivity for progesterone receptors in neoplastic cell nuclei, and a HER2 negative reaction with a score of 3+, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A141-01Z-00-DX2.DBD0D81E-28FC-4466-BDE3-94753BD6CBEB-1",
        "image": "TCGA-BRCA/TCGA-D8-A141-01Z-00-DX2.DBD0D81E-28FC-4466-BDE3-94753BD6CBEB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating absence of estrogen receptor expression, a 75% positivity for progesterone receptors in neoplastic cell nuclei, and a HER2 negative reaction with a score of 3+, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AC-A8OS-01Z-00-DX1.3FD44846-8BD2-4A7A-9A87-8D3D29C25F60-1",
        "image": "TCGA-BRCA/TCGA-AC-A8OS-01Z-00-DX1.3FD44846-8BD2-4A7A-9A87-8D3D29C25F60.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing estrogen receptor (ER) 100% positive with strong intensity, progesterone receptor (PR) 4% positive with weak intensity, HER2 score 1+, and Ki67 index of 12%, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A25D-01Z-00-DX1.41DADDB8-3E3F-4F8F-8BE7-C43F8FBCFD2B-1",
        "image": "TCGA-BRCA/TCGA-A2-A25D-01Z-00-DX1.41DADDB8-3E3F-4F8F-8BE7-C43F8FBCFD2B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith immunohistochemistry indicating positive estrogen receptor status (95% nuclei staining), negative progesterone receptor expression (0% staining), and a negative HER2 score (1+), what is the molecular subtype of this breast cancer? A) HER2-enriched   B) Basal   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AR-A2LE-01Z-00-DX1.E8E1FC5C-9A4A-463F-81D7-E9A8AF43EAD9-1",
        "image": "TCGA-BRCA/TCGA-AR-A2LE-01Z-00-DX1.E8E1FC5C-9A4A-463F-81D7-E9A8AF43EAD9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the IHC results of positive estrogen receptor, negative progesterone receptor, and the confirmation of infiltrating lobular carcinoma, what is the molecular subtype of this breast cancer?  A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AO-A0JI-01Z-00-DX1.4DCDA545-B7E3-49DF-AB10-963E84BEB105-1",
        "image": "TCGA-BRCA/TCGA-AO-A0JI-01Z-00-DX1.4DCDA545-B7E3-49DF-AB10-963E84BEB105.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results demonstrating 98% nuclear staining with strong intensity for estrogen receptor, 0% nuclear staining for progesterone receptor, and negative HER2-NEU status, what is the molecular subtype of this breast cancer?  A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XV-01Z-00-DX1.D0D78B02-2A0D-4107-8083-D2FE1D3F1207-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XV-01Z-00-DX1.D0D78B02-2A0D-4107-8083-D2FE1D3F1207.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing estrogen receptor positivity in over 75% of neoplastic cell nuclei, progesterone receptor positivity in over 75% of neoplastic cell nuclei, HER2 score of 2+ with no HER2 gene amplification by FISH, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XV-01Z-00-DX2.D1988E01-5FDC-4F50-8183-F0CCE74D0CB2-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XV-01Z-00-DX2.D1988E01-5FDC-4F50-8183-F0CCE74D0CB2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing estrogen receptor positivity in over 75% of neoplastic cell nuclei, progesterone receptor positivity in over 75% of neoplastic cell nuclei, HER2 score of 2+ with no HER2 gene amplification by FISH, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A14R-01Z-00-DX1.DDE62ED5-1FC0-4B3B-A874-95C08B33AB20-1",
        "image": "TCGA-BRCA/TCGA-E2-A14R-01Z-00-DX1.DDE62ED5-1FC0-4B3B-A874-95C08B33AB20.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negative estrogen receptor (ER) and progesterone receptor (PR) status, along with negative HER-2, what is the molecular subtype of this tumor? A) Luminal A   B) Luminal B   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AC-A6IW-01Z-00-DX1.C4514189-E64F-4603-8970-230FA2BB77FC-1",
        "image": "TCGA-BRCA/TCGA-AC-A6IW-01Z-00-DX1.C4514189-E64F-4603-8970-230FA2BB77FC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative estrogen receptor (ER), negative progesterone receptor (PR), negative HER2 status, and a high Ki-67 proliferation index, what is the molecular subtype of this breast cancer? A) Luminal A B) Luminal B C) HER2-enriched D) Basal"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-GM-A3XL-01Z-00-DX1.CCE8AA1D-9194-4E49-9546-DBF25A35847C-1",
        "image": "TCGA-BRCA/TCGA-GM-A3XL-01Z-00-DX1.CCE8AA1D-9194-4E49-9546-DBF25A35847C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results indicating cytokeratin stain is negative for metastatic carcinoma in most axillary sentinel lymph nodes with rare positive cells in some nodes, which molecular subtype is most likely associated with these findings? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A42U-01Z-00-DX1.130D060A-3DD8-407E-B8B0-EBBF743491AE-1",
        "image": "TCGA-BRCA/TCGA-BH-A42U-01Z-00-DX1.130D060A-3DD8-407E-B8B0-EBBF743491AE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the immunohistochemical result indicating a negative expression for cadherin, what is the molecular subtype of this cancer?  A) Luminal A   B) HER2-enriched   C) Basal   D) Normal-like"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0W5-01Z-00-DX1.84EA3913-667B-4694-A0F0-E629CAC615C8-1",
        "image": "TCGA-BRCA/TCGA-BH-A0W5-01Z-00-DX1.84EA3913-667B-4694-A0F0-E629CAC615C8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen and progesterone receptors, equivocal HER2 status with no amplification on FISH, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1P0-01Z-00-DX1.6C75EEBD-CE05-4DE2-8C43-8B6435F1379F-1",
        "image": "TCGA-BRCA/TCGA-EW-A1P0-01Z-00-DX1.6C75EEBD-CE05-4DE2-8C43-8B6435F1379F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results of positive ER, negative PR, and negative HER2 status, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AR-A2LQ-01Z-00-DX1.2F579E62-69A8-40F4-A516-542C7C808628-1",
        "image": "TCGA-BRCA/TCGA-AR-A2LQ-01Z-00-DX1.2F579E62-69A8-40F4-A516-542C7C808628.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results confirming the H&E impression in the axillary sentinel lymph nodes through cytokeratin staining, what is the molecular subtype of this case? A) Basal B) HER2-enriched C) Luminal A D) Normal"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XB-01Z-00-DX1.DA8E2FA4-DBBA-4157-8052-B90FB3BB58F1-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XB-01Z-00-DX1.DA8E2FA4-DBBA-4157-8052-B90FB3BB58F1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results indicating over 75% positivity for estrogen and progesterone receptors and a negative HER2 score of 1+, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XB-01Z-00-DX2.B262C269-F22B-4306-8195-079C0874EF8E-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XB-01Z-00-DX2.B262C269-F22B-4306-8195-079C0874EF8E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results indicating over 75% positivity for estrogen and progesterone receptors and a negative HER2 score of 1+, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A14O-01Z-00-DX1.432DB252-35D4-4B02-B0A7-39BF85A38F89-1",
        "image": "TCGA-BRCA/TCGA-E2-A14O-01Z-00-DX1.432DB252-35D4-4B02-B0A7-39BF85A38F89.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR statuses with Allred scores of 8 and 7 respectively, and pending HER2 results, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AO-A0J6-01Z-00-DX1.D0C003CE-E112-4375-953D-78404C9D62DA-1",
        "image": "TCGA-BRCA/TCGA-AO-A0J6-01Z-00-DX1.D0C003CE-E112-4375-953D-78404C9D62DA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression for estrogen receptor (ER), positive for progesterone receptor (PR), and negative HER2 status, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A576-01Z-00-DX1.2E045763-7EB0-48F5-8C47-E4B84287D739-1",
        "image": "TCGA-BRCA/TCGA-E2-A576-01Z-00-DX1.2E045763-7EB0-48F5-8C47-E4B84287D739.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical result of negative E-cadherin and the evaluation of other standard markers, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A9RU-01Z-00-DX1.A06BE284-B9DC-4B45-A202-A9D027AEEDD9-1",
        "image": "TCGA-BRCA/TCGA-E2-A9RU-01Z-00-DX1.A06BE284-B9DC-4B45-A202-A9D027AEEDD9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor with an Allred Score of 6, negative progesterone receptor with an Allred Score of 0, and HER2 negative by FISH methodology, what is the molecular subtype of this breast cancer?   A) Luminal A   B) Luminal B   C) Basal   D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XL-01Z-00-DX2.FDE2C80D-5DC4-4743-A180-C5AFC5BB0BE2-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XL-01Z-00-DX2.FDE2C80D-5DC4-4743-A180-C5AFC5BB0BE2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings of estrogen receptors and progesterone receptors both detected in over 75% of neoplastic cell nuclei, a HER2 protein score of 2+ with no gene amplification on FISH, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XL-01Z-00-DX1.FDF07020-8F40-4C00-9023-E5F40E0D8A7C-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XL-01Z-00-DX1.FDF07020-8F40-4C00-9023-E5F40E0D8A7C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings of estrogen receptors and progesterone receptors both detected in over 75% of neoplastic cell nuclei, a HER2 protein score of 2+ with no gene amplification on FISH, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-B6-A0IM-01Z-00-DX1.E2CBD42F-D933-4446-BE7C-C2F8B5AFB976-1",
        "image": "TCGA-BRCA/TCGA-B6-A0IM-01Z-00-DX1.E2CBD42F-D933-4446-BE7C-C2F8B5AFB976.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor activity with an estimated FMOL value of 113, and borderline progesterone receptor activity with an estimated FMOL value of 14, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1PH-01Z-00-DX1.77e0f907-fe59-4dc2-b582-6f10330a9c01-1",
        "image": "TCGA-BRCA/TCGA-EW-A1PH-01Z-00-DX1.77e0f907-fe59-4dc2-b582-6f10330a9c01.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negativity for ER, PR, and HER2, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A14T-01Z-00-DX1.61B4C988-6D75-447B-A5F4-9DE92CEACC9F-1",
        "image": "TCGA-BRCA/TCGA-E2-A14T-01Z-00-DX1.61B4C988-6D75-447B-A5F4-9DE92CEACC9F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemistry results showing positive estrogen receptor with an Allred score of 8, positive progesterone receptor with an Allred score of 4, and non-amplified HER-2, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-OK-A5Q2-01Z-00-DX4.83B45D6C-E350-4436-812F-4155D9F7D331-1",
        "image": "TCGA-BRCA/TCGA-OK-A5Q2-01Z-00-DX4.83B45D6C-E350-4436-812F-4155D9F7D331.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative HER2, positive ER with strong intensity, and positive PR with strong intensity covering 25% of cells, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-OK-A5Q2-01Z-00-DX1.0D169898-37C6-44CA-AC87-27887123AA6F-1",
        "image": "TCGA-BRCA/TCGA-OK-A5Q2-01Z-00-DX1.0D169898-37C6-44CA-AC87-27887123AA6F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative HER2, positive ER with strong intensity, and positive PR with strong intensity covering 25% of cells, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-OK-A5Q2-01Z-00-DX2.C828A160-87DF-4625-A8C5-2057F61D54F4-1",
        "image": "TCGA-BRCA/TCGA-OK-A5Q2-01Z-00-DX2.C828A160-87DF-4625-A8C5-2057F61D54F4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative HER2, positive ER with strong intensity, and positive PR with strong intensity covering 25% of cells, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-OK-A5Q2-01Z-00-DX3.5F9215C3-E407-46F8-968E-503D7D14605C-1",
        "image": "TCGA-BRCA/TCGA-OK-A5Q2-01Z-00-DX3.5F9215C3-E407-46F8-968E-503D7D14605C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative HER2, positive ER with strong intensity, and positive PR with strong intensity covering 25% of cells, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-EW-A2FS-01Z-00-DX1.A01C9183-2AC8-456A-B5A6-85C5BB0361D8-1",
        "image": "TCGA-BRCA/TCGA-EW-A2FS-01Z-00-DX1.A01C9183-2AC8-456A-B5A6-85C5BB0361D8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the IHC results showing positive ER expression, negative PR and Her2 status, what is the molecular subtype of this invasive carcinoma? A) Luminal B   B) HER2-enriched   C) Basal   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-B6-A2IU-01Z-00-DX1.3C7DF701-4ED9-4989-AA63-A6B7B105F6EE-1",
        "image": "TCGA-BRCA/TCGA-B6-A2IU-01Z-00-DX1.3C7DF701-4ED9-4989-AA63-A6B7B105F6EE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen receptor (FMOL value 30) and positive progesterone receptor (FMOL value 10), what is the molecular subtype of this breast cancer? A) Luminal A B) Basal C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0YM-01Z-00-DX1.A48B4C96-2CC5-464C-98B7-F0F92AE56533-1",
        "image": "TCGA-BRCA/TCGA-A2-A0YM-01Z-00-DX1.A48B4C96-2CC5-464C-98B7-F0F92AE56533.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negative cytokeratin (AE1/AE3) staining for malignancy in lymph node parts D, E, F, G, and H, what is the molecular subtype of this cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AO-A0JF-01Z-00-DX1.3277D13C-F257-4D4C-AB5C-BEBA2E1A63D8-1",
        "image": "TCGA-BRCA/TCGA-AO-A0JF-01Z-00-DX1.3277D13C-F257-4D4C-AB5C-BEBA2E1A63D8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing 95% nuclear staining for estrogen receptor (ER), 70% nuclear staining with moderate intensity for progesterone receptor (PR), and negative (2+) HER-2/neu, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XY-01Z-00-DX1.AC051FB4-1D51-449B-BF2D-9DDB4382414C-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XY-01Z-00-DX1.AC051FB4-1D51-449B-BF2D-9DDB4382414C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results, which indicate positive staining for estrogen and progesterone receptors in over 75% of neoplastic cell nuclei and a positive HER2 protein score of 3+, what is the molecular subtype of the tumor?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XY-01Z-00-DX2.33D96E5C-5291-4864-B282-8BACA2043586-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XY-01Z-00-DX2.33D96E5C-5291-4864-B282-8BACA2043586.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results, which indicate positive staining for estrogen and progesterone receptors in over 75% of neoplastic cell nuclei and a positive HER2 protein score of 3+, what is the molecular subtype of the tumor?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1X5-01Z-00-DX2.E4D28EE2-9C87-4613-BD2E-89FBEF960DEE-1",
        "image": "TCGA-BRCA/TCGA-D8-A1X5-01Z-00-DX2.E4D28EE2-9C87-4613-BD2E-89FBEF960DEE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical profile showing positive estrogen receptors, positive progesterone receptors, and positive HER2 protein expression, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Luminal B   D) Basal"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1X5-01Z-00-DX1.81B10B43-0D99-44D0-A245-D652041B8FEE-1",
        "image": "TCGA-BRCA/TCGA-D8-A1X5-01Z-00-DX1.81B10B43-0D99-44D0-A245-D652041B8FEE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical profile showing positive estrogen receptors, positive progesterone receptors, and positive HER2 protein expression, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Luminal B   D) Basal"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AC-A6IV-01Z-00-DX1.DA4F4B9F-9070-4B3A-996F-311E0A989FFB-1",
        "image": "TCGA-BRCA/TCGA-AC-A6IV-01Z-00-DX1.DA4F4B9F-9070-4B3A-996F-311E0A989FFB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings showing strongly positive expression for both estrogen and progesterone receptors, a borderline to low Ki-67 proliferation index, and equivocal HER-2/neu status, what is the molecular subtype of this breast cancer? A) Luminal B B) Basal C) HER2-enriched D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AR-A2LM-01Z-00-DX1.CB64A062-2E35-41F9-97C7-07BB60754799-1",
        "image": "TCGA-BRCA/TCGA-AR-A2LM-01Z-00-DX1.CB64A062-2E35-41F9-97C7-07BB60754799.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating a positive cytokeratin stain, which confirms the H&E impression, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A28Q-01Z-00-DX1.C6D1CA93-6B2A-4722-9270-5D56592D833D-1",
        "image": "TCGA-BRCA/TCGA-BH-A28Q-01Z-00-DX1.C6D1CA93-6B2A-4722-9270-5D56592D833D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the immunohistochemical results showing positive estrogen receptor and progesterone receptor expression and negative HER2 status, what is the molecular subtype of this tumor? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AO-A0JA-01Z-00-DX1.E3DDBAAF-6FFA-40BE-83FF-942857CFED5D-1",
        "image": "TCGA-BRCA/TCGA-AO-A0JA-01Z-00-DX1.E3DDBAAF-6FFA-40BE-83FF-942857CFED5D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the immunohistochemical results indicating 90% nuclear staining and moderate intensity for Estrogen Receptor, negative Progesterone Receptor, and 50-60% nuclear staining with moderate intensity for HER2/neu, what is the determined molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0W3-01Z-00-DX1.38DCA2B7-1A54-4FFA-BABA-29F80974BB17-1",
        "image": "TCGA-BRCA/TCGA-BH-A0W3-01Z-00-DX1.38DCA2B7-1A54-4FFA-BABA-29F80974BB17.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen and progesterone receptors, with an H-score of 900 and 25 respectively, and a HER-2/neu score of 2+ without gene amplification, what is the molecular subtype of this breast cancer? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-C8-A138-01Z-00-DX1.845A0680-23A4-4A58-A9C4-2EE17BDBD371-1",
        "image": "TCGA-BRCA/TCGA-C8-A138-01Z-00-DX1.845A0680-23A4-4A58-A9C4-2EE17BDBD371.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative ER, PR, and Her-2/neu status, what is the molecular subtype of this cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1P6-01Z-00-DX1.A8024C26-6336-4858-88FD-5679795899BA-1",
        "image": "TCGA-BRCA/TCGA-EW-A1P6-01Z-00-DX1.A8024C26-6336-4858-88FD-5679795899BA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing 21% positivity for estrogen receptor, 1% positivity for progesterone receptor, and negative HER2 status (Score 0), what is the molecular subtype of this breast cancer? A) HER2-enriched   B) Basal   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A147-01Z-00-DX1.159094F2-BB78-4910-B7AE-3D7CAAB1DAD9-1",
        "image": "TCGA-BRCA/TCGA-D8-A147-01Z-00-DX1.159094F2-BB78-4910-B7AE-3D7CAAB1DAD9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating the absence of estrogen and progesterone receptors and a negative HER2 status, what molecular subtype does this profile correspond to? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XW-01Z-00-DX1.10187A1F-086B-4CD9-AC01-ADA2E435CD34-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XW-01Z-00-DX1.10187A1F-086B-4CD9-AC01-ADA2E435CD34.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing no estrogen receptor expression, less than 10% progesterone receptor activity, and a negative HER2 status, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal A   D) Normal"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XW-01Z-00-DX2.9849E503-BE3E-417C-ABE8-93A39583DDE0-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XW-01Z-00-DX2.9849E503-BE3E-417C-ABE8-93A39583DDE0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing no estrogen receptor expression, less than 10% progesterone receptor activity, and a negative HER2 status, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal A   D) Normal"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0YC-01Z-00-DX1.F01F2268-17D8-45FD-8917-FD89454D0709-1",
        "image": "TCGA-BRCA/TCGA-A2-A0YC-01Z-00-DX1.F01F2268-17D8-45FD-8917-FD89454D0709.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical result showing positivity for cytokeratin marking the presence of metastatic adenocarcinoma, what is the determined molecular subtype of this cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AC-A2FF-01Z-00-DX1.012DAC86-E05C-44FA-81C2-FE4C754F409C-1",
        "image": "TCGA-BRCA/TCGA-AC-A2FF-01Z-00-DX1.012DAC86-E05C-44FA-81C2-FE4C754F409C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing estrogen receptor (ER) at 3%, favorable status, PR not available with a favorable note, HER-2/neu at a normal limit of 17, and Ki-67 at 18.8 with a borderline indication, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A14Z-01Z-00-DX1.A1344A78-1842-4578-8CDE-921E50656891-1",
        "image": "TCGA-BRCA/TCGA-E2-A14Z-01Z-00-DX1.A1344A78-1842-4578-8CDE-921E50656891.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith immunohistochemical results indicating negative HER2 status, what is the molecular subtype of this cancer? A) Luminal B   B) HER2-enriched   C) Basal   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0YD-01Z-00-DX1.B81FF541-F154-4C49-950B-B6CB723369E2-1",
        "image": "TCGA-BRCA/TCGA-A2-A0YD-01Z-00-DX1.B81FF541-F154-4C49-950B-B6CB723369E2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positivity for PanKeratin in left sentinel lymph node 1 but negativity in 2, and positivity for Cytokeratin in 1, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1P8-01Z-00-DX1.E9852193-8CDD-49EF-B49B-DA6931198F0D-1",
        "image": "TCGA-BRCA/TCGA-EW-A1P8-01Z-00-DX1.E9852193-8CDD-49EF-B49B-DA6931198F0D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing estrogen receptor and progesterone receptor expression in less than 1% of cells, and a negative HER2/neu score, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AC-A6IX-01Z-00-DX1.45B63C4F-9DC3-4CED-9DF9-0F86E647BEA3-1",
        "image": "TCGA-BRCA/TCGA-AC-A6IX-01Z-00-DX1.45B63C4F-9DC3-4CED-9DF9-0F86E647BEA3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results with 98% positive estrogen receptor, less than 1% positive progesterone receptor, HER2 IHC score 1+, and a Ki67 index of 5%, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A140-01Z-00-DX1.5B9382C0-332C-4FBF-82CD-B9453D02B815-1",
        "image": "TCGA-BRCA/TCGA-D8-A140-01Z-00-DX1.5B9382C0-332C-4FBF-82CD-B9453D02B815.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing 75% positive estrogen receptor (ER) status, 30% positive progesterone receptor (PR) status, and a HER2 score of 3+ with positive reaction, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A140-01Z-00-DX2.0C0A62BB-1FB8-47D8-8FAF-112D221F18BE-1",
        "image": "TCGA-BRCA/TCGA-D8-A140-01Z-00-DX2.0C0A62BB-1FB8-47D8-8FAF-112D221F18BE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing 75% positive estrogen receptor (ER) status, 30% positive progesterone receptor (PR) status, and a HER2 score of 3+ with positive reaction, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0SV-01Z-00-DX1.F5645E47-3540-4753-AF5D-F5709BD8DFC1-1",
        "image": "TCGA-BRCA/TCGA-A2-A0SV-01Z-00-DX1.F5645E47-3540-4753-AF5D-F5709BD8DFC1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen and progesterone receptors, weakly positive HER2 status by IHC, and pending HER2 FISH results, what is the molecular subtype of this breast cancer? A) Luminal A B) Luminal B C) HER2-enriched D) Basal"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-GM-A2D9-01Z-00-DX1.AF4BF2DD-05FB-400B-A1BC-6E7C9B9DDF05-1",
        "image": "TCGA-BRCA/TCGA-GM-A2D9-01Z-00-DX1.AF4BF2DD-05FB-400B-A1BC-6E7C9B9DDF05.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results with negative neuroendocrine markers, negative CD8, a low Ki-67 proliferation index of 10%, and negative HER-2/neu gene amplification, what is the molecular subtype of this tumor? A) Basal   B) Luminal B   C) HER2-enriched   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-S3-AA17-01Z-00-DX1.9B7DC02E-ECB2-4403-A894-F418AD452E49-1",
        "image": "TCGA-BRCA/TCGA-S3-AA17-01Z-00-DX1.9B7DC02E-ECB2-4403-A894-F418AD452E49.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the positive immunohistochemical results for E-cadherin, p63, and Calponin, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-S3-AA10-01Z-00-DX1.C0468882-0DD8-4FC5-8C2F-E18BE8000F69-1",
        "image": "TCGA-BRCA/TCGA-S3-AA10-01Z-00-DX1.C0468882-0DD8-4FC5-8C2F-E18BE8000F69.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative expression for estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu (Score 0), what is the molecular subtype of this tumor? A) HER2-enriched B) Luminal A C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AR-A1AY-01Z-00-DX1.6AC0BE3B-FFC5-4EDA-9E40-B18CAAC52B81-1",
        "image": "TCGA-BRCA/TCGA-AR-A1AY-01Z-00-DX1.6AC0BE3B-FFC5-4EDA-9E40-B18CAAC52B81.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive Cytokeratin and H&E indicating isolated tumor cell cluster, what molecular subtype does this breast cancer belong to? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1LA-01Z-00-DX1.AE49E943-B830-4ED9-B09E-E499441BC2EC-1",
        "image": "TCGA-BRCA/TCGA-E2-A1LA-01Z-00-DX1.AE49E943-B830-4ED9-B09E-E499441BC2EC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression for estrogen receptor (ER), positive for progesterone receptor (PR), and negative HER2 status by FISH, what is the molecular subtype of this breast cancer?   A) Basal   B) Luminal A   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-B6-A0WS-01Z-00-DX1.020ED7BF-9497-4F13-AA07-FE0E839F9A06-1",
        "image": "TCGA-BRCA/TCGA-B6-A0WS-01Z-00-DX1.020ED7BF-9497-4F13-AA07-FE0E839F9A06.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER) status with an FMOL value of 39 and negative progesterone receptor (PR) activity, what is the molecular subtype of this breast cancer? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-B6-A0WZ-01Z-00-DX1.6CFB236E-36F5-43D6-8DE3-C4ECBD3C14C6-1",
        "image": "TCGA-BRCA/TCGA-B6-A0WZ-01Z-00-DX1.6CFB236E-36F5-43D6-8DE3-C4ECBD3C14C6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results indicating positive estrogen receptor and positive progesterone receptor status, what is the molecular subtype of this breast cancer? A) HER2-enriched   B) Basal   C) Luminal A   D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1LH-01Z-00-DX1.F85384B7-1EBF-4F57-A45B-4A668B68E535-1",
        "image": "TCGA-BRCA/TCGA-E2-A1LH-01Z-00-DX1.F85384B7-1EBF-4F57-A45B-4A668B68E535.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative expression for estrogen receptor (ER), progesterone receptor (PR), and HER2, what is the molecular subtype of this tumor?   A) Luminal A   B) HER2-enriched   C) Luminal B   D) Basal"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AR-A24V-01Z-00-DX1.E749C2FE-E26B-4306-80B4-8269EEB23270-1",
        "image": "TCGA-BRCA/TCGA-AR-A24V-01Z-00-DX1.E749C2FE-E26B-4306-80B4-8269EEB23270.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical result showing positive cytokeratin stain, what is the molecular subtype for this sample? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AR-A24Q-01Z-00-DX1.69DC7E35-DC0D-4F20-88DA-04C25F28628C-1",
        "image": "TCGA-BRCA/TCGA-AR-A24Q-01Z-00-DX1.69DC7E35-DC0D-4F20-88DA-04C25F28628C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results indicating the ordered evaluation for Her-2/NEU, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1IK-01Z-00-DX1.25C554BB-AA90-4FF4-9D68-EEC899B8A27D-1",
        "image": "TCGA-BRCA/TCGA-E2-A1IK-01Z-00-DX1.25C554BB-AA90-4FF4-9D68-EEC899B8A27D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive ER and PR expression and negative HER2 status, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0C1-01Z-00-DX1.21FE357E-B182-4397-BFEF-7E96E994236A-1",
        "image": "TCGA-BRCA/TCGA-BH-A0C1-01Z-00-DX1.21FE357E-B182-4397-BFEF-7E96E994236A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results indicating positive expression for ER and PR, along with a negative IHC score of 0 for HER-2/neu, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JE-01Z-00-DX2.CCF3DFEF-E851-425A-BCD0-0F7B377A00BC-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JE-01Z-00-DX2.CCF3DFEF-E851-425A-BCD0-0F7B377A00BC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the immunohistochemical results showing positive expression for both estrogen and progesterone receptors in over 75% of neoplastic cell nuclei, and a negative HER2 score of 1+, what is the molecular subtype of this breast cancer?  A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JE-01Z-00-DX1.714805A1-E337-46DA-88D9-6CE4B4E3C2D0-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JE-01Z-00-DX1.714805A1-E337-46DA-88D9-6CE4B4E3C2D0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the immunohistochemical results showing positive expression for both estrogen and progesterone receptors in over 75% of neoplastic cell nuclei, and a negative HER2 score of 1+, what is the molecular subtype of this breast cancer?  A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1L6-01Z-00-DX1.AFE87067-2BFD-42C2-9334-9DDE8AB61B49-1",
        "image": "TCGA-BRCA/TCGA-E2-A1L6-01Z-00-DX1.AFE87067-2BFD-42C2-9334-9DDE8AB61B49.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative HER2 status, and positive estrogen and progesterone receptors with an Allred Score of 8, what is the molecular subtype of this breast cancer? A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JB-01Z-00-DX1.6CF48257-066C-4B8C-91AA-30A6B4AD4307-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JB-01Z-00-DX1.6CF48257-066C-4B8C-91AA-30A6B4AD4307.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nIn light of the immunohistochemical results revealing over 75% estrogen receptor positivity, progesterone receptor expression in 10-75% of neoplastic cells, a HER2 score of 2+ with no gene amplification found, what is the molecular subtype for this breast cancer?  A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1IL-01Z-00-DX1.46B6AA99-C7CE-4573-B15D-2C56A708B082-1",
        "image": "TCGA-BRCA/TCGA-E2-A1IL-01Z-00-DX1.46B6AA99-C7CE-4573-B15D-2C56A708B082.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive ER and PR, and negative HER2 status, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JK-01Z-00-DX1.3190C919-A403-460D-9F6C-D2AB5FD3FD05-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JK-01Z-00-DX1.3190C919-A403-460D-9F6C-D2AB5FD3FD05.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results with no estrogen receptors, progesterone receptors in less than 10% of cell nuclei, and negative HER2 protein expression, what is the molecular subtype of this tumor? A) Basal B) Luminal A C) Luminal B D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AR-A24M-01Z-00-DX1.D81F1BDF-00DD-42A3-AFFE-55655A877213-1",
        "image": "TCGA-BRCA/TCGA-AR-A24M-01Z-00-DX1.D81F1BDF-00DD-42A3-AFFE-55655A877213.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results indicating the Her-2/Neu test has been ordered on paraffin-embedded tissue, what is the molecular subtype of this breast cancer? A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1IE-01Z-00-DX1.D6BF29A7-4FBD-4F7D-B093-991FA0F49FE8-1",
        "image": "TCGA-BRCA/TCGA-E2-A1IE-01Z-00-DX1.D6BF29A7-4FBD-4F7D-B093-991FA0F49FE8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER) with an Allred Score of 8, positive progesterone receptor (PR) with an Allred Score of 6, and equivocal HER-2 status (Intensity 2+, 20% Tumor Staining), what is the molecular subtype of this breast cancer? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0D0-01Z-00-DX1.4FF6B8E5-703B-400F-920A-104F56E0F874-1",
        "image": "TCGA-BRCA/TCGA-A2-A0D0-01Z-00-DX1.4FF6B8E5-703B-400F-920A-104F56E0F874.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative estrogen receptors, negative progesterone receptors, and HER2 Neu being negative with a 1+ score, what is the molecular subtype for this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JL-01Z-00-DX1.FE3F0C6B-F98A-4036-BF9A-25A8CC66B1FD-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JL-01Z-00-DX1.FE3F0C6B-F98A-4036-BF9A-25A8CC66B1FD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative expression for estrogen receptors, progesterone receptors, and a HER2 score of 1+, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1L8-01Z-00-DX1.842BF73D-2D64-4ABA-880D-DBE8F4C2AA19-1",
        "image": "TCGA-BRCA/TCGA-E2-A1L8-01Z-00-DX1.842BF73D-2D64-4ABA-880D-DBE8F4C2AA19.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results with positive ER and PR, negative HER2 by FISH, and ER Allred Score of 8, along with a PR Allred Score of 6, what is the molecular subtype of this breast cancer?   A) Luminal B   B) Basal   C) HER2-enriched   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AR-A24P-01Z-00-DX1.08BE8830-C55E-4E2B-9378-371A670C75FD-1",
        "image": "TCGA-BRCA/TCGA-AR-A24P-01Z-00-DX1.08BE8830-C55E-4E2B-9378-371A670C75FD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the positive cytokeratin stain in conjunction with histopathological findings from the H&E slide, what is the molecular subtype of this tumor?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1LI-01Z-00-DX1.503dd2fa-23ef-4b11-8aab-301e069eaa88-1",
        "image": "TCGA-BRCA/TCGA-E2-A1LI-01Z-00-DX1.503dd2fa-23ef-4b11-8aab-301e069eaa88.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing ER negativity and borderline HER2 status, what is the molecular subtype of this tumor?   A) Basal   B) Luminal A   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-S3-AA11-01Z-00-DX1.36B83B37-2928-4DB7-A04A-8D511F1183FD-1",
        "image": "TCGA-BRCA/TCGA-S3-AA11-01Z-00-DX1.36B83B37-2928-4DB7-A04A-8D511F1183FD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results with positive estrogen receptor (ER) and progesterone receptor (PR) expression, HER2 not amplified, and negative AE1/AE3, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A3XT-01Z-00-DX1.336D6C78-576A-481B-8C83-F3A0FC4B182C-1",
        "image": "TCGA-BRCA/TCGA-A2-A3XT-01Z-00-DX1.336D6C78-576A-481B-8C83-F3A0FC4B182C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating negative estrogen and progesterone receptor status, negative HER2, and CK7 positivity, what is the molecular subtype of this tumor?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A7-A26I-01Z-00-DX1.0077D012-BC14-4E96-84F7-A1A6A3A778DF-1",
        "image": "TCGA-BRCA/TCGA-A7-A26I-01Z-00-DX1.0077D012-BC14-4E96-84F7-A1A6A3A778DF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing pan cytokeratin AEL/AE3 with no metastatic tumor identified, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AR-A1AX-01Z-00-DX1.2389D54F-545E-499E-B392-DD731834460A-1",
        "image": "TCGA-BRCA/TCGA-AR-A1AX-01Z-00-DX1.2389D54F-545E-499E-B392-DD731834460A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical cytokeratin stain results confirming the H&E impression, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AR-A0TS-01Z-00-DX1.2DB81A2E-16C1-4EE0-8175-65FA46768277-1",
        "image": "TCGA-BRCA/TCGA-AR-A0TS-01Z-00-DX1.2DB81A2E-16C1-4EE0-8175-65FA46768277.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive cytokeratin staining in sentinel node 3, what is the molecular subtype of this case? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HN-A2OB-01Z-00-DX1.14F1FBFB-4540-43CE-9D79-5BC628640424-1",
        "image": "TCGA-BRCA/TCGA-HN-A2OB-01Z-00-DX1.14F1FBFB-4540-43CE-9D79-5BC628640424.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR status, and negative HER2 status, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0E2-01Z-00-DX1.5F6FA19C-D59F-45BE-80CE-F738CAB1EF0B-1",
        "image": "TCGA-BRCA/TCGA-BH-A0E2-01Z-00-DX1.5F6FA19C-D59F-45BE-80CE-F738CAB1EF0B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen and progesterone receptors, with negative HER2 status, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1LG-01Z-00-DX1.8ff0fdd8-e5d5-4ff8-8707-4a760aaa5d36-1",
        "image": "TCGA-BRCA/TCGA-E2-A1LG-01Z-00-DX1.8ff0fdd8-e5d5-4ff8-8707-4a760aaa5d36.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative HERCEPTIN expression, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JM-01Z-00-DX1.3CD15BC8-08B3-4BEE-9FD7-A8BEED33268E-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JM-01Z-00-DX1.3CD15BC8-08B3-4BEE-9FD7-A8BEED33268E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing less than 10% estrogen receptor positivity, absence of progesterone receptors, and a negative HER2 status (Score 1+) in invasive cancer cells, what is the molecular subtype of this cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AR-A24K-01Z-00-DX1.3A56BAEC-484E-4F9B-BCB4-360ABF6DDB4B-1",
        "image": "TCGA-BRCA/TCGA-AR-A24K-01Z-00-DX1.3A56BAEC-484E-4F9B-BCB4-360ABF6DDB4B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the immunohistochemical results confirming the H&E impression through cytokeratin stain, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1L9-01Z-00-DX1.F2CC1036-8EEE-4664-962E-541B8ACB10DE-1",
        "image": "TCGA-BRCA/TCGA-E2-A1L9-01Z-00-DX1.F2CC1036-8EEE-4664-962E-541B8ACB10DE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive ER, positive PR, and HER2 negative status, what is the molecular subtype of this breast cancer? A) Basal B) Luminal A C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-B6-A0RV-01Z-00-DX1.C46C2937-868D-47B7-B9B9-E51F5433BE97-1",
        "image": "TCGA-BRCA/TCGA-B6-A0RV-01Z-00-DX1.C46C2937-868D-47B7-B9B9-E51F5433BE97.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith immunohistochemical results showing positive estrogen receptor (ER) and progesterone receptor (PR) with high fmol values, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JJ-01Z-00-DX1.a986b48f-b295-4d7a-b778-ce829cdf9c38-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JJ-01Z-00-DX1.a986b48f-b295-4d7a-b778-ce829cdf9c38.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor expression (>75%) and progesterone receptor expression (10-75%), with HER2 negative status (score 1+), what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JJ-01Z-00-DX2.7D20F308-7DC6-4367-9459-3AC4C654E7F7-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JJ-01Z-00-DX2.7D20F308-7DC6-4367-9459-3AC4C654E7F7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor expression (>75%) and progesterone receptor expression (10-75%), with HER2 negative status (score 1+), what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AR-A1AJ-01Z-00-DX1.34B9FCF0-74D8-4328-9B5A-698AD57EDA85-1",
        "image": "TCGA-BRCA/TCGA-AR-A1AJ-01Z-00-DX1.34B9FCF0-74D8-4328-9B5A-698AD57EDA85.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive cytokeratin staining and negative HER2/neu protein expression with a score of 0, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1L7-01Z-00-DX1.BE796CD2-2E81-44E8-8CA2-85B4D2A31B64-1",
        "image": "TCGA-BRCA/TCGA-E2-A1L7-01Z-00-DX1.BE796CD2-2E81-44E8-8CA2-85B4D2A31B64.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative estrogen receptor (ER), negative progesterone receptor (PR), and HER2 negative by IHC, what is the molecular subtype of this tumor? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0EB-01Z-00-DX1.70D7BBA0-214D-4D1A-933C-7CFCDA5416A3-1",
        "image": "TCGA-BRCA/TCGA-BH-A0EB-01Z-00-DX1.70D7BBA0-214D-4D1A-933C-7CFCDA5416A3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen receptors, positive progesterone receptors, and HER-2 negative status (FISH not amplified), what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JD-01Z-00-DX2.C6A7667E-25C9-48BD-A4E7-F4BB740FE589-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JD-01Z-00-DX2.C6A7667E-25C9-48BD-A4E7-F4BB740FE589.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating positive expression of estrogen receptors in over 75% of neoplastic cells, progesterone receptors in 10-75% of cells, and a negative HER2 status (Score  1+), what is the molecular subtype of this breast cancer?  A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JD-01Z-00-DX1.6D215B14-DD90-4635-8645-AF06EBD9BA3F-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JD-01Z-00-DX1.6D215B14-DD90-4635-8645-AF06EBD9BA3F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating positive expression of estrogen receptors in over 75% of neoplastic cells, progesterone receptors in 10-75% of cells, and a negative HER2 status (Score  1+), what is the molecular subtype of this breast cancer?  A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1IJ-01Z-00-DX1.00093877-7B01-42D3-857C-987BC1F604A3-1",
        "image": "TCGA-BRCA/TCGA-E2-A1IJ-01Z-00-DX1.00093877-7B01-42D3-857C-987BC1F604A3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results with positive ER, positive PR, and HER2 negative by FISH, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0C0-01Z-00-DX1.2D32D35A-EB7E-4D0E-BE5F-E56F7B930463-1",
        "image": "TCGA-BRCA/TCGA-BH-A0C0-01Z-00-DX1.2D32D35A-EB7E-4D0E-BE5F-E56F7B930463.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith immunohistochemical results indicating positive estrogen receptors, positive progesterone receptors, and weakly positive HER2/neu, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0EE-01Z-00-DX1.872EA586-25C8-4835-A138-152DFA1EBF30-1",
        "image": "TCGA-BRCA/TCGA-BH-A0EE-01Z-00-DX1.872EA586-25C8-4835-A138-152DFA1EBF30.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative estrogen receptor (ER) and progesterone receptor (PR) status, but positive HER-2/neu with a score of 3, what is the molecular subtype of this tumor? A) Luminal A B) Basal C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A27R-01Z-00-DX2.31F47D8F-DFD7-42AE-BBBA-7DBBA12FA97D-1",
        "image": "TCGA-BRCA/TCGA-D8-A27R-01Z-00-DX2.31F47D8F-DFD7-42AE-BBBA-7DBBA12FA97D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results showing estrogen receptors in over 75% of neoplastic cell nuclei, progesterone receptors in 10-75% of neoplastic cell nuclei, and a HER2 protein score of 2+ with recommended FISH verification, what is the molecular subtype of this tumor? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A27R-01Z-00-DX1.F6E2FD1C-0666-4788-8D95-A76D15907270-1",
        "image": "TCGA-BRCA/TCGA-D8-A27R-01Z-00-DX1.F6E2FD1C-0666-4788-8D95-A76D15907270.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results showing estrogen receptors in over 75% of neoplastic cell nuclei, progesterone receptors in 10-75% of neoplastic cell nuclei, and a HER2 protein score of 2+ with recommended FISH verification, what is the molecular subtype of this tumor? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0EY-01Z-00-DX1.2F2428B3-0767-48E0-AC22-443C244CBD16-1",
        "image": "TCGA-BRCA/TCGA-A2-A0EY-01Z-00-DX1.2F2428B3-0767-48E0-AC22-443C244CBD16.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical analysis indicating positive estrogen receptor status, negative progesterone receptor status, and positive HER2 expression, what is the molecular subtype of this breast cancer? A) Luminal B B) Basal C) HER2-enriched D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1IX-01Z-00-DX1.72AE0E0F-B213-454F-8275-76A7C43FAB86-1",
        "image": "TCGA-BRCA/TCGA-EW-A1IX-01Z-00-DX1.72AE0E0F-B213-454F-8275-76A7C43FAB86.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR status, and negative Her2 expression in the tumor cells, what is the molecular subtype of this breast cancer? A) Luminal B B) HER2-enriched C) Basal D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0BV-01Z-00-DX1.3C9CD4F7-A001-430D-AA8D-80CAD61C344E-1",
        "image": "TCGA-BRCA/TCGA-BH-A0BV-01Z-00-DX1.3C9CD4F7-A001-430D-AA8D-80CAD61C344E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating positive ER and PR, along with negative HER2 expression (score 0), what is the determined molecular subtype of this cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0DO-01Z-00-DX1.1684557E-A5D4-4828-B2D5-FA899993A019-1",
        "image": "TCGA-BRCA/TCGA-BH-A0DO-01Z-00-DX1.1684557E-A5D4-4828-B2D5-FA899993A019.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical profiling with positive estrogen and progesterone receptors and negative HER2 status, what is the molecular subtype of this breast cancer? A) Luminal A B) Basal C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-OL-A66J-01Z-00-DX1.661F7F70-E4D4-4875-B8C4-556F7927F3BA-1",
        "image": "TCGA-BRCA/TCGA-OL-A66J-01Z-00-DX1.661F7F70-E4D4-4875-B8C4-556F7927F3BA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing strong expression of ER in 90% of invasive tumor nuclei, strong expression of PR in 80% of invasive tumor nuclei, and HER2/neu antigen (1+) with a Ratio of 1.5, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0B3-01Z-00-DX1.90CB0ED5-FBB7-4ABF-93A0-DD88D60D3D55-1",
        "image": "TCGA-BRCA/TCGA-BH-A0B3-01Z-00-DX1.90CB0ED5-FBB7-4ABF-93A0-DD88D60D3D55.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on immunohistochemical results showing negative estrogen and progesterone receptors, and a HER2/NEU score of 1+, what is the molecular subtype of this cancer?   A) Luminal A   B) Luminal B   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AO-A03M-01Z-00-DX1.9998A9A0-D0A6-48FC-80FB-AE597CB9E8AA-1",
        "image": "TCGA-BRCA/TCGA-AO-A03M-01Z-00-DX1.9998A9A0-D0A6-48FC-80FB-AE597CB9E8AA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive ER (70% nuclear staining with moderate intensity), positive PR (60% nuclear staining with moderate intensity), and HER2/neu with 3+ staining intensity, what is the molecular subtype of this breast cancer? A) Luminal A   B) Luminal B   C) Basal   D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0EW-01Z-00-DX1.F24495CB-63D8-483F-9834-F761E3F16BF0-1",
        "image": "TCGA-BRCA/TCGA-A2-A0EW-01Z-00-DX1.F24495CB-63D8-483F-9834-F761E3F16BF0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating positive expression for both estrogen and progesterone receptors, as well as a negative HER2 status, what is the molecular subtype of this breast cancer? A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A18P-01Z-00-DX1.C66642D3-BE44-4D65-B4AE-C1C3D959D22C-1",
        "image": "TCGA-BRCA/TCGA-BH-A18P-01Z-00-DX1.C66642D3-BE44-4D65-B4AE-C1C3D959D22C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical outcomes showing a positive ER status, negative PR expression, and weakly positive HER-2/neu status with a score of 2+, what is the molecular subtype of this breast tumor? A) Luminal A B) HER2-enriched C) Luminal B D) Basal"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1J2-01Z-00-DX1.F1D8E593-2DF4-44C3-873D-FD3C910011E4-1",
        "image": "TCGA-BRCA/TCGA-EW-A1J2-01Z-00-DX1.F1D8E593-2DF4-44C3-873D-FD3C910011E4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR status, negative Her-2 and E-cadherin, and immunoreactive tumor cells present for predictive markers, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0EP-01Z-00-DX1.1180C406-5C18-4373-8621-1B7B70875113-1",
        "image": "TCGA-BRCA/TCGA-A2-A0EP-01Z-00-DX1.1180C406-5C18-4373-8621-1B7B70875113.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor expression, negative progesterone receptor, and HER2 not amplified, what is the molecular subtype of this breast carcinoma? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0AW-01Z-00-DX1.9D50A0D2-B103-411C-831E-8520C3D50173-1",
        "image": "TCGA-BRCA/TCGA-BH-A0AW-01Z-00-DX1.9D50A0D2-B103-411C-831E-8520C3D50173.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings of weakly positive estrogen receptor, negative progesterone receptor, and HER-1/NEU scoring 3+ positive, what is the molecular subtype of this cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0BJ-01Z-00-DX1.77BE9A20-3D23-4650-843A-0483BF9DD07B-1",
        "image": "TCGA-BRCA/TCGA-BH-A0BJ-01Z-00-DX1.77BE9A20-3D23-4650-843A-0483BF9DD07B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen and progesterone receptors and negative HER2 status, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0DS-01Z-00-DX1.38E82A1F-21B9-4B97-A304-15B886EA68A0-1",
        "image": "TCGA-BRCA/TCGA-BH-A0DS-01Z-00-DX1.38E82A1F-21B9-4B97-A304-15B886EA68A0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating positive estrogen and progesterone receptors, and negative HER2/neu status, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-OL-A6VQ-01Z-00-DX1.E3B81163-0239-47C3-B53F-064405B58685-1",
        "image": "TCGA-BRCA/TCGA-OL-A6VQ-01Z-00-DX1.E3B81163-0239-47C3-B53F-064405B58685.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the IHC results with strong ER expression in 90% of tumor nuclei, weak PR expression in 10-20%, non-amplified HER2 status, and a Ki67 index of 10%, what is the molecular subtype of this breast cancer?  A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0BM-01Z-00-DX1.8BD324F2-60F5-4F59-AF2D-533A5FB230BF-1",
        "image": "TCGA-BRCA/TCGA-BH-A0BM-01Z-00-DX1.8BD324F2-60F5-4F59-AF2D-533A5FB230BF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER expression, negative PR expression, and previously reported negative HER-2/neu status, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0H3-01Z-00-DX1.C6D4DFB9-A4FA-40B2-90EF-75294CBC4523-1",
        "image": "TCGA-BRCA/TCGA-BH-A0H3-01Z-00-DX1.C6D4DFB9-A4FA-40B2-90EF-75294CBC4523.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression for both estrogen receptor (ER) and progesterone receptor (PR), and negative HER2/neu status (FISH non-amplified), what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1OZ-01Z-00-DX1.9639BB06-FF02-475F-A89D-773BE12721CC-1",
        "image": "TCGA-BRCA/TCGA-EW-A1OZ-01Z-00-DX1.9639BB06-FF02-475F-A89D-773BE12721CC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing strong positivity for ER/PR and strongly positive HER-2/neu with a recommendation for HER-2 confirmation by FISH test, what is the molecular subtype of the tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-GM-A3NW-01Z-00-DX1.3B0324F0-4007-4390-AF26-3789A50684E5-1",
        "image": "TCGA-BRCA/TCGA-GM-A3NW-01Z-00-DX1.3B0324F0-4007-4390-AF26-3789A50684E5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nThe immunohistochemical results show that cytokeratin staining on sentinel lymph nodes 1, 2, 3, and 4 is negative for metastatic carcinoma. What is the molecular subtype of this case? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0BD-01Z-00-DX1.CD4A6FC2-BA8C-4E30-972A-E6CD1BEAD8AD-1",
        "image": "TCGA-BRCA/TCGA-BH-A0BD-01Z-00-DX1.CD4A6FC2-BA8C-4E30-972A-E6CD1BEAD8AD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results of ER positive, PR positive, and HER-2/NEU negative (score 1+), what is the molecular subtype of this tumor?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AR-A256-01Z-00-DX1.950D4546-4BF4-4380-9877-51D86A93D755-1",
        "image": "TCGA-BRCA/TCGA-AR-A256-01Z-00-DX1.950D4546-4BF4-4380-9877-51D86A93D755.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative estrogen receptor and negative progesterone receptor status, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0HQ-01Z-00-DX1.0921FCEF-20A2-4D4B-A198-91AF9F6C814C-1",
        "image": "TCGA-BRCA/TCGA-BH-A0HQ-01Z-00-DX1.0921FCEF-20A2-4D4B-A198-91AF9F6C814C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen and progesterone receptor status, with negative HER-2/NEU expression, what is the molecular subtype of this breast cancer?   A) Luminal B   B) Basal   C) HER2-enriched   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-EW-A6S9-01Z-00-DX1.4A8CD2D4-D528-465C-82DC-9CAE35DD424B-1",
        "image": "TCGA-BRCA/TCGA-EW-A6S9-01Z-00-DX1.4A8CD2D4-D528-465C-82DC-9CAE35DD424B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating positive ER status with 50% immunoreactive tumor cells, positive HER2 (Score 3+), and negative keratin, what is the molecular subtype of this tumor?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0DZ-01Z-00-DX1.138BAEC2-589E-4960-B94E-DF48DDAA5490-1",
        "image": "TCGA-BRCA/TCGA-BH-A0DZ-01Z-00-DX1.138BAEC2-589E-4960-B94E-DF48DDAA5490.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results indicating positive ER and PR, along with strongly positive HER2/neu (IHC 2+ with FISH amplification), what is the molecular subtype of this breast cancer?   A) Basal   B) Luminal A   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0BC-01Z-00-DX1.7A91831D-9625-49FC-B783-C633F80F898C-1",
        "image": "TCGA-BRCA/TCGA-BH-A0BC-01Z-00-DX1.7A91831D-9625-49FC-B783-C633F80F898C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the positive expression of both estrogen and progesterone receptors and a HER2/NEU score of 2+, what is the molecular subtype of this breast cancer? A) HER2-enriched   B) Basal   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AQ-A04J-01Z-00-DX1.6A4E16D4-2696-4E5F-BCA8-708556FC3A8C-1",
        "image": "TCGA-BRCA/TCGA-AQ-A04J-01Z-00-DX1.6A4E16D4-2696-4E5F-BCA8-708556FC3A8C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negative expression for estrogen receptor (ER), progesterone receptor (PR), and HER2/neu, what is the molecular subtype of this tumor? A) HER2-enriched B) Luminal B C) Basal D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A18V-01Z-00-DX1.7797760A-05CD-436E-97DA-31D6201F943B-1",
        "image": "TCGA-BRCA/TCGA-BH-A18V-01Z-00-DX1.7797760A-05CD-436E-97DA-31D6201F943B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative status for ER, PR, and HER-2/neu (score 0), as well as positivity for CKT, what is the molecular subtype of this tumor?  A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-LL-A6FR-01Z-00-DX1.107010FD-8EDD-406D-B4DE-DEC9E85576FF-1",
        "image": "TCGA-BRCA/TCGA-LL-A6FR-01Z-00-DX1.107010FD-8EDD-406D-B4DE-DEC9E85576FF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negative ER, positive PR in 3% of tumor cells with weak intensity, equivocal HER2, and amplified HER2 by in situ hybridization, what is the molecular subtype of this breast cancer? A) HER2-enriched   B) Luminal B   C) Basal   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-LL-A73Y-01Z-00-DX1.50C20931-3AA9-40B4-8A73-56B1976423A8-1",
        "image": "TCGA-BRCA/TCGA-LL-A73Y-01Z-00-DX1.50C20931-3AA9-40B4-8A73-56B1976423A8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative expression for estrogen receptor (ER), progesterone receptor (PR), and HER2/neu, what is the molecular subtype of this breast cancer? A) Basal B) Luminal A C) Luminal B D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1B1-01Z-00-DX1.7C8DF153-B09B-44C7-87B8-14591E319354-1",
        "image": "TCGA-BRCA/TCGA-E2-A1B1-01Z-00-DX1.7C8DF153-B09B-44C7-87B8-14591E319354.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith immunohistochemical results indicating positive estrogen receptor (ER) and progesterone receptor (PR) status, as well as HER2 amplification by FISH, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0HK-01Z-00-DX1.019036F5-647A-4EC4-8479-F2C100291AEF-1",
        "image": "TCGA-BRCA/TCGA-BH-A0HK-01Z-00-DX1.019036F5-647A-4EC4-8479-F2C100291AEF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating positive estrogen receptor status, negative progesterone receptor, and negative HER-2/neu (score 0), what is the molecular subtype of this breast cancer? A) Luminal A B) Basal C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1IW-01Z-00-DX1.0DE87057-951F-4887-A2D5-485736D66E4E-1",
        "image": "TCGA-BRCA/TCGA-EW-A1IW-01Z-00-DX1.0DE87057-951F-4887-A2D5-485736D66E4E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression for estrogen receptors (ER) and progesterone receptors (PR), an equivocal HER2 status with confirmed amplification, what is the molecular subtype of this tumor? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A18Q-01Z-00-DX1.E89E49C7-D62A-4408-A3D9-19E79FCB249E-1",
        "image": "TCGA-BRCA/TCGA-BH-A18Q-01Z-00-DX1.E89E49C7-D62A-4408-A3D9-19E79FCB249E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negative ER and PR, with HER-2/NEU weakly positive (2+), what is the molecular subtype of this tumor?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1J3-01Z-00-DX1.F736F6F4-0859-439A-A417-98B520C8D65A-1",
        "image": "TCGA-BRCA/TCGA-EW-A1J3-01Z-00-DX1.F736F6F4-0859-439A-A417-98B520C8D65A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing immunoreactive tumor cells present for both estrogen and progesterone receptors, and a positive HER2/neu score of 3+, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0EV-01Z-00-DX1.EA8C5594-BA4F-47A8-949B-D536E00E62C9-1",
        "image": "TCGA-BRCA/TCGA-A2-A0EV-01Z-00-DX1.EA8C5594-BA4F-47A8-949B-D536E00E62C9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen and progesterone receptors, negative HER2 neu, and positive staining for cytokeratin and E-cadherin in invasive carcinoma, what is the molecular subtype of this breast cancer? A) Luminal A B) Basal C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0DG-01Z-00-DX1.D3C4F57F-608F-46AA-A978-B558117C9DFB-1",
        "image": "TCGA-BRCA/TCGA-BH-A0DG-01Z-00-DX1.D3C4F57F-608F-46AA-A978-B558117C9DFB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor, negative progesterone receptor, and HER-2/neu negative status, what is the molecular subtype of this cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1B6-01Z-00-DX1.8CD458BE-C4F9-4AF3-A927-18C042E9B4B7-1",
        "image": "TCGA-BRCA/TCGA-E2-A1B6-01Z-00-DX1.8CD458BE-C4F9-4AF3-A927-18C042E9B4B7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results indicating negative ER and PR status with an equivocal HER2 expression (2+ intensity and 15% tumor staining), what is the molecular subtype of this breast cancer? A) Luminal A   B) Luminal B   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1IY-01Z-00-DX1.3FD00274-C2CD-491A-915B-23FD535A4723-1",
        "image": "TCGA-BRCA/TCGA-EW-A1IY-01Z-00-DX1.3FD00274-C2CD-491A-915B-23FD535A4723.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemistry results showing positive ER and PR expression, negative HER2-neu status, and negative keratin staining, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-OL-A66K-01Z-00-DX1.C1DC85F1-4FAE-4411-9886-11DCB5E70CC3-1",
        "image": "TCGA-BRCA/TCGA-OL-A66K-01Z-00-DX1.C1DC85F1-4FAE-4411-9886-11DCB5E70CC3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results with moderate ER expression in > 75% of invasive tumor nuclei, strong PR expression in > 99% of invasive tumor nuclei, and equivocal Her2/neu antigen expression with pending FISH results, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-OL-A66L-01Z-00-DX1.E01BA275-57A5-49DF-9376-1AD0BDFFF7E2-1",
        "image": "TCGA-BRCA/TCGA-OL-A66L-01Z-00-DX1.E01BA275-57A5-49DF-9376-1AD0BDFFF7E2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing strong expression of ER in over 80% of tumor nuclei and PR in over 90%, along with non-amplified HER2/neu status, what is the molecular subtype of this breast cancer?   A) HER2-enriched   B) Luminal A   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0BP-01Z-00-DX1.63A87C1D-87FA-494D-9836-74290B5DC30D-1",
        "image": "TCGA-BRCA/TCGA-BH-A0BP-01Z-00-DX1.63A87C1D-87FA-494D-9836-74290B5DC30D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive P63, positive Smooth Muscle Myosin Heavy Chain, and HER2/NEU status of zero or 1+, what is the molecular subtype of this tumor? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0EX-01Z-00-DX1.F4C293E9-9BB2-48A1-8080-5F3082E219C5-1",
        "image": "TCGA-BRCA/TCGA-A2-A0EX-01Z-00-DX1.F4C293E9-9BB2-48A1-8080-5F3082E219C5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative HER2 (1+) and rare tumor cells with cytokeratin expression, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AO-A03P-01Z-00-DX1.D34DA321-D8E3-4D68-BCE2-4A8B72B3D0AE-1",
        "image": "TCGA-BRCA/TCGA-AO-A03P-01Z-00-DX1.D34DA321-D8E3-4D68-BCE2-4A8B72B3D0AE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nHaving immunohistochemistry results showing 95% positive nuclear staining for ER with strong intensity, 40% PR nuclear staining with moderate intensity, and negative HER2 status (0 staining intensity), what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A18M-01Z-00-DX1.56E6935A-62CB-4CBE-BDCA-60DA56422CE0-1",
        "image": "TCGA-BRCA/TCGA-BH-A18M-01Z-00-DX1.56E6935A-62CB-4CBE-BDCA-60DA56422CE0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith immunohistochemical results indicating positive estrogen and progesterone receptors both scored at 3+, alongside nearly positive HER-2/neu expression with a score of 2+, what is the molecular subtype of this breast cancer? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A27F-01Z-00-DX1.C1A87F27-49F1-46BA-B2E2-A89293F7FD0C-1",
        "image": "TCGA-BRCA/TCGA-D8-A27F-01Z-00-DX1.C1A87F27-49F1-46BA-B2E2-A89293F7FD0C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing no estrogen or progesterone receptors and a negative HER2 reaction with a score of 1+, what is the molecular subtype of this cancer? A) Basal B) Luminal A C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0EM-01Z-00-DX1.305CF011-7451-4880-9A5D-AB4432CF53A5-1",
        "image": "TCGA-BRCA/TCGA-A2-A0EM-01Z-00-DX1.305CF011-7451-4880-9A5D-AB4432CF53A5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negative cytokeratin expression, what is the molecular subtype of this case? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AR-A0U4-01Z-00-DX1.DE722DC5-859D-4866-ADCC-ED98EDBFB588-1",
        "image": "TCGA-BRCA/TCGA-AR-A0U4-01Z-00-DX1.DE722DC5-859D-4866-ADCC-ED98EDBFB588.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negative expression for estrogen receptor (ER), progesterone receptor (PR), and HER2/neu, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-OL-A66P-01Z-00-DX1.5ADD0D6D-37C6-4BC9-8C2B-64DB18BE99B3-1",
        "image": "TCGA-BRCA/TCGA-OL-A66P-01Z-00-DX1.5ADD0D6D-37C6-4BC9-8C2B-64DB18BE99B3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing no expression of ER and PR, non-amplified HER2 status, and a high Ki-67 proliferation index, what is the molecular subtype of this breast cancer? A) Basal-like B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0GZ-01Z-00-DX1.9AD4F493-A0A9-499D-B667-B33333FC1A51-1",
        "image": "TCGA-BRCA/TCGA-BH-A0GZ-01Z-00-DX1.9AD4F493-A0A9-499D-B667-B33333FC1A51.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen and progesterone receptor status and negative HER-2/NEU by FISH, what is the molecular subtype of this breast cancer?   A) HER2-enriched   B) Luminal A   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-AR-A0U3-01Z-00-DX1.9BB87F9D-459F-4A18-B591-29822EA5AE18-1",
        "image": "TCGA-BRCA/TCGA-AR-A0U3-01Z-00-DX1.9BB87F9D-459F-4A18-B591-29822EA5AE18.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor with > 10% nuclear staining and focally positive progesterone receptor with 1-10% nuclear staining, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-Z7-A8R6-01Z-00-DX1.CE4ED818-D762-4324-9DEA-2ACB38B9B0B9-1",
        "image": "TCGA-BRCA/TCGA-Z7-A8R6-01Z-00-DX1.CE4ED818-D762-4324-9DEA-2ACB38B9B0B9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical profile showing positive estrogen and progesterone receptors, high Ki-67 proliferation index, negative HER2/neu status, and weak p53 positivity, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A27H-01Z-00-DX1.BE9DFDD4-97C5-4327-B1DA-4B34A6F267C5-1",
        "image": "TCGA-BRCA/TCGA-D8-A27H-01Z-00-DX1.BE9DFDD4-97C5-4327-B1DA-4B34A6F267C5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative estrogen receptor, progesterone receptor, and HER2 status, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AC-A5EH-01Z-00-DX1.DF59B26B-379F-4047-B7AE-4493810D30A0-1",
        "image": "TCGA-BRCA/TCGA-AC-A5EH-01Z-00-DX1.DF59B26B-379F-4047-B7AE-4493810D30A0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating positive estrogen receptor expression, negative progesterone receptor status, negative HER2 score, and high Ki67 proliferation index, what is the molecular subtype of this breast cancer? A) Luminal A   B) Luminal B   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0HY-01Z-00-DX1.D7A1BF42-F268-4220-B71B-354CE2AF32D8-1",
        "image": "TCGA-BRCA/TCGA-BH-A0HY-01Z-00-DX1.D7A1BF42-F268-4220-B71B-354CE2AF32D8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical findings where the estrogen receptor is positive, progesterone receptor is negative, and HER-2/neu is strongly positive (Score 3+), what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0H5-01Z-00-DX1.28F24D4D-EE80-4EDA-BC30-A194E22FD61C-1",
        "image": "TCGA-BRCA/TCGA-BH-A0H5-01Z-00-DX1.28F24D4D-EE80-4EDA-BC30-A194E22FD61C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results showing positive estrogen and progesterone receptors, and negative HER-2/neu by FISH, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A10F-01Z-00-DX1.18F9324C-A38F-478E-95DF-B8E172D0DD07-1",
        "image": "TCGA-BRCA/TCGA-E2-A10F-01Z-00-DX1.18F9324C-A38F-478E-95DF-B8E172D0DD07.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical result showing negative E-Cadherin, which supports lobular differentiation, what is the molecular subtype of this breast cancer? A) HER2-enriched B) Basal C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1Y1-01Z-00-DX1.477390C8-2141-4ADD-813E-25220D2A71FC-1",
        "image": "TCGA-BRCA/TCGA-D8-A1Y1-01Z-00-DX1.477390C8-2141-4ADD-813E-25220D2A71FC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith immunohistochemical results showing estrogen receptors present in 10-75% of neoplastic cell nuclei, progesterone receptors in over 75%, and a negative HER2 protein reaction (Score3+), what is the molecular subtype of this cancer? A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1Y1-01Z-00-DX2.B58DC955-F864-4E78-8B1A-8156E2F7D554-1",
        "image": "TCGA-BRCA/TCGA-D8-A1Y1-01Z-00-DX2.B58DC955-F864-4E78-8B1A-8156E2F7D554.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith immunohistochemical results showing estrogen receptors present in 10-75% of neoplastic cell nuclei, progesterone receptors in over 75%, and a negative HER2 protein reaction (Score3+), what is the molecular subtype of this cancer? A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A8-A0A4-01Z-00-DX1.06C38F98-F34B-49F0-AFB5-7F0086188346-1",
        "image": "TCGA-BRCA/TCGA-A8-A0A4-01Z-00-DX1.06C38F98-F34B-49F0-AFB5-7F0086188346.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor and progesterone receptor status, with negative C-erb B-2 oncoprotein, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A15P-01Z-00-DX1.4C7F95DC-B319-4A78-8F34-8CB9166EA6A8-1",
        "image": "TCGA-BRCA/TCGA-E2-A15P-01Z-00-DX1.4C7F95DC-B319-4A78-8F34-8CB9166EA6A8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER with an Allred Score of 8, positive PR with an Allred Score of 4, and negative HER2 status, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A73X-01Z-00-DX2.1ABCCE71-A70C-48C3-924E-2C8F5F71E269-1",
        "image": "TCGA-BRCA/TCGA-D8-A73X-01Z-00-DX2.1ABCCE71-A70C-48C3-924E-2C8F5F71E269.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings of 75% positivity for both estrogen and progesterone receptors, a negative HER2 status (Score  1+), and a Ki-67 proliferation index of 10%, what is the molecular subtype of this breast cancer? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A73X-01Z-00-DX1.5F0DF75C-594C-42DF-BE3F-E00E5E01DCD6-1",
        "image": "TCGA-BRCA/TCGA-D8-A73X-01Z-00-DX1.5F0DF75C-594C-42DF-BE3F-E00E5E01DCD6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings of 75% positivity for both estrogen and progesterone receptors, a negative HER2 status (Score  1+), and a Ki-67 proliferation index of 10%, what is the molecular subtype of this breast cancer? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A10A-01Z-00-DX1.98B19EF1-0DAE-4DC6-8B0E-963CFABC6724-1",
        "image": "TCGA-BRCA/TCGA-E2-A10A-01Z-00-DX1.98B19EF1-0DAE-4DC6-8B0E-963CFABC6724.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER) with an Allred Score of 7, positive progesterone receptor (PR) with an Allred Score of 8, and non-amplified HER-2, what is the molecular subtype indicated by these findings? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-OL-A5RW-01Z-00-DX1.E16DE8EE-31AF-4EAF-A85F-DB3E3E2C3BFF-1",
        "image": "TCGA-BRCA/TCGA-OL-A5RW-01Z-00-DX1.E16DE8EE-31AF-4EAF-A85F-DB3E3E2C3BFF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negative expression for estrogen receptor (ER) and progesterone receptor (PR), non-amplified HER2/neu status, and CK7 positive with CK20 negative, what is the determined molecular subtype of this cancer? A) HER2-enriched   B) Basal   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BH-A1EN-01Z-00-DX1.F535657F-E2FA-4283-87AE-7DAB663B196B-1",
        "image": "TCGA-BRCA/TCGA-BH-A1EN-01Z-00-DX1.F535657F-E2FA-4283-87AE-7DAB663B196B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen receptor, positive progesterone receptor, and HER2/neu positive (score 3+), what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-E2-A152-01Z-00-DX1.B0860DEB-D34B-4C5D-97F5-C1C646437424-1",
        "image": "TCGA-BRCA/TCGA-E2-A152-01Z-00-DX1.B0860DEB-D34B-4C5D-97F5-C1C646437424.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER, negative PR, and positive HER2 status, what is the molecular subtype of this tumor? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-C8-A12Y-01Z-00-DX1.A15CB3E2-E145-4C75-8FEA-1DD503CD7C20-1",
        "image": "TCGA-BRCA/TCGA-C8-A12Y-01Z-00-DX1.A15CB3E2-E145-4C75-8FEA-1DD503CD7C20.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative ER, PR, Her-2/neu, B-Cell Marker, T-Cell Marker, and other markers, what is the molecular subtype of this tumor?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A155-01Z-00-DX1.A5AF232A-61BB-4FDC-ABF9-2FE9BA461BDC-1",
        "image": "TCGA-BRCA/TCGA-E2-A155-01Z-00-DX1.A5AF232A-61BB-4FDC-ABF9-2FE9BA461BDC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results with positive estrogen receptor (ER) expression, negative progesterone receptor (PR), and negative HER2 status, what is the molecular subtype of this breast cancer? A) Basal B) Luminal B C) HER2-enriched D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-OL-A5RY-01Z-00-DX1.AE4E9D74-FC1C-4C1E-AE6D-5DF38899BBA6-1",
        "image": "TCGA-BRCA/TCGA-OL-A5RY-01Z-00-DX1.AE4E9D74-FC1C-4C1E-AE6D-5DF38899BBA6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing weak expression of ER in 10% of invasive tumor nuclei, no expression of PR, and amplified HER2/neu status (FISH ratio: 7.6), what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-E2-A15K-01Z-00-DX1.9F424BE2-9BFE-4DFF-8CC9-10D2DADBBEA7-1",
        "image": "TCGA-BRCA/TCGA-E2-A15K-01Z-00-DX1.9F424BE2-9BFE-4DFF-8CC9-10D2DADBBEA7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing a positive ER with an Allred Score of 8, a positive PR with an Allred Score of 4, and HER2 status pending, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Luminal B   D) Basal"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A1EU-01Z-00-DX1.5A0956EF-0100-47FD-9026-1994CF22D0F1-1",
        "image": "TCGA-BRCA/TCGA-BH-A1EU-01Z-00-DX1.5A0956EF-0100-47FD-9026-1994CF22D0F1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical result showing a negative HER-2/neu status, what is the molecular subtype of this tumor? A) Luminal A B) Basal C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A15L-01Z-00-DX1.626032DC-D396-48E7-B888-DFEBCF7102FF-1",
        "image": "TCGA-BRCA/TCGA-E2-A15L-01Z-00-DX1.626032DC-D396-48E7-B888-DFEBCF7102FF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR status, and negative HER2 by FISH, what is the molecular subtype of this breast cancer? A) Luminal A B) Basal C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-C8-A12K-01Z-00-DX1.D71C7974-65F7-4EF0-8FFB-9F27CEC85242-1",
        "image": "TCGA-BRCA/TCGA-C8-A12K-01Z-00-DX1.D71C7974-65F7-4EF0-8FFB-9F27CEC85242.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative ER, PR, and Her-2/neu status, along with negative B-Cell and T-Cell markers, what is the molecular subtype of this tumor?   A) Luminal A   B) Luminal B   C) Basal   D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A2-A04Y-01Z-00-DX1.4DC97AD6-4806-4A3A-A998-FD36F93590A4-1",
        "image": "TCGA-BRCA/TCGA-A2-A04Y-01Z-00-DX1.4DC97AD6-4806-4A3A-A998-FD36F93590A4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor status, positive progesterone receptor activity at 10%, and negative HER2 status, what is the molecular subtype for this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A2-A3KD-01Z-00-DX1.E400D529-A0D1-4C78-AD5C-33EB0508B128-1",
        "image": "TCGA-BRCA/TCGA-A2-A3KD-01Z-00-DX1.E400D529-A0D1-4C78-AD5C-33EB0508B128.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression for estrogen receptors (>95%) and progesterone receptors (90%), with negative HER2NEU status (Score 1+), what is the molecular subtype of this breast cancer?  A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A1-A0SN-01Z-00-DX1.5E9B85AE-AFB7-41DC-8A1B-BD6DA39B6540-1",
        "image": "TCGA-BRCA/TCGA-A1-A0SN-01Z-00-DX1.5E9B85AE-AFB7-41DC-8A1B-BD6DA39B6540.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing strong positive estrogen receptor status, moderate positive progesterone receptor status, and HER2/neu positivity (staining intensity score of 3), what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A15E-06Z-00-DX1.D394A007-91A2-4445-9B4A-1629EE684A51-1",
        "image": "TCGA-BRCA/TCGA-E2-A15E-06Z-00-DX1.D394A007-91A2-4445-9B4A-1629EE684A51.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR status and HER2 positive by FISH, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A2-A04W-01Z-00-DX1.F7E7B945-2ADC-4741-8FCE-ACEA657DB9C7-1",
        "image": "TCGA-BRCA/TCGA-A2-A04W-01Z-00-DX1.F7E7B945-2ADC-4741-8FCE-ACEA657DB9C7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical result showing HER2 NEU positivity (3+) and one of 18 positive for tumor by IHC only, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-E2-A108-01Z-00-DX1.B110ED43-08A4-476A-A658-1CA75F7C0DDE-1",
        "image": "TCGA-BRCA/TCGA-E2-A108-01Z-00-DX1.B110ED43-08A4-476A-A658-1CA75F7C0DDE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results of positive estrogen receptor (ER) and progesterone receptor (PR), and negative HER2 status, what is the molecular subtype of this tumor?   A) Basal   B) Luminal A   C) HER2-enriched   D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-D8-A13Z-01Z-00-DX1.517140BB-D34C-42F8-952C-340EF16D382F-1",
        "image": "TCGA-BRCA/TCGA-D8-A13Z-01Z-00-DX1.517140BB-D34C-42F8-952C-340EF16D382F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nAccording to the immunohistochemical results indicating negative estrogen and progesterone receptors, and a HER2 protein score of 1+, what is the molecular subtype of this cancer?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A201-01Z-00-DX1.6D6E3224-50A0-45A2-B231-EEF27CA7EFD2-1",
        "image": "TCGA-BRCA/TCGA-BH-A201-01Z-00-DX1.6D6E3224-50A0-45A2-B231-EEF27CA7EFD2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results with positive ER and PR status and negative HER-2/NEU expression, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A1-A0SI-01Z-00-DX1.AB717348-F964-4F29-BBE2-972B7C640432-1",
        "image": "TCGA-BRCA/TCGA-A1-A0SI-01Z-00-DX1.AB717348-F964-4F29-BBE2-972B7C640432.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results showing positive expression for estrogen receptors (strong in ~50% of tumor cells), positive progesterone receptors (weak to moderate in ~15% of tumor cells), and negative HER2, what is the molecular subtype of this tumor? A) Basal B) Luminal A C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-OL-A5RX-01Z-00-DX1.15A0D4F4-2744-4D44-8883-27FF83D9C824-1",
        "image": "TCGA-BRCA/TCGA-OL-A5RX-01Z-00-DX1.15A0D4F4-2744-4D44-8883-27FF83D9C824.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing strong expression of both estrogen receptor (ER) and progesterone receptor (PR) in over 90% of the invasive tumor nuclei, along with a non-amplified Her2/neu status, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E9-A3X8-01Z-00-DX1.D1532F80-F5F8-47AF-8A1B-B59E345F5D70-1",
        "image": "TCGA-BRCA/TCGA-E9-A3X8-01Z-00-DX1.D1532F80-F5F8-47AF-8A1B-B59E345F5D70.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR status, and negative HER2 expression, what is the molecular subtype of this breast cancer? A) Basal B) Luminal A C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-AQ-A7U7-01Z-00-DX1.AB5629A1-399E-402B-AD3D-DAF9F97D8300-1",
        "image": "TCGA-BRCA/TCGA-AQ-A7U7-01Z-00-DX1.AB5629A1-399E-402B-AD3D-DAF9F97D8300.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing strong positive expression for estrogen receptor (88%) and progesterone receptor (82%) with negative HER2 expression, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A153-01Z-00-DX1.CA994467-E541-4131-A9FC-DCD9944F29C4-1",
        "image": "TCGA-BRCA/TCGA-E2-A153-01Z-00-DX1.CA994467-E541-4131-A9FC-DCD9944F29C4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results with positive ER and PR status, and negative HER2 expression, what is the molecular subtype of this tumor? A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AC-A3W5-01Z-00-DX1.522F702C-776E-45F1-84D3-1648DF04137C-1",
        "image": "TCGA-BRCA/TCGA-AC-A3W5-01Z-00-DX1.522F702C-776E-45F1-84D3-1648DF04137C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen and progesterone receptor assays (3+, S08) and positive HercepTest (IHC score 3+, FISH positive), what is the molecular subtype of this tumor?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-OL-A5RV-01Z-00-DX1.920AC243-1DAC-4854-BEB6-1CBCC950F26B-1",
        "image": "TCGA-BRCA/TCGA-OL-A5RV-01Z-00-DX1.920AC243-1DAC-4854-BEB6-1CBCC950F26B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the immunohistochemical results showing strong expression of ER and PR in more than 90% of invasive tumor nuclei and a non-amplified Her2/neu status, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A1EO-01Z-00-DX1.0E624888-D7E4-48DF-B51A-9AD8F75A66B7-1",
        "image": "TCGA-BRCA/TCGA-BH-A1EO-01Z-00-DX1.0E624888-D7E4-48DF-B51A-9AD8F75A66B7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER), positive progesterone receptor (PR), and negative HER2/neu status, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1Y0-01Z-00-DX1.10F40197-4174-43CC-AAD3-8CB85154FB2D-1",
        "image": "TCGA-BRCA/TCGA-D8-A1Y0-01Z-00-DX1.10F40197-4174-43CC-AAD3-8CB85154FB2D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing estrogen receptors in over 75% of neoplastic cell nuclei, progesterone receptors also in over 75% of neoplastic cell nuclei, and a negative HER2 reaction with a score of 1+, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1Y0-01Z-00-DX2.7C25E941-12A6-46CE-B1A5-488D08E35684-1",
        "image": "TCGA-BRCA/TCGA-D8-A1Y0-01Z-00-DX2.7C25E941-12A6-46CE-B1A5-488D08E35684.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing estrogen receptors in over 75% of neoplastic cell nuclei, progesterone receptors also in over 75% of neoplastic cell nuclei, and a negative HER2 reaction with a score of 1+, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A1FG-01Z-00-DX1.DA665FB6-9DD9-4B18-A925-2EFD9BC4C43B-1",
        "image": "TCGA-BRCA/TCGA-BH-A1FG-01Z-00-DX1.DA665FB6-9DD9-4B18-A925-2EFD9BC4C43B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen and progesterone receptors with negative HER-2/neu status, what is the molecular subtype of this cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A1-A0SH-01Z-00-DX1.90E71B08-E1D9-4FC2-85AC-062E56DDF17C-1",
        "image": "TCGA-BRCA/TCGA-A1-A0SH-01Z-00-DX1.90E71B08-E1D9-4FC2-85AC-062E56DDF17C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative estrogen receptor status, strong positive progesterone receptor expression, and indeterminate HER2/neu status, what is the molecular subtype of this breast cancer? A) HER2-enriched   B) Basal   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A1FU-01Z-00-DX1.3D195750-8C9E-48C6-92EC-44AC6AB56267-1",
        "image": "TCGA-BRCA/TCGA-BH-A1FU-01Z-00-DX1.3D195750-8C9E-48C6-92EC-44AC6AB56267.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor status and HER-2 overexpression (Score 3+), what is the molecular subtype of this tumor? A) Luminal A   B) Luminal B   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A109-01Z-00-DX1.FCF5E9FC-F9FE-4F5F-96DD-5628E2609BEF-1",
        "image": "TCGA-BRCA/TCGA-E2-A109-01Z-00-DX1.FCF5E9FC-F9FE-4F5F-96DD-5628E2609BEF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER status (Allred Score of 8), negative PR status in one focus, positive PR in the second focus (Allred Score of 7), and equivocal HER2 status, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A15C-01Z-00-DX1.26E13415-1D37-43C7-9EBB-4411BE7FCE10-1",
        "image": "TCGA-BRCA/TCGA-E2-A15C-01Z-00-DX1.26E13415-1D37-43C7-9EBB-4411BE7FCE10.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER) and progesterone receptor (PR) status, with pending HER2 results, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A04Q-01Z-00-DX1.DF7ED6B6-7701-486D-9007-F26B6F0682C4-1",
        "image": "TCGA-BRCA/TCGA-A2-A04Q-01Z-00-DX1.DF7ED6B6-7701-486D-9007-F26B6F0682C4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical findings of negative progesterone receptor expression, HER2 NEU 2+ by immunohistochemistry, and HER2 NEU not amplified by FISH, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-GM-A4E0-01Z-00-DX1.55A5D765-AA35-4052-9185-6872B580F0F6-1",
        "image": "TCGA-BRCA/TCGA-GM-A4E0-01Z-00-DX1.55A5D765-AA35-4052-9185-6872B580F0F6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical result showing positive cytokeratin indicative of metastatic carcinoma, what is the molecular subtype of this cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A15M-01Z-00-DX1.6E4671E5-18EA-4464-BE7C-C94767136E5C-1",
        "image": "TCGA-BRCA/TCGA-E2-A15M-01Z-00-DX1.6E4671E5-18EA-4464-BE7C-C94767136E5C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive ER and PR expression, and negative HER2 status, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0T3-01Z-00-DX1.5E96BC87-F4FB-4ABA-8D81-FAB7F4A80661-1",
        "image": "TCGA-BRCA/TCGA-A2-A0T3-01Z-00-DX1.5E96BC87-F4FB-4ABA-8D81-FAB7F4A80661.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive cytokeratin staining in the first sentinel lymph node and negative cytokeratin staining in the second axillary lymph node biopsy, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A107-01Z-00-DX1.3BFCCC24-7286-488D-A9E9-98E498AD0767-1",
        "image": "TCGA-BRCA/TCGA-E2-A107-01Z-00-DX1.3BFCCC24-7286-488D-A9E9-98E498AD0767.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results of positive ER, negative PR, and negative HER2 by FISH, what is the molecular subtype of this tumor? A) Basal B) Luminal A C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-A7-A5ZX-01Z-00-DX2.02F586FE-4775-480B-8035-D6AD3386F45D-1",
        "image": "TCGA-BRCA/TCGA-A7-A5ZX-01Z-00-DX2.02F586FE-4775-480B-8035-D6AD3386F45D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing a positive estrogen receptor (ER) status with 80% moderate intensity, weakly positive progesterone receptor (PR) at 5% with weak intensity, and negative Her2 expression, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A7-A5ZX-01Z-00-DX1.A4C651F0-DB8E-4534-84A2-AD875F62209F-1",
        "image": "TCGA-BRCA/TCGA-A7-A5ZX-01Z-00-DX1.A4C651F0-DB8E-4534-84A2-AD875F62209F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing a positive estrogen receptor (ER) status with 80% moderate intensity, weakly positive progesterone receptor (PR) at 5% with weak intensity, and negative Her2 expression, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A1-A0SF-01Z-00-DX1.7F252D89-EA78-419F-A969-1B7313D77499-1",
        "image": "TCGA-BRCA/TCGA-A1-A0SF-01Z-00-DX1.7F252D89-EA78-419F-A969-1B7313D77499.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor expression, positive progesterone receptor expression, and negative HER2 status, what is the molecular subtype of this breast cancer? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0T4-01Z-00-DX1.AC61ED08-2E42-4D4A-BB81-746D3FEBB653-1",
        "image": "TCGA-BRCA/TCGA-A2-A0T4-01Z-00-DX1.AC61ED08-2E42-4D4A-BB81-746D3FEBB653.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings with no evidence of metastatic disease in the right axillary sentinel and non-sentinel nodes, as well as the left axillary sentinel lymph nodes, what is the determined molecular subtype for these characteristics? A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A15J-01Z-00-DX1.BF7901D1-30B1-4A76-B0A5-E9B8B36EF4C9-1",
        "image": "TCGA-BRCA/TCGA-E2-A15J-01Z-00-DX1.BF7901D1-30B1-4A76-B0A5-E9B8B36EF4C9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR expression and HER2 negativity by FISH, what is the molecular subtype of this breast cancer? A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AO-A0JJ-01Z-00-DX1.D5B636F5-1B47-4033-9938-9DC8CD48CEE9-1",
        "image": "TCGA-BRCA/TCGA-AO-A0JJ-01Z-00-DX1.D5B636F5-1B47-4033-9938-9DC8CD48CEE9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the immunohistochemical results showing positive BR expression (95% nuclear staining with strong intensity), moderate to strong PR expression (70% nuclear staining), and both ER and HER2 negativity, what is the molecular subtype of this breast cancer? A) HER2-enriched B) Basal C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A145-01Z-00-DX2.B834BF47-1CD6-45EA-BB88-D8ECE1FDDC6A-1",
        "image": "TCGA-BRCA/TCGA-D8-A145-01Z-00-DX2.B834BF47-1CD6-45EA-BB88-D8ECE1FDDC6A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing 75% positive estrogen receptors, 10% positive progesterone receptors, and HER2 protein score of 2+, possibly requiring FISH verification, what is the molecular subtype of this breast cancer? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A145-01Z-00-DX1.34D4EC27-7FD7-4BE2-95A4-CA521CB5590E-1",
        "image": "TCGA-BRCA/TCGA-D8-A145-01Z-00-DX1.34D4EC27-7FD7-4BE2-95A4-CA521CB5590E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing 75% positive estrogen receptors, 10% positive progesterone receptors, and HER2 protein score of 2+, possibly requiring FISH verification, what is the molecular subtype of this breast cancer? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XU-01Z-00-DX1.769DBC38-6F0D-425B-A904-79EBA1C119EF-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XU-01Z-00-DX1.769DBC38-6F0D-425B-A904-79EBA1C119EF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing estrogen receptors in over 75% of neoplastic cell nuclei, progesterone receptors in 10-75% of nuclei, and negative HER2 status (Score  1+), what is the molecular subtype?  A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1X9-01Z-00-DX1.28CE7849-EEC5-4ABB-A319-A977A1FD3CD1-1",
        "image": "TCGA-BRCA/TCGA-D8-A1X9-01Z-00-DX1.28CE7849-EEC5-4ABB-A319-A977A1FD3CD1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results where estrogen and progesterone receptors are found in over 75% of neoplastic cell nuclei, HER2 shows a score of 2+ with no gene amplification, what is the molecular subtype of this breast cancer? A) Luminal B B) HER2-enriched C) Basal D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A14X-01Z-00-DX1.24ADDA43-F127-4A6B-9AAD-2FAD982A853D-1",
        "image": "TCGA-BRCA/TCGA-E2-A14X-01Z-00-DX1.24ADDA43-F127-4A6B-9AAD-2FAD982A853D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the immunohistochemical results showing negative estrogen receptor (ER), negative progesterone receptor (PR), and negative HER2 status, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XR-01Z-00-DX2.A103FB8B-4397-4DD4-8587-90A736407484-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XR-01Z-00-DX2.A103FB8B-4397-4DD4-8587-90A736407484.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR status in over 75% of tumor cells, with a negative HER2 score of 1, what is the molecular subtype of this breast cancer? A) Basal B) Luminal A C) HER2-enriched D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XR-01Z-00-DX1.7F443346-C564-47B6-9736-6944230CAF46-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XR-01Z-00-DX1.7F443346-C564-47B6-9736-6944230CAF46.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR status in over 75% of tumor cells, with a negative HER2 score of 1, what is the molecular subtype of this breast cancer? A) Basal B) Luminal A C) HER2-enriched D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-AC-A8OP-01Z-00-DX1.A2AF501D-7DCD-4BE7-93A4-EBCAF0C0D54E-1",
        "image": "TCGA-BRCA/TCGA-AC-A8OP-01Z-00-DX1.A2AF501D-7DCD-4BE7-93A4-EBCAF0C0D54E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen and progesterone receptor status, negative HER2/neu expression, and a Ki-67 proliferation index of 20% positive cells, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AO-A0JM-01Z-00-DX1.94E75EFD-E5F5-4DF8-93A0-ED94CB4D203A-1",
        "image": "TCGA-BRCA/TCGA-AO-A0JM-01Z-00-DX1.94E75EFD-E5F5-4DF8-93A0-ED94CB4D203A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing HER2 positivity with staining intensity of 2+, 18% nuclear staining for PR with moderate to weak intensity, and moderate staining for estrogen receptor (ER), what is the molecular subtype for this sample? A) Luminal A   B) HER2-enriched   C) Luminal B   D) Basal"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A2-A1FX-01Z-00-DX1.35B93F3A-9959-4D72-A702-08B27563D24F-1",
        "image": "TCGA-BRCA/TCGA-A2-A1FX-01Z-00-DX1.35B93F3A-9959-4D72-A702-08B27563D24F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive expression for Cytokeratin (AE1/AE3) and E-cadherin, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0ST-01Z-00-DX1.AE05A5DB-4861-40DE-B0F5-7955FC903A96-1",
        "image": "TCGA-BRCA/TCGA-A2-A0ST-01Z-00-DX1.AE05A5DB-4861-40DE-B0F5-7955FC903A96.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating negative estrogen receptor, positive progesterone receptor, and negative HER2/NEU expression (not amplified, protein score 1+), what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-XX-A89A-01Z-00-DX1.671E2AD6-4D1A-4579-88C1-5B0B15818126-1",
        "image": "TCGA-BRCA/TCGA-XX-A89A-01Z-00-DX1.671E2AD6-4D1A-4579-88C1-5B0B15818126.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on immunohistochemistry showing positive expression for both estrogen and progesterone receptors (70% of tumor cell nuclei staining moderately to strongly), and negative HER-2/neu status (score 0), what is the molecular subtype of this breast cancer?   A) Luminal B   B) HER2-enriched   C) Basal   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A14V-01Z-00-DX1.D6274B5E-644C-478C-817F-B8BB9262D6F4-1",
        "image": "TCGA-BRCA/TCGA-E2-A14V-01Z-00-DX1.D6274B5E-644C-478C-817F-B8BB9262D6F4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER, positive PR, and positive HER2 with an intensity of 3+ and 100% tumor staining, what is the molecular subtype of this tumor? A) Luminal A   B) Luminal B   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1X7-01Z-00-DX2.F0631B8C-EB75-4995-8ED7-1A8972BE8997-1",
        "image": "TCGA-BRCA/TCGA-D8-A1X7-01Z-00-DX2.F0631B8C-EB75-4995-8ED7-1A8972BE8997.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing strong positivity for both estrogen and progesterone receptors (over 75% of neoplastic cell nuclei) and negative HER2 status (Score  0), what is the molecular subtype of this breast cancer? A) HER2-enriched   B) Luminal A   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1X7-01Z-00-DX1.3529AEED-2827-4D94-9A8B-32F116EE49D5-1",
        "image": "TCGA-BRCA/TCGA-D8-A1X7-01Z-00-DX1.3529AEED-2827-4D94-9A8B-32F116EE49D5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing strong positivity for both estrogen and progesterone receptors (over 75% of neoplastic cell nuclei) and negative HER2 status (Score  0), what is the molecular subtype of this breast cancer? A) HER2-enriched   B) Luminal A   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BH-A42V-01Z-00-DX1.B6D78256-05D1-45FA-826A-1B8554D60B7D-1",
        "image": "TCGA-BRCA/TCGA-BH-A42V-01Z-00-DX1.B6D78256-05D1-45FA-826A-1B8554D60B7D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results of positive estrogen and progesterone receptors, and HER2/neu positivity, what is the determined molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1P3-01Z-00-DX1.EF69B964-57D6-4F8E-A183-A3022AF6E835-1",
        "image": "TCGA-BRCA/TCGA-EW-A1P3-01Z-00-DX1.EF69B964-57D6-4F8E-A183-A3022AF6E835.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative keratin staining for the tumor, what is the molecular subtype of this cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A14Q-01Z-00-DX1.C19BA7FD-D986-4E3B-9A79-F3531A78F05D-1",
        "image": "TCGA-BRCA/TCGA-E2-A14Q-01Z-00-DX1.C19BA7FD-D986-4E3B-9A79-F3531A78F05D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical result showing positive expression for ECADHERIN, what is the molecular subtype of this tumor? A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A2-A1FV-01Z-00-DX1.F70ACD9A-7819-4296-BD28-4D24BBA8AFF4-1",
        "image": "TCGA-BRCA/TCGA-A2-A1FV-01Z-00-DX1.F70ACD9A-7819-4296-BD28-4D24BBA8AFF4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen receptor (ER) and progesterone receptor (PR) status with negative HER2 expression, what is the molecular subtype of this tumor? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1P4-01Z-00-DX1.3E9AE553-83D4-4B09-AB7F-D096BCE3BC4D-1",
        "image": "TCGA-BRCA/TCGA-EW-A1P4-01Z-00-DX1.3E9AE553-83D4-4B09-AB7F-D096BCE3BC4D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative ER, PR, and HER2 status, and positive HLA-DR, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Luminal B   D) Basal"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-B6-A0I1-01Z-00-DX1.86BEC5E4-A2D1-4039-8D08-0598FA8BCC2B-1",
        "image": "TCGA-BRCA/TCGA-B6-A0I1-01Z-00-DX1.86BEC5E4-A2D1-4039-8D08-0598FA8BCC2B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results of negative estrogen receptor (FMOL value 0) and negative progesterone receptor (HMOL value 0), what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-B6-A0IO-01Z-00-DX1.D8898C30-4016-4983-9359-5C1507C01715-1",
        "image": "TCGA-BRCA/TCGA-B6-A0IO-01Z-00-DX1.D8898C30-4016-4983-9359-5C1507C01715.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor status, borderline progesterone receptor activity, no HER2 overexpression, and a high proliferation index, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-GM-A2DL-01Z-00-DX1.1CE6992E-B1CE-45AB-B2EB-75338B6FEE9D-1",
        "image": "TCGA-BRCA/TCGA-GM-A2DL-01Z-00-DX1.1CE6992E-B1CE-45AB-B2EB-75338B6FEE9D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER) and progesterone receptor (PR) status, negative HER2 overexpression, and a high Ki-67 proliferation index, what is the molecular subtype of this breast cancer? A) HER2-enriched B) Basal C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A573-01Z-00-DX1.D6633BC2-524D-4153-952F-6B1D8D067370-1",
        "image": "TCGA-BRCA/TCGA-E2-A573-01Z-00-DX1.D6633BC2-524D-4153-952F-6B1D8D067370.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative expression for estrogen receptor (ER) and progesterone receptor (PR), with equivocal HER2 status (intensity 2+, 10% tumor staining), what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0WA-01Z-00-DX1.C0EB7B73-5529-49EC-B660-3F849B041963-1",
        "image": "TCGA-BRCA/TCGA-BH-A0WA-01Z-00-DX1.C0EB7B73-5529-49EC-B660-3F849B041963.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negative expression for estrogen receptors, progesterone receptors, ABL/ABS (1B), and HER2NEU scored as 1+, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A2-A259-01Z-00-DX1.7289CD72-CB74-41D4-B4AC-4EA5FDFEC666-1",
        "image": "TCGA-BRCA/TCGA-A2-A259-01Z-00-DX1.7289CD72-CB74-41D4-B4AC-4EA5FDFEC666.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating positive estrogen and progesterone receptor status, along with HER2 negativity (1+), what is the molecular subtype of this breast cancer? A) Basal B) Luminal B C) HER2-enriched D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AO-A0J4-01Z-00-DX1.2EFC978E-8DF5-4254-9598-C0910B17C5C8-1",
        "image": "TCGA-BRCA/TCGA-AO-A0J4-01Z-00-DX1.2EFC978E-8DF5-4254-9598-C0910B17C5C8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing 0% nuclear staining for both estrogen and progesterone receptors, and the absence of metastatic disease in cytokeratins, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XG-01Z-00-DX1.0A58EF43-B97E-4111-8DC3-2F8D9BDBE7D6-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XG-01Z-00-DX1.0A58EF43-B97E-4111-8DC3-2F8D9BDBE7D6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results that indicate estrogen receptors expressed in 10-75% of neoplastic cell nuclei, progesterone receptors expressed in 10-75% of neoplastic cell nuclei, and a negative HER2 status, what is the molecular subtype of this tumor?  A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EW-A2FW-01Z-00-DX1.4F948681-81F3-46C5-A4E8-FDE8A4116F7A-1",
        "image": "TCGA-BRCA/TCGA-EW-A2FW-01Z-00-DX1.4F948681-81F3-46C5-A4E8-FDE8A4116F7A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings showing negative keratin expression in all tested nodes, how should the molecular subtype of this breast cancer be classified? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A14P-01Z-00-DX1.663B02FF-C64B-41A6-8685-FD61CD76F9C6-1",
        "image": "TCGA-BRCA/TCGA-E2-A14P-01Z-00-DX1.663B02FF-C64B-41A6-8685-FD61CD76F9C6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing ER negative, PR negative, and HER2 positive, what is the molecular subtype of this breast cancer? A) Basal B) Luminal A C) Luminal B D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AR-A2LN-01Z-00-DX1.3EF43524-28B8-4326-9356-6BCBC63A1DA8-1",
        "image": "TCGA-BRCA/TCGA-AR-A2LN-01Z-00-DX1.3EF43524-28B8-4326-9356-6BCBC63A1DA8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results confirming the H&E impression in the right and left axillary sentinel lymph nodes with cytokeratin staining, what is the molecular subtype of this tumor?  A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A1FW-01Z-00-DX1.DC2BC5D7-E57B-444E-833F-9A1B6E11DE6D-1",
        "image": "TCGA-BRCA/TCGA-A2-A1FW-01Z-00-DX1.DC2BC5D7-E57B-444E-833F-9A1B6E11DE6D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing 90% immunoreactive tumor cells for ER, absence of PR activity, and negative PanKeratin, what is the molecular subtype of this tumor?   A) HER2-enriched   B) Basal   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1P5-01Z-00-DX1.B0D59A56-116E-48B3-BC90-237EA4B3F95B-1",
        "image": "TCGA-BRCA/TCGA-EW-A1P5-01Z-00-DX1.B0D59A56-116E-48B3-BC90-237EA4B3F95B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression for estrogen receptor (ER) and progesterone receptor (PR), and negative HER-2 status, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AO-A0JB-01Z-00-DX1.250FE098-345B-4981-9236-0519E1C9058E-1",
        "image": "TCGA-BRCA/TCGA-AO-A0JB-01Z-00-DX1.250FE098-345B-4981-9236-0519E1C9058E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing moderate intensity for both estrogen receptor (ER) and progesterone receptor (PR) and a HER2 score of 1+, what is the molecular subtype of this breast cancer? A) HER2-enriched B) Basal C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0W7-01Z-00-DX1.93F11232-A1FB-4682-B744-3531D4DF11AF-1",
        "image": "TCGA-BRCA/TCGA-BH-A0W7-01Z-00-DX1.93F11232-A1FB-4682-B744-3531D4DF11AF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating positive ER and PR, and negative Her-2/Neu, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1X6-01Z-00-DX1.ABF237D4-708C-46A5-AEF8-58712E5DCC04-1",
        "image": "TCGA-BRCA/TCGA-D8-A1X6-01Z-00-DX1.ABF237D4-708C-46A5-AEF8-58712E5DCC04.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive expression of estrogen and progesterone receptors in over 75% of cell nuclei and negative HER2 status (score 1+), what is the molecular subtype of this tumor?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1X6-01Z-00-DX2.F36D68F2-70C3-4E0E-ABE6-6969170BA6DC-1",
        "image": "TCGA-BRCA/TCGA-D8-A1X6-01Z-00-DX2.F36D68F2-70C3-4E0E-ABE6-6969170BA6DC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive expression of estrogen and progesterone receptors in over 75% of cell nuclei and negative HER2 status (score 1+), what is the molecular subtype of this tumor?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XZ-01Z-00-DX1.8E51A61D-B01C-4A52-8F5D-44D2ABCA46FC-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XZ-01Z-00-DX1.8E51A61D-B01C-4A52-8F5D-44D2ABCA46FC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing over 75% of neoplastic cell nuclei expressing estrogen receptors, absence of progesterone receptors, and a negative HER2 protein reaction in invasive cancerous cells (Score  1+), what is the molecular subtype of this tumor? A) HER2-enriched   B) Basal   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XZ-01Z-00-DX2.73D59546-C003-4DED-80D5-866E7055EC79-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XZ-01Z-00-DX2.73D59546-C003-4DED-80D5-866E7055EC79.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing over 75% of neoplastic cell nuclei expressing estrogen receptors, absence of progesterone receptors, and a negative HER2 protein reaction in invasive cancerous cells (Score  1+), what is the molecular subtype of this tumor? A) HER2-enriched   B) Basal   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AC-A2FB-01Z-00-DX1.A4D93E32-BBD7-45E4-8ACF-3724B059ECBC-1",
        "image": "TCGA-BRCA/TCGA-AC-A2FB-01Z-00-DX1.A4D93E32-BBD7-45E4-8ACF-3724B059ECBC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven immunohistochemistry results showing moderate positive staining for estrogen receptor (ER) at 2+, strong positivity for progesterone receptor (PR) at 3+, and HER2/neu positivity at 3+ with E-cadherin negativity, what is the molecular subtype of this breast cancer? A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-AC-A7VB-01Z-00-DX1.62D7FDB3-280D-43B2-92EA-AB810384B0B7-1",
        "image": "TCGA-BRCA/TCGA-AC-A7VB-01Z-00-DX1.62D7FDB3-280D-43B2-92EA-AB810384B0B7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical findings with focal metastatic carcinoma highlighted in specimens and pending HER2 results, what is the molecular subtype of this carcinoma? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1X8-01Z-00-DX1.DDA3866E-C7CC-4650-BE2B-5C9A98A2D531-1",
        "image": "TCGA-BRCA/TCGA-D8-A1X8-01Z-00-DX1.DDA3866E-C7CC-4650-BE2B-5C9A98A2D531.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing estrogen and progesterone receptors in over 75% of neoplastic cell nuclei and a HER2 score of 2+ without amplification, what is the molecular subtype of this breast cancer?  A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XT-01Z-00-DX1.9E4DEEEB-AB0A-45F6-A69B-65B3E6F22D46-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XT-01Z-00-DX1.9E4DEEEB-AB0A-45F6-A69B-65B3E6F22D46.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative expression for estrogen and progesterone receptors, and positive HER2 protein expression (Score  3+) for both Tumour 1 and Tumour 2, what is the molecular subtype of these tumors? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-E2-A14Y-01Z-00-DX1.804A22A3-FD8D-4C8A-A766-48D28434DE22-1",
        "image": "TCGA-BRCA/TCGA-E2-A14Y-01Z-00-DX1.804A22A3-FD8D-4C8A-A766-48D28434DE22.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results with positive ER, positive PR, and HER2 positive by FISH, what is the molecular subtype of this tumor? A) Basal B) Luminal A C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A2-A25A-01Z-00-DX1.6D311E39-9F96-4775-B9DA-8D034D1AD1DC-1",
        "image": "TCGA-BRCA/TCGA-A2-A25A-01Z-00-DX1.6D311E39-9F96-4775-B9DA-8D034D1AD1DC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative estrogen receptor status, positive progesterone receptor status (80-90% nuclear staining), and non-amplified HER2 status (1.1 FISH result), what is the molecular subtype of this breast cancer? A) HER2-enriched B) Luminal A C) Luminal B D) Normal-like"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1PB-01Z-00-DX1.B2E9B88F-C371-4821-9B7B-8A63BB120D95-1",
        "image": "TCGA-BRCA/TCGA-EW-A1PB-01Z-00-DX1.B2E9B88F-C371-4821-9B7B-8A63BB120D95.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing no immunoreactive tumor cells for estrogen receptor, no immunoreactive tumor cells for progesterone receptor, and a negative HER2/neu status, what is the molecular subtype of this tumor? A) Basal   B) Luminal A   C) Luminal B   D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XA-01Z-00-DX1.36A807F0-2D35-4CE3-8A27-CC59181B1A3D-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XA-01Z-00-DX1.36A807F0-2D35-4CE3-8A27-CC59181B1A3D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results of positive estrogen receptors and progesterone receptors (both in over 75% of neoplastic cell nuclei) and HER2 negative status, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-GM-A2DD-01Z-00-DX1.01332FF3-7488-41B7-A515-7841715DE92B-1",
        "image": "TCGA-BRCA/TCGA-GM-A2DD-01Z-00-DX1.01332FF3-7488-41B7-A515-7841715DE92B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results of low positive estrogen receptor (1-9%), negative progesterone receptor, negative HER-2/neu overexpression, and positive markers for CK903, CK5/6, and vimentin in the left breast, what is the molecular subtype of this breast cancer? A) Basal-like B) Luminal A C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-XX-A899-01Z-00-DX1.08FE27B7-73B8-4CE3-ACF4-0689C81C140B-1",
        "image": "TCGA-BRCA/TCGA-XX-A899-01Z-00-DX1.08FE27B7-73B8-4CE3-ACF4-0689C81C140B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith positive estrogen and progesterone receptors and HER-2/neu negative status as indicated in the immunohistochemical results, what is the molecular subtype of this tumor? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1XO-01Z-00-DX1.A9EF6AFF-62B0-4E2D-ABC7-DC06FF473890-1",
        "image": "TCGA-BRCA/TCGA-D8-A1XO-01Z-00-DX1.A9EF6AFF-62B0-4E2D-ABC7-DC06FF473890.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results of positive Ki67 in 5% of nuclei, negative E-cadherin on neoplastic cells, and positive CK7, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-B6-A0IN-01Z-00-DX1.5C1CBEF7-0C4A-4B22-A85B-6F6FD9435573-1",
        "image": "TCGA-BRCA/TCGA-B6-A0IN-01Z-00-DX1.5C1CBEF7-0C4A-4B22-A85B-6F6FD9435573.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical staining results with positive estrogen receptor, negative progesterone receptor, and a HER2/neu score of 2+, what is the molecular subtype of this tumor? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-OL-A5D6-01Z-00-DX1.6B11331B-4A0D-4E13-B054-A5C7A6FC3AAC-1",
        "image": "TCGA-BRCA/TCGA-OL-A5D6-01Z-00-DX1.6B11331B-4A0D-4E13-B054-A5C7A6FC3AAC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith immunohistochemical results showing no expression of estrogen receptor (ER) and progesterone receptor (PR) in the invasive tumor nuclei, and Her2/neu antigen status pending from FISH analysis, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Normal"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JA-01Z-00-DX1.BD43F94A-D5A8-490E-AED4-5F3AB24080FA-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JA-01Z-00-DX1.BD43F94A-D5A8-490E-AED4-5F3AB24080FA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results with less than 10% positivity for estrogen receptors, no detected progesterone receptors, and a positive HER2 protein reaction with a score of 3+, what is the molecular subtype of this tumor? A) Luminal A B) Basal C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1IO-01Z-00-DX1.C812D02F-3B40-496B-9EF5-7F68ADE64962-1",
        "image": "TCGA-BRCA/TCGA-E2-A1IO-01Z-00-DX1.C812D02F-3B40-496B-9EF5-7F68ADE64962.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR status with HER2 pending, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1IH-01Z-00-DX1.816F0C54-D87E-4E23-891B-98169F5B439B-1",
        "image": "TCGA-BRCA/TCGA-E2-A1IH-01Z-00-DX1.816F0C54-D87E-4E23-891B-98169F5B439B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression for both estrogen receptor (ER) and progesterone receptor (PR), with HER2 status pending further analysis, what is the molecular subtype of this sample?   A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JF-01Z-00-DX1.224EDA43-F822-4A88-814A-BA7D4C60F8CC-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JF-01Z-00-DX1.224EDA43-F822-4A88-814A-BA7D4C60F8CC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing no estrogen or progesterone receptors and a negative HER2 reaction (Score  1+), what is the molecular subtype of this tumor? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AC-A2QH-01Z-00-DX1.00B8BFFF-F1E2-4F99-A969-8DD7EE4F8E0B-1",
        "image": "TCGA-BRCA/TCGA-AC-A2QH-01Z-00-DX1.00B8BFFF-F1E2-4F99-A969-8DD7EE4F8E0B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive p63, CK5/6, and smooth muscle actin, with negative $100, what is the molecular subtype of this tumor? A) HER2-enriched   B) Luminal A   C) Luminal B   D) Basal"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-OL-A5D8-01Z-00-DX1.C0A75731-1DDC-4FAF-A2C5-2E2ECB23DC13-1",
        "image": "TCGA-BRCA/TCGA-OL-A5D8-01Z-00-DX1.C0A75731-1DDC-4FAF-A2C5-2E2ECB23DC13.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing strong expression of ER and PR in 100% of invasive tumor nuclei, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JH-01Z-00-DX1.4A4F2502-612C-421D-9F64-444BF2C85620-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JH-01Z-00-DX1.4A4F2502-612C-421D-9F64-444BF2C85620.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing estrogen and progesterone receptors present in over 75% of neoplastic cell nuclei, and a negative HER2 reaction with a score of 1+, what is the molecular subtype of this breast cancer?   A) Luminal B   B) HER2-enriched   C) Basal   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AR-A24N-01Z-00-DX1.563E9160-9E09-4E3F-8CE9-FFED0AA52927-1",
        "image": "TCGA-BRCA/TCGA-AR-A24N-01Z-00-DX1.563E9160-9E09-4E3F-8CE9-FFED0AA52927.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nImmunohistochemistry results indicate that Her-2/NEU analysis has been conducted on paraffin embedded tissue. Given this information, what is the molecular subtype of this tumor? A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0EI-01Z-00-DX1.929E126A-C9F8-4240-BF00-B6C4A57B7FF6-1",
        "image": "TCGA-BRCA/TCGA-BH-A0EI-01Z-00-DX1.929E126A-C9F8-4240-BF00-B6C4A57B7FF6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen and progesterone receptors, and HER2/neu negative (zero or 1+), what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1IF-01Z-00-DX1.51F5B0AC-E4D6-439D-8168-34934471FA06-1",
        "image": "TCGA-BRCA/TCGA-E2-A1IF-01Z-00-DX1.51F5B0AC-E4D6-439D-8168-34934471FA06.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results with ER positivity (Allred Score: 8) and PR positivity (Allred Score: 6), what molecular subtype does this breast cancer correspond to?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-PE-A5DE-01Z-00-DX1.88B354F2-5485-44AA-A057-89E40B988F69-1",
        "image": "TCGA-BRCA/TCGA-PE-A5DE-01Z-00-DX1.88B354F2-5485-44AA-A057-89E40B988F69.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive ER and PR receptors but negative Her-2/neu (score 0), what is the molecular subtype for this case?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A4Z1-01Z-00-DX1.D39D38B5-FC9F-4298-8720-016407DC6591-1",
        "image": "TCGA-BRCA/TCGA-D8-A4Z1-01Z-00-DX1.D39D38B5-FC9F-4298-8720-016407DC6591.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical staining showing positive estrogen receptor expression in 75% of neoplastic cell nuclei, progesterone receptor expression in 10-75% of nuclei, negative HER2 status, and a Ki-67 index of 10%, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0E7-01Z-00-DX1.7FEE54C4-3795-403C-85B9-FF932BE56788-1",
        "image": "TCGA-BRCA/TCGA-BH-A0E7-01Z-00-DX1.7FEE54C4-3795-403C-85B9-FF932BE56788.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nAccording to the immunohistochemical findings of positive estrogen receptor and progesterone receptor, with negative HER-2/neu status, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AO-A1KP-01Z-00-DX1.612442AB-24E2-489B-9838-7CEE82BCD605-1",
        "image": "TCGA-BRCA/TCGA-AO-A1KP-01Z-00-DX1.612442AB-24E2-489B-9838-7CEE82BCD605.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR status with strong nuclear staining and negative HER2, what is the molecular subtype of this breast cancer? A) Luminal B   B) Luminal A   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-LL-A7T0-01Z-00-DX1.B03BBA63-ACF4-4BCA-9F2B-F631F0C6A25C-1",
        "image": "TCGA-BRCA/TCGA-LL-A7T0-01Z-00-DX1.B03BBA63-ACF4-4BCA-9F2B-F631F0C6A25C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor status, weakly positive progesterone receptor expression, and HER2 positive status (Score 3+), what is the molecular subtype of this breast cancer?   A) Luminal A   B) Luminal B   C) Basal   D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-OL-A5DA-01Z-00-DX1.1B1E9CC4-7B42-43BB-A1D7-A26F1D1F8557-1",
        "image": "TCGA-BRCA/TCGA-OL-A5DA-01Z-00-DX1.1B1E9CC4-7B42-43BB-A1D7-A26F1D1F8557.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing expression of ER in 68% of invasive tumor nuclei, expression of PR in 66% of invasive tumor nuclei, and non-amplified Her2/neu status, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1LB-01Z-00-DX1.B4AFDB08-BA09-4F6E-806E-4054B790AB8E-1",
        "image": "TCGA-BRCA/TCGA-E2-A1LB-01Z-00-DX1.B4AFDB08-BA09-4F6E-806E-4054B790AB8E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results of negative ER, negative PR, and positive HER2, what is the molecular subtype of this tumor? A) Luminal A   B) Basal   C) Luminal B   D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-S3-AA14-01Z-00-DX1.000A865F-19E6-4018-9352-BFA54EF0CE31-1",
        "image": "TCGA-BRCA/TCGA-S3-AA14-01Z-00-DX1.000A865F-19E6-4018-9352-BFA54EF0CE31.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive HER2/NEU expression (Score 3+), positive estrogen receptor (75%), and positive progesterone receptor (75%), what is the molecular subtype of this breast cancer?  A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-B6-A1KF-01Z-00-DX1.2E08E830-4216-4CD0-9646-1F489300E11D-1",
        "image": "TCGA-BRCA/TCGA-B6-A1KF-01Z-00-DX1.2E08E830-4216-4CD0-9646-1F489300E11D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative expression for both estrogen and progesterone receptors but positive HER2 status (2+ in 50-75% of tumor cells), what is the molecular subtype of this tumor? A) Basal B) Luminal A C) Luminal B D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0E0-01Z-00-DX1.01E88024-83DF-4282-ABAF-F4E35807DA06-1",
        "image": "TCGA-BRCA/TCGA-BH-A0E0-01Z-00-DX1.01E88024-83DF-4282-ABAF-F4E35807DA06.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith immunohistochemical results indicating negative estrogen receptor, negative progesterone receptor, and negative HER-2/NEU status (1+), what is the molecular subtype of this breast cancer? A) HER2-enriched   B) Luminal A   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-LL-A740-01Z-00-DX1.757D94A5-EF0F-4A0E-99A9-8809B66438DA-1",
        "image": "TCGA-BRCA/TCGA-LL-A740-01Z-00-DX1.757D94A5-EF0F-4A0E-99A9-8809B66438DA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings showing negative ER and PR status and equivocal HER2 with in situ hybridization not amplified, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0E9-01Z-00-DX1.5FC4A5E1-3984-4869-9FFB-C0C7F9EAF5FE-1",
        "image": "TCGA-BRCA/TCGA-BH-A0E9-01Z-00-DX1.5FC4A5E1-3984-4869-9FFB-C0C7F9EAF5FE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results showing positive estrogen and progesterone receptor status, with HER2NEU reported as Zero or i+, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A3XX-01Z-00-DX1.03C6D70F-2833-4E97-91B7-DE70CD083D92-1",
        "image": "TCGA-BRCA/TCGA-A2-A3XX-01Z-00-DX1.03C6D70F-2833-4E97-91B7-DE70CD083D92.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results of negative estrogen receptors, negative progesterone receptors, and negative HER2 NEU, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1J8-01Z-00-DX1.EADAB43A-87C6-47FA-9120-25B69E23366D-1",
        "image": "TCGA-BRCA/TCGA-D8-A1J8-01Z-00-DX1.EADAB43A-87C6-47FA-9120-25B69E23366D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing estrogen receptors in 75% of the neoplastic cell nuclei, progesterone receptors in 10-75% of the neoplastic cell nuclei, and HER2 negative with a score of 0, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1J8-01Z-00-DX2.5DCB3447-548D-442C-86B1-CEF79B8689DF-1",
        "image": "TCGA-BRCA/TCGA-D8-A1J8-01Z-00-DX2.5DCB3447-548D-442C-86B1-CEF79B8689DF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing estrogen receptors in 75% of the neoplastic cell nuclei, progesterone receptors in 10-75% of the neoplastic cell nuclei, and HER2 negative with a score of 0, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JT-01Z-00-DX2.8DB9BB5B-17F3-4D80-835D-872BA275FD3B-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JT-01Z-00-DX2.8DB9BB5B-17F3-4D80-835D-872BA275FD3B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing over 75% positivity for both estrogen and progesterone receptors, HER2 score of 2+, and no HER2/neu gene amplification confirmed by FISH, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JT-01Z-00-DX1.F278C419-E405-4BDA-BA50-BFBA08801168-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JT-01Z-00-DX1.F278C419-E405-4BDA-BA50-BFBA08801168.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing over 75% positivity for both estrogen and progesterone receptors, HER2 score of 2+, and no HER2/neu gene amplification confirmed by FISH, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-S3-A6ZF-01Z-00-DX1.E50205A0-63CA-49DE-8831-2A8916DEF403-1",
        "image": "TCGA-BRCA/TCGA-S3-A6ZF-01Z-00-DX1.E50205A0-63CA-49DE-8831-2A8916DEF403.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing 99% positivity for estrogen receptors, 40% positivity for progesterone receptors with moderate staining intensity, and an equivocal HER-2NEU score of 2+, what is the molecular subtype of this breast cancer? A) Luminal A B) Basal C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JS-01Z-00-DX1.76C592B0-DC6D-401A-9533-C9FE5B6CA08D-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JS-01Z-00-DX1.76C592B0-DC6D-401A-9533-C9FE5B6CA08D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical findings of estrogen and progesterone receptors found in over 75% of neoplastic cell nuclei, negative HER2 protein status, and a Ki67 proliferation index of 20%, what is the molecular subtype of this tumor? A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1IG-01Z-00-DX1.C894EEA1-708A-4043-8C60-3BCA98AA751E-1",
        "image": "TCGA-BRCA/TCGA-E2-A1IG-01Z-00-DX1.C894EEA1-708A-4043-8C60-3BCA98AA751E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER) and progesterone receptor (PR) status with HER2 negativity, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JI-01Z-00-DX1.9BDB647F-EEAB-4235-BE44-A3815A48CCE0-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JI-01Z-00-DX1.9BDB647F-EEAB-4235-BE44-A3815A48CCE0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing estrogen receptor positivity in 10-75% of cell nuclei, progesterone receptor positivity in over 75% of cell nuclei, and a negative HER2 status (Score  1+), what is the molecular subtype of this breast cancer? A) Luminal A B) Luminal B C) HER2-enriched D) Basal"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JI-01Z-00-DX2.E688E270-26C9-43EC-BC26-86BF8B74A31D-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JI-01Z-00-DX2.E688E270-26C9-43EC-BC26-86BF8B74A31D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing estrogen receptor positivity in 10-75% of cell nuclei, progesterone receptor positivity in over 75% of cell nuclei, and a negative HER2 status (Score  1+), what is the molecular subtype of this breast cancer? A) Luminal A B) Luminal B C) HER2-enriched D) Basal"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-AR-A1AI-01Z-00-DX1.5EF2A589-4284-45CF-BF0C-169E3A85530C-1",
        "image": "TCGA-BRCA/TCGA-AR-A1AI-01Z-00-DX1.5EF2A589-4284-45CF-BF0C-169E3A85530C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results confirming the H&E impression through cytokeratin stain, what is the molecular subtype of this cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JN-01Z-00-DX1.3B02989C-CEA0-4EDD-A6DC-21C3A957C640-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JN-01Z-00-DX1.3B02989C-CEA0-4EDD-A6DC-21C3A957C640.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing 75% positivity for estrogen receptors, 10% positivity for progesterone receptors, and a HER2 score of 2+ (recommendation for FISH verification), what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AR-A24H-01Z-00-DX1.5CFC7E16-3F38-4531-968C-A4E4C9D00659-1",
        "image": "TCGA-BRCA/TCGA-AR-A24H-01Z-00-DX1.5CFC7E16-3F38-4531-968C-A4E4C9D00659.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression for both estrogen receptor (ER) and progesterone receptor (PR), what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AR-A1AN-01Z-00-DX1.1118F9FE-6DF2-4496-B102-D3A10D332EC0-1",
        "image": "TCGA-BRCA/TCGA-AR-A1AN-01Z-00-DX1.1118F9FE-6DF2-4496-B102-D3A10D332EC0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the historical data showing a positive ER status and low Ki-67 index, specimens commonly point to Luminal A. Considering the requested HER2/neu testing, what is the expected molecular subtype of this breast cancer? A) Luminal B B) HER2-enriched C) Basal D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JG-01Z-00-DX1.BA6D5CC7-3A9B-4D17-A86A-B159D345A216-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JG-01Z-00-DX1.BA6D5CC7-3A9B-4D17-A86A-B159D345A216.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical staining results where HER2 protein has a HercepTest™ score of 2+ and HER2 gene amplification is not found using FISH, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal B  D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1II-01Z-00-DX1.7F782477-0F92-4C57-8735-A1E3F95A6B94-1",
        "image": "TCGA-BRCA/TCGA-E2-A1II-01Z-00-DX1.7F782477-0F92-4C57-8735-A1E3F95A6B94.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing patchy positive expression for Cytokeratin AE1/3 marker, what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0C3-01Z-00-DX1.14D3210D-0CBE-4DCA-A986-A26AE5382502-1",
        "image": "TCGA-BRCA/TCGA-BH-A0C3-01Z-00-DX1.14D3210D-0CBE-4DCA-A986-A26AE5382502.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings showing positive estrogen receptor, negative progesterone receptor, membranous E-cadherin staining typical of ductal carcinoma, and strong diffuse cytoplasmic P120 staining indicative of lobular carcinoma, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Luminal B D) Basal"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-OL-A5D7-01Z-00-DX1.A4A45393-9AE1-4370-8B92-CB85CDB04934-1",
        "image": "TCGA-BRCA/TCGA-OL-A5D7-01Z-00-DX1.A4A45393-9AE1-4370-8B92-CB85CDB04934.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing no reactivity for estrogen receptor (ER) and progesterone receptor (PR), and pending Her2/neu results, what is the molecular subtype of this tumor? A) Luminal A   B) Luminal B   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0EA-01Z-00-DX1.85FF2B48-2AF7-4C15-A7E6-FCA68CAB76C7-1",
        "image": "TCGA-BRCA/TCGA-BH-A0EA-01Z-00-DX1.85FF2B48-2AF7-4C15-A7E6-FCA68CAB76C7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results with positive estrogen receptor (ER), positive progesterone receptor (PR), and positive HER-2/neu status, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1IN-01Z-00-DX1.F63F004F-847D-41B0-BAEF-3189D4965838-1",
        "image": "TCGA-BRCA/TCGA-E2-A1IN-01Z-00-DX1.F63F004F-847D-41B0-BAEF-3189D4965838.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR expression and negative HER2 status, what is the molecular subtype of this breast cancer?   A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-B6-A0WX-01Z-00-DX1.1C4F7BCC-8423-4941-9490-0F35038E1878-1",
        "image": "TCGA-BRCA/TCGA-B6-A0WX-01Z-00-DX1.1C4F7BCC-8423-4941-9490-0F35038E1878.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negative expression for estrogen receptor, progesterone receptor, and HER2/neu oncoprotein, what is the molecular subtype of this breast cancer? A) HER2-enriched   B) Luminal A   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-B6-A0X0-01Z-00-DX1.5D67D9D5-C2F0-40BE-A661-E25B6A6287A2-1",
        "image": "TCGA-BRCA/TCGA-B6-A0X0-01Z-00-DX1.5D67D9D5-C2F0-40BE-A661-E25B6A6287A2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor with an estimated fmol value of 166 and progesterone receptor with an estimated fmol value of 11, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-S3-A6ZG-01Z-00-DX1.659A0BFB-D99B-474F-B4C2-6590C9161BD1-1",
        "image": "TCGA-BRCA/TCGA-S3-A6ZG-01Z-00-DX1.659A0BFB-D99B-474F-B4C2-6590C9161BD1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings of positive estrogen receptor (90%), positive progesterone receptor (80%), negative HER2/NEU (score 0), and scattered E-cadherin positivity supported by P63 results, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1JU-01Z-00-DX1.355D93B4-E69E-417C-B3D1-3E1AAF1E02FE-1",
        "image": "TCGA-BRCA/TCGA-D8-A1JU-01Z-00-DX1.355D93B4-E69E-417C-B3D1-3E1AAF1E02FE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing estrogen receptors positive in 75% of neoplastic cell nuclei, progesterone receptors positive in 75% of neoplastic cell nuclei, and a negative reaction (Score  1+) for HER2 protein, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1J9-01Z-00-DX2.E1C59487-9563-4501-845F-2067A0C5C59B-1",
        "image": "TCGA-BRCA/TCGA-D8-A1J9-01Z-00-DX2.E1C59487-9563-4501-845F-2067A0C5C59B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical findings of estrogen receptors present in 10-75% of neoplastic nuclei, absent progesterone receptors, and a positive HER2 (Score  3+) reaction in invasive cancerous cells, what is the molecular subtype of this breast cancer?  A) Basal   B) Luminal A   C) Luminal B   D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1J9-01Z-00-DX1.F81FA9EF-8129-4E17-A9AD-2B850782CC18-1",
        "image": "TCGA-BRCA/TCGA-D8-A1J9-01Z-00-DX1.F81FA9EF-8129-4E17-A9AD-2B850782CC18.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical findings of estrogen receptors present in 10-75% of neoplastic nuclei, absent progesterone receptors, and a positive HER2 (Score  3+) reaction in invasive cancerous cells, what is the molecular subtype of this breast cancer?  A) Basal   B) Luminal A   C) Luminal B   D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-B6-A1KN-01Z-00-DX1.E769FD65-E5CE-4CA4-8BBE-6FC54A2ED870-1",
        "image": "TCGA-BRCA/TCGA-B6-A1KN-01Z-00-DX1.E769FD65-E5CE-4CA4-8BBE-6FC54A2ED870.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results with a positive estrogen receptor at 169 MMOL and a negative progesterone receptor at 0 FMOL, what is the molecular subtype of this breast tumor?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-S3-AA15-01Z-00-DX2.915A4F90-25CB-4535-99C7-D0D0CFC90412-1",
        "image": "TCGA-BRCA/TCGA-S3-AA15-01Z-00-DX2.915A4F90-25CB-4535-99C7-D0D0CFC90412.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative expression for keratins AE1/AE3 in carcinoma, what is the molecular subtype of this case? A) HER2-enriched B) Basal C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-S3-AA15-01Z-00-DX1.A2456A4A-E6E8-4429-8F09-B997AA497BB0-1",
        "image": "TCGA-BRCA/TCGA-S3-AA15-01Z-00-DX1.A2456A4A-E6E8-4429-8F09-B997AA497BB0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative expression for keratins AE1/AE3 in carcinoma, what is the molecular subtype of this case? A) HER2-enriched B) Basal C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-LL-A9Q3-01Z-00-DX1.94FA76F5-008A-401B-BFDC-817804BAE5F6-1",
        "image": "TCGA-BRCA/TCGA-LL-A9Q3-01Z-00-DX1.94FA76F5-008A-401B-BFDC-817804BAE5F6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression of the estrogen receptor in 100% of tumor cells and progesterone receptor positivity in 2% of tumor cells, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1IU-01Z-00-DX1.E2F24814-24BA-4158-8841-F27A8E100589-1",
        "image": "TCGA-BRCA/TCGA-E2-A1IU-01Z-00-DX1.E2F24814-24BA-4158-8841-F27A8E100589.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on immunohistochemical results showing positive expression for both estrogen (ER) and progesterone receptors (PR), and negative HER2 status by FISH, what is the molecular subtype of this tumor? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-S3-AA12-01Z-00-DX1.2A991B9F-E7E6-410B-B0BF-635E3CC40C7E-1",
        "image": "TCGA-BRCA/TCGA-S3-AA12-01Z-00-DX1.2A991B9F-E7E6-410B-B0BF-635E3CC40C7E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen receptor expression at 99%, negative progesterone receptor expression at less than 1%, and HER2 score of 1+, what is the molecular subtype of this tumor? A) Luminal B B) Basal C) HER2-enriched D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-S3-AA12-01Z-00-DX2.4F0A4F18-41C7-4497-A7B8-5DCE610E08AD-1",
        "image": "TCGA-BRCA/TCGA-S3-AA12-01Z-00-DX2.4F0A4F18-41C7-4497-A7B8-5DCE610E08AD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen receptor expression at 99%, negative progesterone receptor expression at less than 1%, and HER2 score of 1+, what is the molecular subtype of this tumor? A) Luminal B B) Basal C) HER2-enriched D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A2-A3XW-01Z-00-DX1.45F5F36F-5503-4A38-AF37-E526915A8DBE-1",
        "image": "TCGA-BRCA/TCGA-A2-A3XW-01Z-00-DX1.45F5F36F-5503-4A38-AF37-E526915A8DBE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER) expression, positive progesterone receptor (PR) expression at 10%, and negative HER2 status, what is the molecular subtype of this tumor? A) Luminal A B) Luminal B C) HER2-enriched D) Basal"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-EW-A423-01Z-00-DX2.5EF1CF39-600A-4ED3-A5A2-AF4435A5F8B5-1",
        "image": "TCGA-BRCA/TCGA-EW-A423-01Z-00-DX2.5EF1CF39-600A-4ED3-A5A2-AF4435A5F8B5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith immunohistochemical findings showing more than 90% positivity for estrogen receptor, 1-10% positivity for progesterone receptor, negative HER-2/neu, and negative keratin at both Axilla hot spots, what is the molecular subtype of this breast cancer? A) Luminal B B) HER2-enriched C) Basal D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-EW-A423-01Z-00-DX1.31502D62-9C83-4A9C-9682-05A185486EAA-1",
        "image": "TCGA-BRCA/TCGA-EW-A423-01Z-00-DX1.31502D62-9C83-4A9C-9682-05A185486EAA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith immunohistochemical findings showing more than 90% positivity for estrogen receptor, 1-10% positivity for progesterone receptor, negative HER-2/neu, and negative keratin at both Axilla hot spots, what is the molecular subtype of this breast cancer? A) Luminal B B) HER2-enriched C) Basal D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A27M-01Z-00-DX1.3020D223-2400-4A2D-8BFE-08A5B78FE13B-1",
        "image": "TCGA-BRCA/TCGA-D8-A27M-01Z-00-DX1.3020D223-2400-4A2D-8BFE-08A5B78FE13B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith immunohistochemical results showing negative estrogen receptors, negative progesterone receptors, and negative HER2 status, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0H0-01Z-00-DX1.B3B394DD-1F4E-42CA-BB51-C002E423B3D0-1",
        "image": "TCGA-BRCA/TCGA-BH-A0H0-01Z-00-DX1.B3B394DD-1F4E-42CA-BB51-C002E423B3D0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER) status, weakly positive progesterone receptor (PR) status, and negative HER-2/neu expression with a score of 0, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1OY-01Z-00-DX1.42AF5C9A-A90F-4A58-B5D4-B615F8CD4333-1",
        "image": "TCGA-BRCA/TCGA-EW-A1OY-01Z-00-DX1.42AF5C9A-A90F-4A58-B5D4-B615F8CD4333.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results of positive ER, positive PR, and negative HER2, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0CX-01Z-00-DX1.F07C75AB-E568-45CB-B497-37C712490393-1",
        "image": "TCGA-BRCA/TCGA-A2-A0CX-01Z-00-DX1.F07C75AB-E568-45CB-B497-37C712490393.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating positive HER2 status and negative cytokeratin in the sentinel lymph node, what is the molecular subtype of this tumor? A) Luminal A B) Basal C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E9-A5FK-01Z-00-DX1.3F002C99-B4CA-4068-A816-EAC370A2E8C4-1",
        "image": "TCGA-BRCA/TCGA-E9-A5FK-01Z-00-DX1.3F002C99-B4CA-4068-A816-EAC370A2E8C4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical findings of estrogen receptor (ER) positive at 85% with a score of 3+, progesterone receptor (PR) positive at 70% with a score of 3+, Her-2/neu negative, and Ki-67 index at 18%, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0H7-01Z-00-DX1.21502FEA-DB37-4630-BA42-778DDF3A6D17-1",
        "image": "TCGA-BRCA/TCGA-BH-A0H7-01Z-00-DX1.21502FEA-DB37-4630-BA42-778DDF3A6D17.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive progesterone receptors and a HER2/neu score of zero or 1+, what is the molecular subtype of this breast cancer? A) Luminal B   B) HER2-enriched   C) Basal   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1BD-01Z-00-DX1.A2AFF7AD-ED47-43E4-87FE-62882BAEB8DA-1",
        "image": "TCGA-BRCA/TCGA-E2-A1BD-01Z-00-DX1.A2AFF7AD-ED47-43E4-87FE-62882BAEB8DA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression for estrogen receptor (ER) and progesterone receptor (PR), with HER2 determined to be negative by FISH, what is the molecular subtype of this breast cancer?   A) Luminal B   B) HER2-enriched   C) Basal   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AO-A03R-01Z-00-DX1.DC317201-7F22-4C4A-86A5-ED82C37757C8-1",
        "image": "TCGA-BRCA/TCGA-AO-A03R-01Z-00-DX1.DC317201-7F22-4C4A-86A5-ED82C37757C8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing 99% ER positive nuclear staining with moderate intensity, PR less than 5% nuclear staining with moderate intensity, and negative HER2 status, what is the molecular subtype of this breast cancer? A) Luminal A B) Basal C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1BC-01Z-00-DX1.FD19F2F8-497F-4D7D-97C6-271DC6B75173-1",
        "image": "TCGA-BRCA/TCGA-E2-A1BC-01Z-00-DX1.FD19F2F8-497F-4D7D-97C6-271DC6B75173.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression for estrogen receptor (ER) and progesterone receptor (PR), with a negative HER2 result, what is the molecular subtype of this breast cancer?   A) HER2-enriched   B) Basal   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0H9-01Z-00-DX1.8AE869C6-5C78-4D52-AC8B-5B6FD5FD91AA-1",
        "image": "TCGA-BRCA/TCGA-BH-A0H9-01Z-00-DX1.8AE869C6-5C78-4D52-AC8B-5B6FD5FD91AA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptors, positive progesterone receptors, weakly positive HER2/neu, and no amplification by FISH analysis, what is the molecular subtype of this breast cancer?   A) Basal   B) Luminal B   C) HER2-enriched   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-S3-AA0Z-01Z-00-DX1.4D96156A-4067-41F2-90B8-41EF7ED794CF-1",
        "image": "TCGA-BRCA/TCGA-S3-AA0Z-01Z-00-DX1.4D96156A-4067-41F2-90B8-41EF7ED794CF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER) expression with varying intensities, negative progesterone receptor (PR) activity overall, equivocal HER2 status, and a low PR expression, what is the molecular subtype of this breast cancer?  A) Luminal B   B) HER2-enriched   C) Basal   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0BG-01Z-00-DX1.0838FB7F-8C85-4687-9F70-D136A1063383-1",
        "image": "TCGA-BRCA/TCGA-BH-A0BG-01Z-00-DX1.0838FB7F-8C85-4687-9F70-D136A1063383.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating negative estrogen receptor, negative progesterone receptor, and HER-2/NEU score of 0, what is the molecular subtype of this tumor?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AR-A255-01Z-00-DX1.E67C081D-50C9-451C-814B-F097B2671300-1",
        "image": "TCGA-BRCA/TCGA-AR-A255-01Z-00-DX1.E67C081D-50C9-451C-814B-F097B2671300.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical result showing positive Cytokeratin and the confirmed H&E impression, what is the molecular subtype of this cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0CV-01Z-00-DX1.B02D017A-61CD-45FE-BB31-705CD127DDAB-1",
        "image": "TCGA-BRCA/TCGA-A2-A0CV-01Z-00-DX1.B02D017A-61CD-45FE-BB31-705CD127DDAB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing HER2 negative, and 100% strong staining for both estrogen receptors and progesterone receptors, what is the molecular subtype of this breast cancer? A) Luminal B B) HER2-enriched C) Basal D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A18H-01Z-00-DX1.4EC9108F-04C2-4B28-BD74-97A414C9A536-1",
        "image": "TCGA-BRCA/TCGA-BH-A18H-01Z-00-DX1.4EC9108F-04C2-4B28-BD74-97A414C9A536.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen receptor (ER), positive progesterone receptor (PR), and negative HER-2/neu, what is the molecular subtype of this breast cancer? A) HER2-enriched B) Luminal B C) Basal D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0AZ-01Z-00-DX1.E20051E8-DEEF-48E5-B519-40777DDBC96B-1",
        "image": "TCGA-BRCA/TCGA-BH-A0AZ-01Z-00-DX1.E20051E8-DEEF-48E5-B519-40777DDBC96B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings showing positive estrogen and progesterone receptor status, equivocal HER2/neu IHC score of 2 with non-amplified HER2 by FISH, what is the molecular subtype of this tumor?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EW-A6SC-01Z-00-DX1.C2D50E7C-3AD0-4038-9A1C-CAE54A3FBE2F-1",
        "image": "TCGA-BRCA/TCGA-EW-A6SC-01Z-00-DX1.C2D50E7C-3AD0-4038-9A1C-CAE54A3FBE2F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER (greater than 50%), positive PR (10-50%), negative HER2, negative E-Cadherin, and negative keratin staining, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0DL-01Z-00-DX1.553F0021-1FC2-4675-810D-BBD9785D065E-1",
        "image": "TCGA-BRCA/TCGA-BH-A0DL-01Z-00-DX1.553F0021-1FC2-4675-810D-BBD9785D065E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER), negative progesterone receptor (PR), and a HER2 score of 2+, what is the molecular subtype of this cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-EW-A6SD-01Z-00-DX1.32D8240E-2076-492B-BB95-300A9FCA96E7-1",
        "image": "TCGA-BRCA/TCGA-EW-A6SD-01Z-00-DX1.32D8240E-2076-492B-BB95-300A9FCA96E7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results of less than 1% expression in both estrogen and progesterone receptors and a positive HER2 (Score 3+) status, what is the molecular subtype of this breast cancer?   A) Luminal A   B) Luminal B   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0BR-01Z-00-DX1.F7912887-8AE9-4391-9B83-9AC7B4FF38EF-1",
        "image": "TCGA-BRCA/TCGA-BH-A0BR-01Z-00-DX1.F7912887-8AE9-4391-9B83-9AC7B4FF38EF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression for both estrogen and progesterone receptors, and a HER2/neu score of zero or 1+, what is the molecular subtype of this breast cancer?   A) HER2-enriched   B) Luminal A   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-OL-A66N-01Z-00-DX1.ABDA3014-7B3A-4D48-A415-CB9608491ECB-1",
        "image": "TCGA-BRCA/TCGA-OL-A66N-01Z-00-DX1.ABDA3014-7B3A-4D48-A415-CB9608491ECB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing moderate to strong expression of ER in 80% of invasive tumor nuclei, no PR expression, and a non-amplified HER2 status (FISH ratio: 1.10), what is the molecular subtype of this breast cancer? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0ES-01Z-00-DX1.5652EE30-48C1-4EC1-AD77-8C72DFCB9A97-1",
        "image": "TCGA-BRCA/TCGA-A2-A0ES-01Z-00-DX1.5652EE30-48C1-4EC1-AD77-8C72DFCB9A97.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor expression, negative progesterone receptor status, and equivocal HER2 status (weakly positive IHC 2+ but negative FISH), what is the molecular subtype of this breast cancer? A) HER2-enriched B) Luminal A C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BH-A18T-01Z-00-DX1.90123A74-F631-4538-AB2E-4076486ADF88-1",
        "image": "TCGA-BRCA/TCGA-BH-A18T-01Z-00-DX1.90123A74-F631-4538-AB2E-4076486ADF88.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative estrogen receptor (ER) and progesterone receptor (PR) status, with HER2/Neu weak positivity (Score 2+), what is the molecular subtype of this tumor? A) HER2-enriched B) Luminal A C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1J6-01Z-00-DX1.F668E978-13B6-4284-9522-37C65C57A21A-1",
        "image": "TCGA-BRCA/TCGA-EW-A1J6-01Z-00-DX1.F668E978-13B6-4284-9522-37C65C57A21A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven that the HER-2 immunohistochemistry result is negative and pending results for estrogen receptor, progesterone receptor, and HER-2 CISH, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-LL-A50Y-01Z-00-DX1.7F08413F-2C59-4322-9296-84F8CD3DF619-1",
        "image": "TCGA-BRCA/TCGA-LL-A50Y-01Z-00-DX1.7F08413F-2C59-4322-9296-84F8CD3DF619.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing 100% ER positivity, 100% PR positivity with moderate strength, and equivocal HER2 status (Score 2+), what is the molecular subtype of this breast cancer? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-LL-A6FP-01Z-00-DX1.6261398A-7288-4924-BBE2-FC1949256E40-1",
        "image": "TCGA-BRCA/TCGA-LL-A6FP-01Z-00-DX1.6261398A-7288-4924-BBE2-FC1949256E40.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor, positive progesterone receptor, and HER-2 is equivocal with a FISH result of not amplified, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AQ-A04H-01Z-00-DX1.5AC1E459-EF27-401D-98FD-0AC16559AF17-1",
        "image": "TCGA-BRCA/TCGA-AQ-A04H-01Z-00-DX1.5AC1E459-EF27-401D-98FD-0AC16559AF17.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER), positive progesterone receptor (PR), and indeterminate HER2 status, what is the molecular subtype of this tumor?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0B7-01Z-00-DX1.6950CDDF-8A81-4B10-BFFF-BE0E33A2C6CC-1",
        "image": "TCGA-BRCA/TCGA-BH-A0B7-01Z-00-DX1.6950CDDF-8A81-4B10-BFFF-BE0E33A2C6CC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER, positive PR, and positive HER-2/NEU status, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0HI-01Z-00-DX1.89DB9F79-0DCC-4C65-831E-96AE026C2C4E-1",
        "image": "TCGA-BRCA/TCGA-BH-A0HI-01Z-00-DX1.89DB9F79-0DCC-4C65-831E-96AE026C2C4E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive expression for both estrogen receptor (ER) and progesterone receptor (PR), and negative HER-2/neu status, what is the molecular subtype of this tumor? A) Basal B) Luminal B C) HER2-enriched D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0B0-01Z-00-DX1.316D35DB-7F13-4AE5-82A7-5716D2519669-1",
        "image": "TCGA-BRCA/TCGA-BH-A0B0-01Z-00-DX1.316D35DB-7F13-4AE5-82A7-5716D2519669.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results indicating positive estrogen and progesterone receptor statuses, along with HER2/neu expression rated at 0 or 1+, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AO-A03N-01Z-00-DX1.79A8816D-961F-4D79-90B4-341919297A90-1",
        "image": "TCGA-BRCA/TCGA-AO-A03N-01Z-00-DX1.79A8816D-961F-4D79-90B4-341919297A90.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing 70% nuclear staining with moderate to strong intensity for ER, 3% nuclear staining with weak intensity for PR, and negative HER2/neu status, what is the molecular subtype of this breast cancer? A) Luminal A   B) Luminal B   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BH-A18S-01Z-00-DX1.B36FC684-0010-4ABB-9E25-303C8DF1C4E2-1",
        "image": "TCGA-BRCA/TCGA-BH-A18S-01Z-00-DX1.B36FC684-0010-4ABB-9E25-303C8DF1C4E2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen receptor (ER) and progesterone receptor (PR) expression with negative HER-2/neu status (score 1/4), what is the molecular subtype of this breast cancer? A) HER2-enriched   B) Luminal B   C) Basal   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1J1-01Z-00-DX1.FFC2D5DB-E6D0-4143-A1E7-0A2027846C8C-1",
        "image": "TCGA-BRCA/TCGA-EW-A1J1-01Z-00-DX1.FFC2D5DB-E6D0-4143-A1E7-0A2027846C8C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results indicating positive estrogen receptor (>1%), positive progesterone receptor (>1%), and negative immunoperoxidase studies (score 0), what is the molecular subtype of this breast cancer? A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0CM-01Z-00-DX1.AC4901DE-4B6D-4185-BB9F-156033839828-1",
        "image": "TCGA-BRCA/TCGA-A2-A0CM-01Z-00-DX1.AC4901DE-4B6D-4185-BB9F-156033839828.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings of negative estrogen receptors, focally positive progesterone receptors, and negative HER2 status, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0ET-01Z-00-DX1.41E86BB9-EA52-4615-94E7-0F09DDB094F4-1",
        "image": "TCGA-BRCA/TCGA-A2-A0ET-01Z-00-DX1.41E86BB9-EA52-4615-94E7-0F09DDB094F4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results showing positive estrogen receptor status, negative progesterone receptor status, and negative HER2 expression, what is the molecular subtype of this carcinoma? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1B4-01Z-00-DX1.E585C4FB-0D3E-4160-8192-53A329648F5C-1",
        "image": "TCGA-BRCA/TCGA-E2-A1B4-01Z-00-DX1.E585C4FB-0D3E-4160-8192-53A329648F5C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the immunohistochemical results showing positivity for both estrogen receptor (ER) and progesterone receptor (PR) while being negative for HER2, what is the molecular subtype of this breast cancer? A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A18I-01Z-00-DX1.EE699DE3-EBF4-4AB4-8319-9911F027FA18-1",
        "image": "TCGA-BRCA/TCGA-BH-A18I-01Z-00-DX1.EE699DE3-EBF4-4AB4-8319-9911F027FA18.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing membranous reactivity for E-cadherin and P20 in invasive tumor cells, what is the molecular subtype of this tumor? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0EN-01Z-00-DX1.F43A5D17-9267-4963-993A-93AC91BDC031-1",
        "image": "TCGA-BRCA/TCGA-A2-A0EN-01Z-00-DX1.F43A5D17-9267-4963-993A-93AC91BDC031.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER) with strong staining in 70% of cells, positive progesterone receptor (PR) in 30% of cells with strong staining, equivocal (2+) HER2 status by Herceptest and non-amplified HER2 by FISH, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AO-A03T-01Z-00-DX1.8B75E203-6DC8-4AC9-A256-6FCB818DA0DD-1",
        "image": "TCGA-BRCA/TCGA-AO-A03T-01Z-00-DX1.8B75E203-6DC8-4AC9-A256-6FCB818DA0DD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results with estrogen receptor at 67% with moderate nuclear staining, progesterone receptor at 60% with moderate nuclear staining, and HER2/neu as negative, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1OV-01Z-00-DX1.93698123-5B34-4163-848B-2D75A5F7B001-1",
        "image": "TCGA-BRCA/TCGA-EW-A1OV-01Z-00-DX1.93698123-5B34-4163-848B-2D75A5F7B001.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative ER, PR, HER2, E-cadherin, CK5/6, EGFR, and positive p-cadherin, what is the molecular subtype of this tumor? A) HER2-enriched B) Basal C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0DX-01Z-00-DX1.45C27E71-9A0A-400E-93A9-5CE7780F3C5E-1",
        "image": "TCGA-BRCA/TCGA-BH-A0DX-01Z-00-DX1.45C27E71-9A0A-400E-93A9-5CE7780F3C5E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor, focally and weakly positive progesterone receptor, and negative HER-2neu status (Score: 0), what is the molecular subtype of this tumor? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0BA-01Z-00-DX1.579E11C9-437C-4D49-8811-DD94D8454712-1",
        "image": "TCGA-BRCA/TCGA-BH-A0BA-01Z-00-DX1.579E11C9-437C-4D49-8811-DD94D8454712.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen receptor, positive progesterone receptor, and negative HER-2/neu (score +1), what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0CP-01Z-00-DX1.ECFD263C-BB17-4ADA-8F2C-654C2AA4C45F-1",
        "image": "TCGA-BRCA/TCGA-A2-A0CP-01Z-00-DX1.ECFD263C-BB17-4ADA-8F2C-654C2AA4C45F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing 40% positivity for estrogen receptors and 80% positivity for progesterone receptors, what is the molecular subtype of this breast cancer?   A) Basal   B) Luminal A   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BH-A18N-01Z-00-DX1.FE0E24A1-8AE9-4021-B9C7-B408EE0DE329-1",
        "image": "TCGA-BRCA/TCGA-BH-A18N-01Z-00-DX1.FE0E24A1-8AE9-4021-B9C7-B408EE0DE329.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results with positive ER and PR expression but negative HER-2/neu status, what is the molecular subtype of this breast cancer? A) Luminal A B) Basal C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0DQ-01Z-00-DX1.5A98747C-52D9-45AD-BC84-934A96F069EB-1",
        "image": "TCGA-BRCA/TCGA-BH-A0DQ-01Z-00-DX1.5A98747C-52D9-45AD-BC84-934A96F069EB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR status along with negative HER2/NEU expression (INC Score 0), what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AR-A0U0-01Z-00-DX1.C8BECD9F-68D9-47B1-B31E-C1C6CAE456B6-1",
        "image": "TCGA-BRCA/TCGA-AR-A0U0-01Z-00-DX1.C8BECD9F-68D9-47B1-B31E-C1C6CAE456B6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative expression for estrogen and progesterone receptors with 0% nuclear staining, what is the molecular subtype of this cancer? A) Luminal A   B) Luminal B   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A18G-01Z-00-DX1.DB2B5819-CE83-4E07-BD03-2CD9CF2E246C-1",
        "image": "TCGA-BRCA/TCGA-BH-A18G-01Z-00-DX1.DB2B5819-CE83-4E07-BD03-2CD9CF2E246C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nThe immunohistochemistry results show positive estrogen receptors, positive progesterone receptors, and negative HER-2/neu. What is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-Z7-A8R5-01Z-00-DX1.3BDB407F-514C-4131-B058-FA1E69154276-1",
        "image": "TCGA-BRCA/TCGA-Z7-A8R5-01Z-00-DX1.3BDB407F-514C-4131-B058-FA1E69154276.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings of positive estrogen receptor (ER) with a 3+ score, trace to 1+ progesterone receptors (PR), aneuploid DNA index of 1.6, an intermediate Ki-67 proliferation index of 16%, and negative HER2/neu, what is the molecular subtype classification of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A27K-01Z-00-DX1.25AF7928-046B-45BF-BAD6-F34156203F5A-1",
        "image": "TCGA-BRCA/TCGA-D8-A27K-01Z-00-DX1.25AF7928-046B-45BF-BAD6-F34156203F5A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing estrogen receptors present in over 75% of neoplastic cell nuclei, progesterone receptors in over 75% of neoplastic cell nuclei, and a negative HER2/neu reaction in invasive cancerous cells, what is the molecular subtype of this tumor?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0H6-01Z-00-DX1.0CF7253A-B42C-4778-B1C6-17EC78A039ED-1",
        "image": "TCGA-BRCA/TCGA-BH-A0H6-01Z-00-DX1.0CF7253A-B42C-4778-B1C6-17EC78A039ED.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptors, positive progesterone receptors, and HER2/neu status of zero or 1+, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-LL-A5YP-01Z-00-DX1.ADA978DF-6625-4C4D-AE0C-F589B2BA4897-1",
        "image": "TCGA-BRCA/TCGA-LL-A5YP-01Z-00-DX1.ADA978DF-6625-4C4D-AE0C-F589B2BA4897.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results showing positive ER (26% with weak intensity), negative PR, equivocal HER2 (2+) with FISH not amplified but in situ hybridization amplified, what is the molecular subtype of this breast cancer?  A) Luminal B   B) Basal   C) HER2-enriched   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0DV-01Z-00-DX1.2F0B5FB3-40F0-4D27-BFAC-390FB9A42B39-1",
        "image": "TCGA-BRCA/TCGA-BH-A0DV-01Z-00-DX1.2F0B5FB3-40F0-4D27-BFAC-390FB9A42B39.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptors, positive progesterone receptors, and negative HER2/neu expression, what is the molecular subtype of this tumor? A) Basal B) Luminal B C) Luminal A D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0BO-01Z-00-DX1.1A704471-FEB3-40F9-9838-3E347A18285F-1",
        "image": "TCGA-BRCA/TCGA-BH-A0BO-01Z-00-DX1.1A704471-FEB3-40F9-9838-3E347A18285F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER), positive progesterone receptor (PR), and negative HER2 status, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1OX-01Z-00-DX1.9B19CBEE-E592-4A4D-839F-CECDCA20F4B1-1",
        "image": "TCGA-BRCA/TCGA-EW-A1OX-01Z-00-DX1.9B19CBEE-E592-4A4D-839F-CECDCA20F4B1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR status, negative HER2 expression, and keratin negative for carcinoma in sentinel nodes, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0GY-01Z-00-DX1.E1AEAA36-94FA-41ED-851F-7BB11DD3C06D-1",
        "image": "TCGA-BRCA/TCGA-BH-A0GY-01Z-00-DX1.E1AEAA36-94FA-41ED-851F-7BB11DD3C06D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER) and positive progesterone receptor (PR), what is the molecular subtype of this cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A27L-01Z-00-DX1.6572593C-B015-4F9A-8C9B-B634CAA0D3B4-1",
        "image": "TCGA-BRCA/TCGA-D8-A27L-01Z-00-DX1.6572593C-B015-4F9A-8C9B-B634CAA0D3B4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression for estrogen and progesterone receptors in over 75% of neoplastic cell nuclei and negative HER2 status (Score1+), what is the molecular subtype of this breast cancer?   A) Luminal B   B) HER2-enriched   C) Basal   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0CL-01Z-00-DX1.5342E971-DCD2-42C4-B4FF-E6942A95829E-1",
        "image": "TCGA-BRCA/TCGA-A2-A0CL-01Z-00-DX1.5342E971-DCD2-42C4-B4FF-E6942A95829E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen receptors (20%), negative progesterone receptors (less than 5%), and negative HER2 neu (1%), what is the molecular subtype of this sample? A) Luminal A B) Luminal B C) HER2-enriched D) Basal"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0EU-01Z-00-DX1.13335BEB-63D4-469B-A389-8A079A096129-1",
        "image": "TCGA-BRCA/TCGA-A2-A0EU-01Z-00-DX1.13335BEB-63D4-469B-A389-8A079A096129.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive expression for both estrogen receptors (95%) and progesterone receptors (95%), and negative HER2 (1+), what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A18R-01Z-00-DX1.07E6FA7F-5072-4327-9982-A40F010B7532-1",
        "image": "TCGA-BRCA/TCGA-BH-A18R-01Z-00-DX1.07E6FA7F-5072-4327-9982-A40F010B7532.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical findings showing a positive score for estrogen receptor (ER) with a score of 20, negative progesterone receptor (PR) with a score of 0, and positive HER2/Neu with a score of 3+, what is the determined molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Luminal B   D) Basal"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-AO-A03O-01Z-00-DX1.054BBC89-69F4-4311-814D-E343472CD2C0-1",
        "image": "TCGA-BRCA/TCGA-AO-A03O-01Z-00-DX1.054BBC89-69F4-4311-814D-E343472CD2C0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the immunohistochemical results showing positive estrogen and progesterone receptors while HER2 is negative with a staining intensity of 1+, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0HO-01Z-00-DX1.D3D66547-F5D4-40F5-B737-2FECEEB35ACB-1",
        "image": "TCGA-BRCA/TCGA-BH-A0HO-01Z-00-DX1.D3D66547-F5D4-40F5-B737-2FECEEB35ACB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (H Score of 200), positive progesterone receptor (H Score of 290), and negative HER-2 status, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A1B5-01Z-00-DX1.AB19FF3D-5C42-4D49-ABEA-D2315709B6EA-1",
        "image": "TCGA-BRCA/TCGA-E2-A1B5-01Z-00-DX1.AB19FF3D-5C42-4D49-ABEA-D2315709B6EA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings of positive estrogen receptor (ER) and progesterone receptor (PR) with her2 negativity, what is the molecular subtype of this tumor? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-LL-A7SZ-01Z-00-DX1.4DAF6421-6A1D-41C8-BFD6-859FE10CB8CC-1",
        "image": "TCGA-BRCA/TCGA-LL-A7SZ-01Z-00-DX1.4DAF6421-6A1D-41C8-BFD6-859FE10CB8CC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression for both estrogen receptor (ER) and progesterone receptor (PR) at 99% each, and negative immunoperoxidase studies (1+), what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0BZ-01Z-00-DX1.45EB3E93-A871-49C6-9EAE-90D98AE01913-1",
        "image": "TCGA-BRCA/TCGA-BH-A0BZ-01Z-00-DX1.45EB3E93-A871-49C6-9EAE-90D98AE01913.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings showing positive estrogen receptor (ER), positive progesterone receptor (PR), and negative HER-2/neu (score of 1+), what is the molecular subtype of this breast tumor? A) Luminal A   B) Luminal B   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A18U-01Z-00-DX1.63940315-59BC-462B-87A8-2BBB33C9503E-1",
        "image": "TCGA-BRCA/TCGA-BH-A18U-01Z-00-DX1.63940315-59BC-462B-87A8-2BBB33C9503E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen receptor (ER) expression, mixed progesterone receptor (PR) positivity, and strongly positive HER2/neu status (3+), what is the molecular subtype of this breast cancer? A) Luminal A   B) Luminal B   C) Basal   D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0CK-01Z-00-DX1.C3226BD1-11B0-4034-946A-BAB42958CE85-1",
        "image": "TCGA-BRCA/TCGA-A2-A0CK-01Z-00-DX1.C3226BD1-11B0-4034-946A-BAB42958CE85.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative HER2/neu overexpression (1+), and negative ER and PR immunostains, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-LL-A6FQ-01Z-00-DX1.D4FEEC16-FC67-4C4A-A4B1-F8BA34ECBCBD-1",
        "image": "TCGA-BRCA/TCGA-LL-A6FQ-01Z-00-DX1.D4FEEC16-FC67-4C4A-A4B1-F8BA34ECBCBD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical findings of positive estrogen receptor at 100% staining, positive progesterone receptor at 2% staining, a high Ki-67 score, and negative Her2/neu, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0AU-01Z-00-DX1.E852F218-B15C-4CF8-8FD0-F284043834C4-1",
        "image": "TCGA-BRCA/TCGA-BH-A0AU-01Z-00-DX1.E852F218-B15C-4CF8-8FD0-F284043834C4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive expression for estrogen receptor (ER), positive progesterone receptor (PR), and equivocal HER2 status, what is the molecular subtype?  A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A27P-01Z-00-DX1.EF426996-D0DC-4418-BEC4-F7CE3C82C869-1",
        "image": "TCGA-BRCA/TCGA-D8-A27P-01Z-00-DX1.EF426996-D0DC-4418-BEC4-F7CE3C82C869.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER) expression in 75% of cell nuclei, low progesterone receptor (PR) expression in 10% of cell nuclei, and a negative HER2 score in invasive cancerous cells, what is the molecular subtype of this breast cancer? A) HER2-enriched   B) Basal   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A0HA-01Z-00-DX1.5A2F5C86-E1E7-445D-A4E3-29980FA37708-1",
        "image": "TCGA-BRCA/TCGA-BH-A0HA-01Z-00-DX1.5A2F5C86-E1E7-445D-A4E3-29980FA37708.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results that indicate positive estrogen receptors, positive progesterone receptors, and negative HER2 status, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-OL-A66O-01Z-00-DX1.5F1E4C60-5CE8-41B4-A94D-4AA80D9253F9-1",
        "image": "TCGA-BRCA/TCGA-OL-A66O-01Z-00-DX1.5F1E4C60-5CE8-41B4-A94D-4AA80D9253F9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results, which show strong ER and PR expression in over 90% of invasive tumor nuclei, non-amplified HER2 status across lesions, and Ki67 indices ranging from 10% to 20%, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-EW-A1IZ-01Z-00-DX1.81D5544E-0A7D-4A92-A3B0-4F22CFB8BBB2-1",
        "image": "TCGA-BRCA/TCGA-EW-A1IZ-01Z-00-DX1.81D5544E-0A7D-4A92-A3B0-4F22CFB8BBB2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor and progesterone receptor, along with negative HER2 status, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-LL-A5YL-01Z-00-DX1.164C74AB-87D5-46CC-9D96-33FE1F88DC80-1",
        "image": "TCGA-BRCA/TCGA-LL-A5YL-01Z-00-DX1.164C74AB-87D5-46CC-9D96-33FE1F88DC80.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER status, negative PR status, HER2 overexpression, and non-amplified HER2 in situ hybridization, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Luminal B   D) Basal"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-OL-A6VO-01Z-00-DX1.291D54D6-EBAF-4622-BD42-97AA5997F014-1",
        "image": "TCGA-BRCA/TCGA-OL-A6VO-01Z-00-DX1.291D54D6-EBAF-4622-BD42-97AA5997F014.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negativity for both estrogen and progesterone receptors, and a non-amplified HER2/neu status, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AC-A23C-01Z-00-DX1.0E67C785-83D3-49AF-B600-FB5B909AE6ED-1",
        "image": "TCGA-BRCA/TCGA-AC-A23C-01Z-00-DX1.0E67C785-83D3-49AF-B600-FB5B909AE6ED.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results with positive estrogen receptor status (01%), positive progesterone receptor expression (63%), and a high Ki-67 proliferation index (33%), what is the determined molecular subtype of this breast cancer?   A) Luminal A   B) Luminal B   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-D8-A27W-01Z-00-DX2.4E0D2E4E-5662-4305-8FC2-C651CDDA4998-1",
        "image": "TCGA-BRCA/TCGA-D8-A27W-01Z-00-DX2.4E0D2E4E-5662-4305-8FC2-C651CDDA4998.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nImmunohistochemical analysis reveals estrogen receptors present in over 75% of neoplastic cell nuclei, progesterone receptors in less than 10%, and a recommendation for HER2 protein score verification. What is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-OL-A66H-01Z-00-DX1.E54AF3FA-E59E-404C-BB83-A6FC6FC9B312-1",
        "image": "TCGA-BRCA/TCGA-OL-A66H-01Z-00-DX1.E54AF3FA-E59E-404C-BB83-A6FC6FC9B312.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing strong positive expression for estrogen receptor (ER) in over 90% of tumor nuclei and strong positive progesterone receptor (PR) expression in over 80%, with a negative HER2 score, what is the molecular subtype of this breast cancer? A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A1EV-01Z-00-DX1.106CF220-1D7D-40DD-88B2-A7F00B758F8F-1",
        "image": "TCGA-BRCA/TCGA-BH-A1EV-01Z-00-DX1.106CF220-1D7D-40DD-88B2-A7F00B758F8F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing a positive c-erbB2 (HER-2/Neu) status with a score of 2+, what is the molecular subtype for this breast cancer? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A15O-01Z-00-DX1.4D0F3975-93EA-4DC2-AD0C-A76A24C3AE0C-1",
        "image": "TCGA-BRCA/TCGA-E2-A15O-01Z-00-DX1.4D0F3975-93EA-4DC2-AD0C-A76A24C3AE0C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen receptor (ER), positive progesterone receptor (PR), and negative HER2, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AC-A3QP-01Z-00-DX1.4B97E53E-1069-40C5-A062-C988663B37DD-1",
        "image": "TCGA-BRCA/TCGA-AC-A3QP-01Z-00-DX1.4B97E53E-1069-40C5-A062-C988663B37DD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical findings where Cytokeratin 7/E3 is strongly positive in sentinel lymph node 1 indicating metastatic tumor cells, but negative in sentinel lymph node 2, what is the molecular subtype of the tumor?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A1-A0SD-01Z-00-DX1.DB17BFA9-D951-42A8-91D2-F4C2EBC6EB9F-1",
        "image": "TCGA-BRCA/TCGA-A1-A0SD-01Z-00-DX1.DB17BFA9-D951-42A8-91D2-F4C2EBC6EB9F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical findings of strong positivity for estrogen receptors and progesterone receptors, and a negative HER2/neu result, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A15H-01Z-00-DX1.E3A9DFDC-204D-4F03-98D9-97BBBB74E840-1",
        "image": "TCGA-BRCA/TCGA-E2-A15H-01Z-00-DX1.E3A9DFDC-204D-4F03-98D9-97BBBB74E840.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER, positive PR, and HER2 positive by FISH, what is the molecular subtype of this breast cancer?   A) HER2-enriched   B) Basal   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A7-A0CG-01Z-00-DX1.D77019C2-96B1-4EF5-A61E-5F2D5B8D9852-1",
        "image": "TCGA-BRCA/TCGA-A7-A0CG-01Z-00-DX1.D77019C2-96B1-4EF5-A61E-5F2D5B8D9852.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive pankeratin staining on sentinel lymph nodes and the left breast superior margin, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A7-A0CG-01Z-00-DX2.81138E90-373A-4C12-B9CA-6EEF5F84A5B5-1",
        "image": "TCGA-BRCA/TCGA-A7-A0CG-01Z-00-DX2.81138E90-373A-4C12-B9CA-6EEF5F84A5B5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive pankeratin staining on sentinel lymph nodes and the left breast superior margin, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-C8-A12O-01Z-00-DX1.A77E552B-7B69-45B7-B341-A03571F2A06C-1",
        "image": "TCGA-BRCA/TCGA-C8-A12O-01Z-00-DX1.A77E552B-7B69-45B7-B341-A03571F2A06C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negative expression for estrogen receptor (ER), progesterone receptor (PR), Her-2/neu, B-cell marker, and T-cell marker, what is the molecular subtype of this tumor? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-WT-AB44-01Z-00-DX1.B6ECEA7C-DA26-4B34-88CE-6834631DFA35-1",
        "image": "TCGA-BRCA/TCGA-WT-AB44-01Z-00-DX1.B6ECEA7C-DA26-4B34-88CE-6834631DFA35.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results with negative pancytokeratin and supportive smooth muscle myosin, what is the molecular subtype?  A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A1F2-01Z-00-DX1.17E2FD6F-0DCF-425B-864B-21ADCDAE734B-1",
        "image": "TCGA-BRCA/TCGA-BH-A1F2-01Z-00-DX1.17E2FD6F-0DCF-425B-864B-21ADCDAE734B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results that show HER2 positivity with a score of 3+, what is the determined molecular subtype for this case? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-D8-A13Y-01Z-00-DX1.02321E77-A11E-41A5-95FE-BB897EA5CE58-1",
        "image": "TCGA-BRCA/TCGA-D8-A13Y-01Z-00-DX1.02321E77-A11E-41A5-95FE-BB897EA5CE58.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results showing estrogen and progesterone receptors present in 10-75% of neoplastic cell nuclei and a negative HER2 reaction in invasive cancerous cells (score of 1+), what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-D8-A13Y-01Z-00-DX2.0043D2BB-B04D-4A44-AAB1-1CAAD97AC246-1",
        "image": "TCGA-BRCA/TCGA-D8-A13Y-01Z-00-DX2.0043D2BB-B04D-4A44-AAB1-1CAAD97AC246.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results showing estrogen and progesterone receptors present in 10-75% of neoplastic cell nuclei and a negative HER2 reaction in invasive cancerous cells (score of 1+), what is the molecular subtype of this tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A1-A0SJ-01Z-00-DX1.C196FA66-C376-4016-86BC-3D8E745B3A51-1",
        "image": "TCGA-BRCA/TCGA-A1-A0SJ-01Z-00-DX1.C196FA66-C376-4016-86BC-3D8E745B3A51.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the provided immunohistochemical results, which show positive expression for estrogen receptors with strong nuclear staining in more than 70% of tumor cells and positive progesterone receptors with at least weak nuclear staining in over 10% of tumor cells, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AC-A5XS-01Z-00-DX1.E5F2481E-9314-4B20-84B7-370EF82AF4BB-1",
        "image": "TCGA-BRCA/TCGA-AC-A5XS-01Z-00-DX1.E5F2481E-9314-4B20-84B7-370EF82AF4BB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negative E-cadherin, positive hormone receptors (ER and PR), and negative HER2 (1+), what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BH-A1EX-01Z-00-DX1.16B6A817-6729-446E-9FCF-A4A333C5295D-1",
        "image": "TCGA-BRCA/TCGA-BH-A1EX-01Z-00-DX1.16B6A817-6729-446E-9FCF-A4A333C5295D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemistry results showing an Estrogen Receptor (ER) HSCORE of 50, Progesterone Receptor (PR) score of 60, and HER-2/neu score of 2+, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E2-A10B-01Z-00-DX1.148CFC4B-EE65-4A7E-918F-10C72F37CB0F-1",
        "image": "TCGA-BRCA/TCGA-E2-A10B-01Z-00-DX1.148CFC4B-EE65-4A7E-918F-10C72F37CB0F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR with Allred scores of 8, and equivocal HER2 status with 2+ intensity, what is the molecular subtype of this breast cancer? A) Luminal A B) HER2-enriched C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A158-01Z-00-DX1.994C60FE-E651-4224-95E7-4669834F2338-1",
        "image": "TCGA-BRCA/TCGA-E2-A158-01Z-00-DX1.994C60FE-E651-4224-95E7-4669834F2338.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing ER negative and PR negative status among multiple block numbers, with equivocal HER-2 expression, what is the molecular subtype of this breast cancer?   A) Luminal A   B) Luminal B   C) Basal   D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A8-A0A7-01Z-00-DX1.A0FD4EEF-B536-47C1-BDA1-7AC71BA3E978-1",
        "image": "TCGA-BRCA/TCGA-A8-A0A7-01Z-00-DX1.A0FD4EEF-B536-47C1-BDA1-7AC71BA3E978.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative estrogen and progesterone receptors, and positive C-erb B-2 oncoprotein, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-AC-A6NO-01Z-00-DX1.61B7F48C-6D6E-4C1B-B236-DD130ECBDA9D-1",
        "image": "TCGA-BRCA/TCGA-AC-A6NO-01Z-00-DX1.61B7F48C-6D6E-4C1B-B236-DD130ECBDA9D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical profile with positive estrogen receptor (ER) and progesterone receptor (PR) assays, coupled with a negative HER2 status, what is the molecular subtype of this breast cancer? A) Luminal A   B) Basal   C) HER2-enriched   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1Y2-01Z-00-DX2.A563ABFE-18DE-4D78-BB66-9CD18D3CBE3A-1",
        "image": "TCGA-BRCA/TCGA-D8-A1Y2-01Z-00-DX2.A563ABFE-18DE-4D78-BB66-9CD18D3CBE3A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results where estrogen receptors are found in over 75% of neoplastic cell nuclei, progesterone receptors in less than 10%, and HER2 protein score is 2+ without gene amplification (as verified by FISH), what is the molecular subtype of this tumor? A) HER2-enriched   B) Luminal A   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1Y2-01Z-00-DX1.77451A0F-00FD-44A9-A0D0-CB7A39CE74CC-1",
        "image": "TCGA-BRCA/TCGA-D8-A1Y2-01Z-00-DX1.77451A0F-00FD-44A9-A0D0-CB7A39CE74CC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results where estrogen receptors are found in over 75% of neoplastic cell nuclei, progesterone receptors in less than 10%, and HER2 protein score is 2+ without gene amplification (as verified by FISH), what is the molecular subtype of this tumor? A) HER2-enriched   B) Luminal A   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-AO-A12A-01Z-00-DX1.4E9609A7-9AAD-40A8-8344-8369DF998006-1",
        "image": "TCGA-BRCA/TCGA-AO-A12A-01Z-00-DX1.4E9609A7-9AAD-40A8-8344-8369DF998006.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing 99% ER positivity, 30% BR positivity, and negative MENZ/RO staining, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A156-01Z-00-DX1.CEF32B4D-A676-4230-992D-45A046E4043A-1",
        "image": "TCGA-BRCA/TCGA-E2-A156-01Z-00-DX1.CEF32B4D-A676-4230-992D-45A046E4043A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen receptor (ER) and progesterone receptor (PR), but negative HER2 expression, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AO-A12H-01Z-00-DX1.C6CCBD9D-FB41-4F6C-84FB-A43E0A77E696-1",
        "image": "TCGA-BRCA/TCGA-AO-A12H-01Z-00-DX1.C6CCBD9D-FB41-4F6C-84FB-A43E0A77E696.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression for estrogen receptor (ER), positive for progesterone receptor (PR), and positive HER2 status (3+), what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-OL-A5RZ-01Z-00-DX1.6394C05E-1C34-4F4B-8859-F5E961E7EFF9-1",
        "image": "TCGA-BRCA/TCGA-OL-A5RZ-01Z-00-DX1.6394C05E-1C34-4F4B-8859-F5E961E7EFF9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the immunohistochemical results showing weak expression of estrogen receptor (ER) in 30% of cells, no expression of progesterone receptor (PR), a Ki-67 proliferation index between 10-20%, and pending HER2 (FISH) results, what is the molecular subtype of this breast cancer? A) HER2-enriched B) Luminal A C) Basal D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A1-A0SQ-01Z-00-DX1.36071264-3407-4224-BCBB-2ED00294569A-1",
        "image": "TCGA-BRCA/TCGA-A1-A0SQ-01Z-00-DX1.36071264-3407-4224-BCBB-2ED00294569A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptors and progesterone receptors with a negative HER2/neu status, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A73U-01Z-00-DX2.91F571C8-303C-463D-952C-263FAA5097DF-1",
        "image": "TCGA-BRCA/TCGA-D8-A73U-01Z-00-DX2.91F571C8-303C-463D-952C-263FAA5097DF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing 75% positivity for both estrogen and progesterone receptors, negative HER2 status, and a low Ki-67 proliferation index of 15%, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A73U-01Z-00-DX1.6ECEF7C0-00CC-4AC2-87BD-DBFB6E0DC042-1",
        "image": "TCGA-BRCA/TCGA-D8-A73U-01Z-00-DX1.6ECEF7C0-00CC-4AC2-87BD-DBFB6E0DC042.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing 75% positivity for both estrogen and progesterone receptors, negative HER2 status, and a low Ki-67 proliferation index of 15%, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A7-A0CH-01Z-00-DX1.48ADDD0B-527A-404C-B794-7D7D35BF861F-1",
        "image": "TCGA-BRCA/TCGA-A7-A0CH-01Z-00-DX1.48ADDD0B-527A-404C-B794-7D7D35BF861F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative expression for Keratin (AE1/AE3), what is the molecular subtype of this cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A04R-01Z-00-DX1.BE3661A3-A2A0-4248-B7D5-D8986E529B6C-1",
        "image": "TCGA-BRCA/TCGA-A2-A04R-01Z-00-DX1.BE3661A3-A2A0-4248-B7D5-D8986E529B6C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor status (80% nuclear staining), positive progesterone receptor status (90% nuclear staining), weakly positive HER2 (2+) by immunohistochemistry, and HER2 not amplified by FISH (1.1), what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AC-A2BM-01Z-00-DX1.162A9FA9-6E61-48BF-B0A5-C6C7640ABD9B-1",
        "image": "TCGA-BRCA/TCGA-AC-A2BM-01Z-00-DX1.162A9FA9-6E61-48BF-B0A5-C6C7640ABD9B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results with both estrogen and progesterone receptors positive, and HER2 not amplified (FISH ratio 1.4), what is the molecular subtype of this breast cancer? A) Basal B) Luminal A C) HER2-enriched D) Triple negative"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-E2-A15G-01Z-00-DX1.BAA5235E-1022-463B-A852-586ED7CA75FF-1",
        "image": "TCGA-BRCA/TCGA-E2-A15G-01Z-00-DX1.BAA5235E-1022-463B-A852-586ED7CA75FF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positivity for estrogen receptor (ER) and progesterone receptor (PR) with a negative HER2 status, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-AC-A5XU-01Z-00-DX1.1AEEFAAF-0906-4086-8022-13B689FAB9F5-1",
        "image": "TCGA-BRCA/TCGA-AC-A5XU-01Z-00-DX1.1AEEFAAF-0906-4086-8022-13B689FAB9F5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing synaptophysin positivity and no evidence of metastatic carcinoma on CK-OSCAR staining, what is the molecular subtype of this tumor? A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A1-A0SK-01Z-00-DX1.A44D70FA-4D96-43F4-9DD7-A61535786297-1",
        "image": "TCGA-BRCA/TCGA-A1-A0SK-01Z-00-DX1.A44D70FA-4D96-43F4-9DD7-A61535786297.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing patchy positivity for keratin cocktail, positive CD56 and PAX-5, negative LCA, chromogranin, synaptophysin, and E-cadherin, what is the molecular subtype of this tumor? A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-GI-A2C8-01Z-00-DX1.09BD8AC9-645A-4C8B-9B36-77D833BDBA09-1",
        "image": "TCGA-BRCA/TCGA-GI-A2C8-01Z-00-DX1.09BD8AC9-645A-4C8B-9B36-77D833BDBA09.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive expression for estrogen receptor (ER) and progesterone receptor (PR), and negative HER2 status, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal B D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A1EY-01Z-00-DX1.25C3DE1F-C702-4959-8DFA-69EF78AD9307-1",
        "image": "TCGA-BRCA/TCGA-BH-A1EY-01Z-00-DX1.25C3DE1F-C702-4959-8DFA-69EF78AD9307.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing a HER2 score of 0, what is the molecular subtype of this breast cancer? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E9-A54Y-01Z-00-DX1.5FD70369-6514-4E5E-8BEF-65DAC5671E1A-1",
        "image": "TCGA-BRCA/TCGA-E9-A54Y-01Z-00-DX1.5FD70369-6514-4E5E-8BEF-65DAC5671E1A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing ER positivity at 98% with a score of 3+, PR positivity at 50% with a score of 3+, negative Her-2/neu expression at 1+, and a Ki-67 proliferation index of 6%, what is the likely molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A1-A0SB-01Z-00-DX1.B34C267B-CAAA-4AB6-AD5C-276C26F997A1-1",
        "image": "TCGA-BRCA/TCGA-A1-A0SB-01Z-00-DX1.B34C267B-CAAA-4AB6-AD5C-276C26F997A1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER, negative PR, and negative HER2/neu status, what is the molecular subtype of this breast tumor? A) Luminal A B) Basal C) HER2-enriched D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-C8-A12N-01Z-00-DX1.8E50110E-A6C0-496F-B44E-7190096C113E-1",
        "image": "TCGA-BRCA/TCGA-C8-A12N-01Z-00-DX1.8E50110E-A6C0-496F-B44E-7190096C113E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing ER-negative, PR-negative, Her-2/neu-negative, with a positive B-Cell marker and other marker, what is the molecular subtype of this case?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-A2-A0T0-01Z-00-DX1.51F904DA-A4B5-4451-8AEF-58E7EF7651DB-1",
        "image": "TCGA-BRCA/TCGA-A2-A0T0-01Z-00-DX1.51F904DA-A4B5-4451-8AEF-58E7EF7651DB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results of HER-2 not amplified and both estrogen and progesterone receptors negative in the malignant cells (0%), what is the molecular subtype of this tumor?   A) Luminal A   B) Luminal B   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A1EW-01Z-00-DX1.A6A5F9C5-FB97-4DA3-A1EA-1F84BC006681-1",
        "image": "TCGA-BRCA/TCGA-BH-A1EW-01Z-00-DX1.A6A5F9C5-FB97-4DA3-A1EA-1F84BC006681.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen receptor status, negative progesterone receptor status, and weakly positive HER-2/neu expression, what is the molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-AR-A5QQ-01Z-00-DX1.4185D6D2-498E-4E71-8CB3-EDB4739C6229-1",
        "image": "TCGA-BRCA/TCGA-AR-A5QQ-01Z-00-DX1.4185D6D2-498E-4E71-8CB3-EDB4739C6229.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nIn the scenario where immunohistochemical results for estrogen receptor, progesterone receptor, and HER2 are pending, which molecular subtype has been identified for this tumor?  A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A1-A0SE-01Z-00-DX1.04B09232-C6C4-46EF-AA2C-41D078D0A80A-1",
        "image": "TCGA-BRCA/TCGA-A1-A0SE-01Z-00-DX1.04B09232-C6C4-46EF-AA2C-41D078D0A80A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive estrogen receptor (ER) and progesterone receptor (PR) status with negative HER2/neu expression, what is the molecular subtype of this breast cancer? A) Basal B) Luminal B C) HER2-enriched D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-AC-A3QQ-01Z-00-DX1.86463263-AB12-49FB-8967-D5FD1F7D221A-1",
        "image": "TCGA-BRCA/TCGA-AC-A3QQ-01Z-00-DX1.86463263-AB12-49FB-8967-D5FD1F7D221A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on these immunohistochemical results showing positive estrogen and progesterone receptors, HER-2 overexpression, and a high Ki-67 index, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-E9-A6HE-01Z-00-DX1.97514DBA-9BC0-4554-9A43-99C48C6B953A-1",
        "image": "TCGA-BRCA/TCGA-E9-A6HE-01Z-00-DX1.97514DBA-9BC0-4554-9A43-99C48C6B953A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing strongly positive ER and PR, and negative Her-2/Neu amplification, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A150-01Z-00-DX1.55643D23-83E6-4058-8EA5-18AAA8547839-1",
        "image": "TCGA-BRCA/TCGA-E2-A150-01Z-00-DX1.55643D23-83E6-4058-8EA5-18AAA8547839.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative ER and PR with an Allred Score of 0, what is the molecular subtype of this breast cancer?   A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A5J0-01Z-00-DX1.73CFBC85-8449-48FF-86F8-D4D49A90498B-1",
        "image": "TCGA-BRCA/TCGA-BH-A5J0-01Z-00-DX1.73CFBC85-8449-48FF-86F8-D4D49A90498B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemistry results showing a positive estrogen receptor, weakly positive progesterone receptor, negative HER-2/neu, negative E-cadherin in areas of atypical lobular hyperplasia, negative P63 in the area of interest, and strong positive cytoplasmic staining of marker 120 in areas of atypical lobular hyperplasia, what is the molecular subtype of this breast cancer?  A) HER2-enriched   B) Basal   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-A1-A0SP-01Z-00-DX1.20D689C6-EFA5-4694-BE76-24475A89ACC0-1",
        "image": "TCGA-BRCA/TCGA-A1-A0SP-01Z-00-DX1.20D689C6-EFA5-4694-BE76-24475A89ACC0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing negative expression for estrogen receptor (ER), progesterone receptor (PR), and HER2/neu, what is the molecular subtype of this breast cancer?   A) Luminal B   B) HER2-enriched   C) Basal   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-A2-A04N-01Z-00-DX1.9E9B7DB0-1CF1-4631-8292-A9DBCA0BD37C-1",
        "image": "TCGA-BRCA/TCGA-A2-A04N-01Z-00-DX1.9E9B7DB0-1CF1-4631-8292-A9DBCA0BD37C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing strong positive ER/PR immunostains and non-amplified HER2 status, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal A   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1Y3-01Z-00-DX1.8AA5F695-A06C-4DEA-AD71-16254A48B218-1",
        "image": "TCGA-BRCA/TCGA-D8-A1Y3-01Z-00-DX1.8AA5F695-A06C-4DEA-AD71-16254A48B218.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing high expression of both estrogen and progesterone receptors (over 75% of neoplastic cell nuclei) and a HER2 score of 2 with recommended FISH verification, what is the molecular subtype of this breast tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-D8-A1Y3-01Z-00-DX2.B9BD14AF-52A6-4241-B3B3-03F8F5DFC8DA-1",
        "image": "TCGA-BRCA/TCGA-D8-A1Y3-01Z-00-DX2.B9BD14AF-52A6-4241-B3B3-03F8F5DFC8DA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing high expression of both estrogen and progesterone receptors (over 75% of neoplastic cell nuclei) and a HER2 score of 2 with recommended FISH verification, what is the molecular subtype of this breast tumor? A) Luminal A   B) HER2-enriched   C) Basal   D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E2-A15R-01Z-00-DX1.B58D2D9D-05EE-4D66-8DC0-9E5C6AD2E3D3-1",
        "image": "TCGA-BRCA/TCGA-E2-A15R-01Z-00-DX1.B58D2D9D-05EE-4D66-8DC0-9E5C6AD2E3D3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER status, positive PR status, and negative HER2 status by FISH, what is the most likely molecular subtype of this breast cancer? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BH-A5IZ-01Z-00-DX1.6C871030-82E1-463E-A67B-976A5F3DCDB2-1",
        "image": "TCGA-BRCA/TCGA-BH-A5IZ-01Z-00-DX1.6C871030-82E1-463E-A67B-976A5F3DCDB2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nConsidering the immunohistochemical results showing positive estrogen receptor, negative progesterone receptor, and negative HER-2 FISH, what is the molecular subtype of this tumor? A) Luminal A   B) Luminal B   C) HER2-enriched   D) Basal"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-OL-A5RU-01Z-00-DX1.A48CAF2D-9310-4611-B27D-400F3A324607-1",
        "image": "TCGA-BRCA/TCGA-OL-A5RU-01Z-00-DX1.A48CAF2D-9310-4611-B27D-400F3A324607.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical results showing positive ER and PR expressions with non-amplified Her2 status in both the left and right breasts, what is the molecular subtype of this breast cancer? A) Basal  B) HER2-enriched  C) Luminal A  D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A10C-01Z-00-DX1.29A2B20B-29C6-4491-ADAB-0584C772EF25-1",
        "image": "TCGA-BRCA/TCGA-E2-A10C-01Z-00-DX1.29A2B20B-29C6-4491-ADAB-0584C772EF25.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the immunohistochemical findings of positive ER and PR status with negative HER2 expression, what is the molecular subtype of this breast cancer?   A) Basal   B) HER2-enriched   C) Luminal B   D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BH-A1FC-01Z-00-DX1.B816A21B-1559-42F5-902A-A1532E59C015-1",
        "image": "TCGA-BRCA/TCGA-BH-A1FC-01Z-00-DX1.B816A21B-1559-42F5-902A-A1532E59C015.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing positive estrogen receptor and progesterone receptor status and negative HER-2/neu expression, what is the molecular subtype of this tumor? A) Basal B) HER2-enriched C) Luminal A D) Luminal B"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E2-A159-01Z-00-DX1.C8DC3356-CAE9-4E7A-AEFF-ABB4BE38192B-1",
        "image": "TCGA-BRCA/TCGA-E2-A159-01Z-00-DX1.C8DC3356-CAE9-4E7A-AEFF-ABB4BE38192B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the immunohistochemical results showing negative expression for estrogen receptor (ER), progesterone receptor (PR), and HER2 negative by FISH, what is the molecular subtype of this tumor? A) Luminal B B) HER2-enriched C) Basal D) Luminal A"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DH-5144-01Z-00-DX1.4DBB9F00-3215-4199-B8D6-16CC5E517E6F-1",
        "image": "TCGA-LGG/TCGA-DH-5144-01Z-00-DX1.4DBB9F00-3215-4199-B8D6-16CC5E517E6F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Ki-67 labeling index of 7-12% in areas of increased cellularity and GFAP reactivity in microgemiatocytic forms and \"gliofibrillary oligodendrocytes,\" what is the molecular subtype in this low-grade glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-A76L-01Z-00-DX1.1FCFF046-82EF-42B4-937F-CEFD63D3E713-1",
        "image": "TCGA-LGG/TCGA-DU-A76L-01Z-00-DX1.1FCFF046-82EF-42B4-937F-CEFD63D3E713.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP with a moderately fibrillary background highlighting prominent microvascular cellular proliferation, and a MIB-1 labeling index of 37%, what is the molecular subtype in this glioblastoma? A) IDHwt B) IDHmut C) 1p/19q codeleted D) BRAF V600E"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-FG-A713-01Z-00-DX1.92B1CBC8-BF31-4748-92B6-EA4ACB3366FF-1",
        "image": "TCGA-LGG/TCGA-FG-A713-01Z-00-DX1.92B1CBC8-BF31-4748-92B6-EA4ACB3366FF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing no highlighting of intraparenchymal cells by Ki-67, Mutant IDH1 R132H, and CD20, and the FISH results indicating loss of chromosomes 1p and 19q, what is the molecular subtype in this glioma?   A) IDHwt-noncodel   B) IDHmut-noncodel   C) IDHmut-codel   D) ATRX-mutated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-FG-A713-01Z-00-DX3.61A211D7-4E07-48F3-BCA4-B05B0EDE5AB3-1",
        "image": "TCGA-LGG/TCGA-FG-A713-01Z-00-DX3.61A211D7-4E07-48F3-BCA4-B05B0EDE5AB3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing no highlighting of intraparenchymal cells by Ki-67, Mutant IDH1 R132H, and CD20, and the FISH results indicating loss of chromosomes 1p and 19q, what is the molecular subtype in this glioma?   A) IDHwt-noncodel   B) IDHmut-noncodel   C) IDHmut-codel   D) ATRX-mutated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-FG-A713-01Z-00-DX5.E66E88FF-6B6E-40D2-9F5D-32354198475D-1",
        "image": "TCGA-LGG/TCGA-FG-A713-01Z-00-DX5.E66E88FF-6B6E-40D2-9F5D-32354198475D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing no highlighting of intraparenchymal cells by Ki-67, Mutant IDH1 R132H, and CD20, and the FISH results indicating loss of chromosomes 1p and 19q, what is the molecular subtype in this glioma?   A) IDHwt-noncodel   B) IDHmut-noncodel   C) IDHmut-codel   D) ATRX-mutated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-FG-A713-01Z-00-DX2.AFC5E32E-29B6-422B-B867-76BE764A3352-1",
        "image": "TCGA-LGG/TCGA-FG-A713-01Z-00-DX2.AFC5E32E-29B6-422B-B867-76BE764A3352.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing no highlighting of intraparenchymal cells by Ki-67, Mutant IDH1 R132H, and CD20, and the FISH results indicating loss of chromosomes 1p and 19q, what is the molecular subtype in this glioma?   A) IDHwt-noncodel   B) IDHmut-noncodel   C) IDHmut-codel   D) ATRX-mutated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-FG-A713-01Z-00-DX4.12FA5CBD-8304-414F-99BD-2FDA6F9DAC00-1",
        "image": "TCGA-LGG/TCGA-FG-A713-01Z-00-DX4.12FA5CBD-8304-414F-99BD-2FDA6F9DAC00.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing no highlighting of intraparenchymal cells by Ki-67, Mutant IDH1 R132H, and CD20, and the FISH results indicating loss of chromosomes 1p and 19q, what is the molecular subtype in this glioma?   A) IDHwt-noncodel   B) IDHmut-noncodel   C) IDHmut-codel   D) ATRX-mutated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DH-5143-01Z-00-DX1.DD05DCF6-FF16-47A3-B3EF-FCB89F6C8566-1",
        "image": "TCGA-LGG/TCGA-DH-5143-01Z-00-DX1.DD05DCF6-FF16-47A3-B3EF-FCB89F6C8566.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Ki-67 labeling index of 5-10% in areas of increased cellularity, P53 immunoreactivity in slightly greater than 50% of tumor cells, and variable reactivity of GFAP throughout the tumor, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q-codeleted D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E1-A7Z6-01Z-00-DX1.85795D31-F597-4AE3-8AE0-7394A428936A-1",
        "image": "TCGA-LGG/TCGA-E1-A7Z6-01Z-00-DX1.85795D31-F597-4AE3-8AE0-7394A428936A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results with positive LEU-7, LCA in 10% of cells, MGMT positive in 20% of tumor cells, EGFR wt positive in 60% of tumor cells, negative EGFR VIII, p53 positive in 50% of tumor cells, and several other markers, what is the molecular subtype in this glioma? A) IDHmut non-codel B) IDH wildtype C) 1p/19q co-deleted D) BRAF V600E mutated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DH-A7UR-01Z-00-DX1.CD0C3921-255F-4415-BE61-240068DD1C9D-1",
        "image": "TCGA-LGG/TCGA-DH-A7UR-01Z-00-DX1.CD0C3921-255F-4415-BE61-240068DD1C9D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Ki-67 labeling index of 15-20% and GFAP immunoreactivity in a few scattered cells but negativity in the majority of the tumor, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHwt C) ATRX-wildtype D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-7012-01Z-00-DX1.3D0ACB4F-8CBB-47F9-B015-0AFF70928A62-1",
        "image": "TCGA-LGG/TCGA-DU-7012-01Z-00-DX1.3D0ACB4F-8CBB-47F9-B015-0AFF70928A62.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong positivity for GFAP and a MIB-1 proliferative index of approximately 128, what is the molecular subtype in this glioblastoma?  A) IDHwt   B) IDHmut   C) 1p/19q codeleted   D) ATRX-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-6399-01Z-00-DX1.1a964643-a0f0-4338-8976-3bf5f832236c-1",
        "image": "TCGA-LGG/TCGA-DU-6399-01Z-00-DX1.1a964643-a0f0-4338-8976-3bf5f832236c.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of about 8-10%, what is the molecular subtype in this low-grade glioma? A) IDHmut-codel B) IDHwt C) IDHmut-non-codel D) 1p/19q co-deletion"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-8563-01Z-00-DX1.78F51983-9EAD-47AA-99B9-D3E16308926E-1",
        "image": "TCGA-LGG/TCGA-HT-8563-01Z-00-DX1.78F51983-9EAD-47AA-99B9-D3E16308926E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing an MIB-1 labeling index of 2.0%, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) BRAF V600E-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-8107-01Z-00-DX1.7AA96D1B-FFA4-458B-9D4A-55166FD6E4C4-1",
        "image": "TCGA-LGG/TCGA-HT-8107-01Z-00-DX1.7AA96D1B-FFA4-458B-9D4A-55166FD6E4C4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing MIB-1 reactivity ranging from 0.7% to 9.7%, what is the molecular subtype in this glioma?   A) IDH-mutant   B) IDHwt   C) 1p/19q co-deleted   D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-E1-A7YN-01Z-00-DX1.74D8BD5D-F0C9-4BD5-8FEC-E1B57E0FEF5C-1",
        "image": "TCGA-LGG/TCGA-E1-A7YN-01Z-00-DX1.74D8BD5D-F0C9-4BD5-8FEC-E1B57E0FEF5C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positivity for GFAP, HAM-56, CD45, and Vimentin; a high Ki-67 labeling index of 20%; negativity for EGFR vIII and ATRX; negativity for IDH1; and widespread expression of VEGF Alpha, VEGF Beta, and PDGF Alpha in this tumor, what is the molecular subtype in this glioblastoma? A) IDH-mutant B) IDHwt C) EGFR-amplified D) MGMT-methylated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HW-A5KL-01Z-00-DX1.9BE3C44C-8738-4F55-8CCD-DBE3A92A88CE-1",
        "image": "TCGA-LGG/TCGA-HW-A5KL-01Z-00-DX1.9BE3C44C-8738-4F55-8CCD-DBE3A92A88CE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index that does not exceed 2%, positive p53 in many tumor cells, and positivity for IDH1 R132H mutant in a subset of tumor cells, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-CS-4942-01Z-00-DX1.67f7928e-e1d9-473b-a317-7c6b4ba7433f-1",
        "image": "TCGA-LGG/TCGA-CS-4942-01Z-00-DX1.67f7928e-e1d9-473b-a317-7c6b4ba7433f.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive GFAP staining in glial tissue including astrocytic neoplasm, and positive Ki67 staining in approximately 7% of tumor cell nuclei, what is the molecular subtype in this low-grade glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q codeletion D) EGFR amplification"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E1-A7YI-01Z-00-DX1.BC6CCA84-ED9A-4945-9B66-8F2884E0712B-1",
        "image": "TCGA-LGG/TCGA-E1-A7YI-01Z-00-DX1.BC6CCA84-ED9A-4945-9B66-8F2884E0712B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive Leukocyte Common Antigen, high proliferation index, negative MGMT, negative EGFR, EGFR VIII, and ATRX, loss of PTEN, and positive p53 and MAPK, what is the molecular subtype in this brain tumor? A) IDHmut-non-codel B) IDHwt C) IDHmut-codel D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-TM-A84I-01Z-00-DX1.755573F1-0378-4E95-A755-CD8AB79ABEC1-1",
        "image": "TCGA-LGG/TCGA-TM-A84I-01Z-00-DX1.755573F1-0378-4E95-A755-CD8AB79ABEC1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffusely strong positivity for GFAP and P53, and a variable Ki67 (MIB-1) proliferation index approximating 5-20%, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-non-codel C) IDHmut-codel D) BRAF V600E-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-7013-01Z-00-DX1.04BAB2CD-8B7D-480F-92D2-3CC8DA1485BC-1",
        "image": "TCGA-LGG/TCGA-DU-7013-01Z-00-DX1.04BAB2CD-8B7D-480F-92D2-3CC8DA1485BC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 proliferation index of 12% to 16% and GFAP demonstrating the glial fibrillary background of the tumor, what is the molecular subtype in this glioma? A) IDHwt B) IDH-mutant C) 1p/19q co-deleted D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-TM-A84S-01Z-00-DX1.5ED4FD31-AE61-4E45-B202-420B37C847D9-1",
        "image": "TCGA-LGG/TCGA-TM-A84S-01Z-00-DX1.5ED4FD31-AE61-4E45-B202-420B37C847D9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive staining for DHT and minimal staining for GFAP, with P53 showing 5-10% positive cells, and negative results for NeuN and synaptophysin, what is the molecular subtype in this glioma?   A) IDHmut-codel   B) IDH-wildtype   C) IDHmut-non-codel   D) MGMT methylated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-RY-A847-01Z-00-DX1.E137897D-0B07-401B-A106-BFF78C14F5D4-1",
        "image": "TCGA-LGG/TCGA-RY-A847-01Z-00-DX1.E137897D-0B07-401B-A106-BFF78C14F5D4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing IDH-1 (R132H mutant) positivity, what is the molecular subtype in this cancer?  A) IDHmut-codel B) IDHwt C) TP53-mutant D) FGFR3-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-RY-A840-01Z-00-DX1.E4D70B62-E2F7-411D-A9A8-DD78C20DF6B8-1",
        "image": "TCGA-LGG/TCGA-RY-A840-01Z-00-DX1.E4D70B62-E2F7-411D-A9A8-DD78C20DF6B8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 proliferative index estimated at 5%, strong positivity for IDH1 (R132H mutant form), and negative p53 expression, what is the molecular subtype in this diffuse glioma? A) IDHmut-non-codel B) IDHmut-codel C) IDHwt D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HW-A5KM-01Z-00-DX1.A8D3FF2B-3E88-46E0-8EFE-E2820F352EB1-1",
        "image": "TCGA-LGG/TCGA-HW-A5KM-01Z-00-DX1.A8D3FF2B-3E88-46E0-8EFE-E2820F352EB1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1/Ki-67 proliferative index of 2-3% with focal increases to 5%, and IDH1 R132H expression present in tumor cells, what is the molecular subtype in this glioma? A) IDHwildtype B) IDHmut-non-codel C) EGFR-amplified D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-TM-A84O-01Z-00-DX1.C05AE734-FABD-4DA7-9FDA-A54564CDED27-1",
        "image": "TCGA-LGG/TCGA-TM-A84O-01Z-00-DX1.C05AE734-FABD-4DA7-9FDA-A54564CDED27.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP negativity and a Ki67 proliferative index focally up to approximately 10%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHwt C) IDHmut-non-codel D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DB-5280-01Z-00-DX1.377DED7C-CE43-4735-A6C1-2C2D0A769B18-1",
        "image": "TCGA-LGG/TCGA-DB-5280-01Z-00-DX1.377DED7C-CE43-4735-A6C1-2C2D0A769B18.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP is focally positive in tumor cells, p53 is positive in tumor cells, and MIB-1 labeling varies from low to moderate (up to 4-6%), what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHmut-codel C) IDHwt D) BRAF-V600E mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DB-5280-01Z-00-DX2.A0AC8AD2-F2A3-477B-970C-71FD6FF7C6F6-1",
        "image": "TCGA-LGG/TCGA-DB-5280-01Z-00-DX2.A0AC8AD2-F2A3-477B-970C-71FD6FF7C6F6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP is focally positive in tumor cells, p53 is positive in tumor cells, and MIB-1 labeling varies from low to moderate (up to 4-6%), what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHmut-codel C) IDHwt D) BRAF-V600E mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-6396-01Z-00-DX1.0a818d89-d17b-45aa-85ce-d3a6631b7807-1",
        "image": "TCGA-LGG/TCGA-DU-6396-01Z-00-DX1.0a818d89-d17b-45aa-85ce-d3a6631b7807.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP demonstrating macro and mini gemistocytic phenotypes of the tumor cells and a MIB-1 labeling index of about 2%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDHwt D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-8106-01Z-00-DX1.E6186AC8-3F27-4AB2-A89B-B44DD5199D88-1",
        "image": "TCGA-LGG/TCGA-HT-8106-01Z-00-DX1.E6186AC8-3F27-4AB2-A89B-B44DD5199D88.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of 16.3%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) EGFR-amplified D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7467-01Z-00-DX3.699E5D9C-7E3C-4559-8F6B-985DF1FC0D23-1",
        "image": "TCGA-LGG/TCGA-HT-7467-01Z-00-DX3.699E5D9C-7E3C-4559-8F6B-985DF1FC0D23.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the IHC result of MIB-1 being greater than or equal to 5%, what is the molecular subtype in this glioma?   A) IDHmut-wt   B) IDHmut-codel   C) Wild-type GBM   D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7467-01Z-00-DX4.2CD993E3-7E94-4152-952F-4B12AB4F5EF7-1",
        "image": "TCGA-LGG/TCGA-HT-7467-01Z-00-DX4.2CD993E3-7E94-4152-952F-4B12AB4F5EF7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the IHC result of MIB-1 being greater than or equal to 5%, what is the molecular subtype in this glioma?   A) IDHmut-wt   B) IDHmut-codel   C) Wild-type GBM   D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7467-01Z-00-DX1.F65868BC-8DD4-4ECF-873B-03C8868345B1-1",
        "image": "TCGA-LGG/TCGA-HT-7467-01Z-00-DX1.F65868BC-8DD4-4ECF-873B-03C8868345B1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the IHC result of MIB-1 being greater than or equal to 5%, what is the molecular subtype in this glioma?   A) IDHmut-wt   B) IDHmut-codel   C) Wild-type GBM   D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7467-01Z-00-DX2.469E8B4F-96A2-4FDB-8397-E585D8AFCB3E-1",
        "image": "TCGA-LGG/TCGA-HT-7467-01Z-00-DX2.469E8B4F-96A2-4FDB-8397-E585D8AFCB3E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith the IHC result of MIB-1 being greater than or equal to 5%, what is the molecular subtype in this glioma?   A) IDHmut-wt   B) IDHmut-codel   C) Wild-type GBM   D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7469-01Z-00-DX1.53A588BD-3B74-4DB6-BE8D-A6E80119E3EB-1",
        "image": "TCGA-LGG/TCGA-HT-7469-01Z-00-DX1.53A588BD-3B74-4DB6-BE8D-A6E80119E3EB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing a MIB-1 labeling index of 16.1%, what is the molecular subtype in this brain tumor? A) IDH-mutant B) IDHwt C) 1p/19q codeleted D) MGMT-methylated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-8011-01Z-00-DX1.C3EBC225-3BE8-4B24-9EAD-2389EB999026-1",
        "image": "TCGA-LGG/TCGA-HT-8011-01Z-00-DX1.C3EBC225-3BE8-4B24-9EAD-2389EB999026.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing variably strong GFAP positivity, positivity for PAS and PAS with diastase, and a MIB-1 reactive labeling index of 33%, what is the molecular subtype in this glioma?   A) IDH-mutant   B) 1p/19q codeleted   C) IDHwt   D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DU-5855-01Z-00-DX1.046a8964-3cdf-49cf-a65c-3254e50ae90d-1",
        "image": "TCGA-LGG/TCGA-DU-5855-01Z-00-DX1.046a8964-3cdf-49cf-a65c-3254e50ae90d.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing moderate p53 positivity in 50% of the tumor cells, mostly negative EMA, and a Ki-67 labeling index focally increased to approximately 15%, along with the additional molecular finding of positive MGMT promoter methylation and no allelic loss on chromosome arms 1p and 19q, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) IDHmut-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-5852-01Z-00-DX1.2abc3f8e-6ed5-4526-80b4-d84dc4d983b8-1",
        "image": "TCGA-LGG/TCGA-DU-5852-01Z-00-DX1.2abc3f8e-6ed5-4526-80b4-d84dc4d983b8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity in reactive astrocytes and occasional tumor cells, a Ki-67 labeling index of approximately 12%, negative loss of heterozygosity for 1p,19q, and positive MGMT promoter methylation, what is the molecular subtype in this glioma? A) IDHmut B) 1p/19q codeleted C) MGMT-unmethylated D) IDHwt"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-FG-A60L-01Z-00-DX1.BE970739-D829-489B-A697-311021B8CD73-1",
        "image": "TCGA-LGG/TCGA-FG-A60L-01Z-00-DX1.BE970739-D829-489B-A697-311021B8CD73.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Ki-67 labeling index of 5%, no nuclei labeling with p53 antibodies, and neoplastic cells labeling with IDH1 (R132H) antibodies, what is the molecular subtype in this brain tumor? A) IDHwt B) 1p/19q co-deleted C) IDHmut-non-codel D) ATRX-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-8018-01Z-00-DX1.1C1BBFD4-8C4A-4A6F-8D64-70A4F41814AF-1",
        "image": "TCGA-LGG/TCGA-HT-8018-01Z-00-DX1.1C1BBFD4-8C4A-4A6F-8D64-70A4F41814AF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of 5.0%, what is the molecular subtype in this low-grade glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deleted D) BRAF V600E"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7468-01Z-00-DX8.BC4AF8CA-E49E-455E-A32F-A99474209DE9-1",
        "image": "TCGA-LGG/TCGA-HT-7468-01Z-00-DX8.BC4AF8CA-E49E-455E-A32F-A99474209DE9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 labeling index of <1% - 8.8%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) IDHmut-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-7468-01Z-00-DX1.9141B9CC-C84D-4226-984C-1DD9E98E4A8D-1",
        "image": "TCGA-LGG/TCGA-HT-7468-01Z-00-DX1.9141B9CC-C84D-4226-984C-1DD9E98E4A8D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 labeling index of <1% - 8.8%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) IDHmut-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-7468-01Z-00-DX5.54889415-0D9B-4472-95F6-355D3284572F-1",
        "image": "TCGA-LGG/TCGA-HT-7468-01Z-00-DX5.54889415-0D9B-4472-95F6-355D3284572F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 labeling index of <1% - 8.8%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) IDHmut-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-7468-01Z-00-DX9.41F63F36-2FB3-40A2-9FA5-E448879DB7EE-1",
        "image": "TCGA-LGG/TCGA-HT-7468-01Z-00-DX9.41F63F36-2FB3-40A2-9FA5-E448879DB7EE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 labeling index of <1% - 8.8%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) IDHmut-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-7468-01Z-00-DX3.623EF604-9D08-4596-8917-E5609A1CFBE1-1",
        "image": "TCGA-LGG/TCGA-HT-7468-01Z-00-DX3.623EF604-9D08-4596-8917-E5609A1CFBE1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 labeling index of <1% - 8.8%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) IDHmut-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-7468-01Z-00-DX2.F7D1413E-AA30-4C8E-8A1B-F258E25A649B-1",
        "image": "TCGA-LGG/TCGA-HT-7468-01Z-00-DX2.F7D1413E-AA30-4C8E-8A1B-F258E25A649B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 labeling index of <1% - 8.8%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) IDHmut-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-7468-01Z-00-DX6.45A051E5-82D2-43F4-B160-C2EFBA31AFDA-1",
        "image": "TCGA-LGG/TCGA-HT-7468-01Z-00-DX6.45A051E5-82D2-43F4-B160-C2EFBA31AFDA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 labeling index of <1% - 8.8%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) IDHmut-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-7468-01Z-00-DX7.64F8DF3B-5821-4BCB-80E5-1252F9EB8DFD-1",
        "image": "TCGA-LGG/TCGA-HT-7468-01Z-00-DX7.64F8DF3B-5821-4BCB-80E5-1252F9EB8DFD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 labeling index of <1% - 8.8%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) IDHmut-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-A74J-01Z-00-DX1.7D0134E1-F89A-401C-9F1E-A14B530E6663-1",
        "image": "TCGA-LGG/TCGA-HT-A74J-01Z-00-DX1.7D0134E1-F89A-401C-9F1E-A14B530E6663.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH1 positivity, negative p53, and a MIB-1 labeling index of 5.1%, what is the molecular subtype in this cancer? A) IDHwt B) IDHmut-non-codel C) IDHmut-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-FG-A60J-01Z-00-DX1.1A313634-0CA2-40B4-998A-58871CF2A5CE-1",
        "image": "TCGA-LGG/TCGA-FG-A60J-01Z-00-DX1.1A313634-0CA2-40B4-998A-58871CF2A5CE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH-1 (R132H) positivity, a Ki-67 labeling index of 11-12% focally, and p53 positive staining in greater than 50% of tumor cells, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDH-wildtype C) 1p/19q codeleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7855-01Z-00-DX1.D1CFAF92-BC0B-443C-8A5A-48147BD0FB84-1",
        "image": "TCGA-LGG/TCGA-HT-7855-01Z-00-DX1.D1CFAF92-BC0B-443C-8A5A-48147BD0FB84.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing intense immunoreactivity for P53 and a MIB-1 labeling index of up to 98.7%, what is the molecular subtype in this cancer type? A) TP53 wild-type B) TP53 mutant C) IDH wild-type D) EGFR-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-A5RB-01Z-00-DX1.6928817C-E954-4245-85D4-90D4501E2424-1",
        "image": "TCGA-LGG/TCGA-HT-A5RB-01Z-00-DX1.6928817C-E954-4245-85D4-90D4501E2424.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffuse p53 immunoreactivity and MIB-1 with a labeling index of 2.8%, what is the molecular subtype in this right frontal brain well-differentiated astrocytoma (WHO Grade II)? A) IDHmut-codel B) IDHwt C) IDHmut-non-codel D) BRAF V600E-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DU-5853-01Z-00-DX1.10c22c4b-d45c-45aa-830a-b2749c8bbcc4-1",
        "image": "TCGA-LGG/TCGA-DU-5853-01Z-00-DX1.10c22c4b-d45c-45aa-830a-b2749c8bbcc4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p53 positivity and a Ki-67 labeling index of approximately 4 to 5%, what is the molecular subtype in this oligoastrocytoma (WHO Grade II)? A) IDHwt B) IDHmut-non-codel C) 1p/19q-codeleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-5854-01Z-00-DX1.b4d00993-a322-4d5a-b7a1-06db7ad078ab-1",
        "image": "TCGA-LGG/TCGA-DU-5854-01Z-00-DX1.b4d00993-a322-4d5a-b7a1-06db7ad078ab.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP with a moderately fibrillary background, EMA with a diffuse tenuous background probably artefactual, moderately activated mostly perivascular microglia with CD163, overexpression of p53 in majority of neoplastic astrocytes, and a MIB-1 proliferation index of about 10%, what is the molecular subtype in this glioblastoma? A) IDH-mutant B) 1p/19q-codeleted C) IDHwt D) MGMT-methylated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DH-A66B-01Z-00-DX1.8669A577-0481-4C15-B4CB-0266E154DEFD-1",
        "image": "TCGA-LGG/TCGA-DH-A66B-01Z-00-DX1.8669A577-0481-4C15-B4CB-0266E154DEFD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP immunoreactivity in the majority of tumor cells, rare individual weakly p53 immunoreactive tumor cells, and an elevated Ki-67 proliferation index of up to approximately 10%, what is the molecular subtype in this low-grade glioma? A) IDHmut-non-codel B) EGFR-amplified C) BRAF V600E D) ATRX-wildtype"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-6400-01Z-00-DX1.46dd4fdb-66b4-445e-b9b7-c0eb8c114ed7-1",
        "image": "TCGA-LGG/TCGA-DU-6400-01Z-00-DX1.46dd4fdb-66b4-445e-b9b7-c0eb8c114ed7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP highlighting glial fibrillary background, a MIB-1 labeling index of 0.5%, and synaptophysin reflecting synaptophysin-rich background of the infiltrated grey matter, what is the molecular subtype in this glioma?  A) IDHwt B) IDHmut-noncodel C) IDHmut-codel D) BRAF V600E+"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-CS-5394-01Z-00-DX1.2ef4d36b-2bf7-4079-990c-3733009db0bd-1",
        "image": "TCGA-LGG/TCGA-CS-5394-01Z-00-DX1.2ef4d36b-2bf7-4079-990c-3733009db0bd.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive staining for Ki67 in up to 109% of tumor cell nuclei, positive staining for GFAP, and negative staining for Chromogranin, what is the molecular subtype in this low-grade glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDHwt D) BRAF V600E-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7884-01Z-00-DX1.36807827-67BE-4B0A-B750-F0690B3CB091-1",
        "image": "TCGA-LGG/TCGA-HT-7884-01Z-00-DX1.36807827-67BE-4B0A-B750-F0690B3CB091.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing numerous p53 immunoreactive cells and a MIB-1 labeling index of 2.5%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHwt C) IDHmut-non-codel D) BRAF V600E-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DU-8161-01Z-00-DX1.f8fa74fe-4793-47dc-9dc1-10e636835536-1",
        "image": "TCGA-LGG/TCGA-DU-8161-01Z-00-DX1.f8fa74fe-4793-47dc-9dc1-10e636835536.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing essentially negative Synaptophysin and NewN, about one third of neoplastic cells strongly overexpressing p53, CD34 depicting focal neovascularization, and a MIB-1 proliferation index of about 20%, what is the molecular subtype in this neoplasm? A) IDHwt B) IDHmut-codel C) ATRX-loss D) H3K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-A6S2-01Z-00-DX1.41E939D2-DE06-4BAB-9600-A1B2DDACA4D8-1",
        "image": "TCGA-LGG/TCGA-DU-A6S2-01Z-00-DX1.41E939D2-DE06-4BAB-9600-A1B2DDACA4D8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH1 positivity, methylated MGMT positivity, and an MIB-1 proliferation index of up to 6%, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-non-codel C) IDHmut-codel D) Mesenchymal"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-FG-A87Q-01Z-00-DX1.FF3D3CFD-BBF1-42F4-8CEA-CF06A2CC451B-1",
        "image": "TCGA-LGG/TCGA-FG-A87Q-01Z-00-DX1.FF3D3CFD-BBF1-42F4-8CEA-CF06A2CC451B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p53 focally positive, IDH negative, and Ki67 diffusely increased to 23%, what is the molecular subtype in this glioblastoma? A) IDH-mutant B) IDHwt C) IDH-PNA D) IDH-FUB"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-FG-A87Q-01Z-00-DX4.9E73D9CC-BE90-4ED4-8F0A-277B25348827-1",
        "image": "TCGA-LGG/TCGA-FG-A87Q-01Z-00-DX4.9E73D9CC-BE90-4ED4-8F0A-277B25348827.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p53 focally positive, IDH negative, and Ki67 diffusely increased to 23%, what is the molecular subtype in this glioblastoma? A) IDH-mutant B) IDHwt C) IDH-PNA D) IDH-FUB"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-FG-A87Q-01Z-00-DX2.28565DCA-8540-4461-87A4-489A0411DAF2-1",
        "image": "TCGA-LGG/TCGA-FG-A87Q-01Z-00-DX2.28565DCA-8540-4461-87A4-489A0411DAF2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p53 focally positive, IDH negative, and Ki67 diffusely increased to 23%, what is the molecular subtype in this glioblastoma? A) IDH-mutant B) IDHwt C) IDH-PNA D) IDH-FUB"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-FG-A87Q-01Z-00-DX3.426D47B6-2D6C-4F6E-9546-2E121A9DDAB2-1",
        "image": "TCGA-LGG/TCGA-FG-A87Q-01Z-00-DX3.426D47B6-2D6C-4F6E-9546-2E121A9DDAB2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p53 focally positive, IDH negative, and Ki67 diffusely increased to 23%, what is the molecular subtype in this glioblastoma? A) IDH-mutant B) IDHwt C) IDH-PNA D) IDH-FUB"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-8168-01Z-00-DX1.e89da367-c6d4-4eb6-8d2e-96a0f8c8cd4a-1",
        "image": "TCGA-LGG/TCGA-DU-8168-01Z-00-DX1.e89da367-c6d4-4eb6-8d2e-96a0f8c8cd4a.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a sparse gliofibrillary background with GFAP, moderate to heavy synaptophysin, NeuN, NSE, and neurofilament infiltration in the cerebral cortex, weak DC99 and BMA reactions with neuropil, small minority overexpression of p53, an organoid microvascular network with CD34, and a 50% MIB-1 proliferation index, what is the molecular subtype in this cerebral neoplasm? A) IDHmut-codel B) IDHwt C) BRAF V600E D) MGMT-methylated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7475-01Z-00-DX5.44227ED7-4D8E-4AA6-B4DC-FEDE74ED5F38-1",
        "image": "TCGA-LGG/TCGA-HT-7475-01Z-00-DX5.44227ED7-4D8E-4AA6-B4DC-FEDE74ED5F38.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative Synaptophysin, strong GFAP positivity, and a MIB-1 labeling index of 10.7%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deleted D) BRAF V600E"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7475-01Z-00-DX3.154DA9D3-55E8-41B4-B442-77839528BB05-1",
        "image": "TCGA-LGG/TCGA-HT-7475-01Z-00-DX3.154DA9D3-55E8-41B4-B442-77839528BB05.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative Synaptophysin, strong GFAP positivity, and a MIB-1 labeling index of 10.7%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deleted D) BRAF V600E"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7475-01Z-00-DX1.1761E0F7-FDBC-480E-AA54-816CA6DE2926-1",
        "image": "TCGA-LGG/TCGA-HT-7475-01Z-00-DX1.1761E0F7-FDBC-480E-AA54-816CA6DE2926.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative Synaptophysin, strong GFAP positivity, and a MIB-1 labeling index of 10.7%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deleted D) BRAF V600E"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7475-01Z-00-DX2.6FAD6473-C6B4-42C3-A2EA-C3101C847409-1",
        "image": "TCGA-LGG/TCGA-HT-7475-01Z-00-DX2.6FAD6473-C6B4-42C3-A2EA-C3101C847409.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative Synaptophysin, strong GFAP positivity, and a MIB-1 labeling index of 10.7%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deleted D) BRAF V600E"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7475-01Z-00-DX4.BC18B0F5-A4D4-40D8-B289-A610A83DFF0E-1",
        "image": "TCGA-LGG/TCGA-HT-7475-01Z-00-DX4.BC18B0F5-A4D4-40D8-B289-A610A83DFF0E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative Synaptophysin, strong GFAP positivity, and a MIB-1 labeling index of 10.7%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deleted D) BRAF V600E"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-6401-01Z-00-DX1.117ba558-9f05-416d-b621-20c5c83895c8-1",
        "image": "TCGA-LGG/TCGA-DU-6401-01Z-00-DX1.117ba558-9f05-416d-b621-20c5c83895c8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing that tumor cells are not immunoreactive to GFAP and Synaptophysin, and a MIB-1 labeling index of less than 1.0%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deleted D) MGMT promoter methylated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-6406-01Z-00-DX1.ad212563-154d-4090-b86c-40d91b4d9e48-1",
        "image": "TCGA-LGG/TCGA-DU-6406-01Z-00-DX1.ad212563-154d-4090-b86c-40d91b4d9e48.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP highlighting the fine gliofibrillary background and a MIB-1 proliferation index of 22%, what is the molecular subtype in this glioblastoma? A) IDH-mutant B) IDHwt C) 1p/19q co-deleted D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-5870-01Z-00-DX1.11f12fa4-b243-4e7a-885a-43f6ca71f024-1",
        "image": "TCGA-LGG/TCGA-DU-5870-01Z-00-DX1.11f12fa4-b243-4e7a-885a-43f6ca71f024.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP with many gemistocytes, p53 overexpressed in about 5% of neoplastic cells, and a MIB-1 proliferation index of about 10%, what is the molecular subtype in this glioma? A) IDHmut-wildtype B) IDHmut-codel C) IDHmut-noncodel D) H3K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7474-01Z-00-DX2.BDFBF2D3-53F0-42D3-BFDB-48967E446390-1",
        "image": "TCGA-LGG/TCGA-HT-7474-01Z-00-DX2.BDFBF2D3-53F0-42D3-BFDB-48967E446390.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of 2.3%, what is the molecular subtype in this low-grade glioma? A) IDH-wildtype B) IDHmut-Codel C) IDHmut-non-codel D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-7474-01Z-00-DX1.B3E88862-6C35-4E30-B374-A7BC80231B8C-1",
        "image": "TCGA-LGG/TCGA-HT-7474-01Z-00-DX1.B3E88862-6C35-4E30-B374-A7BC80231B8C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of 2.3%, what is the molecular subtype in this low-grade glioma? A) IDH-wildtype B) IDHmut-Codel C) IDHmut-non-codel D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-7473-01Z-00-DX2.5A140B5B-DB37-4B24-A3D9-D83B7151FEC5-1",
        "image": "TCGA-LGG/TCGA-HT-7473-01Z-00-DX2.5A140B5B-DB37-4B24-A3D9-D83B7151FEC5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 Labeling Index of 6.1%, what is the molecular subtype in this low-grade glioma?   A) IDHwt   B) IDHmut-non-codel   C) IDHmut-codel   D) BRAF-V600E"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7473-01Z-00-DX3.AA08BB2B-4788-4353-8A3A-EDD1EC72C3E3-1",
        "image": "TCGA-LGG/TCGA-HT-7473-01Z-00-DX3.AA08BB2B-4788-4353-8A3A-EDD1EC72C3E3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 Labeling Index of 6.1%, what is the molecular subtype in this low-grade glioma?   A) IDHwt   B) IDHmut-non-codel   C) IDHmut-codel   D) BRAF-V600E"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7473-01Z-00-DX8.436FDFB3-6908-48E1-A373-8C50314E09E5-1",
        "image": "TCGA-LGG/TCGA-HT-7473-01Z-00-DX8.436FDFB3-6908-48E1-A373-8C50314E09E5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 Labeling Index of 6.1%, what is the molecular subtype in this low-grade glioma?   A) IDHwt   B) IDHmut-non-codel   C) IDHmut-codel   D) BRAF-V600E"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7473-01Z-00-DX5.4626DB85-EEB8-4EEE-9912-4EA2200BCA0A-1",
        "image": "TCGA-LGG/TCGA-HT-7473-01Z-00-DX5.4626DB85-EEB8-4EEE-9912-4EA2200BCA0A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 Labeling Index of 6.1%, what is the molecular subtype in this low-grade glioma?   A) IDHwt   B) IDHmut-non-codel   C) IDHmut-codel   D) BRAF-V600E"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7473-01Z-00-DX7.50CD8048-258B-446A-9A40-DBE75A06E98A-1",
        "image": "TCGA-LGG/TCGA-HT-7473-01Z-00-DX7.50CD8048-258B-446A-9A40-DBE75A06E98A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 Labeling Index of 6.1%, what is the molecular subtype in this low-grade glioma?   A) IDHwt   B) IDHmut-non-codel   C) IDHmut-codel   D) BRAF-V600E"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7473-01Z-00-DX6.76D0E72C-D2EA-4B6A-B43B-28BF23E7FD3B-1",
        "image": "TCGA-LGG/TCGA-HT-7473-01Z-00-DX6.76D0E72C-D2EA-4B6A-B43B-28BF23E7FD3B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 Labeling Index of 6.1%, what is the molecular subtype in this low-grade glioma?   A) IDHwt   B) IDHmut-non-codel   C) IDHmut-codel   D) BRAF-V600E"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7473-01Z-00-DX1.B100DAD7-1292-4B10-B385-F5676B5D09CA-1",
        "image": "TCGA-LGG/TCGA-HT-7473-01Z-00-DX1.B100DAD7-1292-4B10-B385-F5676B5D09CA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 Labeling Index of 6.1%, what is the molecular subtype in this low-grade glioma?   A) IDHwt   B) IDHmut-non-codel   C) IDHmut-codel   D) BRAF-V600E"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7473-01Z-00-DX4.AE71EAC1-5B64-4EFC-9EE2-C3F3256F0455-1",
        "image": "TCGA-LGG/TCGA-HT-7473-01Z-00-DX4.AE71EAC1-5B64-4EFC-9EE2-C3F3256F0455.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an MIB-1 Labeling Index of 6.1%, what is the molecular subtype in this low-grade glioma?   A) IDHwt   B) IDHmut-non-codel   C) IDHmut-codel   D) BRAF-V600E"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-8167-01Z-00-DX1.9ec81b46-f1e9-4611-b018-74f398cb4e90-1",
        "image": "TCGA-LGG/TCGA-DU-8167-01Z-00-DX1.9ec81b46-f1e9-4611-b018-74f398cb4e90.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Ki-67 labeling index of up to approximately 78% and positivity for IDH1 R132H mutation immunostain, what is the molecular subtype in this glioma? A) IDHwt-GBM B) IDHmut-non-codel C) BRAF-mutant D) IDHmut-codel"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-FG-6689-01Z-00-DX1.378dc7f0-a35e-4157-bcb3-1bb8bf87fee8-1",
        "image": "TCGA-LGG/TCGA-FG-6689-01Z-00-DX1.378dc7f0-a35e-4157-bcb3-1bb8bf87fee8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP and Vimentin demonstrating morphologies from mini-gemistocytes to large gemistocytic astrocytic tumor cells, and a low Ki-67 labeling index, what is the molecular subtype in this low-grade glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q codeleted D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-8158-01Z-00-DX1.04fe31d7-0a47-4f5e-a6f5-28974dea86b4-1",
        "image": "TCGA-LGG/TCGA-DU-8158-01Z-00-DX1.04fe31d7-0a47-4f5e-a6f5-28974dea86b4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP demonstrating heavy and diffuse gliofibrilogenesis of the neoplasm, and MIB-1 indicating proliferative indices of 28 to 38 in the more active areas, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut C) 1p/19q co-deleted D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-VV-A829-01Z-00-DX2.4E2AB800-C97E-4293-886B-28793FFBAB47-1",
        "image": "TCGA-LGG/TCGA-VV-A829-01Z-00-DX2.4E2AB800-C97E-4293-886B-28793FFBAB47.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffuse positivity for GFAP, an intermediate Ki-67 index (10-15%), and no p53 over-expression in this glioma, what is the molecular subtype? A) IDHmut-noncodel B) IDHmut-codel C) IDHwt D) MGMTmethylated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-VV-A829-01Z-00-DX3.5ACEDBA9-4972-4E9B-A5BA-4D0CFA28B8CC-1",
        "image": "TCGA-LGG/TCGA-VV-A829-01Z-00-DX3.5ACEDBA9-4972-4E9B-A5BA-4D0CFA28B8CC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffuse positivity for GFAP, an intermediate Ki-67 index (10-15%), and no p53 over-expression in this glioma, what is the molecular subtype? A) IDHmut-noncodel B) IDHmut-codel C) IDHwt D) MGMTmethylated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-VV-A829-01Z-00-DX1.C5464B6B-E673-4AFE-A5A1-7923F2C40450-1",
        "image": "TCGA-LGG/TCGA-VV-A829-01Z-00-DX1.C5464B6B-E673-4AFE-A5A1-7923F2C40450.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffuse positivity for GFAP, an intermediate Ki-67 index (10-15%), and no p53 over-expression in this glioma, what is the molecular subtype? A) IDHmut-noncodel B) IDHmut-codel C) IDHwt D) MGMTmethylated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-A7T8-01Z-00-DX1.2D5A2041-46F5-4571-A933-2629E7617B31-1",
        "image": "TCGA-LGG/TCGA-DU-A7T8-01Z-00-DX1.2D5A2041-46F5-4571-A933-2629E7617B31.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing sparse gliofibrilogenesis by neoplastic cells with GFAP, rich vascularity depicted by CD34, about 5% p53 over-expression, and a proliferation index of 3% in more cellular areas, what is the molecular subtype in this glioma?   A) IDHwt   B) IDHmut-codel   C) IDHmut-non-codel   D) BRAF-mutated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DU-A5TY-01Z-00-DX1.3CE37EFB-9B39-4626-BA68-578E851588D1-1",
        "image": "TCGA-LGG/TCGA-DU-A5TY-01Z-00-DX1.3CE37EFB-9B39-4626-BA68-578E851588D1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive GFAP and p53 expressions, negative IDH1 R132H mutation, approximately 45% Ki-67 labeling index, and negative results for EGFR Variant III mutation, MGMT promoter methylation, and IDH1/IDH2 mutation detection, what is the molecular subtype in this glioblastoma? A) IDH-mutant B) IDH-wildtype C) MGMT-methylated D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DB-A4X9-01Z-00-DX1.D877E4C5-87FA-4289-BDEB-883F6408C094-1",
        "image": "TCGA-LGG/TCGA-DB-A4X9-01Z-00-DX1.D877E4C5-87FA-4289-BDEB-883F6408C094.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing largely negative Vimentin, a focally moderate MIB-1 labeling index, and P53 positivity noted in numerous neoplastic cells, what is the molecular subtype in this low-grade glioma?   A) IDHwt   B) BRAF V600E-mutant   C) IDHmut-non-codel   D) 1p/19q co-deletion"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DB-A4X9-01Z-00-DX2.1C5A66A2-48A5-41B3-98C7-6B668438C4C1-1",
        "image": "TCGA-LGG/TCGA-DB-A4X9-01Z-00-DX2.1C5A66A2-48A5-41B3-98C7-6B668438C4C1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing largely negative Vimentin, a focally moderate MIB-1 labeling index, and P53 positivity noted in numerous neoplastic cells, what is the molecular subtype in this low-grade glioma?   A) IDHwt   B) BRAF V600E-mutant   C) IDHmut-non-codel   D) 1p/19q co-deletion"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DU-A5TP-01Z-00-DX1.93C7592D-91A7-4A89-96A8-190654A36BA9-1",
        "image": "TCGA-LGG/TCGA-DU-A5TP-01Z-00-DX1.93C7592D-91A7-4A89-96A8-190654A36BA9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Ki-67 labeling index that is approximately 10% overall but focally approaches 45%, positive R132H IDH1 mutation, and negative MGMT promoter methylation, what is the molecular subtype in this infiltrating glioma? A) IDHwt B) IDHmut-non-codel C) 1p/19q co-deleted D) MGMT methylated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-7292-01Z-00-DX1.16D2007C-3019-499C-8E5B-9F5308DFF235-1",
        "image": "TCGA-LGG/TCGA-DU-7292-01Z-00-DX1.16D2007C-3019-499C-8E5B-9F5308DFF235.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of about 15% in solid tumor areas and no endothelial microvascular proliferation demonstrated by Factor VIII AA, what is the molecular subtype in this glioblastoma?   A) IDHwt   B) 1p/19q co-deleted   C) MGMT methylated   D) EGFR amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-RY-A83Z-01Z-00-DX1.38167693-2E5A-4179-AA91-8EDA1BA43FB0-1",
        "image": "TCGA-LGG/TCGA-RY-A83Z-01Z-00-DX1.38167693-2E5A-4179-AA91-8EDA1BA43FB0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong positivity for both p53 protein and IDH1 (R132H) mutant protein, patchy GFAP positivity in gemistocytic cells, staining of entrapped neuropil by neurofilament, and an 18% Ki-67 labeling index, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deleted D) TERT promoter mutated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DB-A64S-01Z-00-DX2.FDA93FFC-A258-429A-93B4-B586635F39BC-1",
        "image": "TCGA-LGG/TCGA-DB-A64S-01Z-00-DX2.FDA93FFC-A258-429A-93B4-B586635F39BC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an infiltrative pattern of growth with Neurofilament, moderate to high labeling with P83, and low to moderate labeling index with IGTIMIB-1, what is the molecular subtype in this low-grade gliocytoma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deletion D) BRAF V600E"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DB-A64S-01Z-00-DX1.E44CE325-25A2-4669-8843-E7462547C004-1",
        "image": "TCGA-LGG/TCGA-DB-A64S-01Z-00-DX1.E44CE325-25A2-4669-8843-E7462547C004.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an infiltrative pattern of growth with Neurofilament, moderate to high labeling with P83, and low to moderate labeling index with IGTIMIB-1, what is the molecular subtype in this low-grade gliocytoma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deletion D) BRAF V600E"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-A7T6-01Z-00-DX1.9FCFC32F-0D18-4CE5-8CF3-34A7732FD76D-1",
        "image": "TCGA-LGG/TCGA-DU-A7T6-01Z-00-DX1.9FCFC32F-0D18-4CE5-8CF3-34A7732FD76D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP demonstrating numerous gliofibrillary oligodendrocytes and minigemistocytes, a MIB-1 proliferation index of 50% in more active areas, and Factor VIII depicting a high density of microvessels with prominent microvascular cellular proliferation, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDH-WT C) mIDH1/2 D) ATRX-mutation"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-7007-01Z-00-DX1.DB64D884-B8AA-4540-BF6F-BF83B1D15A26-1",
        "image": "TCGA-LGG/TCGA-DU-7007-01Z-00-DX1.DB64D884-B8AA-4540-BF6F-BF83B1D15A26.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nWith an IHC result showing a MIB-1 Labelling Index of 2.5%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDH-wildtype D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DB-A4XG-01Z-00-DX1.76683FE4-150C-44B9-99C1-DFCCAB337CDE-1",
        "image": "TCGA-LGG/TCGA-DB-A4XG-01Z-00-DX1.76683FE4-150C-44B9-99C1-DFCCAB337CDE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing neoplastic cells are negative for IDH1 (R132H) immunostain, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHwt C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DB-A4XG-01Z-00-DX2.6EC94BAA-8653-4697-AAAA-0B4AF88A82AE-1",
        "image": "TCGA-LGG/TCGA-DB-A4XG-01Z-00-DX2.6EC94BAA-8653-4697-AAAA-0B4AF88A82AE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing neoplastic cells are negative for IDH1 (R132H) immunostain, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHwt C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DB-A64O-01Z-00-DX1.E143BA84-8D09-4FA0-A58F-AF6BEE4E8451-1",
        "image": "TCGA-LGG/TCGA-DB-A64O-01Z-00-DX1.E143BA84-8D09-4FA0-A58F-AF6BEE4E8451.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity in tumor cells, negative IDH1 (R132H), weak to moderate p53 expression, and low Ki67 labeling, what is the molecular subtype in this glioma? A) IDHmut B) 1p/19q co-deleted C) IDHwt D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-CS-6668-01Z-00-DX1.D6E80501-5B34-499A-9899-8167575DBBDB-1",
        "image": "TCGA-LGG/TCGA-CS-6668-01Z-00-DX1.D6E80501-5B34-499A-9899-8167575DBBDB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Ki67 index of 4.7%, scattered tumor cells with positive GFAP staining and many tumor cells negative, and p53 negativity in tumor cells, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHmut-codel C) IDHwt D) ATRX-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-FG-A70Z-01Z-00-DX1.ABAF26D5-7AEE-48EE-B13F-0BE7FCEE6280-1",
        "image": "TCGA-LGG/TCGA-FG-A70Z-01Z-00-DX1.ABAF26D5-7AEE-48EE-B13F-0BE7FCEE6280.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positivity for GFAP in many cells and a Ki-67 proliferation index of about 20-25%, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut C) 1p/19q-codeleted D) BRAF V600E-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-A615-01Z-00-DX1.454CE5AA-213B-4479-B6B9-4CEAB6EC951A-1",
        "image": "TCGA-LGG/TCGA-HT-A615-01Z-00-DX1.454CE5AA-213B-4479-B6B9-4CEAB6EC951A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing scattered MIB-1 reactive cells throughout the tumor with a MIB-1 labeling index of 2.2%, what is the molecular subtype in this glioma?   A) IDHmut-codel   B) IDHwildtype   C) 1p/19q-codeleted   D) Hypermutated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-TQ-A7RW-01Z-00-DX1.05F422AA-ED7B-4D53-9B32-2B7CEFB85021-1",
        "image": "TCGA-LGG/TCGA-TQ-A7RW-01Z-00-DX1.05F422AA-ED7B-4D53-9B32-2B7CEFB85021.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive Anti-GFAP, positive 100 Protein, and a Ki-67 index of 6%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDHwt D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-A7TA-01Z-00-DX1.C0013D54-C292-4060-99F6-A6AB4E54FAA5-1",
        "image": "TCGA-LGG/TCGA-DU-A7TA-01Z-00-DX1.C0013D54-C292-4060-99F6-A6AB4E54FAA5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of 2%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwildtype C) 1p/19q co-deleted D) EGFR amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-KT-A74X-01Z-00-DX3.4DCD7F51-4CA2-4FAA-B2BB-9494D34C21F9-1",
        "image": "TCGA-LGG/TCGA-KT-A74X-01Z-00-DX3.4DCD7F51-4CA2-4FAA-B2BB-9494D34C21F9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing variable positivity for GFAP, positive IDH1 expression, and an overall average MIB-1 labeling of approximately 5%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHwt C) H3 K27M-mutant D) NF1-associated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-KT-A74X-01Z-00-DX2.9CF10646-A8BA-44B7-B099-423861E84494-1",
        "image": "TCGA-LGG/TCGA-KT-A74X-01Z-00-DX2.9CF10646-A8BA-44B7-B099-423861E84494.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing variable positivity for GFAP, positive IDH1 expression, and an overall average MIB-1 labeling of approximately 5%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHwt C) H3 K27M-mutant D) NF1-associated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-KT-A74X-01Z-00-DX1.E6563656-1B4E-440C-8797-B78FE067390D-1",
        "image": "TCGA-LGG/TCGA-KT-A74X-01Z-00-DX1.E6563656-1B4E-440C-8797-B78FE067390D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing variable positivity for GFAP, positive IDH1 expression, and an overall average MIB-1 labeling of approximately 5%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHwt C) H3 K27M-mutant D) NF1-associated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-7294-01Z-00-DX1.42C278DB-951F-46DD-A455-7D5ED4AA7CF0-1",
        "image": "TCGA-LGG/TCGA-DU-7294-01Z-00-DX1.42C278DB-951F-46DD-A455-7D5ED4AA7CF0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing scant gliofibrillogenesis with GFAP, capillary-type microvasculature without cellular proliferation with CD34, no overexpression of p53, and a MIB-1 proliferation index of about 2%, what is the molecular subtype in this low-grade glioma? A) IDHmut-codel B) IDH wild-type C) EGFR amplification D) BRAF fusion"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DB-A64R-01Z-00-DX1.0A2B114A-F7CA-4D94-A7E4-CA482F92B214-1",
        "image": "TCGA-LGG/TCGA-DB-A64R-01Z-00-DX1.0A2B114A-F7CA-4D94-A7E4-CA482F92B214.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH1 (R132H) positivity consistent with IDH1 mutation, expression of p53 in rare cells, and Ki-67 labeling varying from low to focally moderate, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDH-wildtype C) Triple-negative D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-A61C-01Z-00-DX1.034BF077-8710-4F6A-B346-67740B77A277-1",
        "image": "TCGA-LGG/TCGA-HT-A61C-01Z-00-DX1.034BF077-8710-4F6A-B346-67740B77A277.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of 34.7%, p53 minority positive, and negative IDH1 in this left temporal anaplastic oligodendroglioma, grade III, what is the molecular subtype? A) IDH-mutant, 1p/19q-codeleted B) IDHwt C) IDH-mutant, 1p/19q-intact D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DB-A4XH-01Z-00-DX1.56D80999-2AB5-40BB-9326-43B6FF71183A-1",
        "image": "TCGA-LGG/TCGA-DB-A4XH-01Z-00-DX1.56D80999-2AB5-40BB-9326-43B6FF71183A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a low Ki-67 labeling index, low p53 labeling index, and a subset of tumor cells positive for GFAP, what is the molecular subtype in this glioma?   A) IDHmut-codel   B) IDHwt   C) BRAF V600E   D) EGFRamplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DB-A4XH-01Z-00-DX2.2F6F5DB6-0C6E-4D20-9B72-BB274583DFFB-1",
        "image": "TCGA-LGG/TCGA-DB-A4XH-01Z-00-DX2.2F6F5DB6-0C6E-4D20-9B72-BB274583DFFB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a low Ki-67 labeling index, low p53 labeling index, and a subset of tumor cells positive for GFAP, what is the molecular subtype in this glioma?   A) IDHmut-codel   B) IDHwt   C) BRAF V600E   D) EGFRamplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-7008-01Z-00-DX1.C4A4B091-9F79-4B12-AACE-521CF12DFF1C-1",
        "image": "TCGA-LGG/TCGA-DU-7008-01Z-00-DX1.C4A4B091-9F79-4B12-AACE-521CF12DFF1C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing a MIB-1 index of about 8%, what is the molecular subtype in this glioma? A) IDH-wildtype B) IDHmut-codel C) IDHmut-non-codel D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DU-A7TG-01Z-00-DX1.BB74AF60-791A-42D8-8798-8BCEF80F3C1D-1",
        "image": "TCGA-LGG/TCGA-DU-A7TG-01Z-00-DX1.BB74AF60-791A-42D8-8798-8BCEF80F3C1D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing absent or sparse GFAP positivity, no p53 overexpression, no synaptophysin or NeuN expression in neoplastic cells, CD34 indicating neovascularization, and a low Ki-67 proliferative index, what is the molecular subtype in this glioma? A) IDH-wildtype B) IDHmut-codel C) IDHmut-non-codel D) TERT promoter mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DB-A4XA-01Z-00-DX1.108DC8B4-E6B6-4526-9E9B-B42DCF90FF01-1",
        "image": "TCGA-LGG/TCGA-DB-A4XA-01Z-00-DX1.108DC8B4-E6B6-4526-9E9B-B42DCF90FF01.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH-1 (R132H) positivity in tumor cells, occasional positive staining for GFAP, low to moderate staining for P53, and focally moderate Ki-67 staining, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHwt C) IDHmut-noncodel D) MGMT methylated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DB-A4XA-01Z-00-DX2.78A6831F-EA66-4A88-BFEC-C731A00A9C36-1",
        "image": "TCGA-LGG/TCGA-DB-A4XA-01Z-00-DX2.78A6831F-EA66-4A88-BFEC-C731A00A9C36.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH-1 (R132H) positivity in tumor cells, occasional positive staining for GFAP, low to moderate staining for P53, and focally moderate Ki-67 staining, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHwt C) IDHmut-noncodel D) MGMT methylated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-TM-A7CA-01Z-00-DX1.1CEBE1E1-7CBE-4F80-BAFC-828F7FA787B7-1",
        "image": "TCGA-LGG/TCGA-TM-A7CA-01Z-00-DX1.1CEBE1E1-7CBE-4F80-BAFC-828F7FA787B7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing a Ki-67 staining positivity in approximately 2% of tumor nuclei, with IDH1 staining in progress, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HW-8319-01Z-00-DX1.DB3012DE-00C2-4425-B3E4-6F5FF19CE290-1",
        "image": "TCGA-LGG/TCGA-HW-8319-01Z-00-DX1.DB3012DE-00C2-4425-B3E4-6F5FF19CE290.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive IDH1-R132H, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) TP53-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-FG-7636-01Z-00-DX1.BD12D54F-E266-4950-AB43-912C714E338C-1",
        "image": "TCGA-LGG/TCGA-FG-7636-01Z-00-DX1.BD12D54F-E266-4950-AB43-912C714E338C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing an increased nuclear labeling rate of up to 11% for MIB-1 and many nuclei being immunopositive for p53, what is the molecular subtype in this glioma cancer? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) BRAF V600E-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DB-5278-01Z-00-DX2.39A970EE-DD46-4766-82BE-6B9DBFE57F3E-1",
        "image": "TCGA-LGG/TCGA-DB-5278-01Z-00-DX2.39A970EE-DD46-4766-82BE-6B9DBFE57F3E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing a low MIB-1 labeling index and FISH results indicating deletions in both 1p and 19q, what is the molecular subtype in this glioma? A) IDHmut-wildtype B) Oligodendroglioma, IDH-mutant and 1p/19q-codeleted C) Astrocytoma, IDH-mutant D) Glioblastoma, IDH-wildtype"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-6393-01Z-00-DX1.a91ec35c-6b09-4ea7-8c15-e13119177f74-1",
        "image": "TCGA-LGG/TCGA-DU-6393-01Z-00-DX1.a91ec35c-6b09-4ea7-8c15-e13119177f74.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a variable MIB-1 nuclear labeling index ranging from 10-12% in better differentiated areas to as high as 25% in some regions, what is the molecular subtype in this cancer type? A) IDHmut-codel B) ERBB2-positive C) MSI D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-FG-7638-01Z-00-DX1.27EE5A65-D5D9-41B9-998E-049764C18DC8-1",
        "image": "TCGA-LGG/TCGA-FG-7638-01Z-00-DX1.27EE5A65-D5D9-41B9-998E-049764C18DC8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a negative immunostain for the astrocytic marker p53, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHwildtype C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-FG-A4MU-01Z-00-DX3.C4DF3CCE-61FC-4E79-A1AA-528F55285147-1",
        "image": "TCGA-LGG/TCGA-FG-A4MU-01Z-00-DX3.C4DF3CCE-61FC-4E79-A1AA-528F55285147.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative staining for mutant IDH1 and FISH demonstrating preservation of both chromosomes 1p and 19q, what is the molecular subtype in this glioma? A) IDHwt B) IDH-mutant, 1p/19q co-deleted C) IDH-mutant, 1p/19q intact D) IDH-mutant, ATRX-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DB-5276-01Z-00-DX2.8C3B6948-8814-414C-BE52-B7DECB53E7E3-1",
        "image": "TCGA-LGG/TCGA-DB-5276-01Z-00-DX2.8C3B6948-8814-414C-BE52-B7DECB53E7E3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive GFAP in neoplastic cells with astrocytic morphology, p53 overexpression in the majority of tumor cells, and a moderate MIB-1 labeling index, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDHwt D) Extra-neural metaplasia"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DB-5276-01Z-00-DX1.3921BD4C-CC46-43A4-BECF-AAB9A35E6682-1",
        "image": "TCGA-LGG/TCGA-DB-5276-01Z-00-DX1.3921BD4C-CC46-43A4-BECF-AAB9A35E6682.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive GFAP in neoplastic cells with astrocytic morphology, p53 overexpression in the majority of tumor cells, and a moderate MIB-1 labeling index, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDHwt D) Extra-neural metaplasia"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-RY-A845-01Z-00-DX1.224F7848-0356-4EC3-BADF-F64E6EDA9A05-1",
        "image": "TCGA-LGG/TCGA-RY-A845-01Z-00-DX1.224F7848-0356-4EC3-BADF-F64E6EDA9A05.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH1 (R132H mutant) protein positivity, 20% of tumor cells expressing p53, and MIB1 labeling index estimates at 69% in one region and approximately 5% in another, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) TERTm"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DU-7018-01Z-00-DX1.75C2DA95-5661-4CC4-BF42-CF30137CEA9F-1",
        "image": "TCGA-LGG/TCGA-DU-7018-01Z-00-DX1.75C2DA95-5661-4CC4-BF42-CF30137CEA9F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing sparse GFAP gliofibrillarity, focal Synaptophysin positivity, lack of p53 overexpression, a MIB-1 proliferation index of about 20%, and focal Neu N positivity, what is the molecular subtype in this oligodendroglioma? A) IDHmut-codel B) IDHwt C) ATRX-mutant D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-A76O-01Z-00-DX1.79424261-499C-4D61-9C74-3A35E1557501-1",
        "image": "TCGA-LGG/TCGA-DU-A76O-01Z-00-DX1.79424261-499C-4D61-9C74-3A35E1557501.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive IDH1-R132H mutation, MIB-1 proliferation index greater than 8%, negative 1p, 19q LOH, low positive MGMT, GFAP reactivity with a delicate gliofibrillary background, slight dendritic microglial unrest in CD163, and preservation of cortex layering with NeuN and NFP, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDH-wildtype D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-CS-6670-01Z-00-DX1.A767AC46-DA02-41C6-8829-AE53DB0F386E-1",
        "image": "TCGA-LGG/TCGA-CS-6670-01Z-00-DX1.A767AC46-DA02-41C6-8829-AE53DB0F386E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive staining of many tumor cells for GFAP and positive staining of scattered tumor cell nuclei for P53 in hypercellular areas, what is the molecular subtype in this glioma? A) IDH-wildtype B) IDHmut-non-codel C) IDHmut-codel D) ATRX-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DU-7011-01Z-00-DX1.839D54AF-A0C7-4DE4-A7D0-D19C760FFB3D-1",
        "image": "TCGA-LGG/TCGA-DU-7011-01Z-00-DX1.839D54AF-A0C7-4DE4-A7D0-D19C760FFB3D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP with a diffuse but regular sprinkling of the lesion by star-like plump astrocytes with a delicate fibrillary background, and a MIB-1 proliferation index of 1.58 to 2% in the cellular areas, what is the molecular subtype in this low-grade glioma? A) IDHmut-non-codel B) IDH wildtype C) 1p/19q co-deleted D) BRAF V600E mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E1-A7Z2-01Z-00-DX1.241303FD-1841-4BF1-AB52-803B10647049-1",
        "image": "TCGA-LGG/TCGA-E1-A7Z2-01Z-00-DX1.241303FD-1841-4BF1-AB52-803B10647049.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive GFAP, blood vessels highlighted by HAMS6, a 15% Mib-1 index, negative IDH1, negative IDH2, negative p53, and a high Ki-67 of 15% in surgical pathology, what is the molecular subtype in this glioblastoma? A) IDHwt B) IDHmut C) 1p/19q co-deleted D) ATRX-mutated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-P5-A780-01Z-00-DX1.0C36EA77-5B13-4AA8-8C11-BF9EDC5C9153-1",
        "image": "TCGA-LGG/TCGA-P5-A780-01Z-00-DX1.0C36EA77-5B13-4AA8-8C11-BF9EDC5C9153.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing Ki67 at greater than 5%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDHwt D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-TM-A84Q-01Z-00-DX1.692F1A0A-E05E-4C53-8AE0-EF1E1B6297EA-1",
        "image": "TCGA-LGG/TCGA-TM-A84Q-01Z-00-DX1.692F1A0A-E05E-4C53-8AE0-EF1E1B6297EA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong GFAP positivity, approximately 2% Ki67, strongly positive p53, and patchy weak Bcl2 staining, what is the molecular subtype in this low-grade glioma? A) IDH-wildtype B) IDHmut-codel C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-FG-A4MT-02Z-00-DX3.1EB377EB-35FD-420F-9CD9-4A9E4B75EB53-1",
        "image": "TCGA-LGG/TCGA-FG-A4MT-02Z-00-DX3.1EB377EB-35FD-420F-9CD9-4A9E4B75EB53.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH-1 inactivity, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-FG-A4MT-02Z-00-DX6.0CD6853F-A85E-4AD5-86BD-0925F6542453-1",
        "image": "TCGA-LGG/TCGA-FG-A4MT-02Z-00-DX6.0CD6853F-A85E-4AD5-86BD-0925F6542453.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH-1 inactivity, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-FG-A4MT-02Z-00-DX1.F0250524-BEDE-4C23-A3E9-F1D927F5E561-1",
        "image": "TCGA-LGG/TCGA-FG-A4MT-02Z-00-DX1.F0250524-BEDE-4C23-A3E9-F1D927F5E561.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH-1 inactivity, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-FG-A4MT-02Z-00-DX4.5CC76ADE-AFCE-4BDC-AC27-4CD962926AD6-1",
        "image": "TCGA-LGG/TCGA-FG-A4MT-02Z-00-DX4.5CC76ADE-AFCE-4BDC-AC27-4CD962926AD6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH-1 inactivity, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-FG-A4MT-02Z-00-DX2.9CCA63C2-537E-4830-B6C3-ADF6F614AFF3-1",
        "image": "TCGA-LGG/TCGA-FG-A4MT-02Z-00-DX2.9CCA63C2-537E-4830-B6C3-ADF6F614AFF3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH-1 inactivity, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-FG-A4MT-02Z-00-DX5.BC137126-2035-4629-BCCF-EDDD39CC7178-1",
        "image": "TCGA-LGG/TCGA-FG-A4MT-02Z-00-DX5.BC137126-2035-4629-BCCF-EDDD39CC7178.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH-1 inactivity, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-E1-A7YL-01Z-00-DX1.EA6413B5-B000-49AA-97CC-8E9A2495EED1-1",
        "image": "TCGA-LGG/TCGA-E1-A7YL-01Z-00-DX1.EA6413B5-B000-49AA-97CC-8E9A2495EED1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing LEUCOCYTE COMMON ANTIGEN (LCA) positive in 20% of cells, a moderate proliferation index with 68% of tumor cells exhibiting staining, positive MGMT (30%), positive EGFR WT (2+ in 70% of tumor cells), negative EGFR VIII, positive p53 (2+ in 30% of tumor cells), positive AKT (2+ in 25% of tumor cells), positive MAPK (2+ in 30% of tumor cells), negative CARBONIC ANHYDRASE IX, positive VEGF, widespread reactivity for PDGFR-α and PDGFR-β, and positive VEGFR2, what is the molecular subtype in this glioblastoma?  A) IDHwt   B) IDHmutant   C) MGMT methylated   D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-6395-01Z-00-DX1.c2fa922a-48b9-46fe-87d3-ea18e925dd98-1",
        "image": "TCGA-LGG/TCGA-DU-6395-01Z-00-DX1.c2fa922a-48b9-46fe-87d3-ea18e925dd98.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of 40%, what is the molecular subtype in this high-grade glioma (Grade IV) located in the left frontal brain? A) IDHmut-codel B) IDHmut-non-codel C) IDH wildtype D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-R8-A6YH-01Z-00-DX1.8BD665EB-9E34-4E8C-820D-08B796F55DDE-1",
        "image": "TCGA-LGG/TCGA-R8-A6YH-01Z-00-DX1.8BD665EB-9E34-4E8C-820D-08B796F55DDE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP confirming the fibrillary nature of the tumor and a MIB-1 antibody labeling index of 5.1%, what is the molecular subtype in this low-grade glioma? A) IDHmut-non-codel B) IDH-wildtype C) 1p/19q-codeleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DB-5277-01Z-00-DX2.F1B46E37-AC7F-4805-9606-468744147AF8-1",
        "image": "TCGA-LGG/TCGA-DB-5277-01Z-00-DX2.F1B46E37-AC7F-4805-9606-468744147AF8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a high MIB-1 labeling index and strong, diffuse p53 protein expression in neoplastic cells, what is the molecular subtype in this tumor?   A) IDHm-codel   B) IDHwt   C) IDHmut-non-codel   D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DB-5277-01Z-00-DX1.635F8997-B57B-402D-8889-BE84CA858B16-1",
        "image": "TCGA-LGG/TCGA-DB-5277-01Z-00-DX1.635F8997-B57B-402D-8889-BE84CA858B16.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a high MIB-1 labeling index and strong, diffuse p53 protein expression in neoplastic cells, what is the molecular subtype in this tumor?   A) IDHm-codel   B) IDHwt   C) IDHmut-non-codel   D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-TM-A84B-01Z-00-DX1.8736E13D-D47F-462E-BD06-61767245C2F5-1",
        "image": "TCGA-LGG/TCGA-TM-A84B-01Z-00-DX1.8736E13D-D47F-462E-BD06-61767245C2F5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p53 at 15%, negative IDH1, and a Ki-67 index of approximately 24%, what is the molecular subtype in this glioblastoma? A) IDH-mutant B) IDHwt C) 1p/19q co-deleted D) MGMT methylated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-A76R-01Z-00-DX1.EDE40E2C-2364-4B22-B787-E07E0821FF56-1",
        "image": "TCGA-LGG/TCGA-DU-A76R-01Z-00-DX1.EDE40E2C-2364-4B22-B787-E07E0821FF56.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP demonstrating sparse gliofibrillary background with small focal areas with heavier glial processes, lack of p53 overexpression, and a MIB-1 proliferation index of 8% to 10% in more active areas, what is the molecular subtype in this brain tumor? A) IDHmut-codel B) IDHwt C) BRAF V600E D) ATRX-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E1-A7Z4-01Z-00-DX1.5AA456AE-A544-4381-A511-609E58FB95BE-1",
        "image": "TCGA-LGG/TCGA-E1-A7Z4-01Z-00-DX1.5AA456AE-A544-4381-A511-609E58FB95BE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a KI-67 labeling index that focally approaches 58, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) IDHmut-codel D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E1-A7Z4-01Z-00-DX2.4DFFB8EE-BE6E-46F0-AC6D-8CC65BDA9441-1",
        "image": "TCGA-LGG/TCGA-E1-A7Z4-01Z-00-DX2.4DFFB8EE-BE6E-46F0-AC6D-8CC65BDA9441.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a KI-67 labeling index that focally approaches 58, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) IDHmut-codel D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-E1-A7YW-01Z-00-DX1.E64A0F63-0346-4668-B67D-EF7D0358AC4E-1",
        "image": "TCGA-LGG/TCGA-E1-A7YW-01Z-00-DX1.E64A0F63-0346-4668-B67D-EF7D0358AC4E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a low Ki-67 labeling index of 1-2%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDHwt D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-7019-01Z-00-DX1.94F228DF-0184-4D7F-9899-CCFEE24959C4-1",
        "image": "TCGA-LGG/TCGA-DU-7019-01Z-00-DX1.94F228DF-0184-4D7F-9899-CCFEE24959C4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing frequent reactive-type astrocytes with GFAP, strong overexpression of p53 in the majority of neoplastic cells, a proliferation index potentially reaching about 108 with MIB-1, and focal subtle microvascular hyperplasia demonstrated by CD31 and CD34, what is the molecular subtype in this glioma?   A) IDHmut-non-codel   B) IDHmut-codel   C) IDHwt   D) BRAF V600E mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-FG-A711-01Z-00-DX1.69203ECF-0672-428B-81EA-97B94D90E14F-1",
        "image": "TCGA-LGG/TCGA-FG-A711-01Z-00-DX1.69203ECF-0672-428B-81EA-97B94D90E14F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity in occasional cells and a Ki-67 proliferation index ranging from 1-28, what is the molecular subtype in this low-grade glioma? A) IDHmut-non-codel B) IDHwt C) IDHmut-codel D) H3K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-5851-01Z-00-DX1.ebd0a3a5-4127-4ec3-8ef2-2c77515e3266-1",
        "image": "TCGA-LGG/TCGA-DU-5851-01Z-00-DX1.ebd0a3a5-4127-4ec3-8ef2-2c77515e3266.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p53 positivity and a Ki-67 labeling index of approximately 7%, what is the molecular subtype in this glioma specimen? A) IDHmut-codel  B) IDHmut-non-codel  C) IDHwildtype  D) 1p/19q codeletion"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-8015-01Z-00-DX1.A88F5665-931F-4C94-B856-5EE0E6020E84-1",
        "image": "TCGA-LGG/TCGA-HT-8015-01Z-00-DX1.A88F5665-931F-4C94-B856-5EE0E6020E84.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positivity for GFAP, Neurofilament, and P53, weak positivity for NeuN, and a MIB-1 labeling index of 3-5%, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut C) 1p/19q co-deletion D) H3K27M mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7605-01Z-00-DX3.BB430C7D-552A-4C45-86DA-4FF69641DAAC-1",
        "image": "TCGA-LGG/TCGA-HT-7605-01Z-00-DX3.BB430C7D-552A-4C45-86DA-4FF69641DAAC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing a MIB-1 Labeling Index of 0.6%, what is the molecular subtype in this cancer? A) IDHmut-codel B) IDHwt C) BRAFV600E D) ERBB2+"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7605-01Z-00-DX1.CDE02BA4-CE97-4542-BB96-C3D568A32217-1",
        "image": "TCGA-LGG/TCGA-HT-7605-01Z-00-DX1.CDE02BA4-CE97-4542-BB96-C3D568A32217.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing a MIB-1 Labeling Index of 0.6%, what is the molecular subtype in this cancer? A) IDHmut-codel B) IDHwt C) BRAFV600E D) ERBB2+"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7605-01Z-00-DX2.B8FE3450-CB38-49E2-9486-F20388AA1246-1",
        "image": "TCGA-LGG/TCGA-HT-7605-01Z-00-DX2.B8FE3450-CB38-49E2-9486-F20388AA1246.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing a MIB-1 Labeling Index of 0.6%, what is the molecular subtype in this cancer? A) IDHmut-codel B) IDHwt C) BRAFV600E D) ERBB2+"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7605-01Z-00-DX4.05B0D4D8-29B6-4547-B3C0-22B547BDC061-1",
        "image": "TCGA-LGG/TCGA-HT-7605-01Z-00-DX4.05B0D4D8-29B6-4547-B3C0-22B547BDC061.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing a MIB-1 Labeling Index of 0.6%, what is the molecular subtype in this cancer? A) IDHmut-codel B) IDHwt C) BRAFV600E D) ERBB2+"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C9-01Z-00-DX5.F028B05D-0986-42CC-B0AA-F55F9ACE743D-1",
        "image": "TCGA-LGG/TCGA-VM-A8C9-01Z-00-DX5.F028B05D-0986-42CC-B0AA-F55F9ACE743D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity, and negative expression for NeuN and Synaptophysin, what is the molecular subtype in this glioblastoma? A) IDHwt B) IDHmut C) 1p/19q co-deleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C9-01Z-00-DX9.DEF6A890-B06E-42BC-A653-A6BF5E324B8D-1",
        "image": "TCGA-LGG/TCGA-VM-A8C9-01Z-00-DX9.DEF6A890-B06E-42BC-A653-A6BF5E324B8D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity, and negative expression for NeuN and Synaptophysin, what is the molecular subtype in this glioblastoma? A) IDHwt B) IDHmut C) 1p/19q co-deleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C9-01Z-00-DX2.D95CDDEA-8A6D-41D4-B12A-17811CF91CE3-1",
        "image": "TCGA-LGG/TCGA-VM-A8C9-01Z-00-DX2.D95CDDEA-8A6D-41D4-B12A-17811CF91CE3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity, and negative expression for NeuN and Synaptophysin, what is the molecular subtype in this glioblastoma? A) IDHwt B) IDHmut C) 1p/19q co-deleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C9-01Z-00-DX3.E0BF1E61-5F3C-4E15-8A6A-3E1A351FC0A7-1",
        "image": "TCGA-LGG/TCGA-VM-A8C9-01Z-00-DX3.E0BF1E61-5F3C-4E15-8A6A-3E1A351FC0A7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity, and negative expression for NeuN and Synaptophysin, what is the molecular subtype in this glioblastoma? A) IDHwt B) IDHmut C) 1p/19q co-deleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C9-01Z-00-DX4.20D5EE02-3CD2-45C4-AF74-539DC859369B-1",
        "image": "TCGA-LGG/TCGA-VM-A8C9-01Z-00-DX4.20D5EE02-3CD2-45C4-AF74-539DC859369B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity, and negative expression for NeuN and Synaptophysin, what is the molecular subtype in this glioblastoma? A) IDHwt B) IDHmut C) 1p/19q co-deleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C9-01Z-00-DX8.BC79D845-2351-4946-9262-C9D4668957BE-1",
        "image": "TCGA-LGG/TCGA-VM-A8C9-01Z-00-DX8.BC79D845-2351-4946-9262-C9D4668957BE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity, and negative expression for NeuN and Synaptophysin, what is the molecular subtype in this glioblastoma? A) IDHwt B) IDHmut C) 1p/19q co-deleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C9-01Z-00-DX1.C6DD4520-C460-419A-9DB3-DF34D128CA08-1",
        "image": "TCGA-LGG/TCGA-VM-A8C9-01Z-00-DX1.C6DD4520-C460-419A-9DB3-DF34D128CA08.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity, and negative expression for NeuN and Synaptophysin, what is the molecular subtype in this glioblastoma? A) IDHwt B) IDHmut C) 1p/19q co-deleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C9-01Z-00-DX6.4F9BEB00-9BC5-459F-A702-C72583A226ED-1",
        "image": "TCGA-LGG/TCGA-VM-A8C9-01Z-00-DX6.4F9BEB00-9BC5-459F-A702-C72583A226ED.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity, and negative expression for NeuN and Synaptophysin, what is the molecular subtype in this glioblastoma? A) IDHwt B) IDHmut C) 1p/19q co-deleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C9-01Z-00-DX7.95A9AD6B-1293-485E-8A82-7A1939C7B9D4-1",
        "image": "TCGA-LGG/TCGA-VM-A8C9-01Z-00-DX7.95A9AD6B-1293-485E-8A82-7A1939C7B9D4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity, and negative expression for NeuN and Synaptophysin, what is the molecular subtype in this glioblastoma? A) IDHwt B) IDHmut C) 1p/19q co-deleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-A74H-01Z-00-DX1.07757B94-980F-4F0C-95DE-A99DEA555617-1",
        "image": "TCGA-LGG/TCGA-HT-A74H-01Z-00-DX1.07757B94-980F-4F0C-95DE-A99DEA555617.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing focal positivity for P53, negative IDH1, and an MIB-1 labeling index of 13.3%, what is the molecular subtype in this glioblastoma? A) IDHwt B) IDHmut C) 1p/19q-codeleted D) MGMT-methylated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-A5R7-01Z-00-DX1.710C776B-5420-42E6-8D40-C5C36D1CA603-1",
        "image": "TCGA-LGG/TCGA-HT-A5R7-01Z-00-DX1.710C776B-5420-42E6-8D40-C5C36D1CA603.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative p53 expression for IDH1 and an MID-1 labeling index of 11.48, what is the molecular subtype in this glioma? A) IDH1 wildtype B) IDHmut-non-codel C) IDHmut-codel D) ATRX-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-7304-01Z-00-DX1.EA1BD5C1-A8FE-40E1-8287-B703185779CD-1",
        "image": "TCGA-LGG/TCGA-DU-7304-01Z-00-DX1.EA1BD5C1-A8FE-40E1-8287-B703185779CD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP demonstrating tumor cells in a gliofibrillary background, p53 overexpression in the majority of cells, a MIB-1 proliferation index of about 50% in denser white matter zones, and NeuN demonstrating the diffusely infiltrating character of the neoplasm, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDH-wildtype D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-A5R9-01Z-00-DX1.B3EA778F-A070-4DFA-B07C-8C18B948C7F1-1",
        "image": "TCGA-LGG/TCGA-HT-A5R9-01Z-00-DX1.B3EA778F-A070-4DFA-B07C-8C18B948C7F1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MiB-1 Labeling Index of 14.7%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDH wild-type C) 1p/19q non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7694-01Z-00-DX4.E855393D-C8C1-4449-9F64-226DACA4BD89-1",
        "image": "TCGA-LGG/TCGA-HT-7694-01Z-00-DX4.E855393D-C8C1-4449-9F64-226DACA4BD89.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of greater than 25% (estimated), what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHmut-codel C) IDH-wildtype D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7694-01Z-00-DX7.73677CFA-E7DC-483E-8EC9-E6CE9FCBBAF3-1",
        "image": "TCGA-LGG/TCGA-HT-7694-01Z-00-DX7.73677CFA-E7DC-483E-8EC9-E6CE9FCBBAF3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of greater than 25% (estimated), what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHmut-codel C) IDH-wildtype D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7694-01Z-00-DX3.1C5DB315-C10D-46DB-B278-576B40B6150A-1",
        "image": "TCGA-LGG/TCGA-HT-7694-01Z-00-DX3.1C5DB315-C10D-46DB-B278-576B40B6150A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of greater than 25% (estimated), what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHmut-codel C) IDH-wildtype D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7694-01Z-00-DX1.77DBCFB4-FC72-4875-AD95-53350F4A10E7-1",
        "image": "TCGA-LGG/TCGA-HT-7694-01Z-00-DX1.77DBCFB4-FC72-4875-AD95-53350F4A10E7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of greater than 25% (estimated), what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHmut-codel C) IDH-wildtype D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7694-01Z-00-DX6.6CA051B4-B862-4630-86BE-6E6CF5575C78-1",
        "image": "TCGA-LGG/TCGA-HT-7694-01Z-00-DX6.6CA051B4-B862-4630-86BE-6E6CF5575C78.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of greater than 25% (estimated), what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHmut-codel C) IDH-wildtype D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7694-01Z-00-DX8.862B28F9-2900-440F-9D9C-067F301D15E0-1",
        "image": "TCGA-LGG/TCGA-HT-7694-01Z-00-DX8.862B28F9-2900-440F-9D9C-067F301D15E0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of greater than 25% (estimated), what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHmut-codel C) IDH-wildtype D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7694-01Z-00-DX2.B2566D8B-A389-4B3A-807A-AE916A73730B-1",
        "image": "TCGA-LGG/TCGA-HT-7694-01Z-00-DX2.B2566D8B-A389-4B3A-807A-AE916A73730B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of greater than 25% (estimated), what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHmut-codel C) IDH-wildtype D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7694-01Z-00-DX5.D7561F24-C805-4E32-84C1-BE3FD1767AEC-1",
        "image": "TCGA-LGG/TCGA-HT-7694-01Z-00-DX5.D7561F24-C805-4E32-84C1-BE3FD1767AEC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 labeling index of greater than 25% (estimated), what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHmut-codel C) IDH-wildtype D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C8-01Z-00-DX5.D23FADC5-5238-499D-9F5C-662A6A226169-1",
        "image": "TCGA-LGG/TCGA-VM-A8C8-01Z-00-DX5.D23FADC5-5238-499D-9F5C-662A6A226169.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Ki-67 proliferation index of up to 10% and diffuse positivity for IDH-1, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C8-01Z-00-DX8.CFBE7871-B2AD-4D99-8C40-D1EAC34BB272-1",
        "image": "TCGA-LGG/TCGA-VM-A8C8-01Z-00-DX8.CFBE7871-B2AD-4D99-8C40-D1EAC34BB272.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Ki-67 proliferation index of up to 10% and diffuse positivity for IDH-1, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C8-01Z-00-DX9.07AAC35A-A609-479F-843E-1E759A922AFA-1",
        "image": "TCGA-LGG/TCGA-VM-A8C8-01Z-00-DX9.07AAC35A-A609-479F-843E-1E759A922AFA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Ki-67 proliferation index of up to 10% and diffuse positivity for IDH-1, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C8-01Z-00-DX4.980FE353-1CBB-4B38-B26C-F96EFCA462B9-1",
        "image": "TCGA-LGG/TCGA-VM-A8C8-01Z-00-DX4.980FE353-1CBB-4B38-B26C-F96EFCA462B9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Ki-67 proliferation index of up to 10% and diffuse positivity for IDH-1, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C8-01Z-00-DX7.614E87B3-E2F0-4977-AE49-1EDBB26F879C-1",
        "image": "TCGA-LGG/TCGA-VM-A8C8-01Z-00-DX7.614E87B3-E2F0-4977-AE49-1EDBB26F879C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Ki-67 proliferation index of up to 10% and diffuse positivity for IDH-1, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C8-01Z-00-DX6.060E0C36-5EDA-476F-8D1F-2959FE993D3A-1",
        "image": "TCGA-LGG/TCGA-VM-A8C8-01Z-00-DX6.060E0C36-5EDA-476F-8D1F-2959FE993D3A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Ki-67 proliferation index of up to 10% and diffuse positivity for IDH-1, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C8-01Z-00-DX3.505AAA14-DBCC-4554-8A78-E8353B0532CE-1",
        "image": "TCGA-LGG/TCGA-VM-A8C8-01Z-00-DX3.505AAA14-DBCC-4554-8A78-E8353B0532CE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Ki-67 proliferation index of up to 10% and diffuse positivity for IDH-1, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8C8-01Z-00-DX1.119D6F8E-6A1D-4FCA-9C2F-75DB418B880B-1",
        "image": "TCGA-LGG/TCGA-VM-A8C8-01Z-00-DX1.119D6F8E-6A1D-4FCA-9C2F-75DB418B880B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Ki-67 proliferation index of up to 10% and diffuse positivity for IDH-1, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-TQ-A8XE-01Z-00-DX1.106C2DAA-99F8-475A-B383-31824AC4C506-1",
        "image": "TCGA-LGG/TCGA-TQ-A8XE-01Z-00-DX1.106C2DAA-99F8-475A-B383-31824AC4C506.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Cell Proliferation Index (Ki67) positive in 8% of neoplastic cells, what is the molecular subtype in this low-grade glioma? A) IDHmut-codel B) IDHwt C) IDHmut-non-codel D) BRAF V600E mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-TQ-A8XE-02Z-00-DX1.818964A4-457E-4658-AF46-C89629B24EF4-1",
        "image": "TCGA-LGG/TCGA-TQ-A8XE-02Z-00-DX1.818964A4-457E-4658-AF46-C89629B24EF4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a Cell Proliferation Index (Ki67) positive in 8% of neoplastic cells, what is the molecular subtype in this low-grade glioma? A) IDHmut-codel B) IDHwt C) IDHmut-non-codel D) BRAF V600E mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-7604-01Z-00-DX1.6889187F-B89A-4CC0-8224-709DFF523FEE-1",
        "image": "TCGA-LGG/TCGA-HT-7604-01Z-00-DX1.6889187F-B89A-4CC0-8224-709DFF523FEE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing a MIB-1 labeling index of 10.4%, what is the molecular subtype in this glioma? A) IDHwildtype B) IDHmut-codel C) IDHmut-non-codel D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-8013-01Z-00-DX1.2C2597D7-8F5C-406B-97C1-0EFD907B4FA5-1",
        "image": "TCGA-LGG/TCGA-HT-8013-01Z-00-DX1.2C2597D7-8F5C-406B-97C1-0EFD907B4FA5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a MIB-1 stain with scattered reactive cells, a rare mitotic figure, and a MIB-1 labeling index of 2.2%, what is the molecular subtype in this low-grade glioma? A) IDHmut-non-codel B) IDHwt C) BRAF-mutant D) 1p/19q co-deletion"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7858-01Z-00-DX3.509F76CA-BC5E-49AF-844A-DD58BBF32A9C-1",
        "image": "TCGA-LGG/TCGA-HT-7858-01Z-00-DX3.509F76CA-BC5E-49AF-844A-DD58BBF32A9C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing scattered MIB-1 reactive cells with a calculated labeling index of 2.9%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) MGMT-methylated D) ATRX loss"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7858-01Z-00-DX2.81FBFB02-3710-49F6-8287-7D66043056AD-1",
        "image": "TCGA-LGG/TCGA-HT-7858-01Z-00-DX2.81FBFB02-3710-49F6-8287-7D66043056AD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing scattered MIB-1 reactive cells with a calculated labeling index of 2.9%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) MGMT-methylated D) ATRX loss"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7858-01Z-00-DX4.7F6E369E-6CA5-4C61-A0B6-75C3EDDED6A9-1",
        "image": "TCGA-LGG/TCGA-HT-7858-01Z-00-DX4.7F6E369E-6CA5-4C61-A0B6-75C3EDDED6A9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing scattered MIB-1 reactive cells with a calculated labeling index of 2.9%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) MGMT-methylated D) ATRX loss"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7858-01Z-00-DX1.5615B7B9-843B-443F-91BE-DE208A069243-1",
        "image": "TCGA-LGG/TCGA-HT-7858-01Z-00-DX1.5615B7B9-843B-443F-91BE-DE208A069243.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing scattered MIB-1 reactive cells with a calculated labeling index of 2.9%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) MGMT-methylated D) ATRX loss"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8CH-01Z-00-DX4.E0A57F2D-B9E0-4423-8920-8A99CFEC4CE9-1",
        "image": "TCGA-LGG/TCGA-VM-A8CH-01Z-00-DX4.E0A57F2D-B9E0-4423-8920-8A99CFEC4CE9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffuse positivity for Glial Fibrillary Acidic Protein and p53, focal MIB-1 elevation at 20%, and IDH-1 negativity, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deleted D) MGMT methylated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8CH-01Z-00-DX5.992B2EBF-4B11-441E-97DE-9167BDBF797D-1",
        "image": "TCGA-LGG/TCGA-VM-A8CH-01Z-00-DX5.992B2EBF-4B11-441E-97DE-9167BDBF797D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffuse positivity for Glial Fibrillary Acidic Protein and p53, focal MIB-1 elevation at 20%, and IDH-1 negativity, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deleted D) MGMT methylated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8CH-01Z-00-DX7.8A5184E2-AEAF-4665-A09C-044D2B21EDD5-1",
        "image": "TCGA-LGG/TCGA-VM-A8CH-01Z-00-DX7.8A5184E2-AEAF-4665-A09C-044D2B21EDD5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffuse positivity for Glial Fibrillary Acidic Protein and p53, focal MIB-1 elevation at 20%, and IDH-1 negativity, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deleted D) MGMT methylated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8CH-01Z-00-DX1.5CCB3B5B-AE36-47E0-91F6-0DF95BB43A2D-1",
        "image": "TCGA-LGG/TCGA-VM-A8CH-01Z-00-DX1.5CCB3B5B-AE36-47E0-91F6-0DF95BB43A2D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffuse positivity for Glial Fibrillary Acidic Protein and p53, focal MIB-1 elevation at 20%, and IDH-1 negativity, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deleted D) MGMT methylated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8CH-01Z-00-DX6.284D2734-21E1-4C09-9578-6BFE42131D43-1",
        "image": "TCGA-LGG/TCGA-VM-A8CH-01Z-00-DX6.284D2734-21E1-4C09-9578-6BFE42131D43.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffuse positivity for Glial Fibrillary Acidic Protein and p53, focal MIB-1 elevation at 20%, and IDH-1 negativity, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deleted D) MGMT methylated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8CH-01Z-00-DX2.DC834C4C-ADA5-436C-80DD-303E45917C35-1",
        "image": "TCGA-LGG/TCGA-VM-A8CH-01Z-00-DX2.DC834C4C-ADA5-436C-80DD-303E45917C35.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffuse positivity for Glial Fibrillary Acidic Protein and p53, focal MIB-1 elevation at 20%, and IDH-1 negativity, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) 1p/19q co-deleted D) MGMT methylated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HW-7486-01Z-00-DX1.fc5aa2ce-c05e-40b6-934a-d44ef7feda2b-1",
        "image": "TCGA-LGG/TCGA-HW-7486-01Z-00-DX1.fc5aa2ce-c05e-40b6-934a-d44ef7feda2b.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing a MIB-1 (Ki-67) labeling index that does not exceed 4%, what is the molecular subtype in this glioma? A) IDHmut-noncodel B) IDHwt C) IDHmut-codel D) Glioblastoma, IDH-wildtype"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DU-7302-01Z-00-DX1.DF58DDC5-A6B1-4DE2-A048-A800099F8876-1",
        "image": "TCGA-LGG/TCGA-DU-7302-01Z-00-DX1.DF58DDC5-A6B1-4DE2-A048-A800099F8876.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a sparse gliofibrillary background with GFAP, about 20% of the cells overexpressing p53, and a proliferation index with MIB-1 of about 128 in the more active areas, what is the molecular subtype in this glioma? A) IDH-wildtype B) IDHmut-non-codel C) IDHmut-codel D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8CF-01Z-00-DX4.AF3112EB-D194-48BD-B31F-5138814578A3-1",
        "image": "TCGA-LGG/TCGA-VM-A8CF-01Z-00-DX4.AF3112EB-D194-48BD-B31F-5138814578A3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results indicating diffusely positive expression for GFAP, MIB-1 positivity in approximately 20% of nuclei, and diffuse positivity for IDH-1, p53, and PTEN, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8CF-01Z-00-DX3.3CED09BD-4062-4573-A075-84461B82F5B4-1",
        "image": "TCGA-LGG/TCGA-VM-A8CF-01Z-00-DX3.3CED09BD-4062-4573-A075-84461B82F5B4.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results indicating diffusely positive expression for GFAP, MIB-1 positivity in approximately 20% of nuclei, and diffuse positivity for IDH-1, p53, and PTEN, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8CF-01Z-00-DX8.4E93F16B-3CC3-4094-9EF2-9B74351AAF95-1",
        "image": "TCGA-LGG/TCGA-VM-A8CF-01Z-00-DX8.4E93F16B-3CC3-4094-9EF2-9B74351AAF95.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results indicating diffusely positive expression for GFAP, MIB-1 positivity in approximately 20% of nuclei, and diffuse positivity for IDH-1, p53, and PTEN, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8CF-01Z-00-DX9.704D20F4-2DDD-42FB-8AD6-97C2BCA68C83-1",
        "image": "TCGA-LGG/TCGA-VM-A8CF-01Z-00-DX9.704D20F4-2DDD-42FB-8AD6-97C2BCA68C83.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results indicating diffusely positive expression for GFAP, MIB-1 positivity in approximately 20% of nuclei, and diffuse positivity for IDH-1, p53, and PTEN, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8CF-01Z-00-DX5.90CAA7E9-55BA-41D6-A5D1-280E761B17BC-1",
        "image": "TCGA-LGG/TCGA-VM-A8CF-01Z-00-DX5.90CAA7E9-55BA-41D6-A5D1-280E761B17BC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results indicating diffusely positive expression for GFAP, MIB-1 positivity in approximately 20% of nuclei, and diffuse positivity for IDH-1, p53, and PTEN, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8CF-01Z-00-DX7.91F19B77-0929-4068-BFFB-FBA10E4F01DB-1",
        "image": "TCGA-LGG/TCGA-VM-A8CF-01Z-00-DX7.91F19B77-0929-4068-BFFB-FBA10E4F01DB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results indicating diffusely positive expression for GFAP, MIB-1 positivity in approximately 20% of nuclei, and diffuse positivity for IDH-1, p53, and PTEN, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8CF-01Z-00-DX2.9BB80EF8-5600-4BA5-879D-46B8B6D0776D-1",
        "image": "TCGA-LGG/TCGA-VM-A8CF-01Z-00-DX2.9BB80EF8-5600-4BA5-879D-46B8B6D0776D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results indicating diffusely positive expression for GFAP, MIB-1 positivity in approximately 20% of nuclei, and diffuse positivity for IDH-1, p53, and PTEN, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8CF-01Z-00-DX6.DC99FC24-7290-4702-B5DC-45F3780757B6-1",
        "image": "TCGA-LGG/TCGA-VM-A8CF-01Z-00-DX6.DC99FC24-7290-4702-B5DC-45F3780757B6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results indicating diffusely positive expression for GFAP, MIB-1 positivity in approximately 20% of nuclei, and diffuse positivity for IDH-1, p53, and PTEN, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-VM-A8CF-01Z-00-DX1.B02A927B-2E2F-4255-9949-E45813703A7C-1",
        "image": "TCGA-LGG/TCGA-VM-A8CF-01Z-00-DX1.B02A927B-2E2F-4255-9949-E45813703A7C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results indicating diffusely positive expression for GFAP, MIB-1 positivity in approximately 20% of nuclei, and diffuse positivity for IDH-1, p53, and PTEN, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-7478-01Z-00-DX1.B3835ABC-63FC-4AEA-B874-5701429C65B7-1",
        "image": "TCGA-LGG/TCGA-HT-7478-01Z-00-DX1.B3835ABC-63FC-4AEA-B874-5701429C65B7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p53 positivity and a MIB-1 labeling index of 6.2%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDHwt D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-8165-01Z-00-DX1.8d633ff1-6aed-41e5-8518-8856dbe4a718-1",
        "image": "TCGA-LGG/TCGA-DU-8165-01Z-00-DX1.8d633ff1-6aed-41e5-8518-8856dbe4a718.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP with prominent gliofibrillogenesis by neoplastic cells, a proliferation index of about 30% with MIB-1, strong overexpression of p53, and CD34 indicating rich microvasculature with hyperplasia, what is the molecular subtype in this brain tumor? A) IDH-mutant B) IDHwt C) 1p/19q co-deleted D) ATRX-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-A6S8-01Z-00-DX1.278DE6CD-0564-4331-B68D-6F4B7121BAD1-1",
        "image": "TCGA-LGG/TCGA-DU-A6S8-01Z-00-DX1.278DE6CD-0564-4331-B68D-6F4B7121BAD1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive IDH1, positive 4p, 19q LOH (codeletion), positive MGMT, and a MIB-1 proliferation index of 18%, what is the molecular subtype in this brain tumor? A) IDHwt B) IDHmut-codel C) IDHmut-noncodel D) TERTp-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-A6S6-01Z-00-DX1.24E0E59F-ADD0-430D-AC6D-F6FD73C60345-1",
        "image": "TCGA-LGG/TCGA-DU-A6S6-01Z-00-DX1.24E0E59F-ADD0-430D-AC6D-F6FD73C60345.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing sparse glial fibrillogenesis with GFAP, about 20% of neoplastic cells overexpressing p53 protein, and a MIB-1 Proliferation Index of approximately 4% in more active areas, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-noncodel C) IDHmut-codel D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-FG-8182-01Z-00-DX1.287825ff-7486-455b-b3d7-90200806ae87-1",
        "image": "TCGA-LGG/TCGA-FG-8182-01Z-00-DX1.287825ff-7486-455b-b3d7-90200806ae87.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positivity for GFAP in some tumor cells and background reactive astrocytes, and a Ki-67 proliferation index of 3-4%, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) IDHmut-codel D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7482-01Z-00-DX8.2DBC3C6D-B5E8-4FE8-B73B-94B851C46E4F-1",
        "image": "TCGA-LGG/TCGA-HT-7482-01Z-00-DX8.2DBC3C6D-B5E8-4FE8-B73B-94B851C46E4F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a nonenhancing portion of the tumor with an average MIB-1 index of <0.1% and a highest area of 1.6%, and an enhancing area with a MIB-1 labeling index of 5.0%, what is the molecular subtype in this glioma? A) IDHmut-non-codel   B) IDHwt   C) Triple-negative   D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7482-01Z-00-DX2.33C73D10-EBD2-4AB9-AD1F-5109C3319984-1",
        "image": "TCGA-LGG/TCGA-HT-7482-01Z-00-DX2.33C73D10-EBD2-4AB9-AD1F-5109C3319984.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a nonenhancing portion of the tumor with an average MIB-1 index of <0.1% and a highest area of 1.6%, and an enhancing area with a MIB-1 labeling index of 5.0%, what is the molecular subtype in this glioma? A) IDHmut-non-codel   B) IDHwt   C) Triple-negative   D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7482-01Z-00-DX7.1A44DE01-A7D4-40AE-885D-4F72153176FD-1",
        "image": "TCGA-LGG/TCGA-HT-7482-01Z-00-DX7.1A44DE01-A7D4-40AE-885D-4F72153176FD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a nonenhancing portion of the tumor with an average MIB-1 index of <0.1% and a highest area of 1.6%, and an enhancing area with a MIB-1 labeling index of 5.0%, what is the molecular subtype in this glioma? A) IDHmut-non-codel   B) IDHwt   C) Triple-negative   D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7482-01Z-00-DX3.8C1621A1-2C68-49CC-A859-C1F2EA450865-1",
        "image": "TCGA-LGG/TCGA-HT-7482-01Z-00-DX3.8C1621A1-2C68-49CC-A859-C1F2EA450865.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a nonenhancing portion of the tumor with an average MIB-1 index of <0.1% and a highest area of 1.6%, and an enhancing area with a MIB-1 labeling index of 5.0%, what is the molecular subtype in this glioma? A) IDHmut-non-codel   B) IDHwt   C) Triple-negative   D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7482-01Z-00-DX4.5B6C52B2-6DE5-46CC-B8C6-97F1E6DA0EF8-1",
        "image": "TCGA-LGG/TCGA-HT-7482-01Z-00-DX4.5B6C52B2-6DE5-46CC-B8C6-97F1E6DA0EF8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a nonenhancing portion of the tumor with an average MIB-1 index of <0.1% and a highest area of 1.6%, and an enhancing area with a MIB-1 labeling index of 5.0%, what is the molecular subtype in this glioma? A) IDHmut-non-codel   B) IDHwt   C) Triple-negative   D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7482-01Z-00-DX9.694E652E-F952-414C-8295-5810C64454E3-1",
        "image": "TCGA-LGG/TCGA-HT-7482-01Z-00-DX9.694E652E-F952-414C-8295-5810C64454E3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a nonenhancing portion of the tumor with an average MIB-1 index of <0.1% and a highest area of 1.6%, and an enhancing area with a MIB-1 labeling index of 5.0%, what is the molecular subtype in this glioma? A) IDHmut-non-codel   B) IDHwt   C) Triple-negative   D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7482-01Z-00-DX6.3A26CFA8-910B-42C1-B611-E4A6B4F2AEEC-1",
        "image": "TCGA-LGG/TCGA-HT-7482-01Z-00-DX6.3A26CFA8-910B-42C1-B611-E4A6B4F2AEEC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a nonenhancing portion of the tumor with an average MIB-1 index of <0.1% and a highest area of 1.6%, and an enhancing area with a MIB-1 labeling index of 5.0%, what is the molecular subtype in this glioma? A) IDHmut-non-codel   B) IDHwt   C) Triple-negative   D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7482-01Z-00-DX5.07FE2627-7614-4877-858A-1665A8CA20C9-1",
        "image": "TCGA-LGG/TCGA-HT-7482-01Z-00-DX5.07FE2627-7614-4877-858A-1665A8CA20C9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a nonenhancing portion of the tumor with an average MIB-1 index of <0.1% and a highest area of 1.6%, and an enhancing area with a MIB-1 labeling index of 5.0%, what is the molecular subtype in this glioma? A) IDHmut-non-codel   B) IDHwt   C) Triple-negative   D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7482-01Z-00-DX1.A56F0B29-767B-48C6-A522-7A94F868889B-1",
        "image": "TCGA-LGG/TCGA-HT-7482-01Z-00-DX1.A56F0B29-767B-48C6-A522-7A94F868889B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a nonenhancing portion of the tumor with an average MIB-1 index of <0.1% and a highest area of 1.6%, and an enhancing area with a MIB-1 labeling index of 5.0%, what is the molecular subtype in this glioma? A) IDHmut-non-codel   B) IDHwt   C) Triple-negative   D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7476-01Z-00-DX2.41B7E094-152F-485D-BA78-76D5401C3AE3-1",
        "image": "TCGA-LGG/TCGA-HT-7476-01Z-00-DX2.41B7E094-152F-485D-BA78-76D5401C3AE3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing immunoreactive p53 indicative of astrocytic origin and an MIB-1 labeling index of 3.6% to 7.1%, what is the molecular subtype in this astrocytoma? A) IDHmut-codel B) BRAF V600E-mutant C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-7476-01Z-00-DX1.9236049B-7C74-4585-8B46-921C42FC581E-1",
        "image": "TCGA-LGG/TCGA-HT-7476-01Z-00-DX1.9236049B-7C74-4585-8B46-921C42FC581E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing immunoreactive p53 indicative of astrocytic origin and an MIB-1 labeling index of 3.6% to 7.1%, what is the molecular subtype in this astrocytoma? A) IDHmut-codel B) BRAF V600E-mutant C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-7476-01Z-00-DX3.BA9C415D-34F0-4122-BC9A-3E7A57502D19-1",
        "image": "TCGA-LGG/TCGA-HT-7476-01Z-00-DX3.BA9C415D-34F0-4122-BC9A-3E7A57502D19.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing immunoreactive p53 indicative of astrocytic origin and an MIB-1 labeling index of 3.6% to 7.1%, what is the molecular subtype in this astrocytoma? A) IDHmut-codel B) BRAF V600E-mutant C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DB-A75M-01Z-00-DX1.418C4BE6-EDC6-47D1-B3E0-B6B082426D8F-1",
        "image": "TCGA-LGG/TCGA-DB-A75M-01Z-00-DX1.418C4BE6-EDC6-47D1-B3E0-B6B082426D8F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity, high level of p53 labeling, low overall Ki-67 with focal increase, and negative IDH-1 (R132H), what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHwt C) IDHmut-codel D) TERT promoter mutation"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-FG-8185-01Z-00-DX1.99b9779e-d967-47c6-836c-8b71a335b9a0-1",
        "image": "TCGA-LGG/TCGA-FG-8185-01Z-00-DX1.99b9779e-d967-47c6-836c-8b71a335b9a0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p53 positivity and a MIB-1 nuclear labeling rate of up to 20%, what is the molecular subtype in this tumor? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) TP53-wildtype"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-7485-01Z-00-DX1.37BA9895-CDC8-4EE9-8264-233C19ADA0FE-1",
        "image": "TCGA-LGG/TCGA-HT-7485-01Z-00-DX1.37BA9895-CDC8-4EE9-8264-233C19ADA0FE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing rare reactive cells with an estimated MIB-1 labeling index of less than 0.1% and numerous immunoreactive cells for P53, what is the molecular subtype in this glioma? A) IDHmut-codel   B) IDHmut-non-codel   C) IDHwt   D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7610-01Z-00-DX2.FA27FEBA-2400-451A-9E7E-492D150AAAA7-1",
        "image": "TCGA-LGG/TCGA-HT-7610-01Z-00-DX2.FA27FEBA-2400-451A-9E7E-492D150AAAA7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing scattered MIB-I reactive cells with a labeling index of 2.2%, what is the molecular subtype in this low-grade glioma? A) IDHmut-non-codel B) 1p/19q co-deleted C) Wild-type IDH D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7610-01Z-00-DX1.2817EDDA-8B51-4796-B830-DE12FD7998F0-1",
        "image": "TCGA-LGG/TCGA-HT-7610-01Z-00-DX1.2817EDDA-8B51-4796-B830-DE12FD7998F0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing scattered MIB-I reactive cells with a labeling index of 2.2%, what is the molecular subtype in this low-grade glioma? A) IDHmut-non-codel B) 1p/19q co-deleted C) Wild-type IDH D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7610-01Z-00-DX3.8BF3E549-C558-4179-9AA3-7972C451A8AF-1",
        "image": "TCGA-LGG/TCGA-HT-7610-01Z-00-DX3.8BF3E549-C558-4179-9AA3-7972C451A8AF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing scattered MIB-I reactive cells with a labeling index of 2.2%, what is the molecular subtype in this low-grade glioma? A) IDHmut-non-codel B) 1p/19q co-deleted C) Wild-type IDH D) H3 K27M-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-CS-5397-01Z-00-DX1.4AB09928-C5EA-4310-9303-ACD040E4C2B9-1",
        "image": "TCGA-LGG/TCGA-CS-5397-01Z-00-DX1.4AB09928-C5EA-4310-9303-ACD040E4C2B9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing quantification available for estrogen and progesterone receptors, interpretation of HER2 using Hercept Test, and EGFR pharmDx Clone in this cancer, what is the molecular subtype? A) Luminal A B) Triple-negative C) HER2-enriched D) IDHwt"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7873-01Z-00-DX2.F29C3B3E-E7E2-497C-A45A-95ED48CAF790-1",
        "image": "TCGA-LGG/TCGA-HT-7873-01Z-00-DX2.F29C3B3E-E7E2-497C-A45A-95ED48CAF790.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing an MIB-labeling index of 6.1%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDHwt D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7873-01Z-00-DX1.31862E90-F883-4B74-8A38-E63675C5CA81-1",
        "image": "TCGA-LGG/TCGA-HT-7873-01Z-00-DX1.31862E90-F883-4B74-8A38-E63675C5CA81.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing an MIB-labeling index of 6.1%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDHwt D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7873-01Z-00-DX3.FA5456B2-A50E-42DD-A206-92089422E523-1",
        "image": "TCGA-LGG/TCGA-HT-7873-01Z-00-DX3.FA5456B2-A50E-42DD-A206-92089422E523.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing an MIB-labeling index of 6.1%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDHwt D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-CS-5390-01Z-00-DX1.3C241E8A-D2E7-4C8D-ABDF-60391D8A32AD-1",
        "image": "TCGA-LGG/TCGA-CS-5390-01Z-00-DX1.3C241E8A-D2E7-4C8D-ABDF-60391D8A32AD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing Ki67 positive staining in greater than 10% of tumor cell nuclei in a portion of the tumor and GFAP positive staining in scattered tumor cells and reactive astrocytes, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHwildtype C) BRAF-fusion D) MGMT-methylated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7880-01Z-00-DX1.1EF457FD-80E9-4249-8436-E2BC853DF7BC-1",
        "image": "TCGA-LGG/TCGA-HT-7880-01Z-00-DX1.1EF457FD-80E9-4249-8436-E2BC853DF7BC.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing a MIB-1 labeling index of 3.1%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDH wildtype D) BRAF-altered"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7880-01Z-00-DX2.3C084238-8203-4203-8F92-9CEE02922CCF-1",
        "image": "TCGA-LGG/TCGA-HT-7880-01Z-00-DX2.3C084238-8203-4203-8F92-9CEE02922CCF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing a MIB-1 labeling index of 3.1%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-non-codel C) IDH wildtype D) BRAF-altered"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DB-A75L-01Z-00-DX1.132A6368-8624-4091-BCDA-261155BBD426-1",
        "image": "TCGA-LGG/TCGA-DB-A75L-01Z-00-DX1.132A6368-8624-4091-BCDA-261155BBD426.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong overexpression of p53 protein in tumor cells and positivity for mutant IDH1 (IDH1 R132H), indicating an IDH1 mutation, what is the molecular subtype in this tumor? A) IDHwt B) 1p/19q-codeleted C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DB-A75L-01Z-00-DX2.D7AA483E-9CFB-4357-922F-5C2BFCC6159C-1",
        "image": "TCGA-LGG/TCGA-DB-A75L-01Z-00-DX2.D7AA483E-9CFB-4357-922F-5C2BFCC6159C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong overexpression of p53 protein in tumor cells and positivity for mutant IDH1 (IDH1 R132H), indicating an IDH1 mutation, what is the molecular subtype in this tumor? A) IDHwt B) 1p/19q-codeleted C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DB-A75K-01Z-00-DX2.3F9418C2-334D-470A-928E-4D1E80A13978-1",
        "image": "TCGA-LGG/TCGA-DB-A75K-01Z-00-DX2.3F9418C2-334D-470A-928E-4D1E80A13978.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing variable expression of p53 protein, positive Mutant IDH1 (IDH1-R132H), and a moderate Ki-67 labeling index, what is the molecular subtype in this cancer?   A) IDHwt   B) IDHmut-codel   C) Triple negative   D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DB-A75K-01Z-00-DX1.20780A21-CE9E-4ABB-97E9-3D44D47C6218-1",
        "image": "TCGA-LGG/TCGA-DB-A75K-01Z-00-DX1.20780A21-CE9E-4ABB-97E9-3D44D47C6218.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing variable expression of p53 protein, positive Mutant IDH1 (IDH1-R132H), and a moderate Ki-67 labeling index, what is the molecular subtype in this cancer?   A) IDHwt   B) IDHmut-codel   C) Triple negative   D) BRAF-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7479-01Z-00-DX1.E310974D-E52C-4634-8E16-2A41E8C37D45-1",
        "image": "TCGA-LGG/TCGA-HT-7479-01Z-00-DX1.E310974D-E52C-4634-8E16-2A41E8C37D45.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing most neoplastic cells reactive to GFAP, tumor cells negative for Neu-N but cortical neurons positive, strong reactivity in atypical cells for p53, and variable immunoreactivity for MIB-1 (Slide 1A: <0.5%, Slide 2: up to 9.2%), what is the molecular subtype in this brain tumor? A) IDHmut-non-codel B) IDHwt C) EGFR-amplified D) BRAF V600E-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7479-01Z-00-DX3.FF2CDA94-4F2A-4B13-9FAF-5C7EA1586325-1",
        "image": "TCGA-LGG/TCGA-HT-7479-01Z-00-DX3.FF2CDA94-4F2A-4B13-9FAF-5C7EA1586325.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing most neoplastic cells reactive to GFAP, tumor cells negative for Neu-N but cortical neurons positive, strong reactivity in atypical cells for p53, and variable immunoreactivity for MIB-1 (Slide 1A: <0.5%, Slide 2: up to 9.2%), what is the molecular subtype in this brain tumor? A) IDHmut-non-codel B) IDHwt C) EGFR-amplified D) BRAF V600E-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7479-01Z-00-DX2.93C5E5AE-2BF4-45D7-B0F4-1EA48C9D3860-1",
        "image": "TCGA-LGG/TCGA-HT-7479-01Z-00-DX2.93C5E5AE-2BF4-45D7-B0F4-1EA48C9D3860.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing most neoplastic cells reactive to GFAP, tumor cells negative for Neu-N but cortical neurons positive, strong reactivity in atypical cells for p53, and variable immunoreactivity for MIB-1 (Slide 1A: <0.5%, Slide 2: up to 9.2%), what is the molecular subtype in this brain tumor? A) IDHmut-non-codel B) IDHwt C) EGFR-amplified D) BRAF V600E-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7680-01Z-00-DX1.112866BF-8B2F-4007-8F61-FACFC66CDA6C-1",
        "image": "TCGA-LGG/TCGA-HT-7680-01Z-00-DX1.112866BF-8B2F-4007-8F61-FACFC66CDA6C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP diffusely immunoreactive in neoplastic cells and fibrillary background, no EMA punctate cytoplasmic staining, gradation in neurofilament from periphery to center, and an estimated MIB-1 labeling index of less than 0.1%, what is the molecular subtype in this glioma? A) IDH-mutant B) IDHwt C) 1p/19q-codeleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7680-01Z-00-DX2.97354FFD-A8D4-400F-9FEA-7C69C47D4A57-1",
        "image": "TCGA-LGG/TCGA-HT-7680-01Z-00-DX2.97354FFD-A8D4-400F-9FEA-7C69C47D4A57.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP diffusely immunoreactive in neoplastic cells and fibrillary background, no EMA punctate cytoplasmic staining, gradation in neurofilament from periphery to center, and an estimated MIB-1 labeling index of less than 0.1%, what is the molecular subtype in this glioma? A) IDH-mutant B) IDHwt C) 1p/19q-codeleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HT-7680-01Z-00-DX3.C157242E-F4D2-4246-8016-B0A44C4C4AAD-1",
        "image": "TCGA-LGG/TCGA-HT-7680-01Z-00-DX3.C157242E-F4D2-4246-8016-B0A44C4C4AAD.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP diffusely immunoreactive in neoplastic cells and fibrillary background, no EMA punctate cytoplasmic staining, gradation in neurofilament from periphery to center, and an estimated MIB-1 labeling index of less than 0.1%, what is the molecular subtype in this glioma? A) IDH-mutant B) IDHwt C) 1p/19q-codeleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-6405-01Z-00-DX1.f5511a52-10ce-458d-a810-cd9c7fb1a0c6-1",
        "image": "TCGA-LGG/TCGA-DU-6405-01Z-00-DX1.f5511a52-10ce-458d-a810-cd9c7fb1a0c6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP demonstrating a heavy fibrillary component of the neoplasm and a MIB-1 proliferation index of 23%, what is the molecular subtype in this glioblastoma? A) IDH1-mutant B) IDHwt C) 1p/19q co-deleted D) TERT promoter mutation"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DU-6402-01Z-00-DX1.d7027057-55c3-435a-ac9a-41d353f120db-1",
        "image": "TCGA-LGG/TCGA-DU-6402-01Z-00-DX1.d7027057-55c3-435a-ac9a-41d353f120db.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing a MIB-1 proliferative index of about 68% in this glioblastoma, what is the molecular subtype? A) 1p/19q co-deleted B) IDHmut C) IDHwt D) MGMT methylated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HT-7616-01Z-00-DX2.7CA6A88F-9A91-432B-9D52-9780BEF6DE6F-1",
        "image": "TCGA-LGG/TCGA-HT-7616-01Z-00-DX2.7CA6A88F-9A91-432B-9D52-9780BEF6DE6F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive cytoplasmic immunoreactivity for GFAP in neoplastic cells, positive synaptophysin in background brain parenchyma, essentially negative CAM 5.2, and an MIB-1 labeling index of up to 6.5% in the most proliferative regions, what is the molecular subtype in this brain tumor? A) IDHmut-codel B) IDHwt C) H3 K27M-mutant D) MGMT-methylated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-7616-01Z-00-DX1.480841A6-F62C-4E95-A4EA-8DC975894933-1",
        "image": "TCGA-LGG/TCGA-HT-7616-01Z-00-DX1.480841A6-F62C-4E95-A4EA-8DC975894933.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive cytoplasmic immunoreactivity for GFAP in neoplastic cells, positive synaptophysin in background brain parenchyma, essentially negative CAM 5.2, and an MIB-1 labeling index of up to 6.5% in the most proliferative regions, what is the molecular subtype in this brain tumor? A) IDHmut-codel B) IDHwt C) H3 K27M-mutant D) MGMT-methylated"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DB-A4XD-01Z-00-DX1.9CEDBD64-B9D3-4F8C-B51F-4E00085742A1-1",
        "image": "TCGA-LGG/TCGA-DB-A4XD-01Z-00-DX1.9CEDBD64-B9D3-4F8C-B51F-4E00085742A1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing overexpression of p53 in the majority of tumor cells, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDHmut-codel C) IDHwt D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DB-A4XC-01Z-00-DX1.5768EC5F-D8B2-47B3-A685-059792C8751E-1",
        "image": "TCGA-LGG/TCGA-DB-A4XC-01Z-00-DX1.5768EC5F-D8B2-47B3-A685-059792C8751E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity in tumor cells with scant cytoplasm, variable p53 expression in over 50% of tumor cells, and a MIB-1 labeling index ranging from low to moderate, what is the molecular subtype in this brain tumor?  A) IDHmut-non-codel B) EGFR-amplified C) TERT promoter mutant D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DB-A4XC-01Z-00-DX2.7CFAE472-1951-436C-B3E6-F05A96FF5773-1",
        "image": "TCGA-LGG/TCGA-DB-A4XC-01Z-00-DX2.7CFAE472-1951-436C-B3E6-F05A96FF5773.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity in tumor cells with scant cytoplasm, variable p53 expression in over 50% of tumor cells, and a MIB-1 labeling index ranging from low to moderate, what is the molecular subtype in this brain tumor?  A) IDHmut-non-codel B) EGFR-amplified C) TERT promoter mutant D) 1p/19q co-deleted"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-HT-A616-01Z-00-DX1.5B0373D5-0979-4C1B-B9CA-08DFDCC9057B-1",
        "image": "TCGA-LGG/TCGA-HT-A616-01Z-00-DX1.5B0373D5-0979-4C1B-B9CA-08DFDCC9057B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH1 positivity, negative p53, and a low MIB-1 labeling index of no more than 0.6 percent, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-codel C) IDHmut-non-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-TM-A7C3-01Z-00-DX1.8599EB66-7116-4CFA-A08D-9929AB55EA31-1",
        "image": "TCGA-LGG/TCGA-TM-A7C3-01Z-00-DX1.8599EB66-7116-4CFA-A08D-9929AB55EA31.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP positivity, approximately 5% Ki67, and NeuN positivity, what is the molecular subtype in this glioblastoma? A) IDHwt B) 1p/19q co-deleted C) EGFR-amplified D) TP53-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-7298-01Z-00-DX1.1A1DDD06-53F9-4641-AC10-B6F78349DC66-1",
        "image": "TCGA-LGG/TCGA-DU-7298-01Z-00-DX1.1A1DDD06-53F9-4641-AC10-B6F78349DC66.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing moderate glial fibrillogenesis by GFAP, about 25% of the neoplastic cells overexpressing the p53 protein, and CD34 depicting a microvasculature without microvascular cellular proliferation, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDH-wildtype C) 1p/19q codeleted D) BRAF V600E-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-TM-A7C4-01Z-00-DX1.082C7A0D-CCAA-4D40-B7B5-1CDD1812DF57-1",
        "image": "TCGA-LGG/TCGA-TM-A7C4-01Z-00-DX1.082C7A0D-CCAA-4D40-B7B5-1CDD1812DF57.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing Ki-67 immunoreactivity in astrocytic cells of less than 4%, what is the molecular subtype in this low-grade glioma? A) IDHmut-non-codel B) IDHwt C) Oligodendroglioma, IDHmut-codel D) Glioblastoma, IDHwt"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-A5TT-01Z-00-DX1.86A745B4-0819-400D-9044-9A5ADC5276C7-1",
        "image": "TCGA-LGG/TCGA-DU-A5TT-01Z-00-DX1.86A745B4-0819-400D-9044-9A5ADC5276C7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH1-R132H negativity, an 18% MIB-1 proliferation index, numerous CD163-positive microglial cells, and CD34 indicating focal neovascularization and microvascular proliferation, what is the molecular subtype in this glioblastoma? A) IDH mutant B) IDH wild-type C) 1p/19q co-deleted D) TP53 mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-RY-A83Y-01Z-00-DX1.BB00A072-43F7-44B4-8E52-ECFE7C1C263A-1",
        "image": "TCGA-LGG/TCGA-RY-A83Y-01Z-00-DX1.BB00A072-43F7-44B4-8E52-ECFE7C1C263A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing IDH-1 (R132H mutant) positivity and a MIB-1 labeling index of approximately 4%, what is the molecular subtype in this glioma? A) IDH-wildtype B) IDHmut-non-codel C) IDHmut-codel D) TERT promoter mutation"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-TQ-A7RO-01Z-00-DX1.18B7FCA6-3AD0-43A1-B117-A9C8017DD783-1",
        "image": "TCGA-LGG/TCGA-TQ-A7RO-01Z-00-DX1.18B7FCA6-3AD0-43A1-B117-A9C8017DD783.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive expression of GFAP, Bcl-2, and P53, and negative expression of Galectin-3, which molecular subtype is this brain tumor likely to be classified as? A) IDH-wildtype B) IDHmut-codel C) Mesenchymal D) Classical"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DB-A64W-01Z-00-DX1.25848BE9-A940-4827-88AA-555527EB81AA-1",
        "image": "TCGA-LGG/TCGA-DB-A64W-01Z-00-DX1.25848BE9-A940-4827-88AA-555527EB81AA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positivity for p53 in rare cells, positive IDH1-R132H indicating an IDH mutation, and focally high Ki67 labeling index, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHwt C) BRAF-mutant D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DB-A4XE-01Z-00-DX2.895DAAFB-F994-4D4A-BCD7-30533BF94DC7-1",
        "image": "TCGA-LGG/TCGA-DB-A4XE-01Z-00-DX2.895DAAFB-F994-4D4A-BCD7-30533BF94DC7.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p53 positivity in tumor cells and a moderate MIB-1 labeling index, what is the molecular subtype in this glioma? A) IDHmut-non-codel B) IDH-wildtype C) 1p/19q co-deleted D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-DU-7290-01Z-00-DX1.6C7C6F04-43D1-43B4-A68D-677E25AD5627-1",
        "image": "TCGA-LGG/TCGA-DU-7290-01Z-00-DX1.6C7C6F04-43D1-43B4-A68D-677E25AD5627.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP expressed by approximately 20% of the neoplastic cells, and negative results for LCA, EMA, CK-6, and Synaptophysin, with an MIB-1 labeling index of about 10%, what is the molecular subtype in this glioblastoma? A) IDHmut B) IDHwt C) 1p/19q co-deletion D) ATRX loss"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-DB-A64Q-01Z-00-DX1.CD3937C2-015A-490D-B6A6-BAEEFFDC0747-1",
        "image": "TCGA-LGG/TCGA-DB-A64Q-01Z-00-DX1.CD3937C2-015A-490D-B6A6-BAEEFFDC0747.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing GFAP largely positive in background reactive astrocytes and focally in neoplastic cells with gemistocytic morphology, IDH1-R132H positivity consistent with IDH mutation, variable p53 expression, and a Ki-67 labeling index that is low to focally moderate, what is the molecular subtype in this glioma? A) IDHwt B) IDHmut-noncodel C) IDHmut-codel D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-RY-A83X-01Z-00-DX1.1DA8284F-B532-478B-B7BC-C578BE36E2CA-1",
        "image": "TCGA-LGG/TCGA-RY-A83X-01Z-00-DX1.1DA8284F-B532-478B-B7BC-C578BE36E2CA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing cytoplasmic staining for IDH-1 positivity and a MIB-1 labeling index of approximately 3-4%, what is the molecular subtype in this glioma? A) IDHmut-codel B) IDHmut-noncodel C) IDHwt D) EGFR-amplified"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-KT-A7W1-01Z-00-DX1.D416EFED-F654-433B-917C-A9BE98EAA760-1",
        "image": "TCGA-LGG/TCGA-KT-A7W1-01Z-00-DX1.D416EFED-F654-433B-917C-A9BE98EAA760.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positivity for GFAP, an estimated 5-10% labeling for MIB-1, and negative IDH1, what is the molecular subtype in this glioma? A) IDH-mutant B) IDHwt C) MGMT-methylated D) ATRX-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-SN-A84X-01Z-00-DX1.52C9004C-E88F-47EC-AFBA-08A5872B62CA-1",
        "image": "TCGA-TGCT/TCGA-SN-A84X-01Z-00-DX1.52C9004C-E88F-47EC-AFBA-08A5872B62CA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing CD117 highlighting the seminomatous component, what is the molecular subtype in this testicular cancer? A) Non-seminoma B) Seminoma C) Yolk sac tumor D) Teratoma"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-SN-A84X-01Z-00-DX2.6E86250D-DD50-4925-9935-B5A7A6AD25B8-1",
        "image": "TCGA-TGCT/TCGA-SN-A84X-01Z-00-DX2.6E86250D-DD50-4925-9935-B5A7A6AD25B8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing CD117 highlighting the seminomatous component, what is the molecular subtype in this testicular cancer? A) Non-seminoma B) Seminoma C) Yolk sac tumor D) Teratoma"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-XY-A8S3-01Z-00-DX1.18AA1B33-C612-4EBD-BE4A-8BA78139E722-1",
        "image": "TCGA-TGCT/TCGA-XY-A8S3-01Z-00-DX1.18AA1B33-C612-4EBD-BE4A-8BA78139E722.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing CD30 and OCT 3/4 highlighting embryonal carcinoma, Glypican 3 and AFP highlighting yolk sac tumor, and HCG highlighting small foci of choriocarcinoma, what is the molecular subtype in this testicular germ cell tumor? A) Seminoma B) Non-seminoma C) Spermatocytic tumor D) Teratoma"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-XE-A8H1-01Z-00-DX1.75D3D52F-4C79-463C-99D2-4E43F1B8DEC6-1",
        "image": "TCGA-TGCT/TCGA-XE-A8H1-01Z-00-DX1.75D3D52F-4C79-463C-99D2-4E43F1B8DEC6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positivity for Pancytokeratin (AE1/AE3), CD30, and PLAP with membrane staining, and negative hCG for syncytiotrophoblastic elements, what is the molecular subtype in this germ cell tumor? A) Teratoma B) Non-seminoma C) Seminoma D) Yolk sac tumor"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-XE-AAO6-01Z-00-DX1.C4176415-F3D2-4E37-88F9-59F7656AB5E6-1",
        "image": "TCGA-TGCT/TCGA-XE-AAO6-01Z-00-DX1.C4176415-F3D2-4E37-88F9-59F7656AB5E6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative expressions for HCG and CAM 5.2, what is the molecular subtype in this testicular cancer? A) Teratoma B) Seminoma C) Embryonal carcinoma D) Yolk sac tumor"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-XE-AAOF-01Z-00-DX1.6AD88B69-EB1F-4577-AFA6-CA407BFBB697-1",
        "image": "TCGA-TGCT/TCGA-XE-AAOF-01Z-00-DX1.6AD88B69-EB1F-4577-AFA6-CA407BFBB697.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive c-kit and negative AE1/AE3 and CAM 5.2, what is the molecular subtype in this germ cell tumor? A) Yolk sac tumor B) Choriocarcinoma C) Seminoma D) Teratoma"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-S6-A8JX-01Z-00-DX1.C44E5FBF-10BA-43C4-980C-C6280B9ECFE9-1",
        "image": "TCGA-TGCT/TCGA-S6-A8JX-01Z-00-DX1.C44E5FBF-10BA-43C4-980C-C6280B9ECFE9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive expression of placental alkaline phosphatase, what is the molecular subtype in this testicular germ cell tumor? A) Seminoma B) Embryonal carcinoma C) Yolk sac tumor D) Teratoma"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-ZM-AA0E-01Z-00-DX1.D673EF20-56BB-4CBB-96E7-CDE7E38058BF-1",
        "image": "TCGA-TGCT/TCGA-ZM-AA0E-01Z-00-DX1.D673EF20-56BB-4CBB-96E7-CDE7E38058BF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing CD117 positivity and partial PLAP positivity, what is the molecular subtype in this testicular cancer? A) Non-seminomatous germ cell tumor B) Seminoma C) Teratoma D) Yolk sac tumor"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-ZM-AA05-01Z-00-DX1.906300AF-5585-4921-9711-2F4C5C536CFE-1",
        "image": "TCGA-TGCT/TCGA-ZM-AA05-01Z-00-DX1.906300AF-5585-4921-9711-2F4C5C536CFE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing positive PLAP, what is the molecular subtype in this testicular cancer? A) Non-seminoma B) Seminoma C) Yolk sac tumor D) Teratoma"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-XE-AAOD-01Z-00-DX1.F78C46BD-FD97-4B34-8100-0D143B9E4CB9-1",
        "image": "TCGA-TGCT/TCGA-XE-AAOD-01Z-00-DX1.F78C46BD-FD97-4B34-8100-0D143B9E4CB9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong HCG positivity, strong CAMS.2 positivity in choriocarcinoma and negativity in seminoma, and cn Kit positivity in seminoma and intratubular germ cell neoplasia with C5-30 being negative, what is the molecular subtype in this germ cell tumor? A) Seminoma B) Non-seminoma C) Yolk sac tumor D) Embryonal carcinoma"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-XE-AAO3-01Z-00-DX1.ADEEB1FA-BA6B-4907-A643-F0F021702C7E-1",
        "image": "TCGA-TGCT/TCGA-XE-AAO3-01Z-00-DX1.ADEEB1FA-BA6B-4907-A643-F0F021702C7E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive PLAP expression and negative CAM 5.2 and AE1/AE3, what is the molecular subtype in this testicular cancer? A) Seminoma B) Teratoma C) Embryonal carcinoma D) Choriocarcinoma"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-XE-AAOB-01Z-00-DX1.28368FE5-BD13-4225-AA5C-910C3829753A-1",
        "image": "TCGA-TGCT/TCGA-XE-AAOB-01Z-00-DX1.28368FE5-BD13-4225-AA5C-910C3829753A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing small focal tubular areas of strong positivity for AFP and HCG, and strong positivity for CD30 in embryonal carcinoma, what is the molecular subtype in this testicular cancer? A) Seminoma B) Non-seminoma C) Teratoma D) Germinoma"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-WZ-A8D5-01Z-00-DX1.652349A8-0C7A-4D0F-AF39-EA1548701F9D-1",
        "image": "TCGA-TGCT/TCGA-WZ-A8D5-01Z-00-DX1.652349A8-0C7A-4D0F-AF39-EA1548701F9D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing CD30 positivity, what is the molecular subtype in this germ cell tumor? A) Embryonal carcinoma B) Seminoma C) Yolk sac tumor D) Choriocarcinoma"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-ZM-AA0N-01Z-00-DX1.22F4C6EB-C784-4493-9DC5-18D5A1DC6CD5-1",
        "image": "TCGA-TGCT/TCGA-ZM-AA0N-01Z-00-DX1.22F4C6EB-C784-4493-9DC5-18D5A1DC6CD5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive PLAP in all tumor cells and in unclassified intratubular germ cell neoplasia, what is the molecular subtype in this testicular carcinoma? A) Choriocarcinoma B) Yolk sac tumor C) Seminoma D) Teratoma"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-CN-6010-01Z-00-DX1.8a82a2d0-c687-4b75-922f-b5b64b5a99df-1",
        "image": "TCGA-HNSC/TCGA-CN-6010-01Z-00-DX1.8a82a2d0-c687-4b75-922f-b5b64b5a99df.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing HPV negative, p16 negative, and EGFR 2+ membranous reactivity, what is the molecular subtype in this head and neck squamous cell carcinoma? A) HPV+ B) HPV- C) EBV-associated D) MSI"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-T2-A6X0-01Z-00-DX1.B745431A-B9AA-4436-BF69-59EC4D73F14A-1",
        "image": "TCGA-HNSC/TCGA-T2-A6X0-01Z-00-DX1.B745431A-B9AA-4436-BF69-59EC4D73F14A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong and diffuse positivity for p16, and no circumferential membranous staining for EGFR, what is the molecular subtype in this cancer? A) EGFR-mutant B) HER2-amplified C) ALK-rearranged D) HPV+"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BB-A6UM-01Z-00-DX1.403D4D0A-83F4-4D2F-9CBB-C7A1470AC565-1",
        "image": "TCGA-HNSC/TCGA-BB-A6UM-01Z-00-DX1.403D4D0A-83F4-4D2F-9CBB-C7A1470AC565.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive p16 and positive HPV16, what is the molecular subtype in this cancer? A) HPV+ B) MSI C) EBV-associated D) Her2-enriched"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-KU-A6H7-01Z-00-DX1.AFBBE7A7-6261-499F-AEC3-31AEFF1AB651-1",
        "image": "TCGA-HNSC/TCGA-KU-A6H7-01Z-00-DX1.AFBBE7A7-6261-499F-AEC3-31AEFF1AB651.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing diffusely positive p16 in both the cytoplasm and nucleus, what is the molecular subtype in this squamous cell carcinoma? A) HPV+ B) EBV-associated C) MSI D) KRAS-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-CN-6988-01Z-00-DX1.1fc4c572-3495-4f5a-9f1a-60c04096d188-1",
        "image": "TCGA-HNSC/TCGA-CN-6988-01Z-00-DX1.1fc4c572-3495-4f5a-9f1a-60c04096d188.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative P16, positive membranous EGFR with 2+ intensity, and negative HPV, what is the molecular subtype in this head and neck squamous cell carcinoma? A) HPV+ B) MSI C) EBV-associated D) HPV-"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BA-A8YP-01Z-00-DX1.03B95E63-2639-49F6-B8DD-AC2C2FA872B1-1",
        "image": "TCGA-HNSC/TCGA-BA-A8YP-01Z-00-DX1.03B95E63-2639-49F6-B8DD-AC2C2FA872B1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative P16 immunohistochemistry and negative high-risk HPV in situ hybridization, what is the molecular subtype in this cervical cancer? A) HPV+ B) MSI C) HPV- D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-QK-A8ZA-01Z-00-DX1.D169F19F-99A3-4A8C-9AE8-24C529B2CE12-1",
        "image": "TCGA-HNSC/TCGA-QK-A8ZA-01Z-00-DX1.D169F19F-99A3-4A8C-9AE8-24C529B2CE12.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong diffuse positivity for P16, what is the molecular subtype in this cervical carcinoma? A) HPV+ B) EBV-associated C) MSI D) POLE-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-CN-6989-01Z-00-DX1.dd68e391-1d00-4bfc-9be9-ff5024bea237-1",
        "image": "TCGA-HNSC/TCGA-CN-6989-01Z-00-DX1.dd68e391-1d00-4bfc-9be9-ff5024bea237.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing no increase in p53 and Ki-67 expression in the squamoproliferative areas, what is the molecular subtype in this skin carcinoma? A) BRAF-mutant B) HPV-related C) KRAS-mutant D) EGFR-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-CN-A63T-01Z-00-DX1.6AF3A8E6-373B-4D7C-AEDC-CFFC3D6E0FE8-1",
        "image": "TCGA-HNSC/TCGA-CN-A63T-01Z-00-DX1.6AF3A8E6-373B-4D7C-AEDC-CFFC3D6E0FE8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing numerous positive plasma cells with anti-kappa and anti-lambda, prominent Ki-67/MIB-1 marking in germinal centers, and negative bcl-2 and cyclin D1, what is the molecular subtype in this lymphoma? A) MALT lymphoma B) Burkitt lymphoma C) Follicular lymphoma D) Mantle cell lymphoma"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BA-A6DA-01Z-00-DX1.8BFA179A-8E8A-45DC-A036-77A7D6ABB7EA-1",
        "image": "TCGA-HNSC/TCGA-BA-A6DA-01Z-00-DX1.8BFA179A-8E8A-45DC-A036-77A7D6ABB7EA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing P16 positivity, negative HPV High Risk (ISH), and non-contributory TTF-1 and Thyroglobulin, what is the molecular subtype in this cancer?   A) HPV+ (Positive)   B) HPV- (Negative)   C) EBV-associated   D) MSS"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HD-8634-01Z-00-DX1.DD4A56A4-A557-478D-BF86-F3764583D26E-1",
        "image": "TCGA-HNSC/TCGA-HD-8634-01Z-00-DX1.DD4A56A4-A557-478D-BF86-F3764583D26E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative pankeratin staining in multiple lymph nodes (left upper deep cervical, level 3, and level 4) without evidence of infiltrating squamous cell carcinoma, what is the molecular subtype in this cervical cancer? A) HPV+ B) MSI C) HPV- D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-H7-A76A-01Z-00-DX1.E4D824E3-2076-4E46-83F8-9BF5283FCDEE-1",
        "image": "TCGA-HNSC/TCGA-H7-A76A-01Z-00-DX1.E4D824E3-2076-4E46-83F8-9BF5283FCDEE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing a positive result for human papillomavirus associated carcinoma (p16) and HPV high risk (16/18), what is the molecular subtype in this carcinoma? A) MSI B) HPV+ C) EBV-associated D) MSS"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-CN-4730-01Z-00-DX1.a76280e8-6591-4d51-afc9-2f01e87346ab-1",
        "image": "TCGA-HNSC/TCGA-CN-4730-01Z-00-DX1.a76280e8-6591-4d51-afc9-2f01e87346ab.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative p16 expression, what is the molecular subtype in this specific cancer type? A) HPV+ B) MSI C) HPV- D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-MZ-A6I9-01Z-00-DX1.478C5347-BF30-4CAA-8215-58778D79E33B-1",
        "image": "TCGA-HNSC/TCGA-MZ-A6I9-01Z-00-DX1.478C5347-BF30-4CAA-8215-58778D79E33B.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive p16 with diffuse nuclear staining, what is the molecular subtype in this head and neck carcinoma? A) HPV+ B) EBV-associated C) MSI D) POLE-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-BA-A6DG-01Z-00-DX1.B227E4F2-2F78-4AD7-BD85-2A77701BACBA-1",
        "image": "TCGA-HNSC/TCGA-BA-A6DG-01Z-00-DX1.B227E4F2-2F78-4AD7-BD85-2A77701BACBA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing P16 immunostain negative and in situ hybridization for high-risk HPV negative, what is the molecular subtype in this oropharyngeal cancer? A) HPV+ B) EBV-associated C) HPV- D) KRAS-mutant"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BA-A6DI-01Z-00-DX1.4EB42174-5219-43A3-AD93-64446DCE37CF-1",
        "image": "TCGA-HNSC/TCGA-BA-A6DI-01Z-00-DX1.4EB42174-5219-43A3-AD93-64446DCE37CF.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative p16 and negative high-risk HPV by in situ hybridization, what is the molecular subtype in this cervical carcinoma? A) HPV+ B) MSI C) HPV- D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-CN-4731-01Z-00-DX1.07b0bf3b-77f3-4471-a63c-1afc54714a60-1",
        "image": "TCGA-HNSC/TCGA-CN-4731-01Z-00-DX1.07b0bf3b-77f3-4471-a63c-1afc54714a60.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC result showing negative immunohistochemical staining and negative in situ hybridization, what is the molecular subtype in this cervical carcinoma? A) HPV+ B) MSI C) HPV- D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-T2-A6X2-01Z-00-DX1.8A72CC59-D322-4C0B-AD52-ACF91CC3B72F-1",
        "image": "TCGA-HNSC/TCGA-T2-A6X2-01Z-00-DX1.8A72CC59-D322-4C0B-AD52-ACF91CC3B72F.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing carcinoma cells strongly (3+) and diffusely positive for EGFR in this squamous cell carcinoma of the left mandible, what is the molecular subtype? A) HPV+ B) EBV-associated C) EGFR-positive D) MSI"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-HD-8224-01Z-00-DX1.2b08e329-bb26-4605-bb3b-b257cef561b2-1",
        "image": "TCGA-HNSC/TCGA-HD-8224-01Z-00-DX1.2b08e329-bb26-4605-bb3b-b257cef561b2.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nGiven the HER2 overexpression and negative hormone receptor status (ER and PR) in the breast cancer biopsy, what is the molecular subtype of this cancer? A) Luminal A B) Luminal B C) HER2-enriched D) Triple-negative"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-QK-A6IF-01Z-00-DX2.AAF0F8C8-F5F3-4B3B-9664-31EEE893B65E-1",
        "image": "TCGA-HNSC/TCGA-QK-A6IF-01Z-00-DX2.AAF0F8C8-F5F3-4B3B-9664-31EEE893B65E.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong p16 positivity and positive HPV by ISH, what is the molecular subtype in this cancer type? A) MSI B) EBV-associated C) HPV+ D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-QK-A6IF-01Z-00-DX1.7B689FEA-436B-4406-8107-0160732661B0-1",
        "image": "TCGA-HNSC/TCGA-QK-A6IF-01Z-00-DX1.7B689FEA-436B-4406-8107-0160732661B0.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong p16 positivity and positive HPV by ISH, what is the molecular subtype in this cancer type? A) MSI B) EBV-associated C) HPV+ D) HER2-enriched"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-CN-4728-01Z-00-DX1.69fc04ce-cc6b-4c63-9322-b5ffb0056828-1",
        "image": "TCGA-HNSC/TCGA-CN-4728-01Z-00-DX1.69fc04ce-cc6b-4c63-9322-b5ffb0056828.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative expression of p16 as a surrogate marker for HPV, what is the molecular subtype in this cervical carcinoma? A) HPV+ B) MSI C) HPV- D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-CN-6023-01Z-00-DX1.abfbc2c7-109b-4b72-8645-8e4135d00306-1",
        "image": "TCGA-HNSC/TCGA-CN-6023-01Z-00-DX1.abfbc2c7-109b-4b72-8645-8e4135d00306.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing no evidence of additional metastatic papillary thyroid carcinoma with TTF1 and CAM 5.2, what is the molecular subtype in this thyroid carcinoma? A) BRAF-mutant B) RET/PTC rearranged C) NTRK fusion D) HPV-"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-CN-6024-01Z-00-DX1.c5791a72-1ded-4723-a33a-68da0685c80b-1",
        "image": "TCGA-HNSC/TCGA-CN-6024-01Z-00-DX1.c5791a72-1ded-4723-a33a-68da0685c80b.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative p16 and negative HPV, what is the molecular subtype in this head and neck squamous cell carcinoma? A) HPV+ B) MSI C) HPV- D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-CN-4727-01Z-00-DX1.bee9d488-0f05-4579-8c34-aa4197972bb1-1",
        "image": "TCGA-HNSC/TCGA-CN-4727-01Z-00-DX1.bee9d488-0f05-4579-8c34-aa4197972bb1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative P16 immunohistochemistry, negative HPV in-situ hybridization, and 1+ membranous staining for EGFR, what is the molecular subtype in this head and neck carcinoma? A) EBV-associated B) HPV+ C) MSI-high D) HPV-"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-F7-A624-01Z-00-DX1.5626052F-EA0A-43E0-B011-43276FA282C5-1",
        "image": "TCGA-HNSC/TCGA-F7-A624-01Z-00-DX1.5626052F-EA0A-43E0-B011-43276FA282C5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results with positive Vimentin, HMW cytokeratins, CK7, and a Ki-67 proliferation index of 90%, and negative S100, HMB45, Chromogranin, and CD56, what is the molecular subtype in this carcinoma? A) Basal-like B) Neuroendocrine C) HPV D) Melanoma"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-CN-5373-01Z-00-DX1.c423a74f-cdb6-41b1-9483-be854827434e-1",
        "image": "TCGA-HNSC/TCGA-CN-5373-01Z-00-DX1.c423a74f-cdb6-41b1-9483-be854827434e.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative expression for both PV and P16, what is the molecular subtype in this carcinoma? A) HPV+ B) EBV-associated C) MSI D) HPV-"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-QK-A6V9-01Z-00-DX1.0D202E91-5205-4888-A40D-381F7534B34A-1",
        "image": "TCGA-HNSC/TCGA-QK-A6V9-01Z-00-DX1.0D202E91-5205-4888-A40D-381F7534B34A.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strongly positive p16 and pending HPV ISH, what is the molecular subtype in this cancer? A) HPV+ B) MSI C) EBV-associated D) MSS"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-CV-A463-01Z-00-DX1.5391495E-FADF-4F35-AA41-17CF8D80E102-1",
        "image": "TCGA-HNSC/TCGA-CV-A463-01Z-00-DX1.5391495E-FADF-4F35-AA41-17CF8D80E102.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong diffuse positivity for p53, focal rare positivity for p16, and negative in situ hybridization for high-risk HPV, what is the molecular subtype in this oropharyngeal squamous cell carcinoma? A) HPV-positive B) HPV-negative C) EBV-associated D) MSI"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-4P-AA8J-01Z-00-DX1.5B44796F-D099-4076-9CAF-B40C2B83F432-1",
        "image": "TCGA-HNSC/TCGA-4P-AA8J-01Z-00-DX1.5B44796F-D099-4076-9CAF-B40C2B83F432.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative p16 expression, what is the molecular subtype in this cancer? A) HPV+ B) MSI C) HPV- D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-RS-A6TP-01Z-00-DX1.C8674492-472E-4EAC-8DBC-B1004C30BD9C-1",
        "image": "TCGA-HNSC/TCGA-RS-A6TP-01Z-00-DX1.C8674492-472E-4EAC-8DBC-B1004C30BD9C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong and diffuse p16 positivity and high-risk HPV positivity by in-situ hybridization, what is the molecular subtype in this cervical carcinoma? A) MSI B) HPV+ C) HPV- D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-CN-4733-01Z-00-DX1.03cccb3f-c551-450f-b00a-f808a237db0b-1",
        "image": "TCGA-HNSC/TCGA-CN-4733-01Z-00-DX1.03cccb3f-c551-450f-b00a-f808a237db0b.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p16 being negative, EGFR FISH positive, and c-MET FISH negative, what is the molecular subtype in this cancer type? A) HPV+ B) MSI C) HPV- D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-CN-A63W-01Z-00-DX1.57F5E8BA-E352-4AC9-A800-21DF745474B8-1",
        "image": "TCGA-HNSC/TCGA-CN-A63W-01Z-00-DX1.57F5E8BA-E352-4AC9-A800-21DF745474B8.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p16 negativity and in situ hybridization results showing HPV negativity, what is the molecular subtype in this cervical carcinoma? A) HPV+ B) MSI C) HPV- D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BA-A6DL-01Z-00-DX1.A2E13153-88A9-411B-AA0F-56314E72E2CB-1",
        "image": "TCGA-HNSC/TCGA-BA-A6DL-01Z-00-DX1.A2E13153-88A9-411B-AA0F-56314E72E2CB.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative P16 protein expression and negative high-risk HPV by in situ hybridization, both with positive external controls, what is the molecular subtype in this oropharyngeal carcinoma? A) HPV+ B) HPV- C) EBV-associated D) MSI"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BA-A6DE-01Z-00-DX1.3279D372-4A92-4CFA-9E52-19197934378D-1",
        "image": "TCGA-HNSC/TCGA-BA-A6DE-01Z-00-DX1.3279D372-4A92-4CFA-9E52-19197934378D.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing P16 negativity and a negative status for HR and HPV ISH, what is the molecular subtype in this cervical cancer? A) HPV+ B) HPV- C) EBV-associated D) MSS"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-BA-A6DB-01Z-00-DX1.6EC4113A-D48B-4F83-84EF-1A811C67FDFE-1",
        "image": "TCGA-HNSC/TCGA-BA-A6DB-01Z-00-DX1.6EC4113A-D48B-4F83-84EF-1A811C67FDFE.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative P16 and negative HR HPV ISH status, what is the molecular subtype in this cervical cancer? A) HPV+ B) MSI C) HPV- D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-BA-5557-01Z-00-DX1.40be784e-d030-414f-aecf-620c0f8d9be3-1",
        "image": "TCGA-HNSC/TCGA-BA-5557-01Z-00-DX1.40be784e-d030-414f-aecf-620c0f8d9be3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing HPV negative and p16 negative staining, what is the molecular subtype in this head and neck carcinoma? A) HPV+ B) MSI C) HPV- D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-CN-4735-01Z-00-DX1.b7d37666-bd65-4d3b-826b-97e560444956-1",
        "image": "TCGA-HNSC/TCGA-CN-4735-01Z-00-DX1.b7d37666-bd65-4d3b-826b-97e560444956.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive EGFR, negative p16, and negative HPV, what is the molecular subtype in this head and neck squamous cell carcinoma? A) HPV+ B) HPV- C) EBV-associated D) MSI"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-HD-A4C1-01Z-00-DX1.AAE02372-CA5D-463D-937B-B88A1C5321F9-1",
        "image": "TCGA-HNSC/TCGA-HD-A4C1-01Z-00-DX1.AAE02372-CA5D-463D-937B-B88A1C5321F9.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing P16 negativity on slides A1 and A11, what is the molecular subtype in this cervical cancer?   A) HPV+   B) MSI   C) POLE-mutant   D) HPV-"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-BA-A6DJ-01Z-00-DX1.F83A347E-4442-4F06-9715-32E4C4E1A4FA-1",
        "image": "TCGA-HNSC/TCGA-BA-A6DJ-01Z-00-DX1.F83A347E-4442-4F06-9715-32E4C4E1A4FA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results of P16 being negative and HR HPV ISH also being negative, what is the molecular subtype in this cervical carcinoma? A) HPV+ B) MSI C) HPV- D) EBV-associated"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-DS-A7WF-01Z-00-DX1.35D29A85-846A-435E-8D51-83381C6D52E6-1",
        "image": "TCGA-CESC/TCGA-DS-A7WF-01Z-00-DX1.35D29A85-846A-435E-8D51-83381C6D52E6.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negative Pancytokeratin on all lymph node specimens, and negative Synaptophysin and Chromogranin on blocks A9 (section of the tumor), what is the molecular subtype in this carcinoma? A) Squamous Carcinoma B) Neuroendocrine C) Adenocarcinoma D) Lymphoma"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-Q1-A73Q-01Z-00-DX1.E39029C5-48EE-466B-A11B-B884A83250F5-1",
        "image": "TCGA-CESC/TCGA-Q1-A73Q-01Z-00-DX1.E39029C5-48EE-466B-A11B-B884A83250F5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong diffuse nuclear staining supporting the H&E impression of squamous cell carcinoma and ruling against neuroendocrine small cell carcinoma, what is the molecular subtype in this carcinoma? A) Adenocarcinoma B) Squamous Carcinoma C) Neuroendocrine Carcinoma D) Mucinous Carcinoma"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-JX-A3Q8-01Z-00-DX1.4995F70C-BDBE-4435-B57B-C6ACC27B0E91-1",
        "image": "TCGA-CESC/TCGA-JX-A3Q8-01Z-00-DX1.4995F70C-BDBE-4435-B57B-C6ACC27B0E91.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing the endocervical adenocarcinoma tumor cells are diffusely positive for p16, what is the molecular subtype in this cervical cancer? A) MSI B) HPV+ C) EBV-associated D) KRAS-mutant"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-JW-A5VG-01Z-00-DX1.59D9AE20-FE48-44E4-B139-91BF9FD3CBD1-1",
        "image": "TCGA-CESC/TCGA-JW-A5VG-01Z-00-DX1.59D9AE20-FE48-44E4-B139-91BF9FD3CBD1.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing CK5/6 staining highlighting tumor cells, what is the molecular subtype in this cancer? A) Adenocarcinoma B) Neuroendocrine carcinoma C) Squamous carcinoma D) Small cell carcinoma"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-C5-A2M2-01Z-00-DX1.145589C8-870A-49BD-BC54-A8951E2DEDE3-1",
        "image": "TCGA-CESC/TCGA-C5-A2M2-01Z-00-DX1.145589C8-870A-49BD-BC54-A8951E2DEDE3.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive p16, negative Vimentin, and negative Estrogen Receptors, what is the molecular subtype in this carcinoma?  A) Adenosquamous Carcinoma B) Small Cell Carcinoma C) Squamous Cell Carcinoma D) Adenocarcinoma"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-JW-A69B-01Z-00-DX1.1C01BC3B-4DC2-4589-8940-10DFCCB2CF22-1",
        "image": "TCGA-CESC/TCGA-JW-A69B-01Z-00-DX1.1C01BC3B-4DC2-4589-8940-10DFCCB2CF22.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong, diffuse positivity for p16, patchy positivity for CEA, and negativity for both ER and Vimentin, what is the molecular subtype in this adenocarcinoma? A) HPV-associated B) ER-positive C) Vimentin-positive D) EGFR-mutant"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-FU-A770-01Z-00-DX1.67C6E3B1-22BC-41C6-B841-2C01DF1D5071-1",
        "image": "TCGA-CESC/TCGA-FU-A770-01Z-00-DX1.67C6E3B1-22BC-41C6-B841-2C01DF1D5071.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing p16 positivity and WT1 negativity, what is the molecular subtype in this carcinoma? A) Basal-like B) Serous carcinoma C) Neuroendocrine carcinoma D) HPV-associated"
            },
            {
                "from": "gpt",
                "value": "D"
            }
        ]
    },
    {
        "id": "TCGA-EX-A8YF-01Z-00-DX1.79A4FEAD-3D6A-4D15-BDA8-CD100A411302-1",
        "image": "TCGA-CESC/TCGA-EX-A8YF-01Z-00-DX1.79A4FEAD-3D6A-4D15-BDA8-CD100A411302.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing Pancytokeratin (AE1/AE3) positive for isolated tumor cells on Sentinel Lymph Node 1, Right External Iliac, and no tumor seen on Sentinel Lymph Node, Right Obturator, what is the molecular subtype in this carcinoma? A) Basal-like Carcinoma B) Adenocarcinoma C) Squamous Carcinoma D) Neuroendocrine Carcinoma"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-JW-A5VK-01Z-00-DX1.828A50C3-1C95-4552-8C37-CA9556DF4B94-1",
        "image": "TCGA-CESC/TCGA-JW-A5VK-01Z-00-DX1.828A50C3-1C95-4552-8C37-CA9556DF4B94.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing CK20 negativity, focal positivity for CK, and positivity for P16 which favors a cervical origin, what is the molecular subtype in this cervical cancer?   A) Adenocarcinoma   B) Squamous Carcinoma   C) Small Cell Carcinoma   D) Neuroendocrine Tumor"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-Q1-A73S-01Z-00-DX1.D74CFF58-A032-45D2-98FA-4B4D9AB90069-1",
        "image": "TCGA-CESC/TCGA-Q1-A73S-01Z-00-DX1.D74CFF58-A032-45D2-98FA-4B4D9AB90069.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong p16 positivity in surface atypical glandular areas, negative p63 in the tumor, strong mCEA positivity, CK7 positivity, negative Vimentin, and mucin positivity in surface atypical glandular areas, what is the molecular subtype in this carcinoma of the cervix? A) Adenocarcinoma B) Squamous Carcinoma C) Small Cell Carcinoma D) Neuroendocrine Carcinoma"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-Q1-A73R-01Z-00-DX1.1BF1893C-AC21-4FB2-A568-F71B75350374-1",
        "image": "TCGA-CESC/TCGA-Q1-A73R-01Z-00-DX1.1BF1893C-AC21-4FB2-A568-F71B75350374.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong diffuse staining of p16, Pan-Keratin, and Cytokeratin 8/18 within glandular and solid components of the tumor, predominantly negative Cytokeratin 5/6 but with patchy apical membranous staining in the gland forming component, and negative Chromogranin, Synaptophysin, and CD56 staining, what is the molecular subtype in this carcinoma? A) Squamous Cell Carcinoma B) Neuroendocrine Tumor C) AdenoCarcinoma D) Lymphoma"
            },
            {
                "from": "gpt",
                "value": "C"
            }
        ]
    },
    {
        "id": "TCGA-MA-AA42-01Z-00-DX1.060491AB-E11F-44DC-91CA-0AE68DE8C900-1",
        "image": "TCGA-CESC/TCGA-MA-AA42-01Z-00-DX1.060491AB-E11F-44DC-91CA-0AE68DE8C900.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing negativity for EBV and HPV, positive CK 5/6, p63, and p16, and negative CEA and S100, what is the molecular subtype in this carcinoma? A) Adenocarcinoma B) Squamous Carcinoma C) Neuroendocrine Carcinoma D) Melanoma"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-C5-A7CM-01Z-00-DX1.A1886113-2505-4EE3-8170-389AB304EE6C-1",
        "image": "TCGA-CESC/TCGA-C5-A7CM-01Z-00-DX1.A1886113-2505-4EE3-8170-389AB304EE6C.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive expression of p16, CK-7, and CEA-monoclonal, alongside negative expression of Calretinin, CD 10, and CK-20, what is the molecular subtype in this carcinoma? A) Squamous Cell Carcinoma B) Adenocarcinoma C) Neuroendocrine Carcinoma D) Mesothelioma"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-MA-AA43-01Z-00-DX1.ABDB39DC-D3A5-4B34-B573-C918D9783FFA-1",
        "image": "TCGA-CESC/TCGA-MA-AA43-01Z-00-DX1.ABDB39DC-D3A5-4B34-B573-C918D9783FFA.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing positive P63 and CK5/6, CEA positivity for adenocarcinoma, negative ER and Vimentin, and strongly positive P16, what is the molecular subtype in this carcinoma? A) SquamousCarcinoma B) AdenosquamousCarcinoma C) SmallCellCarcinoma D) Basal-likeCarcinoma"
            },
            {
                "from": "gpt",
                "value": "A"
            }
        ]
    },
    {
        "id": "TCGA-FU-A5XV-01Z-00-DX1.42E46204-02C8-4BD4-B14C-4A77895EECA5-1",
        "image": "TCGA-CESC/TCGA-FU-A5XV-01Z-00-DX1.42E46204-02C8-4BD4-B14C-4A77895EECA5.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing WT1 positive for endosalpingiosis, monoclonal CEA focally positive in carcinoma, p16 strongly positive in carcinoma and weakly negative in endosalpingiosis, p63 positive in tumor cells, and CK7 negative in tumor cells, what is the molecular subtype in this carcinoma? A) Endometrioid carcinoma B) Squamous carcinoma C) Serous carcinoma D) Clear cell carcinoma"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    },
    {
        "id": "TCGA-RA-A741-01Z-00-DX1.E14092BA-D4CE-4AD6-ACD7-D463D7C4DE71-1",
        "image": "TCGA-CESC/TCGA-RA-A741-01Z-00-DX1.E14092BA-D4CE-4AD6-ACD7-D463D7C4DE71.pt",
        "conversations": [
            {
                "from": "human",
                "value": "<image>\nBased on the IHC results showing strong, diffuse nuclear staining for P16, diffuse cytoplasmic staining for P63 and 34BE12, minority cell staining for CK5/6 and CEA, and negative Pankeratin staining on lymph nodes, what is the molecular subtype in this carcinoma? A) Adenocarcinoma B) Squamous Carcinoma C) Small Cell Carcinoma D) Melanoma"
            },
            {
                "from": "gpt",
                "value": "B"
            }
        ]
    }
]